Croi 2013 Pocket Program

March 3-6, 2013
Georgia World Congress Center

Atlanta, GA, US
20th Conference on Retroviruses
and Opportunistic Infections
2O13
CR I
Pocket
Program
v
CROI 2013 General Information
OVERVIEW
The 20
th
ConIerence on Retroviruses and Opportunistic InIections (CROI)
is a research meeting created to provide a Iorum Ior basic scientists, clinical
investigators, and global health researchers to present, discuss, and critique
their investigations into the epidemiology and biology oI human retroviruses
and the diseases they produce with the ultimate goal oI translating laboratory
and clinical research into progress against the AIDS epidemic.
To support the goals oI the meeting and the preIerences oI the scientiIic
community the conIerence serves, the ScientiIic Program Committee has
limited registration to researchers actively participating as investigators in
basic science or clinical studies oI retroviral diseases and their complications
and clinician-teachers (Iull-time academic Iaculty members responsible Ior
HIV/AIDS training and research programs). PreIerence will be accorded to
doctoral and proIessional degree level researchers/clinicians. In addition, a
limited number oI slots have been reserved Ior: 1) media, 2) AIDS treatment
and prevention community educators, and 3) senior clinical development
personnel Irom industry who have product development planning
responsibilities.
At the conclusion oI CROI 2013, attendees will again be polled
to determine their programmatic and logistical preIerences Ior Iuture
conIerences. CME Claims and/or Conference Survey should be completed
(online at www.retroconIerence.org) no later than April 6, 2013. The ScientiIic
Program Committee welcomes your opinions on how to continue to improve
the conIerence. The committee will use the survey results to determine the
venue and policies Ior Iuture meetings, so your Ieedback is important.
OBJECTIVES
At the completion oI this activity, the participants should be able to:
1) appraise and critique their individual eIIorts in light oI the most current
knowledge and inIormation about HIV/AIDS and its complications;
2) integrate into their respective proIessional medical endeavors those best
practices emerging Irom laboratory, clinical, and epidemiological research;
and 3) translate the latest laboratory and clinical research into making progress
against the AIDS epidemic.
NEEDS ASSESSMENT
More than 30 million people worldwide are inIected with HIV, with
millions oI new inIections each year. The research eIIorts oI tens oI thousands
oI scientists and clinicians have had considerable success in diagnosing and
treating inIection. Nevertheless, we still do not have either a curative treatment
or a preventive vaccine, without which most oI those presently inIected will die
oI AIDS, and new inIections will continue unabated. The need Ior continued
research on HIV/AIDS is clear. Timely communication oI the results oI such
research among scientists and clinicians working on this subject is critical to
advancing the Iield as rapidly as possible. CROI Iills this need by bringing
about 4,000 oI the leaders in disparate, but interrelated areas oI AIDS research
to interact with and educate one another in the very latest results, treatment
methods, and state-oI-the-art technological advances.
vi
General Information CROI 2013
ABBREVIATIONS AND ICONS USED IN THE PROGRAM

International Scholarship Awardee
(a listing oI the 34 International Scholarship Awardees appears in the Program
& Abstracts book)
Young Investigator Awardee
(a listing oI the 278 Young Investigator Awardees appears in the Program & Abstracts book)
LB Late Breaker Abstract Presentation

Workshop

Oral Abstracts

Plenary

Themed Discussion

Symposium

Poster Abstracts

Session will be Webcast

Session will be Podcast

Session is eligible Ior CME credit
AMERICANS WITH DISABILITIES ACT
Each participating hotel is in compliance to some degree with the Americans
with Disabilities Act. Special services (e.g., wheelchair-accessible
transportation and sign interpreters Ior the hearing impaired) are available iI
requested in advance. Should you require assistance onsite, please visit the
Meeting Headquarters.
BADGES
All registered meeting attendees, aIter showing photo identiIication, will
be issued a meeting badge when they pick up their registration materials
onsite and will be required to wear their badge at all oIIicial Iunctions. Due
to enhanced security measures, attendees will need to present their badges
Ior admittance into the convention center at all times. In the event oI a lost
badge, the attendee will be required to pay another registration Iee, in order
Ior their badge to be reissued.
CHILD CARE
Due to the proIessional nature oI this meeting, children are not allowed
in sessions, the poster hall, or the Welcome Reception, so please plan
accordingly. Child care arrangements can usually be made through the hotel
concierge. Alternatively, the Atlanta Convention and Visitors Bureau has
suggested: TLC Sitters oI Atlanta (770-410-4774 / tlcatlbellsouth.net /
tlcsittersoIatlanta.com).
CONFERENCE COURTESIES
In consideration oI all meeting attendees:
Make sure all cell phones and pagers are silent (in the oII position or in
vibrate mode) in session rooms; kindly step out oI the room prior to
answering or initiating a cell phone call.
ReIrain Irom photography in sessions and the poster hall (as a reminder, all
sessions will be available online).
In keeping with the scientiIic nature oI the conIerence, and to ensure a
productive meeting experience, no disruptions and/or protests are allowed.
The Georgia World Congress Center is a smoke-Iree Iacility. Individuals
who wish to smoke should do so outside oI the building.
vii
CONTINUING MEDICAL EDUCATION (CME)
This activity has been planned and implemented in accordance with the
Essential Areas and policies oI the Accreditation Council Ior Continuing
Medical Education through the joint sponsorship oI the University
oI CaliIornia, San Diego School oI Medicine and the ConIerence on
Retroviruses and Opportunistic InIections. The University oI CaliIornia,
San Diego School oI Medicine is accredited by the ACCME to provide
continuing medical education Ior physicians.
The University oI CaliIornia, San Diego School oI Medicine designates
this live activity Ior a maximum oI 27.25 AMA PRA Categorv 1 Credits.
Physicians should claim only the credit commensurate with the extent oI their
participation in the activity.
To claim credit Ior this conIerence, registrants must complete the CME
Claims and Conference Survey (online at www.retroconIerence.org) no
later than April 6, 2013. Your badge number will be required to access the
Iorms. CME certiIicates will be mailed aIter June 1, 2013.
California Assemblv Bill 1195 requires continuing medical education
activities with patient care components to include curriculum in the subfects
of cultural and linguistic competencv. It is the intent of the bill, which
went into effect on Julv 1, 2006, to encourage phvsicians and surgeons,
CME providers in the state of California, and the Accreditation Council
for Continuing Medical Education to meet the cultural and linguistic
concerns of a diverse patient population through appropriate professional
development. The planners, speakers and authors of this CME activitv have
been encouraged to address issues relevant in their topic area. In addition,
a varietv of resources are available that address cultural and linguistic
competencv, some of which are included in vour svllabus or handout
materials. Additional resources and information about AB1195 can be found
on our website at http.//cme.ucsd.edu.
MEALS
Complimentary continental breakIast, morning coIIee breaks, and aIternoon
snack breaks will be available to conIerence registrants in the Poster Hall.
Attendees are on their own for lunch during the hours of 12 noon to
1:30 pm each day. Below is a list oI Iood service options located in the
Convention Center or within a short walking distance.
At the Convention Center
Starbucks
Outtakes B
Terraces
At the CNN Center (across the street Irom the main entrance oI the Convention Center)
Latitudes Bistro and Grill Fuji Express
Dantanna`s Gorins Homemade CaIe
McCormick & Schmick Great Wraps
Prime Meridian Natural`s Ice Cream,
Arby`s Yogurt and Smoothies
Blimpie Moe`s Southwest Grill
Chick-Iil-A Roman Delight
China Breeze Salad Sensations
DJ Mexicana Atlanta Taco Bell
Dunkin` Donuts Wendy`s
Within 4 blocks of the Convention Center
Truva Der Biergarten
Ruth`s Chris Steak House Rise Sushi Lounge
Park Avenue Deli and Market Stats
Hudson Grille 11 Stories
Subway Peasant Bistro
Max`s Coal Oven Pizza Baja Fresh Mexican Grill
viii
General Information CROI 2013
MOBILE APPLICATION
To download the CROI 2013 mobile app, scan the QR code or go to
www.retroconIerence.org/mobile.
OVERFLOW ACCOMMODATIONS FOR SESSION ROOMS
Most session rooms will have designated overIlow areas. Should any session
draw signiIicantly higher attendance than can be accommodated, a nearby
space will be available to show the live audio/video Ieed.
WEBCASTS AND PODCASTS
www.retroconference.org
Plenaries, symposia, scientiIic overviews, oral abstract sessions, and themed
discussions will be webcast and podcast. Webcasts are also available as
streaming video on the Apple iPad and iPhone. In addition, abstracts and
posters Irom CROI 2013 as well as webcasts, abstracts, and posters Irom
previous meetings (CROI 1994-2012) will be available online.
WELCOME RECEPTION
Sundav, March 3, 7-10 pm
Georgia Aquarium
The Georgia Aquarium, with more than 10 million
gallons oI water, hosts the world`s largest collection oI
aquatic animals. It combines entertainment, education
and science through exhibits and programs which
provide engaging and exciting guest experiences, while
promoting the conservation oI aquatic biodiversity
throughout the world.
WIFI ACCESS
CROI will be oIIering complimentary wireless connectivity within Georgia
World Congress Center. Coverage in the Iacility includes CROI general
session and breakout rooms, poster hall, and registration area. No additional
equipment is required beyond the wireless access card already installed in a
client device (WiFi enabled laptop, PDA, or telephone). The WiFi network
is CROI; the password is CROI2013.
ix
Offices
& Services
Location Hours of Operation Information
Atlanta
Information
& Restaurant
Reservations
Lobby Saturday 12 n-5 pm
Sunday 11 am-7 pm
Monday 10 am-6 pm
Tuesday 10 am-6 pm
Wednesday 10 am-6 pm
For maps, information on
local attractions and
restaurant reservations.
Coat &
Baggage
Check
Lobby Sunday 7 am-7:30 pm
Monday 7 am-7:15 pm
Tuesday 7 am-7:15 pm
Wednesday 7 am-6:30 pm
Coat & Baggage Check
service is complimentary.
CyberCafe Hall B2
Level One
Saturday 12 n-5 pm
Sunday 7 am-7 pm
Monday 7 am-7 pm
Tuesday 7 am-7 pm
Wednesday 7 am-6 pm
Computers will be available
to view webcasts, search
the abstracts and posters,
and check email. In
addition, WiFi service will
be available throughout
the convention center.
Computers in the
CyberCafe will also provide
Message Center functions.
Voice and text messages
may be left for attendees
here and at the Message
Center.
Media Center
404-222-5808
B202
Level Two
Sunday 9 am-7 pm
Monday 8 am-6:30 pm
Tuesday 8 am-6:30 pm
Wednesday 8 am-6:30 pm
Pre-registered journalists
should pick up press kits
and convene for daily
press conferences in the
Media Center. There is no
onsite press registration.
Meeting
Headquarters
404-222-5804
B211
Level Two
Saturday 12 n-5 pm
Sunday 7 am-7 pm
Monday 7 am-6 pm
Tuesday 8 am-6 pm
Wednesday 8 am-6 pm
To contact staff or for lost-
and-found items, please
go to the Meeting
Headquarters.
Message
Center
404-222-5800
Sunday 7 am-7 pm
Monday 7 am-7 pm
Tuesday 7 am-7 pm
Wednesday 7 am-6 pm
Voice and text messages
may be left for attendees at
the Message Center.
Computers in the
CyberCafe will also provide
Message Center functions.
Registration
& Housing
404-222-5801
Sunday 7 am-7 pm
Monday 7 am-6 pm
Tuesday 8 am-6 pm
Wednesday 8 am-6 pm
Pre-registered attendees
should pick up conference
materials including
badges, Program &
Abstracts, and Addenda
during registration hours.
There is no on-site
registration.
Speaker
Services
& Poster
Drop-off
404-222-5807
B208
Level Two
Saturday 12 n-5 pm
Sunday 8 am-6 pm
Monday 8 am-6 pm
Tuesday 8 am-6 pm
Wednesday 8 am-6 pm
Speakers should bring
their presentation (in MS
PowerPoint or Apple
Keynote only) to the
Speaker Services Room
on a disk or drive at least
4 hours prior to
presentation. CROI
supports both MacIntosh
and PC platforms. The
Speaker Services Room
will be equipped with
workstations, and an art
director and AV
technicians will be
available to assist
speakers. This is also
where poster presenters
should submit an
electronic version of their
poster for placement on
the CROI website.
x
Hotel Information CROI 2013
Map
Key
Hotel Rate
# of blocks to
Convention Center
1
Atlanta Marriott Downtown
160 Spring St, NW, Atlanta, GA 30303
phone: 404-688-8600 / fax: 678-686-3327
$133 blocks
2
Atlanta Marriott Marquis
25 Feachtree Ctr Ave, NE, Atlanta, 0A30303
phone: 404-521-0000 / fax: 404-586-6299
$133 blocks
3
Embassy Suites Atlanta
at Centennial Olympic Park
267 Marietta St, Atlanta, GA 30313
phone: 404-223-2300 / fax: 404-223-0925
$159 1 block
4
Hilton Atlanta
255 Courtland St, NE, Atlanta, 0A30303
phone: 404-659-2000 / fax: 404-221-6368
$123 7 blocks
5
Hilton Garden Inn Downtown
275 aker St, Atlanta, 0A30313
phone: 404-577-2001 / fax: 404-577-2002
$149 2 blocks
6
Holiday Inn Atlanta Downtown
101 AndrewJ Young lntl lvd, Atlanta, 0A30303
phone: 404-524-5555 / fax: 404-221-0702
$123 2 blocks
7
Hyatt Regency Atlanta
25 Feachtree St, NE, Atlanta, 0A30303
phone: 404-577-1234 / fax: 404-588-4137
$128 5 blocks
8
Omni Hotel at CNN Center
100 CNNCtr, Atlanta, 0A30303
phone: 404-659-0000 / fax: 404-525-5050
$159 adjacent
9
The Ritz Carlton Atlanta
181 Feachtree Ctr Ave, Atlanta, 0A30303
phone: 404-659-0400 / fax: 404-688-0400
$165 5 block
10
Sheraton Atlanta Hotel
15 Courtland St, NE, Atlanta, 0A30303
phone: 404-659-6500 / fax: 404-524-1259
$123 7 blocks
11
W Atlanta Downtown
15 lvan Allen Jr lvd, Atlanta, 0A30308
phone: 404-582-5800 / fax: 404-582-5805
$149 7 blocks
12
Westin Peachtree Plaza
210 Feachtree St, NW, Atlanta, 0A30303
phone: 404-659-1400 / fax: 404-589-7424
$133 1 blocks
1
6
3
5
2
10
11
9
4
7
12
8
8
xi
CROI 2013 Ground Transportation Information
GROUND TRANSPORTATION
!"#$ &'"()*+,-./0'12)#3 4(-'3(' 53(,"3'(+#3'- 4+"6#"(
7'8+ 9,":+1,
Travel time Irom airport to downtown is approximately 10 miles and can
take up to 30 minutes depending on traIIic. Taxi Iare Irom the airport is
approximately $34.
9;<((-, 9,":+1,
Travel time Irom the airport to downtown can take up to 45 minutes.
Discounts have been arranged with Atlanta Airport Shuttle Service Ior $5
oII round trip. Pre-pay Ior shuttle service at http://www.taass.net/index-4.
html and choose either 'Downtown Round-Trip under 'Group Rates Ior
a Iare oI $27 or 'Downtown One-Way under 'Single Rates Ior a Iare oI
$16.50. Reservations must be made 24 hours in advance.
=<>-+1 7"'3)+(
MARTA is easily accessible at the airport and takes you directly downtown.
The station is located between the two terminals at the end oI the baggage
claim area.
MARTA runs Irom 4:45 am-1 am on weekdays and 6 am-1 am on weekends.
Trains arrive and depart every 15-20 minutes, depending on the time oI day.
Travel time is approximately 20 minutes. Transit Iare is $2.50 one way a
one time Iee oI $2 to load money onto a breeze card.
?#1'- 7"':,-
The Georgia World Congress Center is located at 2000 Convention Center
Concourse, Atlanta, GA 30337. The main entrance to Building B (where
CROI will be held) is through the atrium, between Buildings A and B, oII
oI Andrew Young International Boulevard. Their website oIIers detailed
directions on driving and taking public transportation to, as well as parking
at and around, the Convention Center.
S
u
n
d
a
y
M
a
r
c
h

3
O
r
a
l

S
e
s
s
i
o
n
s
Program 1
CROI 2013 Session 2
!
Sunday, 9 am-1:30 pm; B406

"#$$%&' ()*&+,$-&.
New Investigators and Trainees
The purpose oI this workshop is to educate and engage new
investigators and trainees, to spark interest in the Iield, to provide
opportunities Ior interaction among trainees and Iaculty, and to
orient trainees to the science being presented at the conIerence.
Presentations will be geared toward new trainees (e.g.,undergraduate
students, graduate students, postdoctoral Iellows, and physician
Iellows) and new investigators (both international and domestic)
who have been conducting active research in the Iield Ior less
than 3 years. Priority will be given to awardees Irom the young
investigator, international scholar, and community educator
programs. Other CROI registrants may attend the workshop (on a
space available basis). Boxed lunches will be available Ior awardees
only. No pre-registration is required.
The Iormat is designed to be interactive. Each presenter will provide
a state-oI-the-art summary oI a major area oI HIV investigation
being covered at the conIerence and end by outlining the top 3 to 5
research questions in the Iield Irom his/her perspective. The Iloor
will then be open Ior audience questions and discussion.
Conveners:
Scott Hammer, Columbia Univ, Coll of
Phvsicians & Surgeons, New York, NY, US
John Mellors, Univ of Pittsburgh, PA, US
9:00-9:15 am
Opening Remarks
9:15-9:45 am
1
Transmission/Founder Viruses and Their
Phenotypic Properties
Beatrice Hahn
Univ of Pennsvlvania, Philadelphia, US
9:45-10:15 am
2
Research on Viral Reservoirs, Persistence,
and Cure
Mario Stevenson
Univ of Miami Miller Sch of Med, FL, US
10:15-10:45 am
3
Recent Advances in HIV and SIV Pathogenesis
Guido Silvestri
Emorv Univ Sch of Med and Yerkes Natl Primate Res Ctr,
Atlanta, GA, US
10:45-11:15 am
Coffee Break
11:15-11:45 am
4
HIV Prevention Research: What`s Next?
Susan Buchbinder
San Francisco Dept of Publ Hlth, CA, US
11:45 am-12:15 pm
5
Hepatitis C Virus Research and Treatment
Robert Schooley
Univ of California, San Diego, US
12:15-12:30 pm
Closing Remarks
12:30-12:45 pm
Box Lunch Distribution to Young Investigators, International
Scholars, and Communitv Educators
12:45-1:30 pm
6
/0+1%' 2#30'#4 5#617+#
The Challenge of Marginalization in the Fight
against HIV, and the Resiliency of Individuals
and Communities
Paul Semugoma
African Men for Sexual Hlth and Rights, ANOJA Hlth,
South Africa
"
Sunday, 2:30-4:30 pm; B308

"#$$%&' 8)*&+,$-&.
Frontiers in Laboratory Science
The purpose oI this workshop is to present the main technological
and conceptual developments in liIe sciences that are inIluencing
HIV research or that hold a signiIicant potential Ior research. The
presentations should educate and engage investigators and clinicians,
and spark interest in emerging technologies.CROI registrants may
attend the workshop. No pre-registration is required.
Convener:
Amalio Telenti, Univ of Lausanne, Swit:erland
7
9' :%;& Imaging of Viral and Cellular
Dynamics in HIV Infection
T Murooka
1,2
, M Deruaz
1,2
, F Marangoni
1,2
, E Seung
1,2
,
V Vrbanac
1
, U von Andrian
2
, A Tager
1,2
, A Luster
1,2
,
and Thorsten Mempel*
1,2
1
Ctr for Immunologv and Inflammatorv Diseases,
Massachusetts Gen Hosp, Boston, US and
2
Harvard Med Sch,
Boston, MA, US
8
Systems Vaccinology: Its Promise and
Challenge for HIV Vaccine Development
Helder Nakaya
Emorv Univ Sch of Med, Atlanta, GA, US
9
Crowd-sourcing, Social Networks, and Twitter
Research in Infectious Diseases
Marcel Salathe
Ctr for Infectious Disease Dvnamics, Pennsvlvania State Univ,
Universitv Park, US
10
Using Viral Meta-genomics to Identify
~Novel Human and Animal Viruses
Eric Delwart
Blood Svstems Res Inst and Univ of California, San Francisco, US
41209wo_PA_Orals-R8.indd 1 2/20/13 6:44 PM
Session 3 CROI 2013
2 20th Conference on Retroviruses and Opportunistic Infections
S
u
n
d
a
y
M
a
r
c
h

3
O
r
a
l

S
e
s
s
i
o
n
s
!
Sunday, 2:30-4:30 pm; B313

"#$$%&' ()*&+,$-&.
Clinical Trials Design
This workshop is designed to address several current issues in HIV
clinical trial design and interpretation. These talks are intended Ior
a general audience and will explore issues such as how to integrate
data Irom clinical trials with mathematical models, what you need
to know about adaptive trial designs, and alternatives to randomized
clinical trials. These lectures will use examples Irom recent HIV
treatment and prevention trials and will include time Ior Q&A.
CROI registrants may attend the workshop. No pre-registration is
required.
Conveners:
Susan Buchbinder, San Francisco Dept
of Publ Hlth, CA, US
Richard Chaisson, Johns Hopkins Univ
Sch of Med, Baltimore, MD, US
2:35-3:10 pm
11
Adaptive Methods: What You Really Need to
Know
Michael Proschan
Biostatistics Res Branch, NIAID, NIH, Bethesda, MD, US
3:10-3:45 pm
12
Alternatives to Randomized Controlled Trials:
When and How to Use
Caroline Sabin
Univ Coll London, UK
3:45-4:20 pm
13
The Symbiotic Relationship between Trials
and Mathematical Models
Timothy Hallett
Imperial Coll London, UK
"
Sunday, 5-7 pm; Hall B1

"#$$%&' /)0.#'%'1

Greetings from the Program Committee
Kevin De Cock
CDC Kenva, Nairobi
Remarks from the Director of the US Centers
for Disease Control and Prevention
Thomas Frieden
CDC, Atlanta, GA, US
23
4-
5#+'6+7 8%#97$ :#;4<+#
The Bernard Fields lectureship recognizes a scientist whose body oI
work has signiIicantly contributed to the understanding oI virology
and viral pathogenesis as exempliIied by the career oI Bernard Fields.
14
ARV Drug Discovery: HIV-1 Integrase
Inhibitors and Beyond
Daria Hazuda
Merck Res Labs, West Point, PA, US
Objectives: This session is directed to clinicians and scientists
interested in ART and novel targets Ior drug discovery. It is assumed
that participants have a basic understanding oI retroviral biology
and are Iamiliar with HIV therapeutics. At the completion oI the
session, participants will have a deeper understanding the biology
oI integrase and the development oI integrase inhibitors as well as
increased knowledge oI the drug discovery process as it applies to
Iuture therapeutics.
=
4-
>?@69ABC6'' :#;4<+#
The N`Galy-Mann lectureship was established in 2006 to recognize
an individual researcher or team who has made important and timely
contributions in epidemiology and clinical research as exempliIied
by the collaborative careers oI Bosenge N`Galy and Jonathan Mann.
15
MTCT: From Epidemic to Elimination
Lynne MoIenson
Natl Inst of Child Hlth and Human Devt, NIH, Rockville, MD, US
interested in the evolution oI interventions Ior PMTCT in the US
and globally, and lessons learned. It is assumed that participants are
Iamiliar with mechanisms oI MTCT and interventions to prevent it.
At the completion oI the session, participants will be knowledgeable
about clinical trials and implementation science related to PMTCT,
lessons learned Irom the US, and implications globally
*#9;&D# E#;#.4%&'
7-10 pm
Georgia Aquarium
The Georgia Aquarium is a short walk (3 blocks) Irom the Convention Center.
Program 3
M
o
n
d
a
y
M
a
r
c
h

4
O
r
a
l

S
e
s
s
i
o
n
s
CROI 2013 Session 8
!
Monday, 8:30-9 am; Hall B1

"#$$%&' ()*+#',-.
HIV-1 Eradication Strategies: Design,
Assessment, and Clinical Consequences
16
Robert Siliciano
Johns Hopkins Univ Sch of Med, Baltimore, MD, US
interested in HIV-1 eradication studies. It is assumed participants
are Iamiliar with Iundamental aspects oI HIV-1 treatment such as
the response to HAART, and the need Ior additional interventions
to eliminate the residual virus that persists despite HAART. At the
completion oI the session, participants will be knowledgeable about
assays to measure viral reservoirs and the clinical consequences oI
reductions in reservoir size induced by eradication strategies.

"
Monday, 9-9:30 am; Hall B1

"#$$%&' /)*+#',-.
Reality Check: Is the End of AIDS in Sight?
17
Francois Dabis
Bordeaux Sch of Publ Hlth and INSERM U897, Univ Bordeaux,
Segalen, France
interested in the global perspective oI the Iight against HIV/AIDS.
It is assumed that participants are Iamiliar with the concepts oI
prevention and care and the programmatic diIIerences between
resource-rich and -limited settings. At the completion oI the session,
participants will be knowledgeable about the most recent advances
in biomedical prevention and the Ioreseeable scenarios Ior the
coming years.
#
Monday, 10-11:30 am; B406

"#$$%&' 0)1-,+ 23$4-,54$
Neurocognitive Disorders: New Developments and
Therapies
Moderators:
Christina Marra, Univ of Washington Sch of Med, Seattle, US
Ann Ragin, Northwestern Univ Feinberg Sch of Med, Chicago, IL, US
10:00 18 Very Early Viral Infection of the Central
Nervous System without Evidence of
Compartmentalization during Acute HIV-1
Infection (RV254)
Serena Spudich*
1
, G Kijak
2,3
, J Ananworanich
4,5
, M Bose
2,3
,
V Assawadarachai
5
, S Rattamanee
4,5
, E Sanders-Buell
2,3
, V Valcour
6
,
J Kim
2
, S Tovanabutra
2,3
, and RV254/SEARCH 010 Study Group
1
Yale Univ, New Haven, CT, US,
2
US Militarv HIJ Res Prgm,
Walter Reed Armv Inst of Res, Silver Spring, MD,
3
Henrv M Jackson
Fndn for the Advancement of Militarv Med, Bethesda, MD, US,
4
SEARCH, The Thai Red Cross AIDS Res Ctr, HIJNAT, Bangkok,
5
Armed Forces Res Inst for Med Sci, Bangkok, Thailand, and
6
Univ
of California, San Francisco, US
10:15 19 Neuropsychological Performance in Acute HIV:
Determinants of Baseline Performance and
Effects of Immediate ART

Idil Kore*
1
, J Ananworanich
2,3,4
, V Valcour
5
, J Fletcher
2
,
D Suttichom
2
, P Mangum
2
, L Jagodzinski
6
, J Kim
6
, S Spudich
1
,
and RV254/SEARCH 010 Study Group
1
Yale Univ Sch of Med, New Haven, CT, US,
2
SEARCH, The Thai
Red Cross AIDS Res Ctr, Bangkok,
3
HIJNAT, Bangkok, Thailand,
4
Facultv of Med, Chulalongkorn Univ, Bangkok, Thailand,
5
Univ
of California, San Francisco, US, and
6
US Militarv HIJ Res Prgm,
Silver Spring, MD
10:30 20 A Randomized, Controlled Trial of a Central
Nervous System-targeted ART Strategy for
HIV-associated Neurocognitive Disorders
Ronald Ellis*
1
, F Vaida
1
, S Letendre
1
, R Haubrich
1
, R Heaton
1
,
A McCutchan
1
, M Cherner
1
, A UmlauI
1
, N Sacktor
2
, and D CliIIord
3
1
Univ of California, San Diego, US,
2
Johns Hopkins Univ,
Baltimore, MD, US, and
3
Washington Univ, St Louis, MO, US
10:45 21 Regional Brain Atrophy Is Associated with
Mitochondrial Dysfunction and Elevated
Mitochondrial Oxidative Stress in HIV
+
Individuals
K Kallianpur, M Gerschenson, T Umaki, D Chow, B Nakamoto,
D Libutti, M Lopez, J Taylor, L Marotz, and Cecilia Shikuma*
Univ of Hawaii, Honolulu, US
11:00 22 VLA-4 Treatment Blocks Virus Traffic to the
Gut and Brain Early, and Stabilizes CNS Injury
Late in Infection

JenniIer Campbell*
1
, P Autissier
1
, A MacLean
2
, T Burdo
1
,
S Westmoreland
3
, G Gonzalez
4,5
, E-M Ratai
4,5
, and K Williams
1
1
Boston Coll, Chestnut Hill, MA, US,
2
Tulane Natl Primate Res
Ctr, Covington, LA, US,
3
New England Regional Primate Res Ctr,
Southborough, MA, US,
4
Harvard Med Sch, Boston, MA, US, and
5
Athinoula A Martinos Ctr for Biomed Imaging, Massachusetts Gen
Hosp, Boston, US
11:15 23 Central Nervous System Compartmentalization
of HIV-1 Subtype C Variants Early and Late in
Infection in Young Children

Christa Buckheit Sturdevant*
1
, A Dow
1
, C Jabara
1
, S Joseph
1
,
G Schnell
2
, N Takamune
3
, M Mallewa
4
, R Heyderman
4
, A Van Rie
1
,
and R Swanstrom
1
1
Univ of North Carolina at Chapel Hill, US,
2
Univ of Washington,
Seattle, US,
3
Kumamoto Univ, Japan, and
4
Univ of Malawi Coll of
Med, Blantvre
#
Monday, 10 am-12:15 pm; Ballroom 3-4

"#$$%&' 6)1-,+ 23$4-,54$
HIV Prevention: ARV, Counseling,
Contraception, and Condoms
Moderators:
Monica Gandhi, Univ of California, San Francisco, Sch of Med, US
James McIntyre, Anova Hlth Inst, Johannesburg, South Africa
10:00 24LB Long-acting Parenteral Formulation of
GSK1265744 Protects Macaques against
Repeated Intrarectal Challenges with SHIV
Chasity Andrews*
1
, A Gettie
1
, K Russell-Lodrigue
2
, L Moss
3
,
H Mohri
1
, W Spreen
3
, C Cheng-Mayer
1
, Z Hong
3
, M Markowitz
1
,
and D Ho
1
1
Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York,
NY, US,
2
Tulane Natl Primate Res Ctr, Covington, LA, US, and
3
GlaxoSmithKline, Research Triangle Park, NC, US
10:15 25LB A Tenofovir Disoproxil Fumarate Intravaginal
Ring Completely Protects against Repeated
SHIV Vaginal Challenge in Nonhuman Primates
James Smith*
1
, R Rastogi
2
, R Teller
2
, P Srinivasan
1
, J Mitchell
1
,
J McNicholl
1
, M Hendry
1
, P Mesquita
3
, P Kiser
2
, and B Herold
3
1
CDC, Atlanta, GA, US,
2
Univ of Utah, Salt Lake Citv, US, and
3
Albert Einstein Coll of Med, Bronx, NY, US
10:30 26LB Pre-exposure Prophylaxis for HIV in Women:
Daily Oral Tenofovir, Oral Tenofovir/
Emtricitabine, or Vaginal Tenofovir Gel
in the VOICE Study (MTN 003)
Jeanne Marrazzo*
1
, G Ramjee
2
, G Nair
3
, T Palanee
4
, B Mkhize
5
,
C Nakabiito
6
, M Taljaard
7
, J Piper
8
, K Gomez Feliciano
9
,
M Chirenje
10
, and VOICE Study Team
1
Univ of Washington, Seattle, US,
2
HIJ Prevention Res Unit,
Durban, South Africa,
3
CAPRISA-eThekwini CRS, Duban, South
Africa,
4
Witwatersrand Reproductive Hlth & HIJ Inst,
5
Perinatal
HIJ Res Unit, Johannesburg, South Africa,
6
Makerere-Johns
Hopkins Univ Res Collaboration, Kampala, Uganda,
7
Aurum
Inst, Klerksdorp, South Africa,
8
Division of AIDS, NIH, Bethesda,
MD, US,
9
FHI360, Research Triangle Park, NC, US, and
10
Univ of
Zimbabwe-UCSF CTU, Harare
10:45 27 No Excess in HIV Incidence after Stopping
Oral Emtricitabine/Tenofovir Pre-exposure
Prophylaxis: The iPrEx Trial
Robert Grant*
1,2
, J Guanira
3
, S Buchbinder
2,4
, C Mosquera
3
, V Veloso
5
,
E Kallas
6
, M Mehrotra
1
, V McMahan
1
, R Amico
7
, D Glidden
2
, and iPrEx
Study Team
1
Gladstone Inst, San Francisco, CA, US,
2
Univ of California, San
Francisco, US,
3
INMENSA, Lima, Peru,
4
San Francisco Dept of
Publ Hlth, CA, US,
5
FIOCRUZ, Rio de Janeiro, Bra:il,
6
Univ of Sao
Paulo, Bra:il, and
7
Univ of Connecticut, Storrs, US
M
o
n
d
a
y
M
a
r
c
h

4
O
r
a
l

S
e
s
s
i
o
n
s
Session 8 CROI 2013
11:00 28 Hormonal Contraception and Risk of HIV:
An Analysis of Data from the Microbicides
Development Programme Trial
Angela Crook*
1
, H Rees
2
, G Ramjee
3
, A Kamali
4
, S Kapiga
5
,
M Chisembele
6
, M GaIos
1
, A Nunn
1
, R Hayes
7
, and S McCormack
1
1
MRC Clin Trials Unit, London, UK,
2
Univ of the Witwatersrand,
Johannesburg, South Africa,
3
MRC HIJ Prevention Res Unit,
4
MRC/UJRI Uganda Res Unit, Entebbe,
5
Mwan:a Intervention Trials Unit, Tan:ania,
6
Univ Teaching Hosp,
Lusaka, Zambia, and
7
London Sch of Hvgiene and Tropical Med, UK
11:15 29 Is Depot Medroxyprogesterone Acetate
Likely to Increase Infectivity in HIV-1
+

Women Receiving ART?

Summer Day*
1
, S Graham
1,2
, L Masese
1,2
, B Richardson
1,3
,
J Kiarie
2
, W Jaoko
2
, B Estambale
2
, V Chohan
1,3
, J Overbaugh
3
,
and S McClelland
1,2
1
2
Inst of Tropical and Infectious
Diseases, Univ of Nairobi, Kenva, and
3
Fred Hutchison Cancer Res
Ctr, Seattle, WA, US
11:30 30 Community-level Reductions in Estimated HIV
Incidence: HIV Prevention Trials Network 043,
Project Accept
Thomas Coates*
1
, S Eshleman
2
, S Chariyalertsak
3
, A Chingono
4
,
G Gray
5
, J Mbwambo
6
, L Richter
7
, D Donnell
8
, E Piwowar-Manning
2
,
M Kulich
9
, and the HPTN 043 Project Accept Study Team
1
Univ of California, Los Angeles, US,
2
Johns Hopkins Univ Sch
of Med, Baltimore, MD, US,
3
Chiang Mai Univ, Thailand,
4
Univ
of Zimbabwe, Harare,
5
Univ of the Witwatersrand, Soweto, South
Africa,
6
Muhimbili Univ, Dar es Salaam, Tan:ania,
7
Human Sci Res
Council, Julindlela, South Africa,
8
Statistical Ctr for HIJ/AIDS Res
and Prevention, Fred Hutchinson Cancer Res Ctr, Seattle, WA, US,
and
9
Charles Univ, Prague, C:ech Repulic
11:45 31 Which HIV Testing and Counseling Model
Works Best in African Outpatient Departments?
Results from the Strengthening HIV Test Access
and Treatment Uptake Study
AD McNaghten*
1
, A Schilsky Mneimneh
2
, T Farirai
3
, N Wamai
4
,
M Ntiro
5
, J Sabatier
2
, N Makhunga-RamIolo
6
, S Mwanasalli
7
,
A Awor
4
, J Moore
2
, and Project STATUS Study Team
1
Emorv Univ, Atlanta, GA, US,
2
3
CDC,
Pretoria, South Africa,
4
CDC, Entebbe, Uganda,
5
Ministrv of Hlth
and Social Welfare, Dar es Salaam, Tan:ania,
6
Univ Res Co, LLC,
Pretoria, South Africa, and
7
CDC, Dar es Salaam, Tan:ania
12:00 32 Condom Efficacy by Consistency of Use
among MSM: US
Dawn Smith*, J Herbst, X Zhang, and C Rose
!
Monday, 10 am-12:15 pm; Ballroom 1-2

"#$$%&' ()*+,- ./$0+,10$
Advances in Hepatitis Therapy
Moderators:
Juergen Rockstroh, Univ of Bonn, Germanv
Kimberly Workowski, Emorv Univ Sch of Med, Atlanta, GA, US
10:00 33 Protective Effect of Hepatitis B Virus-active cART
against Primary Hepatitis B Virus Infection
M HeuIt, G van den Berk, T Smissaert, W Blok, R Regez, L Dijksman,
and Kees Brinkman*
On:e Lieve Jrouwe Gasthuis, Amsterdam, The Netherlands
10:15 34 Increased Plasma and Intracellular Ribavirin
Concentrations Associated with Telaprevir Use

Kyle Hammond*
1
, L Jimmerson
1
, C MacBrayne
1
, M Ray
1
,
L Bushman
1
, J Burton
1
, F Baouchi-Mokrane
2
, G Everson
1
,
P Anderson
1
, and J Kiser
1
1
Univ of Colorado Denver, Aurora, US and
2
Denver Hlth Med Ctr,
CO, US
10:30 35 Pharmacokinetic Interactions of Darunavir/
ritonavir, Efavirenz, and Tenofovir with the
Hepatitis C Virus Protease Inhibitor Faldaprevir
in Healthy Volunteers
J Sabo
1
, Jens Kort*
1
, M Haschke
2
, C Ballow
3
, B Girlich
4
, U FeiIel
5
,
B Lang
6
, M Schobelock
1
, and M Elgadi
7
1
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT,
US,
2
Univ Hosp Basel, Swit:erland,
3
Buffalo Clin Res Ctr, NY,
US,
4
Boehringer Ingelheim Schwei: GmbH, Basel, Swit:erland,
5
Boehringer Ingelheim Pharmaceuticals GmbH & Co KG,
Ingelheim, Germanv,
6
Boehringer Ingelheim Pharmaceuticals
GmbH & Co KG, Biberach, Germanv, and
7
Boehringer Ingelheim
Canada Ltd, Burlington
10:45 36 High Early Virological Response with
Telaprevir-Pegylated-Interferon-Ribavirin
in Treatment-experienced Hepatitis C Virus
Genotype 1/HIV Co-infected Patients:
ANRS HC26 TelapreVIH Study
Laurent Cotte*
1
, J Braun
2
, C Lascoux-Combe
3,4
, C Vincent
2
,
S Pol
3,5
, M-A Valentin
3,6
, K Lacombe
3
, D Nau
7
, J-P Aboulker
2
,
J-M Molina
3,4
, and ANRS HC26 Study Group
1
INSERM U1052, Hospices Civils de Lvon, France,
2
INSERM
SC10-US019, Jillefuif, France,
3
Assistance Publ Hosp de Paris,
France,
4
Univ Paris JII Denis Diderot, Paris, France,
5
Univ Paris
Descartes, Paris, France,
6
INSERM UMR-S 943, Paris, France,
and
7
Hosp Pellegrin, Bordeaux, France
11:00 37 ANRS-HC27 BocepreVIH Interim Analysis:
High Early Virologic Response with Boceprevir
+ Pegylated Interferon + Ribivirin in Hepatitis
C Virus/HIV Co-infected Patients with Previous
Failure to Pegylated Interferon + Ribivirin
Isabelle Poizot-Martin*
1
, E Bellissant
2
, L Piroth
3
, A Renault
2
,
Y Quertainmont
4
, E Rosenthal
5
, L Alric
6
, D Guyader
2
, M Bourliere
7
,
J-M Molina
8
, and ANRS-HC27 BOCEPREVIH Study Group
1
Hosp Ste Marguerite, Marseille, France,
2
Hosp de Pontchaillou,
Rennes, France,
3
Hosp du Bocage, Difon, France,
4
Hosp de
Kremlin-Bicetre, Paris, France,
5
Hosp de LArchet, Nice, France,
6
Hosp de Purpan, Toulouse, France,
7
Hosp St-Joseph, Marseille,
France, and
8
Hosp St-Louis, Paris, France
11:15 38 12 Weeks of ABT-450/Ritonavir, Non-nucleoside
Inhibitor and Ribavirin Achieved SVR24 in
>90 of Treatment-nave Hepatitis C Virus GT1
Patients and 47 of Prior Non-responders
Eric Lawitz*
1
, D Cohen
2
, F Poordad
1
, K Kowdley
3
, G Everson
4
,
B Freilich
5
, D Jensen
6
, M Heckaman
2
, T Pilot-Matias
2
, and B Bernstein
2
1
Alamo Med Res, San Antonio, TX, US,
2
Abbott, Abbott Park, IL, US,
3
Digestive Disease Inst, Jirginia Mason Med Ctr, Seattle, WA, US,
4
Univ of Colorado Denver and Univ of Colorado Hosp, Aurora, US,
5
Kansas Citv Gastroenterologv and Hepatologv, MO, US, and
6
Ctr
for Liver Diseases, Univ of Chicago Med Ctr, IL, US
11:30 39 Risk of Virologic Relapse in Hepatitis C Virus
GT1-infected Subjects after 8, 12, and 24 Weeks
of ABT-450/r+ABT-267+ABT-333+Ribavirin:
Identifying Optimal Treatment Duration
Martin King*, W Xie, L Larsen, D Cohen, T Podsadecki,
and B Bernstein
AbbJie, North Chicago, IL, US
11:45 40LB STARTVerso 4: High Rates of Early Virologic
Response in Hepatitis C Virus Genotype 1/HIV
Co-infected Patients Treated with Faldaprevir +
Pegylated Interferon and Ribavirin
Douglas Dieterich*
1
, V Soriano
2
, M Nelson
3
, J Rockstroh
4
,
K Arasteh
5
, S Bhagani
6
, A Talal
7
, C Tural
8
, R Vinisko
9
, and J Kort
9
1
Mt Sinai Sch of Med, New York, NY, US,
2
Hosp Carlos III, Madrid,
Spain,
3
Chelsea and Westminster Hosp, London, UK,
4
Univ of Bonn,
Germanv,
5
EPIMED, Jivantes Auguste-Jiktoria Hosp, Berlin,
Germanv,
6
Roval Free Hosp, London, UK,
7
State Univ of New York,
Buffalo, US,
8
Hosp Univ Germans Trias i Pufol, Barcelona, Spain,
and
9
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, US
12:00 41LB ELECTRON: 100 Suppression of Viral Load
through 4 Weeks Post-treatment for Sofosbuvir
+ Ledipasvir (GS-5885) + Ribavirin for 12 Weeks
in Treatment-nave and -experienced Hepatitis C
Virus GT1 Patients
Edward Gane*
1
, R Hyland
2
, X Ding
2
, P Pang
2
,
J McHutchison
2
, W Symonds
2
, and C Stedman
3
1
Auckland Clin Studies, New Zealand,
2
Gilead Sci, Foster Citv, CA,
US, and
3
Christchurch Hosp, New Zealand
Program 5
M
o
n
d
a
y
M
a
r
c
h

4
O
r
a
l

S
e
s
s
i
o
n
s
CROI 2013 Session 12
!
Monday, 10 am-12:15 pm; Hall B1

"#$$%&' ()*+,-. /0$1,-21$
Is There Hope for HIV Eradication?
Moderators:
Kersten Koelsch, Univ of New South Wales, Kirbv Inst for Infection and
Immunitv in Societv, Svdnev, Australia
Ronald Swanstrom, Ctr for AIDS Res, Univ of North Carolina at Chapel
Hill, US
10:00 42 Increase in 2-LTR Circles after Raltegravir
Intensification in HAART-suppressed Patients
with High CD4
+
T Cell Counts: A Randomized,
Controlled Trial
Hiroyu Hatano*
1
, M Strain
2
, R Scherzer
1
, E Sinclair
1
, S Palmer
3
,
M Busch
1,4
, P Bacchetti
1
, P Hsue
1
, D Richman
2
, and S Deeks
1
1
Univ of California, San Francisco, US,
2
Diego and JA San Diego Hlthcare Svstem, US,
3
Karolinska Inst,
Solna, Sweden, and
4
Blood Svstems Res Inst, San Francisco, CA, US
10:15 43 Characterization of Non-induced HIV-1 Proviruses
Dampens the Hope for HIV-1 Eradication

Ya-Chi Ho*
1
, L Shan
1
, J Wang
2
, N Hosmane
1
, J Blankson
1
,
and R Siliciano
1,3
1
Johns Hopkins Univ Sch of Med, Baltimore, MD, US,
2
Louisiana
State Univ Hlth Sci Ctr Sch of Med, New Orleans, US, and
3
Howard
Hughes Med Inst, Chevv Chase, MD, US
10:30 44 T Memory Stem Cells Are a Long-term Reservoir
for HIV-1

Maria Buzon*
1
, H Sun
1
, C Li
1
, E Martin-Gayo
1
, K Seiss
1
,
A Shaw
1
, E Rosenberg
2
, F Pareyra
1,3
, X Yu
1
, and M LichterIeld
2
1
Ragon Inst of MGH, MIT and Harvard, Boston, MA, US,
2
Massachusetts Gen Hosp, Boston, US, and
3
Brigham and Women`s
Hosp, Boston, MA, US
10:45 45 High Levels of CD2 Expression Identify HIV-1
Latently Infected Resting Memory CD4
+
T Cells
in Virally Suppressed Subjects
M Iglesias-Ussel
1
, C Vandergeeten
2
, L Marchionni
3
, N Chomont
2
,
and Fabio Romerio*
1
1
Inst of Human Jirologv, Baltimore, MD, US,
2
JGTI Florida, Port St
Lucie, US, and
3
Johns Hopkins Univ, Baltimore, MD, US
11:00 46 Study of Transitional Memory CD4
+
T Cells
and y T Cells as Latent Reservoirs for
Replication Competent HIV-1

Natalia Soriano-Sarabia*, N Archin, and D Margolis
Univ of North Carolina at Chapel Hill, US
11:15 47 Early ART Intervention Restricts the Seeding
of the HIV Reservoir in Long-lived Central
Memory CD4 T Cells
Jintanat Ananworanich*
1,2,3,4
, C Vandergeeten
5
, N Chomchey
1,2
,
N Phanuphak
1,2
, V Ngauy
6
, R-P Sekaly
5
, M Robb
7
, N Michael
7
,
J Kim
1,7
, N Chomont
5
1
SEARCH, Bangkok, Thailand,
2
The Thai Red Cross AIDS Res
Ctr, Bangkok,
3
4
Facultv of Med,
Chulalongkorn Univ, Bangkok, Thailand,
5
Jaccine and Gene
Therapv Inst, Port St Lucie, FL, US,
6
Armed Forces Res Inst of Med
Sci, Bangkok, Thailand, and
7
US Militarv HIJ Res Prgm, Silver
Spring, MD
11:30 48LB Functional HIV Cure after Very Early ART
of an Infected Infant
Deborah Persaud*
1
, H Gay
2
, C Ziemniak
1
, YH Chen
1
, M Piatak
3
,
T-W Chun
4
, M Strain
5
, D Richman
5
, and K Luzuriaga
6
1
2
Univ of
Mississippi Med Ctr, Jackson, US,
3
Frederick Natl Lab for Cancer
Res, MD,US,
4
NIAID, NIH, Bethesda, MD, US,
5
Univ of California
San Diego, La Jolla and JA San Diego Hlthcare Svstem, US, and
6
Univ of Massachusetts Med Sch, Worcester, US
11:45 49 Novel Approaches for the Assessment of the
%' 3%3& Residual Virus Pool and Viral Eradication
Strategies in SIV
+
Rhesus Macaques
Gregory Del Prete*
1
, X Wu
2
, C Trubey
1
, R Kiser
1
, V Coalter
1
,
J Smedley
3
, J Hesselgesser
4
, M Piatak
1
, R Geleziunas
4
, and J LiIson
1
1
AIDS and Cancer Jirus Prgm, SAIC-Frederick, Inc, Frederick
Natl Lab for Cancer Res, MD, US,
2
Advanced Tech Prgm, SAIC-
Frederick, Inc, Frederick Natl Lab for Cancer Res, MD, US,
3
Lab
Animal Sci Prgm, SAIC-Frederick, Inc, Frederick Natl Lab for
Cancer Res, MD, US, and
4
Gilead Sci, Foster Citv, CA, US
12:00 50LB The Safety and Effect of Multiple Doses of
Vorinostat on HIV Transcription in HIV
+

Patients Receiving cART
J Elliott
1,2,3
, A Solomon
2,3
, F Wightman
2,3
, M Smith
2,3
, S Palmer
4
,
M Prince
5
, J Watson
6
, J Hoy
1,2
, J McMahon
1
, and Sharon Lewin*
1,2,3
1
Alfred Hosp, Melbourne, Australia,
2
Monash Univ, Melbourne,
Australia,
3
Burnet Inst, Melbourne, Australia,
4
Karolinska Inst,
Stockholm, Sweden,
5
Peter MacCallum Cancer Ctr, Melbourne,
Australia, and
6
Natl Assoc of People Living with HIJ, Svdnev,
Australia
"
Monday, 1:30-2:30 pm; B402

"#$$%&' ((*45#6#7 8%$29$$%&'
(see Session 94 on Tuesdav for corresponding Poster Abstracts)
Simian Viral Reservoirs
Discussants:
Cristian Apetrei, Univ of Pittsburgh Ctr for Jaccine Res, PA, US
Mirko Paiardini, Yerkes Natl Primate Res Ctr, Emorv Univ, Atlanta, GA, US
482 Discovery of Novel and Highly Divergent SIV in Three
Wild Monkey Species in Kibale National Park, Uganda
William Switzer*
1
, M Lauck
2
, A Shankar
1
, D Hyeroba
3,4
, A Tumukunde
4
,
C Chapman
4,5,6
, N Ting
7
, T Friedrich
2,8
, D O`Connor
2,8
, and T Goldberg
2,4,6,8
1
2
Univ of Wisconsin-Madison, US,
3
Jane Goodall
Inst, Entebbe, Uganda,
4
Kibale EcoHlth Profect, Makerere Univ Bio Field
Station, Kanvawara, Uganda,
5
McGill Univ, Montreal, Canada,
6
Makerere
Univ, Kampala, Uganda,
7
Univ of Oregon, Eugene, US, and
8
Wisconsin
Natl Primate Res Ctr, Madison, US
483 Full-length Genome Analyses of Two Highly
Divergent SIV
mus
Strains Isolated in Mustached
Monkeys (:; 2#<59$) Hunted for Bushmeat in Gabon
Florian Liegeois*
1,2
, V Boue
1,2
, C Butel
1
, P Ngari
2
, F Mouacha
1
, B Mve
Ondo
2
, L Eric
2
, M Peeters
1
, and F Rouet
2
1
UMI 233, Inst de Recherche pour le Devt and Univ of Montpellier, France
and
2
Ctr Intl de Recherches Med de Franceville, Gabon
484 Gorillas in Southwest Cameroon Are the Reservoir
of HIV-1 Group P Ancestors

Mirela Dàrc*
1,2
, A Ayouba
1
, A Esteban
1
, L Etienne
1
, S Locatelli
1
,
A Aghokeng
1,3
, E Delaporte
1
, EM Ngole
3
, and M Peeters
1
1
UMI 233, IRD and Univ of Montpellier 1, France,
2
Univ Federal do Rio
de Janeiro, Bra:il, and
3
Profet PRESICA and IMPM/CREMER, Yaounde,
Cameroon
485 Non-Invasive Follow-up of SIV
cpz=11
Infection in Wild-
living Chimpanzees in Northeast Gabon

Vanina Boue*
1,2
, F Liegeois
1,2
, AP Okouga
2
, S Locatelli
1
, C Butel
1
,
P Ngari
2
, E Delaporte
1
, M Peeters
1
, and F Rouet
2
1
UMI 233, Inst de Recherche pour le Devt and Univ of Montpellier, France
and
2
486 Expanded Screening for Simian Foamy Virus in New
World Primates Identifies 2 Novel Simian Foamy
Virus in Tamarin and Uakari Monkeys from Brazil

Claudia Muniz*
1
, A Santos
1
, H Jia
2
, L Troncoso
1
, L Faria
1
, A Augusto
3
,
L Fedullo
3
, A Pissinatti
4
, M Soares
1,5
, and W Switzer
2
1
Univ Federal do Rio de Janeiro, Bra:il,
2
3
Fndn
Rio-Zoo, Rio de Janeiro, Bra:il,
4
Ctr de Primatologia do Rio de Janeiro,
Bra:il, and
5
Prgm de Oncovirologia, Inst Nacional de Cancer, Rio de
Janeiro, Bra:il
487 Co-infection of Wild African Primates with SIV and
Simian Hemorrhagic Fever Viruses
Tony Goldberg*
1,2,3
, M Lauck
2
, W Switzer
4
, D Hyeroba
3
, A Tumukunde
3
,
J Kuhn
5
, C Chapman
6
, N Ting
7
, T Friedrich
1,2
, and D O`Connor
1,2
1
2
Wisconsin Natl Primate Res Ctr,
Madison, US,
3
Kibale EcoHlth Profect, Makerere Univ Bio Field Station,
Kanvawara, Uganda,
4
5
IRF-Frederick, NIH, Fort
Detrick, MD, US,
6
Sch of Environment, McGill Univ, Montreal, Canada,
and
7
Univ of Oregon, Eugene, US
"
Monday, 1:30-2:30 pm; B406

"#$$%&' (>*45#6#7 8%$29$$%&' ? "2%#'1%@%2 +3#,3%#A
(see Session 179 on Wednesdav for corresponding Poster Abstracts)
Tenofovir in Children
Discussants:
Peter Havens, Med Coll of Wisconsin, Childrens Hosp of Wisconsin,
Childrens Res Inst, Milwaukee, US
Cristina HoIer, Federal Univ of Rio de Janeiro, Bra:il
971
Tenofovir Disoproxil Fumarate Use in
Children and Youth
Peter Havens*
1
and R Hazra
2
1
Med Coll of Wisconsin, Children`s Hosp of Wisconsin,
Children`s Res Inst, Milwaukee, US and
2
Natl Inst of Child Hlth
and Human Devt, NIH, Bethesda, MD, US
972 48-Week Safety of Tenofovir when Administered
According to Weight-band Dosing in HIV
+
Children
15 kg as Part of a Once-daily HAART Regimen
L Aurpibul
1
, T Narkbunnam
2
, Virat Sirisanthana*
1
, O Wittawatmongkol
2
,
W Phongsamart
2
, T Sudjaritruk
1
, T Cressey
1,3,4
, and K Chokephaibulkit
2
1
2
Mahidol Univ, Bangkok, Thailand,
3
Harvard
Sch of Publ Hlth, Boston, MA, US, and
4
Inst de Recherche pour le Devt,
Marseille, France
M
o
n
d
a
y
M
a
r
c
h

4
O
r
a
l

S
e
s
s
i
o
n
s
Session 12 CROI 2013
973 Pharmacokinetics of Tenofovir in Thai Adolescents
Using Ritonavir-boosted Protease Inhibitor-based
Regimens
Wasana Prasitsuebsai*
1
, S Kerr
1,2
, N Thammajaruk
1
, A Colbers
3
,
S Keadpudsa
1
, T Chuanjaroen
1
, M Gorowara
1
, D Burger
3
, A Sohn
4
,
and J Ananworanich
1,5
1
HIJ-NAT Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok,
2
Kirbv Inst, Univ of New South Wales, Svdnev, Australia,
3
Radboud Univ
Nifmegen Med Ctr, The Netherlands,
4
TREAT Asia/amfAR-Fndn for AIDS
Res, Bangkok, Thailand, and
5
SEARCH, Thai Red Cross AIDS Res Ctr,
Bangkok
!
Monday, 1:30-2:30 pm; B308

"#$$%&' ()*+,#-#. /%$01$$%&' 2 "0%#'3%4%0 56#76%#8
New Approaches to ARV Drug Delivery
Discussants:
Marta BoIIito, Chelsea and Westminster Hosp, London, UK
Kimberly Struble, FDA, Silver Spring, MD, US
511
Challenges and Opportunities for the
Development of Long-acting ARVs
Marta BoIfto
Chelsea and Westminster Hosp, London, UK
512a Improved Biodistribution, Pharmacokinetics, and
ARV Responses for Folate-targeted Nanoformulated
ART

Pavan Puligujja*, H Gendelman, L Kendrick, N Smith, S Balkundi,
U Roy, R Veerubhotla, J McMillan, and X Liu
Univ of Nebraska Med Ctr, Omaha, US
512b Development of Small Magnetite ARV Nanoparticles
for Targeted Drug Delivery to Viral Reservoirs

Dongwei Guo*, T Li, J McMillan, M Boska, X Liu, and H Gendelman
513 Enhanced Pharmacological Properties of Efavirenz
Formulated as Solid Drug Nanoparticles
P Martin
1
,

Neill Liptrott*
1
, T McDonald
1
, M Giardiello
1
, P Roberts
1
,
P Curley
1
, D Smith
2
, M Siccardi
1
, S Rannard
1
, and A Owen
1
1
Univ of Liverpool, UK and
2
Univ of Northumbria, Newcastle Upon Tvne, UK
Concluding Comments: The Regulatory Pathway for
Development of Long-acting ARVs
Kimberly Struble FDA, Silver Spring, MD, US
!
Monday, 1:30-2:30 pm; B313

"#$$%&' (9*+,#-#. /%$01$$%&'
Implementation and Cost-effectiveness of Male
Circumcision
Discussants:
Connie Celum, Univ of Washington, Seattle, US
Kenneth Freedberg, Massachusetts Gen Hosp, Boston, US (invited)
1007 Shang Ring vs Forceps-guided Adult Male Circumcision,
a Randomized Controlled Effectiveness Study: Western
Uganda
Samuel Kanyago*
1,2
, D Riding
1,3
, E Mutakooha
1
, A Lopez
1
, and M Siedner
4
1
Mbarara Univ of Sci and Tech, Uganda,
2
Good Shepherd Hosp, Siteki,
Swa:iland,
3
Northwest Deanerv, Manchester, UK, and
4
Massachusetts Gen
Hosp Ctr for Global Hlth, Boston, US
1008 Factors Associated with Voluntary Medical Male
Circumcision Adverse Events: Nyanza Province, Kenya
Kipruto Chesang*
1
, Z Mwandi
1
, S Mwalili
1
, P Cherutich
2
, A Ochieng
2
,
P Oyaro
3
, G Otieno
4
, K Serrem
5
, D Odera
6
, and A Kim
1
1
CDC, Ctr for Global Hlth, Nairobi, Kenva,
2
Natl AIDS and STD Control
Prgm, Kenva Ministrv of Publ Hlth and Sanitation, Nairobi,
3
Kenva Med
Res Inst, Nairobi,
4
Nvan:a Reproductive Hlth Societv, Kisumu, Kenva,
5
Catholic Med Mission Board, Nairobi, Kenva, and
6
Impact Res and Devt
Org, Kisumu, Kenva
1009 Male Circumcision Coverage by Risk Profiles:
Rakai, Uganda
Xiangrong Kong*
1
, A Ndyanabo
2
, G Kigozi
2
, F Nalugoda
2
, D Serwadda
3
,
M Wawer
1
, R Gray
1
, and Rakai Hlth Sci Prgm
1
Johns Hopkins Univ, Baltimore, MD, US,
2
Rakai Hlth Sci Prgm, Kalisi:o,
Uganda, and
3
Makerere Univ, Kampala, Uganda
1010 Costs and Effectiveness of Male Circumcision
Scale-up for the Prevention of HIV and Other
Sexually Transmitted Infections: Sub-Saharan Africa

Seema Kacker*
1
, K Frick
2
, T Quinn
1,3
, R Gray
2
, and A Tobian
1
1
2
Johns Hopkins
Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US, and
3
NIAID, NIH,
Bethesda, MD, US
1011 Uptake of Neonatal Male Circumcision as Part of HIV
Prevention Efforts in Botswana: Maternal Motivators
and Barriers
Rebeca Plank*
1,2,3
, K Wirth
2,3
, N Ndubuka
3
, P Kebaabetswe
4
, C Lesetedi
5
,
J Makhema
3
, D Halperin
6
, R Shapiro
2,3,7
, M Mmalane
3
, and S Lockman
1,2,3
1
Brigham and Women`s Hosp,
2
Harvard Sch of Publ Hlth,
3
Botswana-
Harvard Partnership,
4
Univ of Botswana, Sch of Med,
5
Botswana
Ministrv of Hlth,
6
Univ of North Carolina at Chapel Hill, and
7
Beth Israel
Deaconess Med Ctr
!
Monday, 1:30-2:30 pm; Ballroom 3-4

"#$$%&' (:*+,#-#. /%$01$$%&'
What Is Latency and What Can We Do about It?
Discussants:
Mary Kearney, Ctr for Cancer Res, NCI, NIH, Frederick, MD, US
Robert Siliciano, Johns Hopkins Univ Sch of Med, Baltimore, MD, US
371 Only a Small Fraction of HIV-1 Proviruses in Resting
CD4
+
T Cells Can Be Induced to Produce Virions
#; 6%6& with Anti-CD3/CD28 or Vorinostat

Anthony Cillo*
1
, M Sobolewski
1
, J CoIIin
2
, and J Mellors
1
1
Univ of Pittsburgh, PA, US and
2
Tufts Univ, Boston, MA, US
372 A Comparison of Methods Used to Measure Rectal
HIV Levels Suggests that HIV DNA Resides in Cells
Other than CD4
+
T Cells, Including CD45
+
CD13
+
Cells
Steven Yukl*
1,2
, H Hatano
2,3
, L Epling
2,3
, P Hunt
2,3
, P Li
1,2
, D Havlir
2,3
,
M Somsouk
2,3
, E Sinclair
2,3
, S Deeks
2,3
, J Wong
1,2
, and DARE
1
San Francisco JAMC, CA, US,
2
and
3
San Francisco Gen Hosp, CA, US
373 Integrated HIV DNA and Associated Histiocyte
Marker mRNA in Autopsy Samples of Non-lymphoid
Tissue Including the Central Nervous System
Benjamin Gelman*
1
, T Chen
1
, J Lisinicchia
1
, and A Rice
2
1
Univ of Texas Med Branch, Galveston, US and
2
Bavlor Coll of Med,
Houston, TX, US
374 HIV Preferentially Infects Hematopoietic Progenitor
Cells with High CD4 and Can Be Found in CD133
+

Hematopoietic Progenitor Cells in a Subset of
Optimally Treated People with Long-term Viral
Suppression

Lucy McNamara*, N Sebastian, A OnaIuwa-Nuga, J Riddell,
D Bixby, and K Collins
Univ of Michigan, Ann Arbor, US
375 Differences in Integration Site Distributions for
Latent and Expressed HIV-1 Proviruses

Scott Sherrill-Mix*, K Ocwieja, N Malani, U O`Doherty,
and F Bushman
376 Histone Deacetylase Inhibitor Romidepsin Induces
HIV in CD4
+
T Cells from ART-suppressed Subjects
at Concentrations Achieved by Clinical Dosing
George Wei*
1
, V Chiang
1
, E Fyne
2
, M Balakrishnan
1
, G Stepan
1
, A Tsai
1
,
J Lalezari
3
, J Mellors
2
, R Geleziunas
1
, and T Cihlar
1
1
Gilead Sci Inc, Foster Citv, CA, US,
2
Univ of Pittsburgh Sch of Med, PA,
US, and
3
Quest Clin Res, San Francisco, CA, US
Program 7
M
o
n
d
a
y
M
a
r
c
h

4
O
r
a
l

S
e
s
s
i
o
n
s
!
Monday, 1:30-2:30 pm; Ballroom 1-2

"#$$%&' ()*+,#-#. /%$01$$%&'
Statin Use and HIV: How Sweet Is It?
Discussants:
Steven Grinspoon, Massachusetts Gen Hosp, Boston, US
Priscilla Hsue, Univ of California, San Francisco, US
764 Statin Therapy and Mortality in HIV
+
Individuals:
A Danish Nationwide Population-based Cohort Study

Line Rasmussen*
1
, G Kronborg
2
, C Larsen
3
, C Pedersen
1
, J GerstoIt
4
,
and N Obel
4
1
Odense Univ Hosp, Denmark,
2
Copenhagen Univ Hosp, Hvidovre,
Denmark,
3
Aarhus Univ Hosp, Skefbv, Denmark, and
4
Copenhagen Univ
Hosp, Rigshospitalet, Denmark
765 Impact of Statin Exposure on Mortality and
Non-AIDS Complications in HIV Patients on HAART
Henning Drechsler*
1,2
, S Zhang
2
, N MaalouI
2
, J Cutrell
2
, P Tebas
3
,
and R Bedimo
1,2
1
JA North Texas Hlth Care Svstem, Dallas, US,
2
Univ of Texas Southwestern
Med Ctr, Dallas, US, and
3
766 Association between Statin Use and Type-2 Diabetes
Mellitus Occurrence among HIV-1
+
Patients
Receiving ART

Vincenzo Spagnuolo*
1
, L Galli
1
, A Poli
1
, S Salpietro
1
, N Gianotti
1
,
P Piatti
1
, C Vinci
1
, E Carini
1
, A Lazzarin
1,2
, and A Castagna
1
1
San Raffaele Sci Inst, Milan, Italv and
2
Univ Jita-Salute San Raffaele,
Milan, Italv
767 Statin Use Is Associated with Incident Diabetes
Mellitus among Patients in the HIV Outpatient
Study
Kenneth Lichtenstein*
1
, R Debes
2
, K Wood
2
, S Bozzette
2,3
, K Buchacz
4
,
J Brooks
4
, and HIV Outpatient Study Investigators
1
Natl Jewish Hlth, Denver, CO, US,
2
Cerner Corp, Kansas Citv, MO, US,
3
Univ of California, San Diego, US, and
4
"
Monday, 2:30-4 pm; Hall B2
2&$3#4 56$34703$
(see full session listings starting on page 24)
Session 53. HIV Persistence, Reservoirs, and Viremic Control
Session 55. Envelope/Entry/Tropism/Transmission
Session 58. AssemblyPutting It All Together
Session 59. Restriction Factors: Old and New
Session 64. HIV Compartments
Session 67. HIV InIection Models
Session 71. Immune Restoration
Session 73. Immune Activation/Function in HIV InIection
Session 74. Immune Activation, T Cell Homeostasis, and Therapy
Session 75. Mucosal Factors in HIV Transmission and InIection
Session 77. HIV Compartmentalization and Evolution on Therapy
Session 84. Progressive MultiIocal Leukoencephalopathy and Other
Central Nervous System InIections
Session 85. Central Nervous System Penetration, ART IntensiIication,
and Cerebrospinal Fluid Escape
Session 86. ART, Neurocognitive Outcomes, and New Central Nervous
System-targeted Therapies
Session 87. Central Nervous System Viral Evolution and
Compartmentalization
Session 95. Mining Sequence Data to Understand Transmission and
Disease
Session 96. Transmission Clusters
Session 98. Within-patient Diversity Compartmentalization, Dual
InIection, and Recombination
Session 100. ARV Pharmacogenetics: Metabolism, Drug Interactions,
and Response
Session 101. ARV Drug Exposure, SaIety, and EIIicacy
Session 105. New ARV Agents
Session 106. Randomized Trials oI ART: A Potpourri
Session 118. Hepatic Injury and Fibrosis
Session 119. Laboratory Assessment and Imaging oI Hepatic Injury
Session 120. Hepatitis E Virus
Session 121. Hepatitis B Virus
Session 128. HIV-associated Malignancies: Miscellaneous
Session 130. Cardiovascular Disease: Predicting Risk and Monitoring
Outcomes
Session 131. Endothelial DysIunction in HIV InIection
Session 132. Vascular Imaging and Subclinical Atherosclerosis
Session 141. Diabetes, Metabolic Syndrome, and Vitamin D DeIiciency
Session 143. Bone Loss: Risk Factors and Pathogenesis
Session 144. ART and Bone Disease
Session 150. Cryptococcal InIections
Session 151. Herpes Zoster
Session 152. CytomegalovirusHost Pathogen Interactions
Session 153. Syphilis: Not Gone, Not Forgotten
Session 154. Opportunistic InIections and Other Novel Pathogens
Session 155. Vaccines: TB, Pneumococcus, and InIluenza
Session 156. HIV Shedding and Impact oI InIection on Immune Cells in
Women
Session 161. HIV Testing and ARV Drug Resistance during Pregnancy
Session 162. ART, Viral Suppression, and MTCT
Session 170. Incidence and Prevention oI PMTCT-associated Drug
Resistance
Session 171. New HIV InIections among Children in the US
Session 172. ART Initiation and Immune Reconstitution InIlammatory
Syndrome among InIants and Children
Session 173. ART Strategies and Outcomes among Children
Session 174. Cost and Cost-eIIectiveness oI ART and Monitoring
Strategies in Children
Session 178. Characteristics oI Youth with HIV
Session 180. ARV Pharmacokinetics in Children
Session 183. Preclinical Studies oI Topical ARV Ior Prevention
Session 187. Voluntary Medical Male Circumcision
Session 190. The Cascade oI Care
Session 191. Engagement and Retention in Care
Session 197. PerIormance and Innovation in ART Programs in RLS
M
o
n
d
a
y
M
a
r
c
h

4
O
r
a
l

S
e
s
s
i
o
n
s
!
Monday, 4-6 pm; B406

"#$$%&' ()*"+,-&$%.,
Is Something Bugging You?
Conveners:
Giulia Marchetti, San Paolo Hosp,
Univ of Milan, Italv
John Zaunders, St Jincents Hosp,
Svdnev, Australia
51
The Human Microbiome in Health and
Immunodeficient States
Frederic Bushman*, G Wu, J Lewis, H Li, K Bittinger,
E Charlson, C HoIImann, and R Collman
Univ of Pennsvlvania Perleman Sch of Med, Philadelphia, US
52
HIV and SIV Pathogenesis at the Interface of
Gut Mucosal Immune Defense and Microbiota
I Grishina, L Hirao, L Nagy, S Sankaran, A Baumler, M Marco,
H Cheng, and Satya Dandekar*
Univ of California, Davis, US
53
Treating Microbial Translocation in
Progressive HIV/SIV Infections
N Klatt
1
, Z Klase
1
, M Quinones
2
, D Hazuda
3
, M Miller
4
, J Segre
5
,
J LiIson
6
, E Haddad
7
, J Estes
6
, and Jason Brenchley*
1
1
Prgm in Barrier Immunitv and Repair, NIAID, NIH, Bethesda,
MD, US,
2
Bioinformatics and Computational Biosci Branch
OCICB, OSMO, OD, NIAID, NIH, Bethesda, MD, US,
3
Merck
Res Labs, West Point, PA, US,
4
Gilead Sci, Inc., Foster Citv, CA,
US,
5
Genetics and Molecular Microbio Branch, NHGRI, NIH,
Bethesda, MD, US,
6
ACJP, SAIC-Frederick, Inc, Frederick Natl
Lab for Cancer Res, MD, US, and
7
Jaccine and Gene Therapv
Inst-Florida, Port St Lucie, US
54
The Enteric Virome in AIDS
S Handley
1
, L Thackray
1
, G Zhao
1
, R Presti
1
, J Brenchley
2
,
R Veazey
3
, T Stappenbeck
1
, D Wang
1
, D Barouch
4,5
,
and Herbert Virgin*
1
1
Washington Univ Sch of Med, St Louis, MO, US,
2
Lab of
Molecular Microbio, NIAID, NIH, Bethesda, MD, US,
3
Tulane
Natl Primate Res Ctr, Tulane Univ Sch of Med, Covington, LA,
US,
4
Ctr for Jirologv and Jaccine Res, Beth Israel Deaconess
Med Ctr, Boston, MA, US, and
5
Ragon Inst of MGH, MIT, and
Harvard Med Sch, Boston, MA, US
5:30-6 pm
Panel Discussion
interested in understanding the roles oI the microbiome and the
virome in the pathogenesis oI HIV inIection and AIDS. Recent
discoveries in these areas will be discussed. It is assumed that
participants are Iamiliar with the general concept oI microbiomes
and have some understanding oI the molecular mechanisms used
Ior its investigation. At the completion oI the session, participants
will be knowledgeable about the gut and lung microbiomes, the
alterations in the gut virome associated with lentiviral inIections,
and their inIluence in pathogenesis.
!
Monday, 4-6 pm; Ballroom 3-4

"#$$%&' (/*"+,-&$%.,
Preventing HIV/AIDS in the US: Can We Do Better?
Conveners:
Wayne DuIIus, CDC, Atlanta, GA, US
Monica Sweeney, New York Citv Dept
of Hlth, NY, US
55
Drivers of the HIV Epidemic in the Southern
US
Adaora Adimora
56
What Do Sexual Networks Tell Us about How
to Block Transmission?
Steven Goodreau
Univ of Washington, Seattle, US
57
How Should We Spend Our Prevention
Dollars?
Carlos del Rio
Emorv Univ Ctr for AIDS Res, Atlanta, GA, US
58
Addressing the Cascade of Care
Alan Greenberg
George Washington Univ and District of Columbia Devt Ctr for
AIDS Res, US
5:30-6 pm
Panel Discussion
interested in HIV prevention, treatment, and policy. It is assumed
participants are Iamiliar with basic knowledge oI HIV epidemiology
in the US, and HIV prevention and treatment modalities. At the
completion oI the session, participants will be knowledgeable about
which populations in the US are not being reached adequately,
Iactors that may be driving these Iailures to prevent HIV inIection
and diagnose and adequately treat HIV inIected persons, and some
proposed solutions Ior addressing the HIV/AIDS epidemic in the US.
Program 9
M
o
n
d
a
y
M
a
r
c
h

4
O
r
a
l

S
e
s
s
i
o
n
s
!
Monday, 4-6 pm; Ballroom 1-2

"#$$%&' ()*+,-. /0$1,-21$
Cardiovascular Disease and Other Non-AIDS
Events: Epidemiology and Pathogenesis
Moderators:
Matthew Freiberg, Ctr for Res on Hlth Care, Univ of Pittsburgh, PA, US
Peter Reiss, Academic Med Ctr, Univ of Amsterdam, The Netherlands
4:00 59 HIV
+
Adults Are at Greater Risk for Myocardial
Infarction, Non-AIDS Cancer, and End-stage
Renal Disease, but Events Occur at Similar Ages
Compared to HIV
-
Adults
Keri AlthoII*
1
, C Wyatt
2
, C Gibert
1
, KA Oursler
3
, D Rimland
4
,
M Rodriguez-Barradas
5
, K McGinnis
6
, M Skanderson
6
, K Gebo
7
,
A Justice
6
, Ior Veterans Aging Cohort Study
1
JAMC and George Washington Univ Med Ctr, Washington, DC,
US,
2
3
Univ of Marvland
and JA Marvland Hlth Care Svstem, Baltimore, US,
4
Atlanta JAMC
and Emorv Univ Sch of Med, GA, US,
5
Bavlor Coll of Med and
the Michael E DeBakev JAMC, Houston, TX, US,
6
Yale Univ and
the JA Connecticut Hlthcare Svstem, New Haven, US, and
7
Johns
Hopkins Univ, Baltimore, MD, US
4:15 60 Combined Effect of Interleukin-6 and D-dimer
on the Risk of Serious Non-AIDS Conditions:
Data from 3 Prospective Cohorts
Birgit Grund*
1
, J Baker
2
, S Deeks
3
, J WolIson
1
, D Wentworth
1
,
A Cozzi-Lepri
4
, C Cohen
5
, A Phillips
4
, J Lundgren
6
, J Neaton
1
,
and INSIGHT SMART/ESPRIT/SILCAAT Study Group
1
Univ of Minnesota, Minneapolis, US,
2
Hennepin Countv Med
Ctr, Minneapolis, MN, US,
3
San Francisco Gen Hosp and Univ of
California, San Francisco, US,
4
Univ Coll London, UK,
5
Univ of
California, San Francisco, US, and
6
Copenhagen Univ Hosp and
Univ of Copenhagen, Denmark
4:30 61 Increased Risk of Cardiovascular Disease with
Age in Men: A Comparison of D:A:D with HIV
-

Cardiovascular Disease Risk Equations
Kathy Petoumenos*
1
, W El-Sadr
2
, A dÀrminio MonIorte
3
,
C Sabin
4
, P Reiss
5
, L Ryom
6
, S De Wit
7
, M Rickenbach
8
, J Lundgren
6
,
M Law
1
, Ior D:A:D Study Group
1
The Kirbv Inst, Univ of New South Wales, Svdnev, Australia,
2
Intl
Ctr for AIDS Care and Treatment Prgms, Columbia Univ and
Harlem Hosp, New York, NY, US,
3
A:ienda Ospedaliera-Polo Univ
San Paolo, Milan, Italv,
4
5
ATHENA, HIJ
Monitoring Fndn, Academic Med Ctr, Amsterdam, The Netherlands,
6
Copenhagen HIJ Prgm, Univ of Copenhagen, Facultv of Hlth
and Med Sci, Denmark,
7
St-Pierre Cohort, CHU St-Pierre Hosp,
Brussels, Belgium, and
8
Inst for Social and Preventive Med, Univ of
Lausanne, Swit:erland
4:45 62 Age and Noncalcified Coronary Plaque
in the Multicenter AIDS Cohort Study
Wendy Post*
1,2
, L Jacobson
2
, X Li
2
, F Palella
3
, L Kingsley
4
,
M Witt
5
, T Brown
1
, M Plankey
6
, M BudoII
5
, and J Margolick
2
1
2
Johns
Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US,
3
Northwestern Univ, Chicago, IL, US,
4
Univ of Pittsburgh, PA, US,
5
Harbor UCLA, US, and
6
Georgetown Univ, Washington, DC, US
5:00 63 Increased Coronary Atherosclerotic Plaque
Vulnerability Features on Computed
Tomography Angiography among HIV
+

Subjects vs Matched HIV
-
Controls
M Zanni, J Lo, B Wai, B Shah, D Hark, E Marmarelis, S Abbara,
and Steven Grinspoon*
Massachusetts Gen Hosp, Boston, US
5:15 64 Elevated Numbers of CD163
+
Macrophages in
Hearts of SIV
+
Rhesus Macaques with Cardiac
Disease Are Decreased Using PA300

Joshua Walker*
1
, T Burdo
1
, A Miller
2
, K Misgin
1
, M Sulciner
1
,
M McGrath
3
, and K Williams
1
1
2
New England Primate
Res Ctr, Southborough, MA, US, and
3
Francisco, US
5:30 65 Comparison of Aspirin Use and Incident
Myocardial Infarction Rates in HIV
+
and HIV
-

Patients in a Large US Healthcare System

Sujit Suchindran*, S Regan, J Meigs, S Grinspoon, and V Triant
5:45 66LB Monocyte Activation, but Not T Cell Activation,
Predicts Progression of Coronary Artery
Calcium in a Contemporary HIV Cohort
Jason Baker*
1,2
, K Huppler Hullsiek
2
, A Singh
3
, E Wilson
3
,
K Henry
1,2
, P Patel
4
, J Brooks
4
, H Hodis
5
, M BudoII
6
, I Sereti
3
,
Ior CDC SUN Study Investigators
1
Hennepin Countv Med Ctr, Minneapolis, MN, US,
2
Univ of
Minnesota, Minneapolis, US,
3
4
Division of HIJ/AIDS Prevention, CDC, Atlanta, GA, US,
5
Univ of
Southern California Keck Sch of Med, Los Angeles, US, and
6
Los
Angeles Biomed Res Inst at Harbor-UCLA, CA, US
!
Monday, 4-6 pm; Hall B1

"#$$%&' 34*"567&$%86
New Frontiers in Hepatitis C Virus Treatment
Conveners:
Arthur Kim, Massachusetts Gen Hosp,
Boston, US
Susanna Naggie, Duke Univ Med Ctr,
Durham, NC, US
67
The Test and Treat Era of Hepatitis C:
Expanding the Individual and Public
Health Benefits of Hepatitis C Virus
Treatment
John Ward
68
Pathogenesis of Accelerated Hepatitis C
Virus Liver Disease Progression
Raymond Chung
69
Liver Transplant in HIV
+
Persons: Current
Prospects and Prospects for the New
Therapeutic Era
Norah Terrault
Univ of California, San Francisco, US
70
Cure without Interferon: The Scientific Basis
and Clinical Evidence
David Thomas
interested in the challenge oI hepatitis C virus (HCV) inIection.
It is assumed that participants are Iamiliar with basic principles
oI virology and clinical practice. At the completion oI the session,
participants will be knowledgeable about the burden oI HCV
inIection in the US, the principles oI testing Ior HCV inIection,
and how HIV accelerates the course oI disease. Participants are
also expected to appreciate upcoming treatments Ior HCV inIection
including the steps in the viral liIe cycle that they aIIect.
T
u
e
s
d
a
y
M
a
r
c
h

5
O
r
a
l

S
e
s
s
i
o
n
s
!
Tuesday, 8:30-9 am; Hall B1

"#$$%&' ()*+,#'-./
The Global MSM HIV Epidemic: Time to Act
71
Chris Beyrer
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore,
MD, US
Objectives: This session is directed to clinicians, epidemiologists,
and scientists interested in HIV among MSM, HIV prevention, and
stigma and discrimination. It is assumed that participants are Iamiliar
with both the epidemiology and risks Ior HIV inIection among
these men in the US and in developing countries. At the completion
oI the session, participants will be knowledgeable about why HIV
epidemics among gay, bisexual, and other MSM continue to expand
in 2013, and about what prevention and treatment approaches hold
promise Ior prevention and control.
"
Tuesday, 9-9:30 am; Hall B1

"#$$%&' ((*+,#'-./
Evolution of the HostVirus Interaction: A Guide to
the Development of Novel Therapeutics?
72
Jonathan Stoye
MRC-Natl Inst for Med Res, London, UK
interested in the interaction between inIecting retroviruses and
their targets. It is assumed that participants are Iamiliar with basic
aspects oI retrovirus replication. At the completion oI the session,
participants will be knowledgeable about the properties oI restriction
Iactors and ways in which this inIormation might be used to devise
novel therapeutic strategies.
#
Tuesday, 10 am-12 n; B406

"#$$%&' (0*1.-, 23$4.-54$
HIV/SIVHost Interaction
Moderators:
Eric Hunter, Yerkes Natl Primate Res Ctr, Emorv Univ, Atlanta, GA, US
George Shaw, Univ of Pennsvlvania, Philadelphia, US
10:00 73 Immunologic Profile Distinguishes Aviremic
HIV
+
Adults
Christina Ramirez Kitchen*
1
, P Hunt
2
, S Lee
2
, J Toyama
1
,
E Sinclair
2
, L Epling
2
, P Hsue
2
, F Hecht
2
, J Martin
2
, and S Deeks
2
1
Univ of California, Los Angeles, US and
2
Francisco, US
10:15 74 Persistent Abnormalities of Lymphoid
Structures in HIV Viremic Controllers
Joyce Sanchez*
1
, P Hunt
2
, J Jessurun
1
, M Rothenberger
1
, C Reilly
1
,
J Jasurda
1
, M Somsouk
2
, S Russ
1
, S Deeks
2
, and T Schacker
1
1
Univ of Minnesota, Minneapolis, US and
2
Francisco, US
10:30 75LB Prospective ART of Asymptomatic HIV
+
Controllers
Hiroyu Hatano*
1
, S Yukl
1,2
, A Ferre
3
, E Sinclair
1
, P Hunt
1
,
P Bacchetti
1
, M Busch
1,4
, B Shacklett
3
, J Wong
1,2
, and S Deeks
1
1
2
San Francisco JA Med Ctr,
CA, US,
3
Univ of California, Davis, US, and
4
Blood Svstems Res
Inst, San Francisco, CA, US
10:45 76 Effects of Interferon-u Treatment on Anti-HIV-1
Intrinsic Immunity %' 6%6&
M Abdel-Mohsen
1
, T Liegler
1
, J Guatelli
2
, M Salama
3
, H Ghanem
3
,
A Rauch
4
, B Ledergerber
5
, H Gunthard
5
, J Wong
1,6
, Satish Pillai*
1,6
,
and Swiss HIV Cohort Study
1
2
Univ of California, San Diego,
US,
3
Ain Shams Univ, Cairo, Egvpt,
4
Univ Hosp Berne, Swit:erland,
5
Univ Hosp Zurich, Swit:erland, and
6
JAMC, San Francisco, CA, US
11:00 77 Blockade of Type I Interferon during Acute SIV
Infection Results in Accelerated Progression to
AIDS and Death

Netanya Sandler*
1
, R Zhu
1
, J Estes
2
, E Boritz
1
, J LiIson
2
,
D Levin
3
, J Langer
4
, G Schreiber
3
, S Rao
1
, and D Douek
1
1
NIH, Bethesda, MD, US,
2
NIH, Frederick, MD, US,
3
Wei:mann
Inst of Sci, Rehovot, Israel, and
4
Univ of Med and Dentistrv of New
Jersev and Robert Wood Johnson Med Sch, Piscatawav, US
11:15 78 Experimental CD4 Depletion in SIV
+
Macaques
Results in Macrophage and Microglia Infection,
Rapid Turnover of Infected Cells, and Encephalitis
L Micci
1
, R Iriele
1
, X Alvarez-Hernandez
2
, C McGary
1
, C Derdeyn
1
,
J Estes
3
, M Davenport
4
, A Lackner
2
, G Silvestri
1
, and Mirko Paiardini*
1
1
Yerkes Natl Primate Res Ctr, Emorv Univ, Atlanta, GA, US,
2
Tulane Natl
Primate Res Ctr, Covington, LA, US,
3
AIDS Cancer Jirus Prgm, NCI-
Frederick, MD, US, and
4
Univ of New South Wales, Svdnev, Australia
11:30 79 7' 6%6& Evaluation of a Novel Variant of SIV
mac

Lacking CD4 Tropism

Adrienne Swanstrom*
1
, B Haggarty
1
, A Jordan
1
, G Leslie
1
,
X Alvarez-Hernandez
2
, C LaBranche
3
, D MonteIiori
3
, P Marx
2
,
A Lackner
2
, and J Hoxie
1
1
Univ of Pennsvlvania, Philadelphia, US,
2
Tulane Natl Primate Res
Ctr, Covington, LA, US, and
3
Duke Univ, Durham, NC, US
11:45 80 Neutralization-sensitive Env with Exposed
Co-receptor Binding Sites Dominate %' 6%6&
during SIV Infection of Macaques Depleted
of CD4
+
T Cells

Nicholas Francella*
1
, Y Yi
1
, B Li
2
, S Gwyn
1
, S Elliott
1
,
A Ortiz
2
, M Paiardini
2
, G Silvestri
2
, C Derdeyn
2
, and R Collman
1
1
Univ of Pennsvlvania Perelman Sch of Med, Philadelphia, US
and
2
Yerkes Natl Primate Ctr, Emorv Univ, Atlanta, GA, US
#
Tuesday, 10 am-12:15 pm; Ballroom 3-4

"#$$%&' (8*1.-, 23$4.-54$
MTCT and HIV Treatment in Children
Moderators:
Denise Jamieson, CDC, Atlanta, GA, US
Denis Tindyebwa, African Network for Care of Children Affected bv
AIDS, Kampala, Uganda
10:00 81 Birth Defects and ART in the French Perinatal
Cohort, a Prospective Exhaustive Study among
13,124 Live Births from 1994 to 2010
Jeanne Sibiude*
1
, L Mandelbrot
1,2,3
, S Blanche
4
, J Le Chenadec
3,5
,
N Boullag-Bonnet
3
, A Faye
2,6
, C DollIus
7
, R Tubiana
8
, B Khoshnood
9
,
J Warszawski
3,5,10
, and ANRS CO1/CO10/CO11
1
Hosp Louis Mourier, Colombes, France,
2
Univ Diderot Paris
7, Paris, France,
3
CESP, INSERM U1018, Le Kremlin-Bicetre,
France,
4
Hosp Necker, EA 3620, Univ Paris Descartes 5, Paris,
France,
5
INED, Paris, France,
6
Hosp Robert Debre, Paris, France,
7
Hosp Trousseau, Paris, France,
8
Hosp Pitie Salpetriere, INSERM
U943, Paris, France,
9
INSERM, UMR S953, Univ Paris-6, Paris,
France, and
10
Univ Paris Sud, Le Kremlin-Bicetre, France
10:15 82 Uptake and Retention in Malawis Option B+
PMTCT Program: Lifelong ART for All HIV
+

Pregnant or Lactating Women
Beth Tippett Barr*
1
, E Mhango
2
, L Tenthani
2,3
, G Zomba
2,3
,
S Makombe
2
, M Eliya
2
, D Midiani
2
, S Gupta
1
, F Chimbwandira
2
,
and A Jahn
2,3
1
CDC, Lilongwe, Malawi,
2
Ministrv of Hlth, Lilongwe, Malawi,
and
3
Intl Training and Ed Ctr for Hlth, Lilongwe, Malawi
10:30 83 Optimization of ART Initiation in Pregnancy
through Linkage of Services vs Integration of
ART into Antenatal Care
Landon Myer*
1
, V Manuelli
2
, E Abrams
3
, J McIntyre
1,4
, and L-G Bekker
1
1
Univ of Cape Town, South Africa,
2
Obstetrics, Gvnaecologv and
Reproductive Sci, Univ of California, San Francisco, US,
3
Intl
Ctr for AIDS Care and Treatment Prgm, Mailman Sch of Publ
Hlth, Columbia Univ, New York, NY, US, and
4
Anova Hlth Inst,
Johannesburg, South Africa
10:45 84LB Efficacy and Safety of 6 Months vs 6 Weeks
Nevirapine for Prevention of Postnatal HIV-1
Transmission 18 Month Follow-up:
HPTN 046 Trial
Mary Glenn Fowler*
1
, H Coovadia
2
, E Brown
3
, L Stranix-Chibanda
4
,
D Moodley
5
, R Kisenge
6
, P Richardson
1
, S Zwerski
7
, L MoIenson
8
, and
B Jackson
1
1
2
Maternal
Adolescent and Child Hlth, Univ of the Witwatersrand, South Africa,
3
Fred Hutchinson Cancer Res Ctr, Seattle, WA, US,
4
Univ of Zimbabwe
Coll of Med, Harare,
5
Ctr for the AIDS Prgm of Res in South Africa,
Nelson R Mandela Sch of Med, Univ of KwaZulu Natal, Durban,
6
Muhimbili Univ of Hlth and Allied Sci, Dar es Salaam, Tan:ania,
7
NIAID, NIH, Bethesda, MD, US, and
8
Eunice Kennedv Shriver Natl
Inst of Child Hlth and Human Devt, NIH, Rockville, MD, US
Program 11
T
u
e
s
d
a
y
M
a
r
c
h

5
O
r
a
l

S
e
s
s
i
o
n
s
11:00 85 Impact of Routine Laboratory Monitoring after
ART Initiation in 1206 HIV
+
African Children: The
5-Year Anti-Retroviral Research for Watoto Trial
Adeodata Kekitiinwa*
1
, A Cook
2
, K Nathoo
3
, P Mugyenyi
4
,
P Nahirya-Ntege
5
, M Bwakura-Dangarembizi
3
, P Munderi
5
,
P Musoke
6
, S Walker
2
, D Gibb
2
, and ARROW Trial Team
1
Bavlor-Uganda/Paediatric Infectious Diseases Clin, Mulago,
2
MRC
Clinical Trials Unit, London, UK,
3
Univ of Zimbabwe, Harare,
4
Joint
Clinical Res Ctr, Kampala, Uganda,
5
MRC/UJRI Uganda Res Unit
on AIDS, Entebbe, and
6
11:15 86 Randomized Comparison of Stopping vs
Continuing Cotrimoxazole Prophylaxis among
758 HIV
+
Children on Long-term ART:
The Anti-Retroviral Research for Watoto Trial
Mutsa Bwakura-Dangarembizi*
1
, L Kendall
2
, S Bakeera-Kitaka
3
,
P Nahirya-Ntege
4
, R Keishanyu
5
, A Kekitiinwa
3
, E Natukunda
5
,
S Walker
2
, D Gibb
2
, A Prendergast
2
, and ARROW Study Group
1
2
MRC Clinical Trials Unit, London,
UK,
3
Bavlor-Uganda, Paediatric Infectious Diseases Clin, Mulago
Hosp, Kampala,
4
MRC/Uganda Res Unit on AIDS, Uganda Jirus
Res Inst, Entebbe, and
5
Joint Clinical Res Ctr, Kampala, Uganda
11:30 87 Selection of ARV Regimen Impacts Antimalarial
Pharmacokinetics and Treatment Outcomes in
HIV-Malaria Co-infected Children in Uganda
Norah Mwebaza*
1
, R Kajubi
1
, J Ssebuliba
1
, S Kiconco
1
, L Huang
2
,
Q Gao
2
, A Kakuru
1
, J Achan
1
, F Aweeka
2
, and S Parikh
2,3
1
Makerere Univ, Kampala, Uganda,
2
Univ of California, San Francisco,
US, and
3
Yale Univ Sch of Publ Hlth and Med, New Haven, CT, US
11:45 88LB Comparison of Virologic and Immunologic
Outcomes between HIV
+
Ugandan Children
Randomized to Ritonavir-boosted Lopinavir
or NNRTI-based ART
Theodore Ruel*
1
, A Kakuru
2
, G Ikilezi
2
, F Mwangwa
2
, G Dorsey
1
,
P Rosenthal
1
, E Charlebois
1
, D Havlir
1
, M Kamya
3
, and J Achan
3
1
2
Infectious Diseases Res
Collaboration, Kampala, and
3
12:00 89LB A Novel Innate HIV-1 Neutralizing Protein
Isolated from Breast Milk
G Fouda, F Jaeger, J Amos, C Ho, K Anasti, T Ohashi, A Moseley,
H Erickson, M Alam, and Sallie Permar*
Duke Univ Med Ctr
!
Tuesday, 10 am-12 n; Ballroom 1-2

"#$$%&' ()*+,-. /0$1,-21$
North and South: Epidemiology and Engagement in
Care
Moderators:
GottIried Hirnschall, WHO, Geneva, Swit:erland
Manya Mangus, George Washington Univ, Washington, DC, US (invited)
10:00 90 HIV Prevalence and Awareness of Infection in
2008 and 2011 among MSM: 20 US Cities
Cyprian Wejnert*, B Le, J Zhu, T Finlayson, A Oster, A Smith,
G Paz-Bailey, Ior NHBS Study Group
10:15 91 Age and Racial Disparities in Per-contact Risk
of HIV Seroconversion among MSM: US

Hyman Scott*
1,2
, E VittinghoII
1
, and S Buchbinder
21
Univ of California, San Francisco, US and
2
San Francisco Dept of
Publ Hlth, CA, US
10:30 92 Determinants of Mortality and Loss to Follow-up
among Adult Patients in Pre-ART Care and on
ART: Rwanda

Chloe Teasdale*
1
, V Mugisha
1
, C Wang
1
,
H Nuwagaba-Biribonwoha
1
, E Tayebwa
1
, E Ingabire
1
, P Ingabire
2
,
M Lahuerta
1
, R Sahabo
1
, and E Abrams
1
1
Intl Ctr for AIDS Care and Treatment Prgms, Columbia Univ,
Mailman Sch of Publ Hlth, New York, NY, US and
2
Rwanda Ministrv
of Hlth, Kigali
10:45 93 ART Initiation Substantially Improves Retention
among Patients Enrolling in Care: Lusaka, Zambia
M Li
1,2
, Brad GuIIey*
1,3
, P Musonda
1,4
, I Sikazwe
5
, A Mwango
5
,
B Chi
1,2
, and J Stringer
1,2
1
Ctr for Infectious Disease Res in Zambia, Lusaka,
2
Univ of North
Carolina at Chapel Hill, US,
3
Univ of Alabama at Birmingham, US,
4
Univ
of East Anglia, Norwich, UK, and
5
Zambian Ministrv of Hlth, Lusaka
11:00 94 CD4 Count and Late Enrollment into HIV Care:
Comparison between 2006 and 2011 in 4
Sub-Saharan African Countries
Susie HoIIman*
1,2
, Y Wu
3
, W El-Sadr
1,3
, M Lahuerta
3
,
H Nuwagaba-Biribonwoha
3
, V Mugisha
3
, M Hawken
3
, E Chuva
4
,
D Nash
1,2,5
, B Elul
3
, and LSTART Team and IdentiIying Optimal
Models oI HIV Care Collaboration
1
HIJ Ctr for Clinical and Behavioral Studies at New York State
Psvchiatric Inst and Columbia Univ, New York, US,
2
Mailman Sch
of Publ Hlth, Columbia Univ, New York, NY, US,
3
Intl Ctr for AIDS
Care and Treatment Prgms, Columbia Univ, Mailman Sch of Publ
Hlth, New York, NY, US,
4
Ministrv of Hlth, Maputo, Mo:ambique,
and
5
CUNY Sch of Publ Hlth at Hunter Coll, New York, US
11:15 95LB Home Assessment and Initiation of ART following
HIV Self-Testing: A Cluster-Randomized Trial
to Improve Linkage to ART in Blantyre, Malawi
Peter MacPherson*
1,2
, D Lalloo
1
, A Choko
3
, J van Oosterhout
2
,
D Thindwa
3
, E Webb
4
, B Squire
1
, S Makombe
5
, R Hayes
4
, and E Corbett
3,4
1
Liverpool Sch of Tropical Med, UK,
2
Coll of Med, Univ of Malawi,
Blantvre,
3
Malawi-Liverpool-Wellcome Trust Clin Res Prgm,
Blantvre,
4
London Sch of Hvgiene and Tropical Med, UK, and
5
HIJ
Dept, Ministrv of Hlth, Lilongwe, Malawi
11:30 96 Population HIV Viral Load Estimate in Swaziland:
Assessing ART Program Effectiveness and
Transmission Potential
Jessica Justman*
1
, T Ellman
2
, D Donnell
3
, Y Duong
4
, J Reed
5
,
G Bicego
4
, P Ehrenkranz
6
, L Wang
3
, N Bock
4
, and R Nkambule
7
1
Intl Ctr for AIDS Care and Treatment Prgms, Columbia Univ,
Mailman Sch of Publ Hlth, New York, NY, US,
2
Columbia Univ Med
Ctr, New York, NY, US,
3
Fred Hutchinson Cancer Res Ctr, Seattle, WA,
US,
4
5
State Dept, Washington, DC, US,
6
CDC,
Mbabane, Swa:iland, and
7
Ministrv of Hlth, Mbabane, Swa:iland
11:45 97 Molecular Characterization of the Source of New
Infections in a High-risk Population in Uganda:
Implications for Test and Treat as Prevention
Chris Parry*
1
, J Levin
1
, J Nazziwa
1
, G Asiki
1
, J Mpendo
2
, H Njai
1
,
J Seeley
1
, A Kamali
1
, L Nieslen
3
, and PK Kaleebu
1
1
MRC/UJRI Research Unit on AIDS, Entebbe,
2
UJRI-IAJI HIJ
Jaccine Prgm, Entebbe, and
3
IAJI, Entebbe, Uganda
!
Tuesday, 10 am-12:15 pm; Hall B1

"#$$%&' (3*+,-. /0$1,-21$
ART: New Agents and New Insights
Moderators:
Roger Paredes, IrsiCaixa Inst for AIDS Res, Badalona, Catalonia, Spain
Raymond Schinazi, Emorv Univ and JAMC, Atlanta, GA, US
10:00 98 Role of APOBEC3G in the Emergence of M184I
%' 4%4&
W Shao
1
, E Wilson
2
, S Hill
2
, J Spindler
2
, R Dewar
1
, C Rehm
3
,
M Sneller
3
, M Kearney
2
, J CoIIin
4
, and Frank Maldarelli*
2
1
SAIC-Frederick, NCI-Frederick, MD, US,
2
NCI, Frederick Natl
Lab for Cancer Res, MD, US,
3
and
4
10:15 99LB Comparative Study of Tenofovir Alafenamide
vs Tenofovir Disoproxil Fumarate, Each with
Elvitegravir, Cobicistat, and Emtricitabine,
for HIV Treatment
Andrew Zolopa*
1
, R Ortiz
2
, P Sax
3
, I Brar
4
, R Elion
5
, H Wang
6
,
C Callebaut
6
, S Ramanathan
6
, M Fordyce
6
, and S McCallister
6
1
Stanford Univ, Palo Alto, CA, US,
2
Orlando Imm Ctr, FL, US,
3
Brigham and Women`s Hosp, Harvard Med Sch, Boston MA, US,
4
Henrv Ford Hosp, Detroit, MI, US,
5
George Washington Univ
Hosp, Washington, DC, US, and
6
10:30 100 Safety and Antiviral Activity of MK-1439, a
Novel NNRTI, in Treatment-nave HIV
+
Patients
Matt Anderson*
1
, J Gilmartin
1
, M Robberechts
1
, I De Lepeleire
1
,
E Tetteh
1
, Y Guo
1
, D Schurman
2
, F Wagner
3
, J Wagner
1
,
and J Butterton
1
1
Merck Sharp & Dohme, Corp, Whitehouse Station, NJ, US,
2
Charite
Universitatsmedi:in, Berlin, Germanv, and
3
Charite Res Org,
Berlin, Germanv
10:45 101 Mechanism by which K103N in HIV-1 Reverse
Transcriptase Confers Efavirenz Resistance
Revealed by Single-molecule Fluorescence
Spectroscopy

Grant Schauer*, N Sluis-Cremer, and S Leuba
Univ of Pittsburgh Sch of Med, PA, US
T
u
e
s
d
a
y
M
a
r
c
h

5
O
r
a
l

S
e
s
s
i
o
n
s
11:00 102 The E138A Mutation in HIV-1 Reverse
Transcriptase Is More Common in Subtype C
than B and Decreases Susceptibility to NNRTI
Nicolas Sluis-Cremer*
1
, K Huber
1
, C Brumme
2
, C Wallis
3
,
J Mellors
1
, and R Harrigan
2
1
Univ of Pittsburgh Sch of Med, PA, US,
2
BC Ctr for Excellence in
HIJ/AIDS, Jancouver, Canada, and
3
Lancet, Johannesburg, South
Africa
11:15 103 Non-Catalytic Site Integrase Inhibitors Target
the Integrase Domain during Virus Production
and Induce a Reverse Transcription Block
Stephen Yant*, L Tsai, C O`Sullivan, T Cihlar, and M Balakrishnan
11:30 104 Viral Particles Produced in Presence of LEDGIN
Are Impaired for Infectivity
B Desimmie
1
, Frauke Christ*
1
, W Thys
1
, J Demeulemeester
1
,
D Borrenberghs
1
, R Schrijvers
1
, J HoIkens
1
, N Bannert
2
, and Z Debyser
1
1
Katholieke Univ Leuven, Belgium and
2
Robert Koch Inst, Berlin,
Germanv
11:45 105 Potent Antiviral Activity of 2nd Generation
Maturation Inhibitors Against Bevirimat-resistant
Polymorphic HIV-1 Isolates
E Urano
1
, S Ablan
1
, D Martin
2
, T Nitz
2
, E Freed
1
, and Carl Wild*
2
1
NCI-Frederick, MD, US and
2
DFH Pharma, Inc, Gaithersburg, MD, US
12:00 106LB Week-24 Primary Analysis of Cenicriviroc
vs Efavirenz, in Combination with
Emtricitabine/Tenofovir, in Treatment-nave
HIV-1
+
Adults with CCR5-tropic Virus
Joseph Gathe*
1
, J Cade
2
, E DeJesus
3
, J Feinberg
4
, J Lalezari
5
,
J Morales-Ramirez
6
, A Scarsella
7
, M Saag
8
, M Thompson
9
,
and E LeIebvre
10
1
Therapeutic Concepts, Houston, TX, US,
2
Nevada AIDS Res Ed
Societv, Las Jegas, US,
3
Orlando Immunologv Ctr, FL, US,
4
Univ
of Cincinnati, OH, US,
5
Quest Clin Res, San Francisco, CA, US,
6
Clin Res PR, Inc, San Juan, Puerto Rico,
7
Pacific Oaks Med Group,
Beverlv Hills, CA, US,
8
9
AIDS
Res Consortium of Atlanta, GA, US, and
10
Tobira Therapeutics, Inc,
San Francisco, CA, US
!
Tuesday, 1:30-2:30 pm; B402

"#$$%&' ()*+,#-#. /%$01$$%&'
(see Session 95 on Mondav for corresponding Poster Abstracts)
Mining Sequence Data to Understand
Transmission and Disease
Discussants:
Chanson Brumme, BC Ctr for Excellence in HIJ/AIDS, Jancouver,
Canada
Jacques Fellay, Fed Inst of Tech, Lausanne, Swit:erland
488 The Global Transmission Network of HIV-1

Joel Wertheim*
1
, A Leigh Brown
2
, L Hepler
1
, S Mehta
1
, D Richman
1,3
,
D Smith
1,3
, and S Kosakovsky Pond
1
1
2
Univ of Edinburgh, UK, and
3
JA San
Diego Hlthcare Svstem, CA, US
489 Frequent HIV Introductions into Communities
Sustain Local Epidemics in Rural Rakai, Uganda

Mary Grabowski*
1
, J Lessler
1
, A Redd
2
, O Laeyendecker
2,3
,
J Kagaayi
4
, T Lutalo
4
, M Wawer
1,4
, D Serwadda
4,5
, T Quinn
2,3
, R Gray
1,4
,
and Rakai Hlth Sci Prgm
1
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US,
2
Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US,
3
Johns
Hopkins Univ Sch of Med, Baltimore, MD, US,
4
Rakai Hlth Sci Prgm,
Entebbe, Uganda, and
5
Makerere Univ Sch of Med, Kampala, Uganda
490 Dynamics of Non-B HIV Transmission in the UK

Manon Ragonnet-Cronin*
1
, S Lycett
1
, E HodcroIt
1
, S Hue
2
,
E Fearnhill
3
, D Dunn
3
, V Delpech
4
, A Leigh Brown
1
, and UK Collaborative
Group on HIV Drug Resistance
1
Univ of Edinburgh, UK,
2
3
MRC Clin Trials Unit,
London, UK, and
4
Hlth Protection Agencv, London, UK
491 Defining HLA Genotypes from Bulk HIV Sequences
A Kreimer
1
, M ShaeIer
2
, N PIeiIer
1
, V Tan
1
, P Goulder
3
, M John
4
,
Z Brumme
5
, E Hunter
2
, D Heckerman
1
, Jonathan Carlson*
1
,
and Intl and Southern AIrica HIV Assn Collaboratives
1
Microsoft Res, Los Angeles, CA, US,
2
3
Univ of Oxford, UK,
4
Murdoch Univ, Australia, and
5
Simon Fraser Univ,
Burnabv, Canada
492 Whole Genome Sequencing of HIV
+
African
Americans with Rapid Disease Progression or Long-
term Non-progression
Amy Weintrob*
1,2
, K Pelak
3
, R Thomas
2
, P Ehrenberg
2
, P Shea
3
,
J Okulicz
1
, A Ganesan
1
, B Agan
1
, N Michael
2
, and D Goldstein
3
1
Uniformed Svcs Univ Infectious Disease Clin Res Prgm, Bethesda, MD,
US,
2
Militarv HIJ Res Prgm, Bethesda, MD, US, and
3
Duke Univ Ctr for
Human Genome Jariation, Durham, NC, US
493 Exome Sequencing of Elite and Rapid HIV
Progressors: Results from the Exploratory Pilot
of the UK HIV Genomics Consortium

Deepti Gurdasani*
1,2
, C Scott
1
, E Young
1,2
, K Porter
3
, P Kellam
1,4
,
M Sandhu
1,2
, and UK HIV Genomics Consortium
1
Wellcome Trust Sanger Inst, Cambridge, UK,
2
Univ of Cambridge, UK,
3
MRC Clin Trials Unit, London, UK, and
4
!
Tuesday, 1:30-2:30 pm; B406

"#$$%&' (2*+,#-#. /%$01$$%&'
Restriction Factors: Old and New
Discussants:
Nathaniel Landau, New York Univ Sch of Med, NY, US
Stuart Neil, Kings Coll London Sch of Med, Guvs Hosp, UK
222 Evolutionarily Conserved Requirement of CBF- for
the Assembly of HIV/SIV Vif Cul5 Cullin-Ring Ligase

Sean Evans*
1
, X Han
1,2
, X Zhou
1,2
,

J Du
2
, W Zhang
2
, G Wang
2
,
and X-F Yu
1,2
1
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US and
2
First Hosp of Jilin Univ, China
223 Sooty Mangabey SIV, the Ancestor of HIV-2,
Efficiently Counteracts Human APOBEC3G

Michael Letko*
1
, M Ooms
1
, G Silvestri
2
, and V Simon
1
1
Mt Sinai Sch of Med, New York, NY, US and
2
Emorv Univ Sch of Med,
Atlanta, GA, US
224 Exploring the Relationship between P-body
Localization and Virion Incorporation of Human
Antiviral Proteins APOBEC3G and Mov10

Taisuke Izumi*, R Burdick, W-S Hu, and V Pathak
HIJ Drug Resistance Prgm, Natl Lab for Cancer Res, NCI-Frederick, MD,
US
225 HIV-1 Vpr Targets Restriction Factor CTIP2
to Proteasomal Degradation

Sultan Ali*
1
, C Schwartz
1,2
, and O Rohr
1,2
1
Univ of Strasbourg, France and
2
IUT of Schiltigheim, Strasbourg, France
226 Small Molecule Compounds Inhibit Vpu-mediated
Down-regulation BST-2

Zeyun Mi*, Q Zhang, J Zhou, J Ding, L Yu, and S Cen
Inst of Med Biotech, Chinese Academv of Med Sci, Beifing
227 Novel Regulation of SIV Vpx-mediated SAMHD1
Degradation
Wei Wei*
1
, H Guo
1
, X Han
1
, X Liu
1
, S Evans
2
, X Zhou
2
, W Zhang
1
, and X-F Yu
2
1
First Hosp of Jilin Univ, Inst of Jirologv and AIDS Res, China and
2
Johns
Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US
!
Tuesday, 1:30-2:30 pm; B308

"#$$%&' (3*+,#-#. /%$01$$%&'
MSM in the Developing World
Discussants:
Chris Beyrer, John Hopkins Univ Bloomberg Sch of Publ Hlth,
Baltimore, MD, US
Harold JaIIe, CDC, Atlanta, GA, US
1021 HIV Prevalence and Associated Risk Factors among
MSM: A Respondent-driven Sampling Survey,
Abidjan, Cote dÌvoire
Avi Hakim*
1
, J Aho
2
, G Semde
3
, M Diarrassouba
4
, K Ehoussou
4
,
B Vuylsteke
2
, C Murrill
1
, M Thiam
5
, T Wingate
4
, and SHARM Study Group
1
2
Inst of Tropical Med, Antwerp, Belgium,
3
Familv
Hlth Intl 360, Abidfan, Cote dIvoire,
4
CDC, Abidfan, Cote dIvoire, and
5
Ministrv of Hlth and Publ Hvgiene, Abidfan, Cote dIvoire
1022 HIV Prevalence and Correlates of Infection among
MSM: 4 Areas in Ghana, the Ghana Men`s Health
Study, 2010-2011
John Aberle-Grasse*
1
, W McFarland
2,3
, A El-Adas
4
, S Quaye
1
,
K Atuahene
4
, W AmpoIo
5
, R Adanu
6
, S Chaturvedi
2
, R Fisher
2
,
and E Harrison
5
1
2
3
San
Francisco Dept of Publ Hlth, CA, US,
4
Ghana AIDS Commission, Accra,
5
Univ of Ghana, Noguchi Memorial Inst for Med Res, Legon, and
6
Univ of
Ghana, Sch of Publ Hlth, Legon
Program 13
T
u
e
s
d
a
y
M
a
r
c
h

5
O
r
a
l

S
e
s
s
i
o
n
s
1023 Risk Factors for Unprotected Anal Sex and HIV
Infection among Male Sex Workers: Vietnam
Donn Colby*
1,2,3
, N Trang
4
, T Mai
2
, T Nguyen
2
, HT Lan
4
, DD Thien
4
,
NA Ngoc
5
, K Mayer
1,3,6
, and M Mimiaga
3,6,7,8
1
Beth Israel Deaconess Med Ctr, Boston, MA, US,
2
Harvard Med Sch AIDS
Initiative in Jietnam, Ho Chi Minh Citv,
3
Harvard Med Sch, Boston, MA,
US,
4
Life Ctr, Ho Chi Minh Citv, Jietnam,
5
Ctr for Applied Res on Men and
Hlth, Ho Chi Minh Citv, Jietnam,
6
The Fenwav Inst, Fenwav Hlth, Boston,
MA, US,
7
Massachusetts Gen Hosp, Boston, US, and
8
Harvard Sch of Publ
Hlth, Boston, MA, US
1024 Longitudinal Analysis of HIV-risk Behavior Patterns
and Their Predictors in MSM: Bangkok, Thailand,
2006-2008
P Girault
1
, W Wimonsate
2
, Timothy Holtz*
2,3
, A Varangrat
2
,
S Chaikummao
2
, W Thienkrua
2
, T Chemnasri
2
, W Sukwicha
2
, R Thiebaut
4
,
and F van Griensven
2,3,5
1
FHI 360 AsiaPacific Regional Office, Bangkok, Thailand,
2
Thailand
Ministrv of Publ HlthCDC Collaboration, Nonthaburi,
3
CDC, Atlanta, GA,
US,
4
INSERM U897 and Inst de Sante Publ, dEpidemiologie et de Devt,
Univ Bordeaux Segalen, France, and
5
AJRAM Corp, Miami, FL, US
1025 Herpes Simplex 2 Virus Type 2 Incidence and
Risk Factors among MSM: Bangkok, Thailand
Warunee Thienkrua*
1
, W Chonwattana
1
, P Mock
1
, S Chaikummao
1
,
W Wimonsate
1
, J Tongtoyai
1
, C Todd
1,2,3
, A Chitwarakorn
4
, M Curlin
1,5
,
and F van Griensven
1,3,5
1
Thailand Ministrv of Publ Hlth-CDC Collaboration, Nonthaburi,
2
FHI360
Asia Pacific Regional Office, Bangkok, Thailand,
3
AJRAM Corp, Miami, FL,
US,
4
Thailand Ministrv of Publ Hlth, Nonthaburi, and
5
!
Tuesday, 1:30-2:30 pm; B313

"#$$%&' ()*+,#-#. /%$01$$%&'
Family Planning: Unintended Pregnancy and Unmet
Need
Discussants:
Gina Brown, Office of AIDS Res, NIH, Bethesda, MD, US
Sharon Hiller, Univ of Pittsburgh, Magee-Womens Res Inst, PA, US
895 Periconception HIV Risk Behavior among Men
and Women Reporting Serodiscordant Partners:
KwaZulu-Natal, South Africa
Lynn Matthews*
1
, D Bangsberg
1
, C MilIord
2
, N Mosery
2
, R Greener
2
,
A Kaida
3
, C Psaros
1
, S SaIren
1
, and J Smit
2
1
Massachusetts Gen Hosp, Boston, US,
2
MatCH, Durban, South Africa,
and
3
Simon Fraser Univ, Jancouver, Canada
896 Predictors of Unplanned Pregnancies among
Women Living with HIV: US
Lisa Rahangdale*
1
, S Cohn
2
, R Stewart
3
, J Levison
4
, G Lazenby
5
,
M Badell
6
, M Nguyen
6
, M KempI
7
, M Sturdevant
7
, P Ellis
8
, and HIV
and OB Pregnancy Ed Study
1
2
Northwestern Univ Feinberg
Sch of Med, Chicago, IL, US,
3
Univ of Texas Southwestern Med Ctr, Dallas,
US,
4
Bavlor Coll of Med, Houston, TX, US,
5
Med Univ of South Carolina,
US,
6
7
and
8
Louisiana State Univ, Baton Rouge, US
897 Trends in Contraceptive Use and Choice of
Contraceptive Method in a Rural South African
Population-based Cohort during the ART Era,
2005-2011
Nuala McGrath*
1,2
, J Eaton
3
, and M-L Newell
2,4
1
London Sch of Hvgiene and Tropical Med, UK,
2
Africa Ctr for Hlth and
Population Studies, KwaZulu-Natal, South Africa,
3
Imperial Coll London,
UK, and
4
Inst of Child Hlth, Univ Coll London, UK
898 Unmet Need for Family Planning, Contraceptive
Failure, and Unintended Pregnancy among Women
Living with HIV Infection: Zimbabwe
Sandra McCoy*
1
, R Buzdugan
1
, L Ralph
1
, A Mushavi
2
, A Mahomva
3
,
C Watadzaushe
4
, J Dirawo
4
, C Frances
4,5
, and N Padian
1
1
Univ of California, Berkelev, US,
2
Ministrv of Hlth and Child Welfare,
Harare, Zimbabwe,
3
Eli:abeth Glaser Pediatric AIDS Fndn, Harare,
Zimbabwe,
4
Ctr for Sexual Hlth and HIJ Res, Harare, Zimbabwe, and
5
!
Tuesday, 1:30-2:30 pm; Ballroom 3-4

"#$$%&' (2*+,#-#. /%$01$$%&'
The Cascade of Care
Discussants:
Andrea Howard, Columbia Univ Mailman Sch of Publ Hlth, New York,
NY, US
Ian Williams, Univ Coll London, UK
1026 Application of Indicators to Monitor US Department
of Health and Human Services-funded HIV Services
in the North American AIDS Cohort Collaboration
on Research and Design
Keri AlthoII*
1
, P Rebeiro
1
, M Horberg
2
, K Buchacz
3
, K Gebo
1
, T Sterling
4
,
M Kitahata
5
, A Justice
6
, J Brooks
3
, R Moore
1
, Ior North American AIDS
Cohort Collaboration on Res and Design
1
2
Kaiser Permanente Mid-
Atlantic States, Rockville, MD, US,
3
4
Janderbilt
Univ, Nashville, TN, US,
5
Univ of Washington, Seattle, US, and
6
Yale Univ
and the JA Connecticut Hlthcare Svstem, New Haven, US
1027 An Encouraging HIV Care Cascade: Anomaly,
Progress, or 1ust More Accurate Data?
Julia Dombrowski*
1,2
, J Kent
2
, S Buskin
1,2
, J Stekler
1,2
, E Barash
2
,
A Bennett
2
, and M Golden
1,2
1
Univ of Washington, Seattle, US and
2
Publ Hlth-Seattle & King Countv, WA, US
1028 Health Insurance Coverage and Type Predict
Durable Viral Suppression among HIV
+
Adults
in Care: US, Medical Monitoring Project, 2009
Kelly Quinn* and J Skarbinski
1029 The Evolution of the Cascade of HIV Care: British
Columbia, Canada, 1996-2010
Julio Montaner*
1
, B Nosyk
1
, G Colley
1
, H Samji
1
, R Hogg
1
, R GustaIson
2
,
and M Gilbert
3
1
BC Ctr for Excellence in HIJ/AIDS, Jancouver, Canada,
2
Jancouver
Coastal Hlth, Canada, and
3
BC Ctr for Disease Control, Canada
1030 The Spectrum of Engagement in HIV Care in France:
Strengths and Gaps
V Supervie
1
and Dominique Costagliola*
1,2
1
INSERM U943, UMR S943, UPMC Univ Paris 06, Paris, France and
2
APHP, Hosp Pitie Salpetriere, Paris, France
T
u
e
s
d
a
y
M
a
r
c
h

5
O
r
a
l

S
e
s
s
i
o
n
s
!
Tuesday, 1:30-2:30 pm; Ballroom 1-2

"#$$%&' ()*+,#-#. /%$01$$%&'
Cardiovascular Disease: Predicting Risk and
Monitoring Outcomes
Discussants:
John Brooks, CDC, Atlanta, GA, US
Monica Shah, Natl Heart, Lung, and Blood Inst, NIH, Bethesda, MD,US
747 Projecting 10-year, 20-year, and Lifetime Risks of
Cardiovascular Disease in HIV
+
Individuals in the
US: Competing Risks and Premature Aging
Elena Losina*
1,2,3,4
, B Linas
4,5
, E Hyle
1,3
, C Rusu
4
, F Noubary
4
,
B Berkowitz
4
, P Sax
1,2
, M Weinstein
6
, R Walensky
1,2,3,4
, and K Freedberg
1,3,4,5
1
Ctr for AIDS Res, Harvard Med Sch, Boston, MA, US,
2
Brigham and
Women`s Hosp, Boston, MA, US,
3
4
Boston Med Ctr, MA, US,
5
Boston Univ Sch of Publ Hlth, MA, US, and
6
Harvard Sch of Publ Hlth, Boston, MA, US
748 Improvements in Short-term Mortality following
Myocardial Infarction: The Data Collection on
Adverse events of Anti-HIV Drugs Study
Caroline Sabin*
1
, L Ryom
2
, M Law
3
, W El-Sadr
4
, O Kirk
2,5
, M Bruyand
6
,
P Reiss
7
, C Pradier
8
, B Ledergerber
9
, J Lundgren
2,5
, and D:A:D Study
1
2
Copenhagen HIJ Prgm, Denmark,
3
The Kirbv
Inst, Univ of New South Wales, Svdnev, Australia,
4
Intl Ctr for AIDS Care
and Treatment Prgms, Columbia Univ and Harlem Hosp, New York, NY,
US,
5
Copenhagen Univ Hosp/Rigshospitalet, Denmark,
6
Univ of Bordeaux,
ISPED, Ctr INSERM U897-Epidemiologie-Biostatistique, France,
7
Academic Med Ctr, Univ of Amsterdam, The Netherlands,
8
Ctr Hosp Univ,
Nice, France, and
9
Univ Hosp Zurich, Swit:erland
749 ST2 and NT-proBNP Are Associated with Cardiac
Dysfunction and Mortality in HIV
+
Individuals
Eric Secemsky*
1
, R Scherzer
2
, E Nitta
2
, A Wu
2
, D Lange
2
, S Deeks
2
,
J Martin
2
, J Snider
3
, P Ganz
2
, and P Hsue
2
1
2
US, and
3
Critical Diagnostics, San Diego, CA, US
750 The Risk of and Survival with Preserved vs Reduced
Ejection Fraction Heart Failure by HIV Status
Matthew Freiberg*
1
, C-C Chang
1
, KA Oursler
2,3
, J Gottdiener
4
,
S Gottlieb
4
, A Warner
5
, D LeaI
5
, M Rodriguez-Barradas
6,7
, S Felter
8
,
A Butt
1,9
, and VACS Project Team
1
2
Baltimore JAMC, MD, US,
3
Univ
of Marvland Sch of Med, Baltimore, US,
4
Univ of Marvland Med Ctr,
Baltimore, US,
5
JA Greater Los Angeles Hlthcare Svstem, CA, US,
6
Bavlor
Coll of Med, Houston, TX, US,
7
Michael E DeBakev JAMC, Houston, TX,
US,
8
JA Pittsburgh Hlthcare Svstem, PA, US, and
9
Sheikh Khalifa Med
Citv, Abu Dhabi, United Arab Emirates
751 Emergency Medical Service Utilization and
Reperfusion Times among HIV
+
Individuals
Presenting with ST-elevation Myocardial Infarction

Mark Dela Cruz*
1
, K Thomas
1
, D Brenner
1
, A Kulkarni
2
, J McCabe
3
,
P Hsue
1
, P Ganz
1
, and S Waldo
1
1
2
Massachusetts Gen Hosp, Boston,
US, and
3
Brigham and Women`s Hosp, Boston, MA, US
"
Tuesday, 2:30-4 pm; Hall B2
2&$3#4 56$34703$
Session 56. Transcription/Reverse and Forward, Splicing/Replication
Session 60. Restriction Factors: APOBEC and Others
Session 62. Shutting the Door on HIV Entry
Session 63. Transmitted/ Founder Viruses
Session 66. Markers oI HIV Disease Progression
Session 69. CD8 T Cells in HIV InIection
Session 70. Killer T Cells
Session 78. Viral DNA Dynamics
Session 79. InIected Cell Dynamics on Therapy
Session 80. What Is Latency and What Can We Do about It?
Session 82. Novel Vaccine Strategies
Session 88. Neuropathogenesis Mechanisms
Session 89. Central Nervous System InIlammation and Biomarkers
oI HIV-associated Neurocognitive Disorders
Session 90. Aging and Neurocognitive Function in HIV InIection
Session 94. Simian Viral Reservoirs
Session 97. HIV Subtypes: Epidemiology and Disease Progression
Session 99. New Approaches to ARV Drug Delivery
Session 102. ARV Pharmacokinetics: New Assays, Drugs, and
Special Populations
Session 110. Tropism Testing/Maraviroc Resistance
Session 111. HIV Drug Resistance: Trends and Emergence
Session 112. Detecting and Interpreting HIV Drug Resistance
Session 113. Innovation in Measuring Viral Nucleic Acids
Session 114. Transmitted Drug Resistance
Session 115. Drug Resistance Mutational Pathways and Subtype
Associations
Session 116. Advances in Sequencing and Analysis
Session 117. Detecting HIV InIection
Session 122. Hepatitis C Virus Treatment Today and Tomorrow
Session 123. Hepatitis C Virus Resistance and Virology
Session 124. Innate Immunity and Hepatitis C Virus
Session 126. Hepatic Failure and Transplantation
Session 127. Emergence and Persistence oI HPV-associated
Malignancies in the ART Era
Session 133. Statin Use and HIV: How Sweet Is It?
Session 134. Dyslipidemia: Risks, Pathogenesis, and Treatment
Session 135. Risk Prediction, Risk Factors, Biomarkers, and
Outcomes
Session 137. InIlammatory Biomarkers, Microparticles, and Clinical
Outcomes in HIV
Session 138. ART EIIects: Monocyte and T Cell Activation
Session 147. TB Screening Strategies: Diagnostics New and Old and
Latent TB Treatment
Session 149. Mechanisms oI Immune Reconstitution
Session 157. Hepatitis C Virus Testing in Women
Session 163. ARV Strategies, MTCT, and HIV-Iree Survival
Session 164. PMTCT Implementation: Barriers and Program
Innovations
Session 167. Breast Feeding and Prevention oI Postnatal MTCT
Session 168. ARV Pharmacokinetics during Pregnancy and Breast
Feeding
Session 169. ARV Regimens and SaIety during Pregnancy
Session 175. HIV Drug Resistance in Children and Youth
Session 176. Co-inIections among HIV-inIected and -exposed Children
Session 184. Non-human Primate Models oI STI, PrEP, and Vaccines
Session 186. Implementation and Cost-eIIectiveness oI Male
Circumcision
Session 188. The Ongoing Epidemic in MSM
Session 193. Estimating Incidence
Session 194. New Testing Strategies
Session 198. Adherence and Retention in RLS
Program 15
T
u
e
s
d
a
y
M
a
r
c
h

5
O
r
a
l

S
e
s
s
i
o
n
s
!
Tuesday, 4-6 pm; B406

"#$$%&' (()"*+,&$%-+
HIV HostCell Interactions
Conveners:
Chioma Okeoma, Univ of Iowa, Iowa
Citv, US
Paul Spearman, Emorv Univ, Atlanta,
GA, US
107
Interferon-inducible Siglec, CD169, Is the
Mature Dendritic Cell Receptor Essential for
HIV-1 Trans-infection
W Blay Puryear
1
, H Akiyama
1
, S Geer
1
, N Ramirez
1
, X Yu
2
,
B Reinhard
2
, and Rahm Gummuluru*
1
1
Boston Univ Sch of Med, MA, US and
2
Boston Univ, MA, US
108
TRIM5u Restriction, HIV-1 Uncoating,
and Relationship to Reverse Transcription
Felipe Diaz-GriIIero
Albert Einstein Coll of Med, Bronx, NY, US
109
SAMHD1 Restricts HIV-1 Infection in Resting
CD4
+
T Cells
Oliver Keppler
Inst of Med Jirologv, Natl Reference Ctr for Retroviruses,
Univ of Frankfurt, Germanv
110
The Antiviral Activities of Tetherin
RP Galao, S Pickering, A Le Tortorec, T Kueck,
and Stuart Neil*
Kings Coll London Sch of Med, Guvs Hosp, UK
interested in understanding the host cell Iactors that promote and
restrict HIV-1 replication. It is assumed that participants are Iamiliar
with cell biology, the retroviral liIecycle, and the proteins encoded
in the HIV genome. At the completion oI the session, participants
will be knowledgeable about how dendritic cells Iacilitate HIV
inIection through their expression oI speciIic cell-surIace proteins,
how host restriction proteins interIere with speciIic steps during
virus replication, and mechanisms by which the virus has evolved to
escape Irom these restrictions.
!
Tuesday, 4-6 pm; Ballroom 3-4

"#$$%&' (.)"*+,&$%-+
Reproductive Hormones and HIV
Conveners:
Ward Cates, FHI360, Research Triangle
Park, NC, US
Nelly Mugo, Univ of Washington,
Nairobi, Kenva
111
Effects of Hormonal Contraceptives that May
Affect Susceptibility to HIV Acquisition in
Women
Christine Mauck
CONRAD, Arlington, JA, US
112
Assessing the Impact of Hormonal
Contraceptives on HIV Risk and
Prevention in Animal Models
Gerardo Garcia-Lerma
113
What Have the Epidemiological Studies
Taught Us about Hormonal Contraceptives
and HIV-related Risks?
Chelsea Polis
*1
and R HeIIron
2
1
USAID, Office of Population and Reproductive Hlth,
Washington, DC and
2
114
Programmatic Implications: Balancing
Maternal Mortality and HIV Risk
JenniIer Smith*
1
, A Butler
1
, C Polis
2
, S Gregson
1
, D Stanton
2
,
and T Hallett
1
1
Imperial Coll London, UK and
2
US Agencv for Intl Devt,
Washington, DC
5:30-6 pm
Panel Discussion
interested in womens health, Iamily planning, and HIV prevention.
This session will be oI interest to scientists conducting clinical
studies oI HIV prevention and epidemiologists evaluating risk
Iactors Ior HIV acquisition and transmission. It is assumed
that participants are Iamiliar with reproductive biology and
the data linking HIV risk with contraceptive hormones. At the
completion oI the session, participants will be knowledgeable
about the epidemiologic and biologic data supporting the impact
oI reproductive and contraceptive hormones on HIV risk. In
addition, participants will appreciate the public health impact oI
eIIective contraceptives and will learn how modeling studies have
demonstrated that modest increases in HIV risk among women
on hormonal contraceptives are oIIset by decreases in maternal
mortality associated with unwanted pregnancy.
T
u
e
s
d
a
y
M
a
r
c
h

5
O
r
a
l

S
e
s
s
i
o
n
s
!
Tuesday, 4-6 pm; Hall B1

"#$$%&' ()*"+,-&$%.,
Opportunities and Threats to ART Success
Conveners:
Melanie Thompson, AIDS Res
Consortium, Atlanta, GA, US
Francois Venter, Wits Reproductive Hlth
and HIJ Res Inst, Johannesburg, South
Africa
119
!"#$%$&'# ')* +&")",$& -./0'%1 %" 231%'$)'4#0
567 -/0'%,0)%
JenniIer Kates
Kaiser Familv Fndn, Washington, DC, US
120
56- ')* 8)9#',,'%$"): 8,;#$&'%$")1 9"/ %.0
5;;/"'&. %" <'/0 $) =>?@
Sharon Lewin
Alfred Hosp, Monash Univ and Burnet Inst, Melbourne,
Australia
121
567 A/3B 601$1%')&0: C#"4'# <.'##0)B01
Raph Hamers
Academic Med Ctr of the Univ of Amsterdam, Amsterdam Inst
for Global Hlth and Devt, PharmAccess Fndn, Amsterdam,
The Netherlands
122
D0E F87 A/3B1 ')* G"/,3#'%$")1: +990&% ")
-.0/';03%$& !'/'*$B,1
Roy Gulick
Weill Cornell Med Coll, New York, NY, US
H4I0&%$J01: This session is directed to clinicians
and scientists interested in ART including threats
to current progress, relationship to the chronic inIlammatory state,
and the promise oI new agents and Iormulations. It is assumed that
participants are Iamiliar with the essentials oI HIV pathogenesis and
ARV therapeutics. At the completion oI the session, participants
will recognize the political and economic threats to sustaining the
progress made in the era oI potent ART, understand the role that
artGG might play in the chronic immune activation state seen in
HIV
persons with controlled viremia, appreciate the current state-

oI-the-art oI ARV drug resistance, and gain knowledge oI new ARV
drugs and Iormulations and the implications Ior changing paradigms
oI therapy.
!
Tuesday, 4-6 pm; Ballroom 1-2

"#$$%&' (/*"+,-&$%.,
When Worlds Collide Adolescents and HIV,
a symposium in memory of Edward Handelsman
Conveners:
Sabrina Bakeera-Kitaka, Makerere Univ,
Kampala, Uganda
Bill Kapogiannis, Natl Inst of Child Hlth
and Human Devt, NIH, Bethesda, MD, US
115
+%.$&'# 811301 $) 5*"#01&0)% F87 !/0J0)%$")
6010'/&.
Sean Philpott
Ctr for Bioethics and Clinical Leadership, Union Grad Coll,
Schenectadv, NY, US
116
K.'%L1 G30#$)B %.0 F87 +;$*0,$& $) C'MN
O$10P3'# Q'#0 5*"#01&0)%1 ')* "%.0/ R"3)B
Q2QS
Gary Harper
Univ of Michigan Sch of Publ Hlth, Ann Arbor, US
117
!/0J0)%$)B D0E F87 8)90&%$")1 ',")B R"3)B
59/$&') K",0)TK.M 81 8% 1" A$99$&3#%S
Sinead Delany-Moretlwe
Univ of the Witwatersrand, Johannesburg, South Africa
118
O0.'J$"/'# <.'##0)B01 $) !0/$)'%'##M 8)90&%0*
R"3%.
Claude Ann Mellins
New York State Psvchiatric Inst and Columbia Univ, New York, US
H4I0&%$J01: This session is designed Ior clinicians and
scientists interested in challenging issues pertaining
to adolescents and young adults living with HIV. It is assumed
that participants are Iamiliar with basic epidemiology oI HIV in
adolescents in high- and low-resource countries, and behavioral
and sociologic issues observed in youth with adult risk behaviors
and perinatally acquired HIV. At the completion oI the session,
participants will be knowledgeable about ethical considerations
surrounding youth participation in vaccine and pre- and post-
exposure prophylaxis trials, Ioundations and accelerators oI the
epidemic in young MSM, impediments and successes in prevention
strategies in young women in AIrica, and mental health outcomes in
youth who acquired HIV in inIancy.
Program 17
W
e
d
n
e
s
d
a
y
M
a
r
c
h

6
O
r
a
l

S
e
s
s
i
o
n
s
!
Wednesday, 8:30-9 am; Hall B1

"#$$%&' ()*+,#'-./
Incorporating New Drugs into Regimens
that Will Change the TB Treatment Paradigm:
The Magic Mountain Meets Table Mountain
123
Andreas Diacon
Stellenbosch Univ, Tvgerberg, Cape Town, South Africa
interested in TB and anti-TB drugs. It is assumed that participants
are Iamiliar with the basics oI clinical TB and current principles oI
TB treatment. At the completion oI the session, participants will be
inIormed about novel anti-TB drugs and regimens, the methods used
to explore them, and how they might best be deployed to transIorm
treatment oI drug-susceptible and drug-resistant TB.
"
Wednesday, 9-9:30 am; Hall B1

"#$$%&' (0*+,#'-./
Treatment with Gene-modified Hematopoietic
Stem Cells May Definitively Abolish HIV-1 Infection
124
Marina Cavazzana-Calvo
U768 INSERM, AP-HP, Hosp Univ Necker-Enfants Malades,
Univ Paris Descartes, Sorbonne Paris Cite, IMAGINE Inst, CIC
Biotherapie GHU Ouest, INSERM-APHP, Paris, France
interested in new genetic approaches Ior HIV-1 inIections able to
eliminate the need Ior indeIinite treatment oI inIected patients. It
is assumed participants are Iamiliar with the human hematopoietic
stem cell system as well as with the biological tools able to introduce
de novo gene Iunctions into these cells or alternatively to disrupt
cellular genes to conIer to the hematopoietic compartment a stable
resistance to HIV. At the completion oI the session, participants will
be knowledgeable about the Iirst clinical results obtained in this Iast-
moving Iield.
#
Wednesday, 10-11:45 am; B402

"#$$%&' (1*2.-, 34$5.-65$
New Discoveries in Vaccines and Gene Therapy
Moderators:
Richard Koup, Jaccine Res Ctr, NIAID, NIH, Bethesda, MD, US
Alexandra Trkola, Univ of Zurich, Swit:erland
10:00 125 Dendritic Cells Transduced with Vpx-packaged
LV Vector Encoding CD40L Enhance Cytotoxic
T Cell Responses and Disrupt HIV-1 Latency

Thomas Norton*, E Miller, N Bhardwaj, and N Landau
New York Univ Sch of Med, NY, US
10:15 126 Central Memory T Cell Is the Critical
Component for Sustained CD4 Reconstitution
in HIV Subjects Receiving ZFN CCR5 Modified
CD4 T Cells (SB-728-T)
J Zeidan
1
, G Lee
2
, J Lalezari
3
, R Mitsuyasu
4
, S Wang
2
, M Giedlin
2
,
G Nichol
2
, W Tang
2
, Rafck-Pierre Sekaly*
1
, and D Ando
2
1
Jector and Gene Therapv Inst of Florida, Port St Lucie, US,
2
Sangamo BioSci, Richmond, CA, US,
3
Quest Clin Res, San
Francisco, CA, US, and
4
Univ of California, Los Angeles, US
10:30 127 Protection of Stem Cells Results in Enhanced
Virus-specific Immunity with Recovery of
Unprotected CD4
+
T Cells in a Primate AIDS
Model

Patrick Younan*
1
, P Polacino
2,3
, J Kowalski
1
, C Peterson
1
,
N Maurice
1
, N Williams
1
, G Trobridge
1
, D Von Laer
4
, S-L Hu
2,3
,
and H-P Kiem
1,2
1
Fred Hutchinson Cancer Res Ctr, Seattle, WA, US,
2
Univ of
Washington, Seattle, US,
3
Washington Natl Primate Res Ctr, Seattle,
US, and
4
Innsbruck Med Univ, Austria
10:45 128 Levels of CD4
+
CCR5
+
Target T Cells in Rectal
Mucosa Predict Risk of SIV Acquisition and
Replication in Rhesus Macaques Vaccinated
with SIV Gag/Tat Vectors
Diane Carnathan*
1
, K Sheehan
2
, J Yu
1
, D Weiner
2
, H Ertl
3
,
and G Silvestri
1
1
Yerkes Natl Primate Res Ctr, Emorv Univ, Atlanta, GA, US,
2
Univ of Pennsvlvania, Philadelphia, US, and
3
The Wistar Inst,
Philadelphia, PA, US
11:00 129 T Cells Edited to Express CCR5 or CXCR4
Fused to the C34 Peptide from gp41 Heptad
Repeat-2 Exhibit Robust Protection from
Diverse HIV-1 Isolates

George Leslie*
1
, J Wang
2
, B Haggarty
1
, A Jordan
1
, J Romano
1
,
K Hua
2
, M Holmes
2
, and J Hoxie
1
1
Univ of Pennsvlvania, Philadelphia, US and
2
Sangamo BioSci Inc,
Richmond, CA, US
11:15 130 Poor Neutralizing Antibody Response Is
Associated with Subsequent HIV-1
Superinfection

Gabriel Wagner*
1
, L Hepler
1
, G Caballero
2
, P Phung
3
, S Little
1
,
S Kosakovsky Pond
1
, D Richman
1,2
, and D Smith
1,2
1
Univ of California, San Diego, La Jolla, US,
2
JA Hlthcare
Svstem, San Diego, CA, US, and
3
Monogram Biosci Inc, South San
Francisco, CA, US
11:30 131LB Antibody-induced Perturbation of HIV-1 Env
Structure Is a Quantifiable Parameter that
Modulates the Inhibitory Potency of Antibodies
Hillel Haim*
1,2
, I Salas
1
, and J Sodroski
1,3,4
1
DanaFarber Cancer Inst, Harvard Med Sch, Boston, MA, US,
2
Carver Coll of Med, Univ of Iowa, Iowa Citv, US,
3
Harvard Sch
of Publ Hlth, Boston, MA, US, and
4
Ragon Inst of MGH, MIT and
Harvard, Boston, MA, US
#
Wednesday, 10 am-12 n; B406

"#$$%&' 78*2.-, 34$5.-65$
Virology: From the Outside In
Moderators:
Anna Aldovini, Childrens Hosp Boston, Harvard Univ, MA, US (invited)
James Hoxie, Univ of Pennsvlvania, Philadelphia, US
10:00 132 Transmitted/Founder HIV-1 Virions Exhibit
High Env Content, Efficient Dendritic Cell
Binding, Enhanced Infectivity, and Resistance
to Alpha Interferon
N Parrish
1
, E Giorgi
2
, C Wilen
1
, S Iyer
1
, J Kappes
3
, F Gao
4
,
B Haynes
4
, B Korber
2
, G Shaw
1
, and Beatrice Hahn*
1
1
Univ of Pennsvlvania Perelman Sch of Med, Philadelphia, US,
2
Los
Alamos Natl Lab, NM, US,
3
and
4
Duke Univ Sch of Med, Durham, NC, US
10:15 133 Proteolytic Processing of the HIV Envelope
Glycoprotein Precursor Decreases
Conformational Flexibility
Hillel Haim*
1,2
, I Salas
1
, and J Sodroski
1,3,4
1
DanaFarber Cancer Inst, Boston, MA, US,
2
Carver Coll of Med, Univ
of Iowa, Iowa Citv, US,
3
Harvard Sch of Publ Hlth, Boston, MA, US,
and
4
Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US
10:30 134 Siglec-1 Is a Novel Dendritic Cell Receptor
that Mediates HIV-1 Trans-infection Through
Recognition of Viral Membrane Gangliosides

Nuria Izquierdo-Useros*
1
, M Lorizate
2
, M Puertas
1
,
M Rodriguez-Plata
1
, N Zangger
3
, M Pino
1
, I Erkizia
1
, A Telenti
3
,
H-G Krausslich
2
, and J Martinez-Picado
1,4
1
AIDS Res Inst IrsiCaixa, Spain,
2
Univ Heidelberg, Germanv,
3
Univ
Hosp Ctr and Univ of Lausanne, Swit:erland, and
4
Inst Catalana de
Recerca i Estudis Avancats, Spain
10:45 135 Inhibition of HIV-1 Vif Function by AML Factor
CBF-SMMHC Fusion Proteins

Ke Zhao*
1
,

J Du
1
, P Li
1
, Y Rui
1
, M Yan
1
, W Zhang
1
, X-F Yu
1,2
,
and G Wang
1
1
Inst of Jirologv and AIDS Res, First Hosp of Jilin Univ,
Changchun, China and
2
Johns Hopkins Univ Bloomberg Sch of Publ
Hlth, Baltimore, MD, US
11:00 136 Crystal Structure of HIV-1 Nef in Complex
with the Hck SH3-SH2 Region Reveals New
Intermolecular Interactions with Functional
Implications
John JeII Alvarado*, S TaraIdar, T Smithgall, and J Yeh
Univ of Pittsburgh, PA, US
W
e
d
n
e
s
d
a
y
M
a
r
c
h

6
O
r
a
l

S
e
s
s
i
o
n
s
11:15 137 LIM Kinase-mediated Actin Dynamics Modulate
Retrovirus Budding

Xiaoyun Wen*, L Ding, E Hunter, and P Spearman
Emorv Univ, Atlanta, GA, US
11:30 138 Incorporation of LEDGF/p75 in Viral Particles
Is Crucial for HIV Infectivity
B Desimmie
1
, R Schrijvers
1
, S Vets
1
, J Demeulemeester
1
, P Proost
1
,
J De Rijck
1
, N Bannert
2
, F Christ
1
, R Gijsbers
1
, and Zeger Debyser*
1
1
2
Robert Koch Inst, Berlin,
Germanv
11:45 139LB Treatment with Sub-optimal Doses of Raltegravir
Leads to Aberrant HIV-1 Integrations
Janani Varadarajan*
1
, MJ McWilliams
1
, D Hazuda
2
, and S Hughes
1
1
HIJ Drug Resistance Prgm, Frederick Natl Lab for Cancer Res,
NIH, MD, US and
2
Merck Res Labs, West Point, PA, US
!
Wednesday, 10-11 am; Ballroom 3-4

"#$$%&' ()*+,-. /0$1,-21$
HIV-associated Malignancies
Moderators:
Kishor Bhatia, NCI, NIH, Bethesda, MD, US
Margaret Borok-Williams, Univ of Zimbabwe, Harare
10:00 140 Substantial Burden of Non-AIDS Cancers in
Persons with HIV: Early Results from a
Computerized HIV and Cancer Registry Match
in Pune, India
Sheela Godbole*
1
, K Nandy
2
, M Gauniyal
1
, S Koyande
3
, P Virgo
4
,
K Bhatia
5
, R Paranjape
1
, A Risbud
1
, S Mbulaiteye
5
, and R Mitsuyasu
2
1
Natl AIDS Res Inst-ICMR, Pune India,
2
Univ of California, Los
Angeles, US,
3
Bombav Cancer Registrv, Mumbai, India,
4
Computer
Svcs Corp, Rockville, MD, US, and
5
NCI, NIH, Bethesda, MD, US
10:15 141 Timing and Predictors of Cancer Incidence
following Initiation of ART: Centers for AIDS
Research Network of Integrated Clinical
Systems, 1996-2011

Elizabeth Yanik*
1
, S Napravnik
1
, S Cole
1
, C Achenbach
2
,
S Gopal
1
, D Dittmer
1
, M Kitahata
3
, M Mugavero
4
, M Saag
4
, J Eron
1
,
and Ctr Ior AIDS Res Network oI Integrated Clin Systems
1
2
Northwestern Univ,
Chicago, IL, US,
3
4
Univ of
Alabama at Birmingham, US
10:30 142 Random Biopsy Increases Diagnostic Rate and
Total Anal High-grade Squamous Intraepithelial
Lesions Found by High-resolution Anoscopy

Richard Silvera*, M Gaisa, and S Goldstone
Mt Sinai Sch of Med, New York, NY, US
10:45 143 Evaluating Serum microRNA as Potential
Biomarkers for Early Detection of Non-Hodgkin
Lymphomas in HIV
+
Individuals
Dharma Thapa*
1
, W-C Tran
1
, L Jacobson
2
, J Margolick
2
, J Phair
3
,
C Rinaldo
4
, R Detels
1
, and O Martinez-Maza
1
1
David Geffen Sch of Med, Fielding Sch of Publ Hlth, and AIDS
Inst Univ of California, Los Angeles, US,
2
Johns Hopkins Univ
Bloomberg Sch of Publ Hlth, Baltimore, MD, US,
3
Northwestern
Univ Feinberg Sch of Med, Chicago, IL, US, and
4
Univ of Pittsburgh
Grad Sch of Publ Hlth, PA, US
!
Wednesday, 11 am-12:15 pm; Ballroom 3-4

"#$$%&' (3*+,-. /0$1,-21$
TB and Cryptococcal Meningitis
Moderators:
Haileyesus Getahun, WHO, Geneva, Swit:erland
Graeme Meintjes, Univ of Cape Town, South Africa
11:00 144 ART Initiation within the First 2 Weeks of
Cryptococcal Meningitis Is Associated with
Higher Mortality: A Multisite Randomized Trial
David Boulware*
1
, D Meya
2,3
, C Muzoora
4
, M RolIes
1
, K Huppler
Hullsiek
1
, A Musubire
2,3
, K Taseera
4
, H Nabeta
2,3
, C Schutz
5
,
G Meintjes
5
, and Cryptococcal Optimal ART Timing Trial
1
2
Infectious Disease Inst,
Kampala, Uganda,
3
4
Mbarara
Univ, Uganda, and
5
Univ of Cape Town, South Africa
11:15 145 HAART Does Not Reduce the Incidence of TB
in HIV
+
Infants with Early HIV Disease Enrolled
in a Primary TB Prevention Trial
Bret Zeldow*
1
, S Kim
2
, G McSherry
3
, M Cotton
4
, S Madhi
5
,
A Violari
5
, R Bobat
6
, C Mitchell
7
, and P1041 Study Team
1
2
New Jersev Med
Sch, Newark, US,
3
Pennsvlvania State Univ Coll of Med, Hershev,
US,
4
Stellenbosh Univ, Cape Town, South Africa,
5
Univ of the
Witwatersrand, Johannesburg, South Africa,
6
Univ of KwaZulu-
Natal, Durban, South Africa, and
7
Univ of Miami, FL, US
11:30 146 Comparative Performance of Rapid Urinary
Lipoarabinomannan Assays and Xpert
MTB/RIF in HIV
+
TB Suspects: Uganda
Maunank Shah*
1
, W Ssengooba
2
, D Armstrong
1
,

L Nakiyingi
2
,
M Holshouser
1
, J Ellner
3
, M Joloba
2
, Y Manabe
1,4
, and S Dorman
1
1
2
Makerere
Univ Coll of Hlth Sci, Kampala, Uganda,
3
Boston Med Ctr, Boston
Univ Sch of Med, MA, US, and
4
Infectious Diseases Inst, Makerere
Univ Coll of Hlth Sci, Kampala, Uganda
11:45 147LB A Multicenter Randomized Clinical Trial
to Evaluate High-dose Rifapentine with a
Quinolone for Treatment of Pulmonary TB:
The RIFAQUIN Trial
Amina Jindani*
1
, M Hatherill
2
, S Charalambous
3
, S MungoIa
4
,
S Zizhou
5
, J van Dijk
6
, J Shepherd
7
, P Phillips
8
, A Nunn
8
,
D Mitchison
1
, and RIFAQUIN Trial Team
1
St Georges, Univ of London, UK,
2
Univ of Cape Town, South
Africa,
3
Aurum Inst, Johannesburg, South Africa,
4
Harare Citv
Hlth Dept, Zimbabwe,
5
Med Directorate of Mashonaland East,
Marondera, Zimbabwe,
6
Macha Med Mission, Zambia,
7
CDC/
BOTUSA, Gaborone, Botswana, and
8
London, UK
12:00 148LB What Is the Right Dose of Rifampin?
Martin Boeree*
1
, A Diacon
2
, R Dawson
3
, A Venter
2
, J du Bois
2
,
K Narunsky
3
, M Hoelscher
4
, S Gillespie
5
, P Phillips
6
, R Aarnoutse
1
,
and PanACEA Consortium
1
Radboud Univ Nifmegen Med Ctr, The Netherlands,
2
Univ of
Stellenbosch, Cape Town, South Africa,
3
Africa,
4
Med Ctr of the Univ of Munich, Germanv,
5
Univ of St
Andrews, UK, and
6
MRC Clin Trial Unit, London, UK
!
Wednesday, 10 am-12:15 pm; Ballroom 1-2

"#$$%&' (4*+,-. /0$1,-21$
Advances in ARV and Anti-Hepatitis C
Virus Therapy
Moderators:
Jintanat Ananworanich, HIJ-NAT, Bangkok, Thailand
Jean-Francois DelIraissy, French Natl Agencv for Res on AIDS and Jiral
Hepatitis, Paris
10:00 149 Trend in Transmitted HIV-1 ARV Drug
Resistance-associated Mutations: 10 HIV
Surveillance Areas, US, 2007-2010
David Kim*
1
, R Ziebell
1
, N Saduvala
2
, R Kline
1
, C Banez OcIemia
1
,
J Prejean
1
, X Zhang
1
, M Pearson
1
, I Hall
1
, and Variant, Atypical, and
Resistant HIV Surveillance Group
1
CDC, Atlanta, GA, US and
2
ICF Intl, Atlanta, GA, US
10:15 150 Mortality after Starting ART in Treatment-nave
Adults in 3 Continents: Collaborative Analysis
of International Epidemiologic Databases to
Evaluate AIDS in Southern Africa and ART
Cohort Collaboration Cohorts
Andrew Boulle*
1
, M Schomaker
1
, M May
2
, M Egger
3
, J Sterne
2
,
and site investigators Irom IeDEA-SA and ART-CC Collaborations
1
2
Bristol Univ, UK, and
3
Univ of
Bern, Swit:erland
10:30 151 Superiority of Routine Viral Load Monitoring
in Rural Kenya: the Kericho Clinic-based ART
Diagnostic Evaluation (CLADE) Trial
Fredrick Sawe*
1,2
, P Yegon
1
, R Langat
1
, E Obiero
3
, J Maswai
1
,
M Bii
1
, A Aoko
1
, K Shikuku
1
, N Close
4
, D ShaIIer
1,2
, and CLADE Team
1
Kenva Med Res Inst/Walter Reed Profect, Kericho,
2
US Militarv
HIJ Res Prgm, Bethesda, MD,
3
Kenva Ministrv of Med Svcs,
Kericho, and
4
EmpiriStat, Mt Airv, MD, US
10:45 152 Renal Insufficiency among Women Treated with
Tenofovir/Emtricitabine/Lopinavir/Ritonavir or
Tenofovir/Emtricitabine/Nevirapine
A MwaIongo
1
, K Nkanaunena
2
, Mina Hosseinipour*
1,3
,
S Lockman
4
, M Hughes
4
, J Currier
5
, and ACTG 5208
1
Univ of Northern Carolina Profect, Lilongwe, Malawi,
2
Coll of
Med-John Hopkins Univ Res Profect, Blantvre, Malawi,
3
Univ of
North Carolina at Chapel Hill, US,
4
Boston, MA, US, and
5
Program 19
W
e
d
n
e
s
d
a
y
M
a
r
c
h

6
O
r
a
l

S
e
s
s
i
o
n
s
11:00 153LB Omitting NRTI from ARV Regimens Is Not
Inferior to Adding NRTI in Treatment-experienced
HIV
+
Subjects Failing a Protease Inhibitor
Regimen: The ACTG OPTIONS Study
Karen Tashima*
1
, L Smeaton
2
, A Andrade
3
, J Eron
4
, C Fichtenbaum
5
,
R Gandhi
6
, V Johnson
7
, K Klingman
8
, K Hollabaugh
2
, R Haubrich
9
, and
A5241 Study Team
1
The Miriam Hosp, Alpert Med Sch of Brown Univ, Providence, RI,
US,
2
Ctr for Biostatistics in AIDS Res, Harvard Sch of Publ Hlth,
Boston, MA, US,
3
4
Univ
of North Carolina at Chapel Hill, US,
5
Univ of Cincinnati, OH, US,
6
Massachusetts Gen Hosp and Ragon Inst, Boston, US,
7
Birmingham
JA Med Ctr and Univ of Alabama at Birmingham Sch of Med, US,
8
HIJ Res Branch, TRP, DAIDS, NIAID, NIH, Bethesda, MD, US,
and
9
11:15 154LB Simeprevir with Pegylated Interferon/Ribavirin
in Patients Co-infected with Chronic Hepatitis C
Virus and HIV-1: Week-24 Interim Analysis of
the TMC435-C212 Study
Douglas Dieterich*
1
, J Rockstroh
2
, C Orkin
3
, F Gutierrez
4
,
M Klein
5
, J Reynes
6
, W Jessner
7
, O Lenz
7
, M Peeters
7
, and M
Beumont-Mauviel
7
1
2
Medi: Universittsklinik-
Immunologische Ambulan:, Bonn, Germanv,
3
Roval London
Hosp, UK,
4
Hosp Gen de Elche and UMH, Alicante, Spain,
5
Muhc
Montreal Chest Inst, Canada,
6
Hosp Gui De Chauliac, Montpellier,
France, and
7
Janssen Infectious Diseases BJBA, Beerse, Belgium
11:30 155LB Suppression of Viral Load through 4 Weeks
Post-Treatment Results of a Once-daily Regimen
of Simeprevir + Sofosbuvir with or without
Ribavirin in Hepatitis C Virus GT1 Null
Responders
Eric Lawitz*
1
, R Ghalib
2
, M Rodriguez-Torres
3
, Z Younossi
4
,
A Corregidor
5
, I Jacobson
6
, K Callewaert
7
, W Symonds
8
, G Picchio
9
,
and K Lindsay
9
1
Alamo Med Res, San Antonio, TX, US,
2
The Liver Inst, Dallas, TX,
US,
3
Fndn de Investigacion, San Juan, Puerto Rico,
4
Inova Fairfax
Hosp, Falls Church, JA, US,
5
Borland-Groover Clin, Jacksonville,
FL, US,
6
Weill Cornell Med Coll, New York, NY, US,
7
Janssen Res
and Devt, Beerse, Belgium,
8
Gilead Sci, Inc, Foster Citv, CA, US,
and
9
Janssen Res and Devt LLC, Titusville, FL, US
11:45 156LB Telaprevir for Acute Hepatitis C Virus in HIV
+

Men both Shortens Treatment and Improves
Outcome
Daniel Fierer
Mt Sinai Sch of Med
12:00 157LB High Efficacy of Sofosbuvir with Weight-based
Ribavirin for 24 Weeks in Difficult-to-Treat
Patients
Anu Osinusi*
1,2
, D Bon
3
, E Herrmann
3
, G TeIeri
4
, R Talwani
5
,
H Masur
6
, W Symonds
7
, J McHutchison
7
, A Fauci
1
, S Kottilil
1
,
and NIAID SPARE Study Team
1
LIR, NIAID, Bethesda, MD, US,
2
CMRP, SAIC-Frederick, Inc,
Frederick Natl Lab for Cancer Res, MD, US,
3
IBBM, Johann
Wolfgang Goethe Univ, Frankfurt,
4
Unitv Health Care Inc,
Washington, DC, US,
5
Univ of Marvland Med Ctr, Baltimore, US,
6
CCMD, CC, NIH, Bethesda, MD, US, and
7
Gilead Sci, Foster Citv,
CA, US
!
Wednesday, 1:30-2:30 pm; B402

"#$$%&' (()*+#,#- .%$/0$$%&'
Aging and Neurocognitive Function in HIV Infection
Discussants:
Bruce Brew, St Jincents Hosp and Univ of New South Wales, Svdnev, Australia
Kevin Robertson, AIDS Dementia Ctr, Univ of North Carolina at
Chapel Hill, US
439 Older Age and Neurocognitive Function:
Multi-center AIDS Cohort Study
Karl Goodkin*
1
, E Miller
2
, C Cox
3
, S Reynolds
3
, D Ostrow
4
, O Selnes
5
,
E Martin
6
, N Sacktor
5
, and J Becker
7
1
AIDS Hlthcare Fndn, Los Angeles, CA, US,
2
Angeles, US,
3
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore,
MD, US,
4
Univ of Chicago, IL, US,
5
Johns Hopkins Univ Sch of Med,
Baltimore, MD, US,
6
Univ of Illinois at Chicago, US, and
7
Univ of
Pittsburgh, PA, US
440 Veterans Aging Cohort Study Index Score Is
Associated with Neurocognitive and Functional
Impairment: A CHARTER Study
D Franklin Jr
1
, R Heaton
1
, S Woods
1
, S Letendre
1
, A Collier
2
, D CliIIord
3
,
B Gelman
4
, J McArthur
5
, D Simpson
6
, Igor Grant*
1
, and CHARTER Group
1
2
3
Washington Univ, St Louis, MO, US,
4
Univ of Texas Med Branch,
Galveston, US,
5
Johns Hopkins Univ, Baltimore, MD, US, and
6
Mt Sinai
Sch of Med, New York, NY, US
441 Changing Cerebrospinal Fluid Concentrations
of Neurofilament Light Chain Protein, Tau, and
Amyloid Proteins Characterize Evolving Central
Nervous System Injury in HIV-1 Infection
Julia Peterson*
1
, H Zetterberg
2
, L Hagberg
2
, S Spudich
3
, M Gisslen
2
,
and R Price
1
1
2
Sahlgrenska Academv at Univ of
Gothenburg, Sweden, and
3
Yale Univ, New Haven, CT, US
442 Prevalence of Cerebrospinal Fluid Alzheimer`s
Disease-like Profiles in Chronic Middle-aged HIV
+

Individuals
L Cysique
1,2
, J Lamoury
2
, T Hewitt
2,3
, K Taddei
4,5,6
, R Martins
4,5
, C Chew
5
,
P Price
5
, and Bruce Brew*
1,2
1
St Jincents Hosp, Svdnev, Australia,
2
Univ of New South Wales, Svdnev,
Australia,
3
Notre Dame Univ, Svdnev, Australia,
4
Edith Cowan Univ,
Australia,
5
Univ of Western Australia, Perth, and
6
Hollvwood Private
Hosp, Nedlands, Australia
443 Axonal Disturbance in Neuroasymptomatic Patients
off and on Suppressive ART: An Aging Effect of
Central Nervous System Infection?
Jan Jessen Krut*
1
, T Mellberg
1
, R Price
2
, L Hagberg
1
, D Fuchs
3
,
L Rosengren
1
, S Nilsson
4
, H Zetterberg
1,5
, and M Gisslen
1
1
Sahlgrenska Academv, Univ of Gothenburg, Sweden,
2
Univ of California,
San Francisco, US,
3
Innsbruck Med Univ, Austria,
4
Chalmers Univ of Tech,
5
Univ Coll London, Inst of Neurologv, UK
444 Longitudinal Association of HIV-associated
Neurocognitive Disorders with Frailty in HIV-1
+
Men

Bryan Smith*
1
, R Skolasky
1
, F Mateen
1
, J Becker
2
, E Martin
3
, E Miller
4
,
J Margolick
5
, O Selnes
1
, N Sacktor
1
, and Multictr AIDS Cohort Group
1
2
Univ of Pittsburgh
Sch of Med, PA, US,
3
Univ of Illinois Sch of Med, Chicago, US,
4
David
Geffen Sch of Med, Univ of California, Los Angeles, US, and
5
Johns
Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD US
445 HIV and Aging: New Graph Theoretical Models
of rs-fcMRI Neuropathophysiology
Jewell Thomas*, M Brier, and B Ances
Washington Univ in St. Louis
!

"#$$%&' (1)*+#,#- .%$/0$$%&'
Transmitted/Founder Viruses
Discussants:
Feng Gao, Duke Univ, Durham, NC, US
Thomas Hope, Northwestern Univ, Chicago, IL, US
244 Recombination Shapes Viral Evolution during
Early Infection in Individuals Infected with Multiple
Transmitted/Founder HIV-1

Hongshuo Song*
1
, F Cai
1
, V Ganusov
2
, J Pavlicek
1
, B Keele
3
, H Li
4
,
G Shaw
4
, B Haynes
1
, B Hahn
4
, and F Gao
1
1
Duke Univ Med Ctr, Durham, NC, US,
2
Univ of Tennessee, Knoxville, US,
3
SAIC-Frederick Inc, MD, US, and
4
245 MTCT Is Associated with a Gag-Protease-driven
Viral Fitness Bottleneck

Vanessa Naidoo*
1
, J Mann
1
, J Carlson
2
, C Brumme
3
, C Thobakgale
1
,
P Goulder
4
, D Heckerman
2
, Z Brumme
3,5
, M Brockman
3,5
, and T Ndungù
1
1
HIJ Pathogenesis Prgm, Univ of KwaZulu-Natal, Durban, South Africa,
2
3
BC Ctr for Excellence in HIJ/
AIDS, Jancouver, Canada,
4
Univ of Oxford, UK, and
5
Simon Fraser Univ,
Burnabv, Canada
246 Subtype C HIV-1 Variants Transmitted by
Breastfeeding Have Less Glycosylated V2 Loops
and Are More Susceptible to V2-Targeted Antibodies
PG9 and PG16

Kyle Nakamura*
1
, C Cerini
1
, E Sobrera
1
, L Heath
2
, M Sinkala
3
,
C Kankasa
4
, D Thea
5
, J Mullins
2
, L Kuhn
6
, and G Aldrovandi
1
1
Children`s Hosp Los Angeles, CA, US,
2
3
Lusaka District Hlth Mgmt Team, Zambia,
4
Univ of Zambia, Lusaka,
5
6
Columbia Univ, New York,
NY, US
247 Transmitted/Founder and Chronic HIV-1 Env
Proteins Differentially Utilize CCR5

Zahra Parker*
1
, S Iyer
1
, C Wilen
1
, N Parrish
1
, R Berro
2
, B Lee
3
,
J Moore
2
, G Shaw
1
, B Hahn
1
, and R Doms
1,4
1
2
Weill Med
Coll of Cornell Univ, New York, NY, US,
3
Univ of California, Los Angeles,
US, and
4
Children`s Hosp of Philadelphia, PA, US
W
e
d
n
e
s
d
a
y
M
a
r
c
h

6
O
r
a
l

S
e
s
s
i
o
n
s
248 Phenotypic Differences Between Transmitted/Founder
and Chronic Env Proteins Revealed by Quantitative,
High-Throughput Receptor Affinity Profiling

Kelechi Chikere*
1
, N Webb
1
, T Chou
1
, P Gorry
2
, and B Lee
1
1
2
Burnet Inst, Melbourne, Australia
249 Transmitted/Founder Infectious Molecular Clones
of Divergent SIV
smm
Strains Are Infectious and
Replication Competent !" $!$%
D Ma
1
, H Li
2
, C Xu
1
, B Keele
3
, J Estes
3
, J LiIson
3
, I Pandrea
1
, G Shaw
2
,
B Hahn
2
, and Cristian Apetrei*
1
1
Ctr for Jaccine Res, Univ of Pittsburgh, PA, US,
2
Univ of Pennsvlvania
Perelman Sch of Med, Philadelphia, US, and
3
Frederick Natl Lab, MD, US
250 The Number and Genetic Relatedness of
Transmitted/Founder Virus Impact Clinical
Outcome in Vaginal R5 SHIV
SF162P3N
Transmission
Lily Tsai*
1
, I Tasovski
2
, AR Leda
1
, M Chin
2
, and C Cheng-Mayer
1
1
Aaron Diamond AIDS Res Ctr, New York, NY, US and
2
Temple Univ Sch of
Med, Philadelphia, PA, US
!

&'((!%" )*+,-'.'/ 0!(12((!%"
Emergence and Persistence of HPV-associated
Discussants:
Elizabeth Chiao , Bavlor Coll of Med, Houston, TX, US
Cynthia Firnhaber, Univ of the Witwatersrand, Johannesburg, South Africa
730 AIDS-defining Cancers in Switzerland 1985-2011:
Separating the Effects of Age and Period
F Schoni-AIIolter
1
, L Elzi
2
, R Weber
3
, A Calmy
4
, A Bregenzer
5
,
M Cavassini
6
, H Furrer
7
, G CliIIord
8
, M Egger
1
, Olivia Keiser*
1
,
1
Univ of Bern, Swit:erland,
2
3
Univ Hosp
Zurich, Swit:erland,
4
Geneva Univ Hosp, Swit:erland,
5
Cantonal Hosp St
Gallen, Swit:erland,
6
Univ Hosp Lausanne, Swit:erland,
7
Univ Hosp Bern,
Swit:erland, and
8
Intl Agencv for Res on Cancer
731 Incidence of AIDS-defining and Non-AIDS-defining
Cancers following Expansion of ART: Botswana
2003-2008
Scott Dryden-Peterson*
1,2,3
, H Medhin
4
, G Seage
2
, M Pusoentsi
4
, S El-Halabi
4
,
T Rebbeck
5
, G Suneja
5
, M Mmalane
3
, M Essex
2,3
, and S Lockman
1,2,3
1
Brigham and Women`s Hosp, Boston, MA, US,
2
Boston, MA, US,
3
Botswana Harvard AIDS Inst Partnership, Gaborone,
4
Botswana Ministrv of Hlth, Gaborone, and
5
Univ of Pennsvlvania,
Philadelphia, US
732 Frequent Detection of Human Papillomavirus before
and after Initiation of ART among HIV
+
Women:
Uganda

Anne Rositch*
1
, P Gravitt
1,2
, A Tobian
1,3
, K Newell
4
, T Quinn
3,5
,
D Serwadda
6
, P Ssebbowa
6
, V Kiggundu
6
, R Gray
1,6
, and S Reynolds
3,5
1
2
Perdana Univ Grad Sch of Med, Serdang, Malavsia,
3
Johns Hopkins Univ
Sch of Med, Baltimore, MD, US,
4
Frederick Natl Lab for Cancer Res, MD, US,
5
6
Rakai Hlth Sci Prgm, Entebbe, Uganda
733 HPV Genotype Impacts T Cell Activation and
Cervical Cellular Infiltrates Irrespective of Lesion
Grade in ART-suppressed Human Papillomavirus/
HIV-1 Co-infected Women
Emmanouil Papasavvas*
1
, D Glencross
2,3
, N Mayisela
4
, T Omar
2
,
A-L Williamson
5,6
, M Siminya
4
, X Yin
1
, Q Liu
1
, C Firnhaber
2,4
,
and L Montaner
1
1
The Wistar Inst, Philadelphia, PA, US,
2
3
Natl Hlth Lab Svc, Johannesburg, South
Africa,
4
Right to Care, Johannesburg, South Africa,
5
Univ of Cape Town,
South Africa, and
6
Natl Hlth Lab Svc, Cape Town, South Africa
734 Human Papillomavirus, Cervical Neoplasia, and
Invasive Cancer in Women with HIV-2 Infection in
the ART Era: Senegal, West Africa
S Hawes
1
, Q Feng
1
, S Ba
2
, M Toure
1,2
, M-P Sy
2
, F Traore
2
, R Smith
1
, N Kiviat
1
,
PS Sow
1,2
, GeoIIrey Gottlieb*
1
, and UW-Dakar HIV-2 Study Group
1
2
Ctr Hosp Univ de Fann, Univ Cheikh
Anta Diop de Dakar, Senegal
735 Anal Human Papillomavirus Infection in HIV
+

Patients: Prevalence, Incidence, and Predictors
of High-risk Human Papillomavirus Infection

Alberto Borghetti*
1
, P Cattani
2
, G Maria
3
, M Sanguinetti
2
,
S DÒnghia
2
, R Santangelo
2
, S Marchetti
2
, R Cauda
1
, A De Luca
1,4
,
and S Di Giambenedetto
1
1
Inst of Clin Infectious Diseases, Catholic Univ of Sacred Heart, Rome,
Italv,
2
Inst of Microbiologv, Catholic Univ of Sacred Heart, Rome, Italv,
3
Inst of Clin and Surgical Therapv, Catholic Univ of Sacred Heart, Rome,
Italv, and
4
Siena Univ Hosp, Italv
736 The Effect of Protease Inhibitors on the Incidence of
HIV-associated Squamous Cell Carcinoma of the Anus

Pamela Mbang*
1
, M Kowalkowski
2
, and E Chiao
1,2
1
Bavlor Coll of Med, Houston, TX, US and
2
Houston Hlth Svcs Res and Devt
Ctr of Excellence, Michael E DeBakev JAMC, TX, US
737 Prevalence and Genotypes of Human Papillomavirus at
Penile and Perianal Sites among HIV
+
and HIV
-
MSM
Han-Zhu Qian*
1
, Y Hu
2
, L Yin
1
, Y Ruan
2
, Y Shao
2
, and S Vermund
1
1
Janderbilt Univ, Nashville, TN, US and
2
Natl Ctr for STD/AIDS Control
and Prevention of China CDC, Beifing
!

&'((!%" )3+,-'.'/ 0!(12((!%"
Mechanisms of Immune Reconstitution
Discussants:
Brigitte Autran, Univ Pierre and Marie Curie, Pitie-Salpetriere Hosp,
Paris, France (invited)
Robert Colebunders, Inst of Tropical Med Antwerp, Belgium
859 Early ART after Cryptococcal Meningitis Increases
Cerebrospinal Fluid Macrophage Activation and
Aberrant Th2 Responses in a Multisite Randomized Trial
James Scriven*
1,2
, J Rhein
3,4
4
, M von Hohenberg
4
,
G Linder
4
, M RolIes
4
, D Williams
3,4
, D Meya
3,4,5
, G Meintjes
2
, D Boulware
4
,
and Cryptococcal Optimal ART Timing Trial
1
2
Africa,
3
Infectious Disease Inst, Kampala, Uganda,
4
Univ of Minnesota,
Minneapolis, US, and
5
860 Impact of TB-associated Immune Reconstitution
Inflammatory Syndrome on T Cell Activation and
Reconstitution in Highly Immunosuppressed HIV/TB
Co-infected Patients Starting ART
V Haridas
1
, P Pean
2
, L Jasenosky
1
, Y Madec
3
, D Laureillard
4
, L Borand
2
,
O Marcy
5
, T Sok
5
, X Blanc
6
, and Anne GoldIeld*
1,5
1
Prgm in Cellular and Molecular Med, Children`s Hosp, Boston, MA, US,
2
Inst Pasteur du Cambodge, Phnom Penh, Cambodia,
3
Inst Pasteur, Paris,
France,
4
ANRS, Ho Chi Minh Citv, Jietnam,
5
Cambodian Hlth Committee,
Phnom Penh, and
6
Bicetre Hosp Assistance Publ-Hosp de Paris, France
861 45 $!$% Interferon Gamma Release Assay Responses
to Cryptococcal Capsule Antigen Predict Outcomes
of Death or Immune Reconstitution Inflammatory
Syndrome after Cryptococcal Meningitis

Darin Wiesner*
1
, A Akamps
2
, J Rhein
1,3
, D Williams
1,3
, D Meya
1,2,3
,
P Bohjanen
1
, K Nielsen
1
, D Boulware
1
, and Cryptococcal Optimal ART
Timing Trial
1
2
and
3
Infectious Disease Inst, Kampala, Uganda
862 Biomarkers of CD4
+
T Cell Activation in HIV
+

Patients Developing 671%891:';!2. :28';12<%(!(-
associated Immune Reconstitution Inflammatory
Syndrome
Lisa Chakrabarti*
1
, C Boucherie
2
, F Bugault
1
, M-C Cumont
1
,
C Roussillon
2
, G Breton
3
, O Patey
4
, L Richert
2
, G Chene
2,5
, O Lortholary
6
,
and ANRS 129 BKVIR-CYTOK Substudy Group
1
Inst Pasteur, Paris, France,
2
INSERM U897, Univ Bordeaux, France,
3
Hosp de La Pitie-Salpetriere, Paris, France,
4
Hosp Jilleneuve St-Georges,
France,
5
CHU de Bordeaux, France, and
6
Univ Paris Descartes, Hosp
Necker Enfants Malades, APHP, Paris, France
!
Wednesday, 1:30-2:30 pm; Ballroom 3-4

&'((!%" )=+,-'.'/ 0!(12((!%"
Adherence and Retention in RLS
Discussants:
David Bangsberg, Massachusetts Gen Ctr for Global Hlth, Boston, US
WaIaa El-Sadr, Columbia Univ, Harlem Hosp Ctr, New York, NY, US
1101 Validating Measures of Distance to HIV Clinic in
Rural Uganda and Its Impact on Clinic Attendance

Mark Siedner*
1
, A Lankowski
1
, A Tsai
1,2
, C Muzoora
3
, P Hunt
4
,
J Martin
4
, J Haberer
1
, and D Bangsberg
1,5
1
Massachusetts Gen Hosp Ctr for Global Hlth, Boston, US,
2
Massachusetts
Gen Hosp, Boston, US,
3
4
Univ
5
Harvard Med Sch, Boston, US
1102 Site and Program Determinants of Patient Retention
in HIV Care: Nigeria

Chinenye Ugoji*
1
, R Ake-Uzoigwe
1
, MY Ladele
1
, C Akolo
1
, G Mendy
1
,
P Dakum
1
, M Charurat
2
, D Onotu
3
, O Nwanyanwu
3
, and W Blattner
2
1
Inst of Human Jirologv Nigeria, Abufa,
2
Inst of Human Jirologv, Univ of
Marvland, Baltimore, US, and
3
Ctr for Disease Control, Nigeria
Program 21
W
e
d
n
e
s
d
a
y
M
a
r
c
h

6
O
r
a
l

S
e
s
s
i
o
n
s
1103 Attrition through Multiple Stages of HIV Care
in South Africa: A Challenge for Test-and-Treat
Matthew Fox*
1,2,3
and K Shearer
3
1
Ctr for Global Hlth and Devt, Boston Univ, MA, US,
2
Boston Univ Sch of
Publ Hlth, MA, US, and
3
Hlth Economics and Epidemiologv Res Office,
1104 Retention in Care up to ART Initiation within a
Decentralized HIV Program in South Africa:
The Critical Role of the First Clinic Visit

Melanie Plazy*
1,2
, R Dray-Spira
3
, J Orne-Gliemann
1,2
, F Dabis
1,2
,
and M-L Newell
4
1
Univ Bordeaux, ISPED, INSERM U897, France,
2
ISPED, INSERM
U897, Bordeaux, France,
3
Epidemiologv of Occupational and Social
Determinants of Hlth-Ctr for Res in Epidemiologv and Population Hlth,
INSERM U1018, Jillefuif, France, and
4
Africa Ctr for Hlth and Population
Studies, Univ of KwaZulu-Natal, South Africa
1105 Co-enrollment of HIV
+
Family Members in Care
Is Associated with Improved Outcomes for Women
on ART: A Cohort Study
Landon Myer*
1
, J Duong
2
, Y Zhang
2
, E Abrams
3
, R Carter
3
,
and MTCT-Plus Initiative
1
2
Mailman Sch of Publ Hlth, Columbia
Univ, New York, US, and
3
Intl Ctr for AIDS Care and Treatment Prgms,
Mailman Sch of Publ Hlth, Columbia Univ, New York, NY, US
1106 A Sampling-based Approach to Assessing
Patient-reported Barriers to Retention among
HIV
+
Patients on ART: East Africa
Elvin Geng*
1
, T Odeny
2
, L Rita
3
, A Nakiwogga-Muwanga
4
, M Bwana
5
,
E Bukusi
6
, G Somi
3
, P Braitstein
7
, C Yiannoutsos
7
, J Martin
1
, and East
AIrica Intl Epidemiologic Databases to Evaluate AIDS
1
2
Familv AIDS Care and Ed Svcs,
Kisumu, Kenva,
3
Natl AIDS Control Prgm, Dar es Salaam, Tan:ania,
4
5
Mbarara Univ of Sci
and Tech, Uganda,
6
Kenva Med Res Inst, Nairobi, and
7
Indiana Univ,
Indianapolis, US
1107 Real-time HIV ART Adherence Monitoring
Predicts Loss of Viral Suppression and Subsequent
Resuppression: Rural Uganda
Jessica Haberer*
1,2
, C Muzoora
3
, P Hunt
4
, J Martin
4
, M Siedner
1,2
,
and D Bangsberg
1,2,3
1
2
US,
3
Mbarara Univ of Sci and Tech, Uganda, and
4
Univ of California,
San Francisco, US
!
Wednesday, 1:30-2:30 pm; Ballroom 1-2

"#$$%&' ()*+,#-#. /%$01$$%&'
Inflammatory Biomarkers, Microparticles, and
Clinical Outcomes in HIV
Discussants:
Tricia Burdo, Boston Coll, MA, US
Esteban Martinez, Hosp Clin, Barcelona, Spain (invited)
788 Inflammatory Cytokines and Mortality in a Cohort
of HIV
+
Patients with Alcohol Problems

Daniel Fuster*
1
, D Cheng
1,2
, E Quinn
3
, K Armah
4
, R Saitz
1
,
M Freiberg
5
, J Samet
1
, and J Tsui
1
1
Boston Med Ctr and Boston Univ Sch of Med, MA, US,
2
Boston Univ Sch of
Publ Hlth, MA, US,
3
Data Coordinating Ctr, Boston Univ Sch of Publ Hlth,
MA, US,
4
Univ of Pittsburgh Grad Sch of Publ Hlth, PA, US, and
5
Univ of
Pittsburgh, PA, US
789 Tissue Factor Microparticles among HIV
+
Persons
Are Reduced with ART and Associated with D-dimer
Levels after Treatment
Jason Baker*
1,2
, K Huppler Hulsiek
1
, R BradIord
3
, R Prosser
1,2
, R Tracy
4
,
and N Key
3
1
2
Hennepin Countv Med Ctr,
Minneapolis, MN, US,
3
and
4
Univ of Jermont, Burlington, US
790 Soluble Markers of Inflammation and Coagulation,
but Not T Cell Activation, Predict Non-AIDS-defining
Events during Suppressive ART
Allan Tenorio*
1
, E Zheng
2
, R Bosch
2
, S Deeks
3
, B Rodriguez
4
,
S Krishnan
2
, P Hunt
3
, C Wilson
5
, M Lederman
4
, A Landay
1
, and ACTG
1
Rush Univ Med Ctr, Chicago, IL, US,
2
Harvard Sch of Publ Hlth, Boston,
MA, US,
3
San Francisco Gen Hosp and Univ of California, San Francisco,
US,
4
Case Western Reserve Univ Sch of Med, Cleveland, OH, US, and
5
Univ of Colorado Hosp, Aurora, US
791 Inflammation and Coagulation Markers Are
Predictive of Anemia in ARV-treated HIV Disease

Alvaro Borges*
1
, J Weitz
2
, G Collins
3
, J Baker
3,4
, Y Levy
5
, R Davey
6
,
A Phillips
7
, J Neaton
3
, J Lundgren
1
, S Deeks
8
, Ior INSIGHT SILCAAT
Study Group
1
Copenhagen HIJ Prgm and Rigshospitalet, Denmark,
2
Thrombosis
and Atherosclerosis Res Inst, Hamilton, Canada,
3
Univ of Minnesota,
Minneapolis, US,
4
5
Assistance Publ-Hosp de Paris, INSERM U955, Univ Paris 12, Creteil,
France,
6
7
Univ Coll London Med Sch,
UK, and
8
792 Osteoprotegerin and Receptor Activator of Nuclear
Factor Kappa Ligand Are Associated with
Subclinical Coronary Atherosclerosis: Multicenter
AIDS Cohort Study
Kerunne Ketlogetswe*
1
, W Post
1,2
, X Li
2
, L Jacobson
2
, F Palella
3
,
J Margolick
2
, L Kingsley
4
, M Witt
5
, M BudoII
5
, T Brown
1,2
, and Multictr
AIDS Cohort Study
1
2
Johns Hopkins Univ
Bloomberg Sch of Publ Hlth, Baltimore, MD, US,
3
Northwestern Univ
Feinberg Sch of Med, Chicago, IL, US,
4
Univ of Pittsburgh Grad Sch of
Publ Hlth, PA, US, and
5
Harbor UCLA Med Ctr, Torrance, CA, US
W
e
d
n
e
s
d
a
y
M
a
r
c
h

6
O
r
a
l

S
e
s
s
i
o
n
s
!
Wednesday, 2:30-4 pm; Hall B2
!"#$%& ()#$&*+$#
Session 54. ART, Complications, and TB
Session 57. Accessory Proteins/Gag
Session 61. Macrophage HIV Interactions: Cell Biology and Treatment
Session 65. HIV Genotypes and Phenotypes
Session 68. HIV and Monocytes, Macrophages, and Dendritic Cells
Session 72. Microbial Translocation
Session 76. Neutralizing Antibodies and How to Stimulate Them
Session 81. Mechanism oI HIV Latency and Reactivation
Session 83. Gene and Adoptive Immunotherapy
Session 91. NeuroAIDS Clinical Studies
Session 92. Neuroimaging Studies
Session 93. Human Genomics
Session 103. Compartment Penetration oI ARV
Session 104. ARV Drug Interactions
Session 107. ART: Too Early or Too Late? Or Better Late than Never!
Session 108. ART: Host and Viral Determinants oI Outcome
Session 109. ART: Care and Adherence
Session 125. Hepatitis C Virus Epidemiology and Clinical Outcomes
Session 129. HIV-associated Malignancies: Lymphoma
Session 136. Microbial Translocation Measurement and Associations
Session 139. ART EIIects: Gene Expression and Cellular Function
Session 140. Frailty: From Mice to Men and Women
Session 142. Renal Disease: Diagnosis, Predictors, and Drugs
Session 145. TB: Incidence, Risk Factors, and Outcomes
Session 146. TB Diagnostics
Session 148. The 'ART oI TB Treatment
Session 158. HIV Risk Factors, Prevalence, and Barriers to Care
Session 159. Family Planning: Unintended Pregnancy and Unmet Need
Session 160. HIV in Peri- and Post-menopause
Session 165. Pregnancy Complications among HIV
Women
Session 166. PMTCT: Maternal and Child Health Outcomes
Session 177. HIV and ART-related Complications and Treatment in
Children and Youth
Session 179. TenoIovir in Children
Session 181. Immune Response to Perinatal HIV
Session 182. Response to Pediatric Vaccines in Children and Youth
Session 185. Oral PrEP and ARV Adherence
Session 189. MSM in the Developing World
Session 192. Disease Progression, Morbidity, and Mortality
Session 195. Biological and Behavioral Transmission Risks
Session 196. Reducing Risk
Session 199. Virologic Failure, 2
nd
- and 3
rd
-line Therapy in RLS
"
Wednesday, 4-6 pm; B406

,%##-". /01,234"#-53
Progress in Deciphering HIV Protective Immunity,
a symposium in memory of Norman Letvin
Conveners:
Beatrice Hahn, Univ of Pennsvlvania,
Philadelphia, US
Gary Nabel, Sanofi, Cambridge, MA, US
158
Viral Escape and Neutralizing Antibody
Evolution in Early HIV-1 Infection
Cynthia Derdeyn
159
The Promise and Challenge of Broad and
Potent Neutralizing Antibody Responses to
HIV-1
Mark Connors
HIJ-Specific Immunitv Section, NIAID, NIH, Bethesda, MD, US
160
The Role of CD4 T in Developing Durable
Antibody Responses and as HIV Vaccine
Hendrik Streeck
US Militarv HIJ Res Prgm, Walter Reed Armv Inst of Res, Henrv
M Jackson Fndn, Silver Spring, MD

161
Stringent Control and Eventual Clearance of
Highly Pathogenic SIV by Effector Memory
T Cells
Louis Picker
Jaccine and Gene Therapv Inst, Oregon Natl Primate Res Ctr,
Oregon Hlth and Sci Univ, Beaverton, US
interested in basic immunology, the immunology oI HIV inIection,
or HIV vaccine development. It is assumed that participants will
have some knowledge oI basic immunological concepts including
the impact oI HIV on the immune system. At the completion oI the
session, participants will be knowledgeable about how replicating
vaccine vectors might provide protection against SIV, how diIIerent
CD4 T cells populations may be active in Iighting HIV inIection,
how broadly neutralizing antibodies develop in some HIV
subjects,
and the characteristics and potential uses oI newly discovered
broadly neutralizing antibodies.
Program 23
W
e
d
n
e
s
d
a
y
M
a
r
c
h

6
O
r
a
l

S
e
s
s
i
o
n
s
!
Wednesday, 4-6 pm; Ballroom 3-4

"#$$%&' ()*"+,-&$%.,
HIV Testing and Monitoring the Epidemic: New
Tools for Patients and Populations
Conveners:
Tsehaynesh Messele, African Societv
for Lab Med, Addis Ababa, Ethiopia
Trevor Peter, Clinton Hlth Access
Initiative, Boston, MA, US
162
HIV Self-testing: Opportunities and
Challenges
Julie Myers
New York Citv Dept of Hlth and Mental Hvgiene and Columbia
Univ Med Ctr, NY, US
163
When Diagnosis Gets up Close and Personal:
Point-of-Care Assays for Immunological and
Virological Monitoring of HIV Disease
Ilesh Jani
Inst Nacional de Saude, Maputo, Mo:ambique
164
Accurate Cross-sectional HIV Incidence Testing
Oliver Laeyendecker*
1,2
, R Brookmeyer
3
, M Kulich
4
,
T Quinn
1,2
, J KonikoII
3
, M Cousins
2
, D Donnell
5,6
, and S Eshleman
2
1
NIAID, NIH, Baltimore MD, US,
2
Johns Hopkins Univ,
Baltimore, MD, US,
3
4
Charles Univ Prague, C:ech Republic,
5
Fred Hutchinson
Cancer Res Ctr, Seattle, WA, US, and
6
Univ of Washington,
Seattle, US
165
Viral Load Measures: Patients, Populations,
and Interpretations
Irene Hall
Objectives: The session is directed to clinicians and
scientists interested in new laboratory methods Ior diagnosing HIV
inIection and monitoring the impact oI treatment on individuals and
populations. It is assumed that participants are Iamiliar with the basic
methods used to diagnose HIV inIection and monitor the response
to treatment. At the completion oI the session, participants will be
knowledgeable about home testing Ior HIV, monitoring response
to therapy in resource-limited settings, measuring HIV incidence in
populations, and the eIIect oI treatment on community viral load.
!
Wednesday, 4-6 pm; Ballroom 1-2

"#$$%&' (/*"+,-&$%.,
TB on the Verge
Conveners:
Constance Benson, Univ of California,
San Diego Antiviral Res Ctr, US
Papa SaliI Sow, Global Hlth Prgm, Bill &
Melinda Gates Fndn, Seattle, WA, US
166
Strategies for Prevention of Active TB
Gavin Churchyard
Aurum Inst and Sch of Publ Hlth, Univ of the Witwatersrand,
167
Impact of Rapid Diagnostic Testing-
Changing the TB Diagnostic Landscape
Catharina Boehme
Fndn for Innovative New Diagnostics, Geneva, Swit:erland
168
Treatment of TB in Women and Children
Soumya Swaminathan
Natl Inst for Res in TB, Chennai, India
169
Management of Drug-resistant TB
Alexander Pym
KwaZulu-Natal Res Inst for TB and HIJ, Nelson R Mandela Sch
of Med, Univ of KwaZulu-Natal, Durban, South Africa
interested in the pathogenesis, diagnosis, treatment, and prevention
oI TB. It is assumed that participants are Iamiliar with basic aspects
oI the disease and the current tools available Ior management oI
the disease. At the completion oI the session, participants will be
knowledgeable about challenges and limitations in prevention oI
HIV-related TB, newer molecular diagnostic tools Ior detecting
Mvcobacterium tuberculosis and drug resistance, unique challenges
in the diagnosis and treatment oI TB in pregnant women and children,
and new approaches Ior the treatment oI multidrug resistant TB.
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' ()*+&$,#- ./$,-01,$
HIV Persistence, Reservoirs, and Viremic Control
170aLB Impact of Interleukin-7 and Raltegravir + Maraviroc
Intensification on Total HIV DNA Reservoir: Results from
ERAMUNE 01
Christine Katlama*
1
, S Lambert
2
, L Assoumou
3
, L Papagno
4
,
F Lecardonnel
4
, G Tambussi
5
, B Clotet
6
, M Youle
7
, D Costagliola
3
,
B Autran
8
, and ERAMUNE-01 Study Group
1
Hosp Pitie-Salpetriere, Paris, France,
2
Lab of Jirologv, Univ Pierre
et Marie Curie Paris 6, INSERM U943, France,
3
Univ Pierre et Marie
Curie Paris 6, INSERM U943, France,
4
ORJACS with the support of
the Bettencourt-Schueller Fndn,
5
San Raffaele Hosp, Milan, Italv,
6
Hosp
Univ Germans Trias i Pufol, Fndn irsiCaixa, Badalona, Spain,
7
Roval
Free Hosp NHS Trust, London, UK, and
8
Lab of Cellular and Tissular
Immunologv, Univ Pierre et Marie Curie Paris 6, INSERM U945, France
170bLB Early Viral Dynamics after Cord Blood Stem Cell
Transplantation (with and without CCR532) Combined
with HLA Mismatched Donor in 2 HIV
+
Patients
M Nijhuis
1
, M Kwon
2
, J Kuball
1
, P Ellerbroek
1
, J Berenguer
2
, A Stam
1
,
J Symons
1
, D Richman
3
, JL Diez-Martin
2
, Annemarie Wensing*
1
,
and European HIV Cure and Transplant Consortium
1
Univ Med Ctr Utrecht, The Netherlands,
2
Gregorio Maranon G U Hosp,
Madrid, Spain, and
3
171LB Absent HIV-specific Immune Responses and Replication-
competent HIV Reservoirs in Perinatally Infected Youth
Treated from Infancy: Towards Cure
Katherine Luzuriaga*
1
, YH Chen
2
, C Ziemniak
2
, G Siberry
3
, M Strain
4
,
D Richman
4
, T-W Chun
5
, C Cunningham
6
, and D Persaud
2
1
Univ of Massachusetts Med Sch, Worcester, US,
2
Johns Hopkins Univ
3
Maternal and Pediatric Infectious
Disease Branch, NICHD, NIH, Bethesda, MD, US,
4
Univ of California
San Diego, La Jolla and JA San Diego Hlthcare Svstem, US,
5
NIAID,
NIH, Bethesda, MD, US, and
6
172LB HIV-1 DNA Decay Patterns in Blood during More than a
Decade of Suppressive ART: Results from ACTG NWCS 360

Guillaume Besson*
1
, C Lalama
2
, R Bosch
2
, R Gandhi
3
, M Bedison
1
,
E Aga
2
, S Riddler
1
, D McMahon
1
, F Hong
1
, and J Mellors
1
1
Univ of Pittsburgh Sch of Med, Division of Infectious Diseases, PA, US,
2
Ctr for Biostatistics in AIDS Res, Harvard Sch of Publ Hlth, Boston, MA,
US, and
3
Massachusetts Gen Hosp and Ragon Inst, Harvard Med Sch,
Boston, US
173LB Multifocal Detection of HIV-1 RNA in Lymphatic Tissues
during Early Viral Recrudescence after Treatment Interruption
Meghan Rothenberger*
1
, M Stevenson
2
, G Beilman
1
, J Chipman
1
,
A Khoruts
1
, C Fletcher
3
, C Reilly
1
, S WietgreIe
1
, A Haase
1
, and T Schacker
1
1
Univ of Minesota, Minneapolis, US,
2
Univ of Miami, FL, US, and
3
Univ
of Nebraska, Omaha, US
174LB A Rapid Virion Recovery Assay Reveals a Larger Population
of Inducible Proviruses in Resting CD4
+
T Cells than
Previously Recognized
Michele Sobolewski*
1
, A Cillo
1
, C Lalama
2
, R Bosch
2
, and J Mellors
1
1
2
Harvard Univ, Boston, MA, US
175LB Natural Killer Cells Can Target and Eliminate Latently
HIV-1
+
Primary T Cells following Proviral Reactivation
Mary Ann Checkley Luttge*, C Dobrowolski, M Shukla, B Luttge,
H Mao, and J Karn
Sch of Med, Case Western Reserve Univ, Cleveland, OH, US
176LB Limited HIV Infection of Central Memory CD4
+
T Cells Is
Associated with Lack of Progression in Viremic Individuals
Nichole Klatt*
1,2
, S Bosinger
3
, A Specht
4
, M Lederman
5
, D Camerini
6
,
M Paiardini
3
, J Brenchley
2
, F KirchhoII
4
, P Hunt
7
, and G Silvestri
3
1
Washington Natl Primate Res Ctr, Univ of Washington, Seattle, US,
2
Lab
of Molecular Microbiologv, NIAID, NIH, Bethesda, MD, US,
3
Yerkes
Primate Res Ctr, Emorv Jaccine Ctr, Emorv Universitv, Atlanta, GA, US,
4
Inst of Molecular Jirologv, Ulm Univ Med Ctr, Germanv,
5
Case Western
Reserve Univ/Univ Hosp Case Med Ctr, Cleveland, OH, US,
6
Inst for
Immunologv, Univ of California, Irvine, US, and
7
UCSF Positive Hlth
Prgm, San Francisco, CA, US
177LB Dynamics of Viral Evolution and the Neutralizing Antibody
Response in HIV-1 Superinfection
Antoine Chaillon*
1,2
, G Wagner
1
, J Wertheim
1
, L Hepler
1
, S Kosakovsky
Pond
1
, G Caballero
1
, M Pacold
3
, T Wrin
4
, D Richman
1,5
, and D Smith
1,5
1
2
INSERM UMR U966,
Tours, France,
3
Life Technologies, Foster Citv, CA, US,
4
Monogram
BioSci, Inc, San Francisco, CA, US, and
5
JA San Diego Hlthcare Svstem,
CA, US

!

"#$$%&' (2*+&$,#- ./$,-01,$
ART, Complications, and TB
178LB Distribution and Antiviral Activity in Cerebrospinal Fluid of
the Integrase Inhibitor, Dolutegravir: ING116070 Week 16
Results
Scott Letendre*
1
, A Mills
2
, K Tashima
3
, D Thomas
4
, S Min
4
, S Chen
4
,
I Song
4
, S Piscitelli
4
, and extended ING116070 Study Team
1
UCSD Antiviral Res Ctr, San Diego, CA, US,
2
Anthonv Mills MD, Inc,
Los Angeles, CA, US,
3
The Miriam Hosp, Providence, RI, US,
and
4
179LB Dolutegravir vs Raltegravir in ART-experienced,
Integrase-nave Subjects: 24-Week Interim Results from
SAILING (ING111762)
Anton Pozniak*
1
, H Mingrone
2
, A Shuldyakov
3
, C Brites
4
, J Andrade
5
,
D Hagins
6
, C Beltran Buendia
7
, D Dorey
8
, S GriIIith
9
, and S Min
9
1
2
Ciudad Autonoma de
Buenos Aires, Argentina,
3
Saratov Regional Ctr of Prophvlactic AIDS,
Russian Federation,
4
Hosp Univ Professor Edgar Santos, Salvador,
Bra:il,
5
Hosp Civil de Guadalafare Frav Antonio Alcalde, Mexico,
6
Chatham CARE Ctr, Savannah, GA, US,
7
Hosp Barros Luco Trudeau,
Santiago, Chile,
8
GlaxoSmithKline, Mississauga, Canada,
and
9
180LB SECOND-LINE: Ritonavir-boosted Lopinavir with 2-3N(t)
RTI or Raltegravir in HIV
+
Subjects Virologically Failing 1
st
-
line NNRTI/2N(t)RTI
Mark Boyd and SECOND-LINE Study Team
The Kirbv Inst, Univ of New South Wales, Svdnev, Australia
181LB Increasing Retention of Patients Starting ART: Karonga
District, North Malawi, 2005-2012
Rein Houben*
1
, T Mzembe
2
, T van Boeckel
3
, L Munthali
2
, P Mzumara
4
,
A Jahn
5
, F Chimbwandira
5
, J Glynn
1
, and A Crampin
1,2
1
2
Karonga Prevention
Studv, Chilumba, Malawi,
3
Univ Libre de Bruxelles, Belgium,
4
Karonga
District Hosp, Malawi, and
5
Ministrv of Hlth, Lilongwe, Malawi
182LB Efficacy and Safety of Maraviroc to Prevent Immune
Reconstitution Inflammatory Syndrome in High-risk
Subjects Initiating ART: 24-week Results of a Randomized,
Placebo-controlled Trial
Juan Sierra-Madero*
1
, A Tierney
2
, M Rassool
3
, L Azzoni
4
, I Sereti
5
,
J Andrade
6
, L Mosqueda-Gomez
7
, A Pineirua
1
, I Sanne
3
, M Lederman
8
,
and CADIRIS Study Team
1
Inst Nacional de Ciencias Med v Nutricion SZ, Mexico Citv, Mexico,
2
3
Clin HIJ Res Unit Facultv
of Hlth Sci, Univ of the Witwatersrand,
4
The Wistar Inst, Philadelphia,
PA, US,
5
6
Hosp Civil de Guadalafara,
Mexico,
7
Capasits, Leon, Mexico, and
8
Case Western Reserve Univ,
Cleveland, OH, US
183LB No Difference in Risk of Preterm Birth among Pregnant
Ugandan Women Randomized to Lopinavir/Ritonavir vs
Efavirenz-based ART
Deborah Cohan*
1
, P Natureeba
2
, A Plenty
1
, F Luwedde
2
, J Mwesigwa
2
,
V Ades
3
, B Nzarubara
2
, T Clark
1
, B Osterbauer
1
, and E Charlebois
1
1
2
Infectious Disease Res
Collaboration, Kampala, Uganda, and
3
New York Univ, NY, US
184LB Short-term Benefits of 4-Drug 1
st
-Line ART Do Not Persist
with 3-Drug Maintenance in 1206 HIV
+
African Children:
The 5-Year ARROW Trial
Patricia Nahirya-Ntege*
1
, A Cook
2
,

V Musiime
3
, A Kekitiinwa
4
, K
Nathoo
5
, P Munderi
1
, P Mugyenyi
3
, S Bakeera-Kitaka
4
, S Walker
2
, and D Gibb
2
1
MRC/UJRI Uganda Res Unit on AIDS, Entebbe,
2
MRC Clinical Trials
Unit, London, UK,
3
Joint Clinical Res Ctr, Kampala, Uganda,
4
Bavlor-
Uganda/Paediatric Infectious Diseases Clin, Mulago, Kampala, and
5
Univ of Zimbabwe, Harare
185LB Non-Calcified Coronary Plaque and Macrophage Activation
Markers Are Increased in HIV
+
Women
Kathleen Fitch*
1
, S Abbara
1
, T Burdo
2
, K Williams
2
, P Eneh
1
, J Lo
1
,
and S Grinspoon
1
1
2
Boston Coll, Chestnut Hill, MA, US
186LB Effect of Statins on Immune Activation and Inflammation in
HIV
+
Subjects on ART: A Randomized Placebo Controlled
Trial
Grace McComsey*
1,2,3
, Y Jiang
1
, S Debanne
1
, B Clagett
1
, J Robinson
1
,
D Labbato
1,2,3
, N Storer
1,2,3
, M Lederman
1,2
, and N Funderburg
1
1
Case Western Reserve Univ, Cleveland, OH, US,
2
Univ Hosp Case Med
Ctr, Cleveland, OH, US, and
3
Rainbow Babies and Childrens Hosp,
Cleveland, OH, US
187LB Pitavastatin 4 mg Provides Greater Low-density Lipoprotein
Cholesterol Reduction Compared to Pravastatin 40 mg over
12 weeks of Treatment in HIV+ Adults with Dyslipidemia
Craig Sponseller*
1
, R Morgan
2
, S Campbell
2
, J Aberg
3
, and M Thompson
4
1
Kowa Pharmaceuticals America, Inc, Montgomerv, AL,
2
Kowa Res Inst,
Inc, Morrisville, NC, US,
3
New York Univ Sch of Med, NY, US, and
4
AIDS
Res Consortium of Atlanta, GA, US
41209wo_PA_Posters-R4.indd 24 2/20/13 5:58 AM
Program 25
P
o
s
t
e
r

L
i
s
t
i
n
g
s
188LB Safety and Pharmacokinetics of PA-824, an Investigational
Anti-TB Drug, and Co-administered Efavirenz, among Healthy
Subjects: ACTG Study A5306
Kelly Dooley*
1
, A Luetkemeyer
2
, J-G Park
3
, R Allen
4
, D Sutherland
5
,
F Aweeka
2
, S Koletar
6
, Y Cramer
3
, J Bao
7
, D Haas
5
, and A5306 Study Team
1
2
Univ of
3
Statistical and Data Analvsis Ctr,
Harvard Sch of Pub Hlth, Cambridge, MA, US,
4
Social and Sci Svstems,
Inc, Silver Spring, MD, US,
5
Janderbilt Univ Sch of Med, Nashville,
TN, US,
6
Ohio State Univ, Columbus, US, and
7
Division of AIDS, NIH,
Bethesda, MD, US
189LB Effect of Tuberculin Skin Testing or Interferon-release on
the Benefit of Concurrent Isoniazid Preventive Therapy with
ART: Subgroup Analysis
of a Randomized Controlled Trial
Molebogeng Rangaka*
1,2,3
, R Wilkinson
2,4,5,6
, K Wilkinson
2,5
, J Glynn
3
,
A Boulle
1
, G Maartens
7
, and ART plus IPT Study Team
1
Ctr for Infectious Disease Epidemiologv and Res, Sch of Hlth Sci, Cape
Town, South Africa,
2
Clinical Infectious Disease Res Initiative, Univ of
Cape Town, South Africa,
3
London Sch of Hvgiene and Tropical Med,
UK,
4
Inst of Infectious Diseases and Molecular Med,
5
MRC Natl Inst for
Med Res, London, UK,
6
Imperial Coll London, Norfolk Place, UK, and
7
Univ of Cape Town, South Africa
190LB Durability of Isoniazid Preventive Therapy in HIV
+
Patients
in a Medium Burden TB Setting
Jonathan Golub*
1,2
, V Saraceni
3
, S Cavalcante
3,4
, S Cohn
1
, A Pacheco
4
,
L Moulton
1,2
, R Chaisson
1,2
, and B Durovni
3,5
1
2
Johns Hopkins
Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US,
3
Rio de Janeiro
Citv Hlth Secretariat, Bra:il,
4
FIOCRUZ, Rio de Janeiro, Bra:il, and
5
Federal Univ of Rio de Janeiro, Bra:il
!

"#$$%&' (()*&$+#, -.$+,/0+$
Envelope/Entry/Tropism/Transmission
192 Dendritic Cell-to-T Cell HIV Transmission Is a
Drug-insensitive Mode of Infection

Jocelyn Kim*
1,2
, A Sigal
1
, and D Baltimore
1
1
California Inst of Tech, Pasadena, US and
2
David Geffen Sch of Med,
193 Actin Dynamics Differentially Regulate Cell-to-Cell Transfer
of HIV in Memory and Nave CD4
+
T Cells

Marc Permanyer*, E Pauls, B Clotet, and J Este
IrsiCaixa AIDS Res Inst, Badalona, Spain
194 HIV-1 Cell-Cell Infection Is Inhibited by Purinergic Receptor
Antagonists by Blocking Viral Membrane Fusion within
Virological Synapse Target Cells

Talia Swartz*, A Esposito, N Durham, and B Chen
Mt Sinai Sch of Med, New York, NY, US
195 Bidirectional Passage of HIV between T Cells and Renal
Epithelial Cells through Virological Synapse Formation

Maria Blasi*
1
, P Chen
2
, B Chen
2
, B Balakumaran
1
, D Negri
1,3
, A Cara
1,3
,
and M Klotman
1
1
2
Mt Sinai Sch of Med, New York,
NY, US, and
3
Inst Superiore di Sanita, Rome, Italv
196 Productive CD4-dependent HIV-1 Fusion, Entry, and
Infection Dynamically Studied by Total Internal Reflection
Fluorescence Microscopy in Living Cells
MS Valera
1
, S Ziglio
1
, Laura de Armas Rillo*
1
, J Barroso Gonzalez
1
,
L Garcia Exposito
1
, I Puigdomenech
2
, JD Machado
1
, J Blanco
2
,
and A Valenzuela-Fernandez
1
1
Univ of La Laguna, Spain and
2
Univ Autonoma de Barcelona, Spain
197 Inhibition of HIV-1 Infection on CD4
+
T Cells by Blocking
Adhesion Molecule Mediated Virus Adsorption

Joseph Kononchik Jr* and P Sun
NIAID, NIH, Rockville, MD, US
198 From HIV Inhibition to HIV Escape: CCR5 Conformations
Are Differentially Exploited by Chemokines and R5 HIV-1
P Colin
1
, Y Benureau
1
, I Staropoli
1
, Y Wang
1
, O Hartley
2
, A Brelot
1
,
F Arenzana-Seisdedos
1
, and Bernard Lagane*
1
1
Inst Pasteur, Paris, France and
2
Univ of Geneva, Swit:erland
199 2nd Generation Affinofile Profiling Reveals Distinct Entry
Phenotypes Associated with Subtype Specificity and
Resistance Mutations to Broadly Neutralizing Antibodies
Kelechi Chikere*
1
, N Webb
1
, T Chou
1
, P Gorry
2
, and B Lee
1
1
2
Burnet Inst, Melbourne,
Australia
200 HIV-1 Co-receptor Switch in Treatment-nave Patients:
Frequency, Predictors, and Genetic Mechanisms

Virginie Mortier*
1
, D Staelens
1
, K Dauwe
1
, L Vancoillie
1
,
W Cabooter
2
, F Van Wanzeele
3
, L Vandekerckhove
3
, D Vogelaers
3
,
K Chalmet
1
, and C VerhoIstede
1
1
Ghent Univ, Belgium,
2
MSD Belgium, and
3
Ghent Univ Hosp, Belgium
201 Divergent Patterns of CCR5 versus Alternative Co-receptor-
mediated Entry in Pathogenic Rhesus Macaque and Non-
pathogenic Sooty Mangabey SIV Infection
Sarah Elliott*
1
, N Riddick
1
, N Francella
1
, M Paiardini
2
, C Derdeyn
2
,
G Silvestri
2
, and R Collman
1
1
2
Yerkes Natl Primate Res
Ctr, Emorv Univ, Atlanta, GA, US
202 HIV-1 Tropism and Co-receptor Binding Stoichiometry

Melissa Zarr*
1
and R Siliciano
1,2
1
Johns Hopkins Univ Sch of Med, Baltimore, MD, US and
2
Howard
Hughes Med Inst, Baltimore, MD, US
203 Germinal Center T Follicular Helper Cells from Nave Hosts
Are Highly Permissive to HIV-1 #1 2%2&
S Kohler, Joy Folkvord*, and E Connick
Univ of Colorado Denver, Aurora, US
204 Development of a High-throughput Cell-based Assay for
Monitoring HIV-1 Envelope Maturation
Z Stolp, S Diaz, A Stotland, B Hilton, and Roland Wolkowicz*
San Diego State Univ, CA, US
205 Polymorphisms in the Cytoplasmic Tail of gp41 Modulate
Viral Replication in CD4
+
T Lymphocytes

Eveline Santos da Silva*
1
, M Mulinge
1
, M Lemaire
1
, A Rybicki
1
,
C Masquelier
1
, J-Y Servais
1
, J-C Schmit
1,2
, and D Perez BercoII
1
1
CRP-Sante, Luxembourg and
2
Ctr Hosp de Luxembourg
!

"#$$%&' (3)*&$+#, -.$+,/0+$
Transcription/Reverse and Forward,
Splicing/Replication
206 Cyclin-dependent Kinases Support HIV-1 Reverse Transcription

Jin Leng*
1,2
, H-P Ho
3
, M Buzon
1,2
, F Pereyra
2,4
, X Yu
2
, E Chang
3
,
and M LichterIeld
1
1
2
Ragon Inst of MGH, MIT,
and Harvard, Boston, MA, US,
3
Citv Univ of New York, NY, US,
and
4
Brigham and Womens Hosp, Boston, MA, US
207 HIV-1 Vpu and Cellular TASK Proteins Suppress
Transcription of Unintegrated HIV-1 DNA
Nkiruka Emeagwali*
1
and J Hildreth
2
1
Warren Alpert Med Sch of Brown Univ, Providence, RI, US and
2
Univ of
California, Davis, US
208 Functional Characterization of Cyclin T1 N-terminus Region
for Regulation of P-TEFb Activity and HIV Replication

Alona Kuzmina*
1
, N Verstraete
2
, O Bensaude
2
, and R Taube
1
1
Ben Gurion Univ of the Negev, Beer Sheba, Israel and
2
Inst de Biologie
de lEcole Normale Superieure, Paris, France
209 Identification of Anti-HIV Activity of RNA Processing/Splicing
Cellular Factor SRp30c Protein

Yoon-Jeoung Koh* and J-C You
Natl Res Lab for Molecular Jirologv, Catholic Univ of Korea Sch of
Med, Seoul
210 Staufen-1 Interacts with HIV-1 Rev and HERV-K Rec Proteins
to Assist in Nucleocytoplasmic Viral RNA Transport
K Hanke, O Hohn, K Fiddeke, and Norbert Bannert*
Robert Koch Inst, Berlin, Germanv
211 Identification of MED14 as a Key Mediator Complex Factor
in HIV Transcription

Alba Ruiz*, E Pauls, B Clotet, and J EsteRetrovirology Lab Irsi
Caixa, Hosp Germans Trias i Pufol, Badalona, Spain
212 The IL-2 Inducible Kinase ITK Is Critically Required for
HIV-1 Replication in 1urkat T Cells

Ananda Ayyappan Jaguva Vasudevan*
1
, M Kramer
1
, A Hain
1
,
R Linka
2
, R Hartig
2
, B Schraven
1
, D Haussinger
1
, A Borkhardt
1
,
and C Munk
1
1
Heinrich Heine Univ, Med Facultv, Dusseldorf, Germanv and
2
Otto-von-Guericke Univ of Magdeburg, Germanv
!

"#$$%&' (4)*&$+#, -.$+,/0+$
Accessory Proteins/Gag
213 Bimolecular Fluorescence Complementation Reveals Novel
Interactions of HIV-1 Nef with Tec/Btk Family Kinases

Sreya TaraIdar*
1,2
, J Poe
1
, and T Smithgall
1
1
Univ of Pittsburgh Sch of Med, PA, US and
2
Univ of Pittsburgh Grad Sch
of Publ Hlth, PA, US
214 Vpr Is Required for the Expression and Replication of
Unintegrated, but Not Integrated, HIV-1 in Resting CD4
+

T Cells

Benjamin Trinite*, E Ohlson, S Rana, J Alster, I Voznesensky,
and D Levy
New York Univ Coll of Dentistrv, NY, US
P
o
s
t
e
r

L
i
s
t
i
n
g
s
215 HIV-1 BF Intersubtype Recombinant Vpu Second Alpha
!"#$% '#()* (+ ,-./01(+1 2/#" $+ 13" 4$0(# 2"#"(*" (+5
BST-2 Degradation
C De Candia,

Gabriel Duette*, C Espada, H Salomon, and M Carobene
Inst de Investigaciones Biomed en Retrovirus v SIDA, Univ de Buenos
Aires, Consefo Nacional de Investigaciones Cientficas v Tcnicas,
Argentina
216 Influence of HIV-1 Genetic Background on the Fitness Cost
of Single Amino Acid Mutations in Gag-p24

Siriphan Manocheewa*
1
, V Swain
1
, E Lanxon-Cookson
1
, M Kim
1
,
D WestIall
1
, M Rolland
2
, and J Mullins
1
1
2
US Militarv HIJ Res Prgm, Henrv M
Jackson Fndn for the Advancement of Militarv Med, Rockville, MD, US
!

"#$$%&' ()*+&$,#- ./$,-01,$
AssemblyPutting It All Together
217 Host Molecule ICAM-1 Is Selectively Acquired by HIV-1 in a
Matrix-dependent Fashion

Pascal Jalaguier*
1
, R Cantin
1
, and M Tremblay
1,2
1
Ctr Hosp Univ de Quebec-CHUL, Canada and
2
Univ Laval, Canada
218 Characterizing the Role of HIV-1 p6-Alix Binding in HIV-1
2".#$6(1$/+

Lillian Kuo*, K Fujii, and E Freed
HIJ Drug Resistance Prgm, NCI-Frederick, MD, US
219 78(#91(::"5 !,49; '0/<$08* =+3(+6"* 7)+(-$6 >185$"* /?
HIV Assembly

Mingli Qi*
1
, L Ding
1
, and P Spearman
1,2
1
Emorv Univ, Atlanta, GA, US and
2
Atlanta Childrens Hosp, GA, US
220 Citron Kinase Enhances Ubiquitylation of HIV-1 Gag and
,+10(6"##8#(0 !,49; @855$+:

Jiwei Ding*
1
, L Sun
2
, P Du
2
, S Cen
1
, G Gao
2
, and L Su
3
1
Inst of Med Biotech, Chinese Academv of Med Sci, and Peking Univ Med
Coll, Beifing,
2
Inst of Biophvsics, Chinese Academv of Med Sci, Beifing,
and
3
Univ of North Carolina at Chapel Hill Sch of Med, US
221 !,49; 4$0$/+* ,+6/0./0(1" ABA 7CD !"#$6(*" E3$63
A/58#(1"* 4$0(# 2".#$6(1$/+ $+ 13" C"F#) ,+?"61"5 B"##*

Steven Santos*
1
, Y Obukhov
2
, S Nekhai
2
, M Bukrinsky
1
,
and S Iordanskiy
1
1
The George Washington Univ Sch of Med and Hlth Sci, Washington, DC,
US and
2
Howard Univ Coll of Med, Washington, DC, US
!

"#$$%&' (2*+&$,#- ./$,-01,$
(see Session 28 on Tuesdav for corresponding Themed Discussion)
Restriction Factors: Old and New
222 Evolutionarily Conserved Requirement of CBF- ?/0 13"
Assembly of HIV/SIV Vif Cul5 Cullin-Ring Ligase

Sean Evans*
1
, X Han
1,2
, X Zhou
1,2
,

J Du
2
, W Zhang
2
, G Wang
2
,
and X-F Yu
1,2
1
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US
and
2
First Hosp of Jilin Univ, China
223 Sooty Mangabey SIV, the Ancestor of HIV-2, Efficiently
Counteracts Human APOBEC3G

Michael Letko*
1
, M Ooms
1
, G Silvestri
2
, and V Simon
1
1
2
Emorv Univ Sch of Med,
Atlanta, GA, US
224 Exploring the Relationship between P-body Localization
(+5 4$0$/+ ,+6/0./0(1$/+ /? !8-(+ D+1$<$0(# '0/1"$+*
APOBEC3G and Mov10

Taisuke Izumi*, R Burdick, W-S Hu, and V Pathak
HIJ Drug Resistance Prgm, Natl Lab for Cancer Res, NCI-Frederick,
MD, US
225 HIV-1 Vpr Targets Restriction Factor CTIP2 to Proteasomal
7":0(5(1$/+

Sultan Ali*
1
, C Schwartz
1,2
, and O Rohr
1,2
1
Univ of Strasbourg, France and
2
IUT of Schiltigheim, Strasbourg, France
226 Small Molecule Compounds Inhibit Vpu-mediated
Down-regulation BST-2

Zeyun Mi*, Q Zhang, J Zhou, J Ding, L Yu, and S Cen
Inst of Med Biotech, Chinese Academv of Med Sci, Beifing
227 C/<"# 2":8#(1$/+ /? >,4 4.%9-"5$(1"5 >DA!7; 7":0(5(1$/+
Wei Wei*
1
, H Guo
1
, X Han
1
, X Liu
1
, S Evans
2
, X Zhou
2
, W Zhang
1
,
and X-F Yu
2
1
First Hosp of Jilin Univ, Inst of Jirologv and AIDS Res, China and
2
!

"#$$%&' 34*+&$,#- ./$,-01,$
Restriction Factors: APOBEC and Others
228 APOBEC3 Increases HIV-1 V3 Diversity at Residues
Involved in Co-receptor Usage and Recognition by
Neutralizing Antibodies: A Refined UDPS Analysis
Valentina Svicher*
1
, C Alteri
1
, MC Bellocchi
1
, S Fourati
2
, D Armenia
1
,
L Carioti
1
, A-G Marcelin
2
, V Calvez
2
, F Ceccherini-Silberstein
1
,
C-F Perno
1,3
, and DIVA Study Group
1
Univ of Tor Jergata, Rome, Italv,
2
Hosp Pitie Salpietrere, Paris, France,
and
3
Natl Inst for Infectious Diseases L Spallan:ani, Rome, Italv
229 Leucine Zipper Formation Mediates Encapsidation into
Virion Cores and Anti-HIV Functions of APOBEC3F and
Not APOBEC3G
Chisu Song*
1
, R Levinson
2
, L Sutton
2
, R Daquila
1
, and J Donahue
2
1
Northwestern Univ, Feinberg Sch of Med, Chicago, IL, US and
2
Janderbilt Univ Sch of Med, Nashville, TN, US
230 The Catalytic Activity of APOBEC3G Is Not Involved in
'0"<"+1$+: 2"10/<$0(# ,+1":0(1$/+ @81 ,* 7"5$6(1"5 1/ ,-.($0
the Fitness of Progeny Viruses
K Belanger, M Savoie, J-F Couture, and Marc-Andre Langlois*
Univ of Ottawa, Canada
231 4$?9,+5"."+5"+1 %' 5%5& =*6(." /? !,4 ?0/- G"13(#
Restriction by APOBEC

John Krisko*, F Martinez-Torres, V Garcia, and J Foster
232 B/-.81(1$/+(# ,5"+1$?$6(1$/+ /? '0/1"$+ B/-.#"%"* ,+</#<"5
$+ B"##8#(0 2":8#(1$/+ /? !,4 ,+?"61$/+ 2"586"* 13"
B/-.#"%$1) /? 13" !,4 2":8#(1/0) C"1F/0H
Kevin Olivieri*
1
, L Pache
1
, S Chanda
1
, J Young
2
, S Jaeger
3
, N Krogan
3
,
D Emig
4
, and T Idekker
4
1
Sanford-Burnham Med Res Inst, San Diego, CA, US,
2
Salk Inst, San
Diego, CA, US,
3
Univ of California, San Francisco, US, and
4
Univ of
California, San Diego, US
233 B/-.(0(1$<" '0/?$#$+: /? 7"(-$+(1$/+ 2(1"* (+5 I(0:"1
Sites on Vif-deficient HIV-1 and MoMLV Retroviral DNA by
All the 7 Human APOBEC3 Family Members

Kasandra Belanger*, M Savoie, and M-A Langlois
Univ of Ottawa, Canada
234 Feline Immunodeficiency Virus 5%6 B/+10/#* 4$0(# 2".#$6(1$/+
Capacity in an APOBEC3-dependent Manner

Ryan Troyer*
1
, J Thompson
1
, J Elder
2
, and S VandeWoude
1
1
Colorado State Univ, Fort Collins, US and
2
The Scripps Res Inst,
La Jolla, CA, US
235 J"#*/#$+ 2"*10$61* !,49; 580$+: =(0#) 4$0(# ,+?"61$/+

Laura de Armas Rillo*, L Garcia Exposito, S Ziglio, J Barroso
Gonzalez, MS Valera, JD Machado, and A Valenzuela-Fernandez
Univ of La Laguna, Spain
236 APOBEC3H Variants Impact HIV-1 Replication %' 5%5&

Marcel Ooms*
1
, B Brayton
2
, M Letko
1
, S Majdak
1
, F Hecht
3
,
J Barbour
2
, and V Simon
1
1
2
Hawaii Ctr for AIDS, Univ of
Hawaii at Manoa, Honolulu, US, and
3
!

"#$$%&' 37*+&$,#- ./$,-01,$
MacrophageHIV Interactions: Cell Biology and
Treatment
237 Placental Hofbauer Cells Assemble and Sequester HIV-1 in
I"10(*.(+$+ (+5 7B9>,JC =+0$63"5 B/-.(01-"+1* 13(1 D0"
Partially Accessible to Antibodies

Erica Johnson*, H Chu, P Spearman, and R Chakraborty
Emorv Univ and Children`s Hlthcare of Atlanta, GA, US
238 Raltegravir Contributes to the Induction of Apoptosis in
D681"#) !,4
K
U937 Cells
Dwayne Baxa*
1
, M Golembieski
1
, M Golembieski
1
, L Shetron-Rama
2
,
and N Markowitz
1
1
Henrv Ford Hosp, Detroit, MI, US and
2
Eastern Michigan Univ,
Ypsilanti, US
239 MicroRNA-155 Inhibits HIV-1 Infection in Primary
Macrophages by Altering Trafficking and/or Nuclear Import
/? '0"9$+1":0(1$/+ B/-.#"%"*

Gokul Swaminathan*, S Navas-Martin, and J Martin-Garcia
Drexel Univ Coll of Med, Philadelphia, PA, US
240 ;L-estradiol Inhibits HIV Infection of Primary Macrophages
130/8:3 ,+5861$/+ /? ,+1"0?"0/+9u

Carley Tasker*
1
, J Ding
1
, M Schmolke
2
, A Rivera-Medina
1
,
A Garcia-Sastre
2
, and T Chang
1
1
Univ of Med and Dentistrv of New Jersev, Newark, US and
2
Mt Sinai Sch
of Med, New York, NY, US
Program 27
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' ()*+&$,#- ./$,-01,$
Shutting the Door on HIV Entry
241 Griffithsin, in Combination with All ARV Drugs, Potently
Inhibits HIV Cellular Transmission and Destruction of
Target CD4 T Cells
GeoIIrey Ferir*, K Palmer, and D Schols
Rega Inst for Med Res, Univ of Leuven, Belgium
242 Inhibition of HIV-1 Entry by Peptides Derived from the
Extracellular Loops of CXCR4
Andy Chevigne*
1
, V Fievez
1
, S Delhalle
1
, M Counson
1
, J-M Plesseria
1
,
C Devaux
1
, J-C Schmit
1,2
, and S Deroo
1
1
CRP-Sante, Luxembourg and
2
Ctr Hosp de Luxembourg
243 Selection of CXCR4 Antagonists Based on the N-terminus of
vCCL2 by Phage Display Screening
on Magnetic Proteoliposomes

Virginie Fievez*
1
, S Deroo
1
, S Delhalle
1
, J Mathu
1
, F Martin
1
,
C Devaux
1
, J-C Schmit
1,2
, and A Chevigne
1
1
CRP Sante, Luxembourg and
2
CHL, Luxembourg
!

"#$$%&' (2*+&$,#- ./$,-01,$
(see Session 45 on Wednesdav for corresponding Themed Discussion)
Transmitted/Founder Viruses
244 Recombination Shapes Viral Evolution during Early
Infection in Individuals Infected with Multiple Transmitted/
Founder HIV-1

Hongshuo Song*
1
, F Cai
1
, V Ganusov
2
, J Pavlicek
1
, B Keele
3
, H Li
4
,
G Shaw
4
, B Haynes
1
, B Hahn
4
, and F Gao
1
1
2
Univ of Tennessee, Knoxville,
US,
3
SAIC-Frederick Inc, MD, US, and
4
Philadelphia, US
245 MTCT Is Associated with a Gag-Protease-driven Viral
Fitness Bottleneck

Vanessa Naidoo*
1
, J Mann
1
, J Carlson
2
, C Brumme
3
, C Thobakgale
1
,
P Goulder
4
, D Heckerman
2
, Z Brumme
3,5
, M Brockman
3,5
, and T Ndungù
1
1
HIJ Pathogenesis Prgm, Univ of KwaZulu-Natal, Durban, South Africa,
2
3
BC Ctr for Excellence in HIJ/
AIDS, Jancouver, Canada,
4
Univ of Oxford, UK, and
5
Simon Fraser
Univ, Burnabv, Canada
246 Subtype C HIV-1 Variants Transmitted by Breastfeeding Have
Less Glycosylated V2 Loops and Are More Susceptible to
V2-Targeted Antibodies PG9 and PG16

Kyle Nakamura*
1
, C Cerini
1
, E Sobrera
1
, L Heath
2
, M Sinkala
3
,
C Kankasa
4
, D Thea
5
, J Mullins
2
, L Kuhn
6
, and G Aldrovandi
1
1
Childrens Hosp Los Angeles, CA, US,
2
3
Lusaka District Hlth Mgmt Team, Zambia,
4
Univ of Zambia, Lusaka,
5
Boston
Univ Sch of Publ Hlth, MA, US, and
6
Columbia Univ, New York, NY, US
247 Transmitted/Founder and Chronic HIV-1 Env Proteins
Differentially Utilize CCR5

Zahra Parker*
1
, S Iyer
1
, C Wilen
1
, N Parrish
1
, R Berro
2
, B Lee
3
,
J Moore
2
, G Shaw
1
, B Hahn
1
, and R Doms
1,4
1
2
Weill
Med Coll of Cornell Univ, New York, NY, US,
3
Angeles, US, and
4
Childrens Hosp of Philadelphia, PA, US
248 Phenotypic Differences Between Transmitted/Founder
and Chronic Env Proteins Revealed by Quantitative, High-
Throughput Receptor Affinity Profiling

Kelechi Chikere*
1
, N Webb
1
, T Chou
1
, P Gorry
2
, and B Lee
1
1
2
Burnet Inst, Melbourne, Australia
249 Transmitted/Founder Infectious Molecular Clones of
Divergent SIV
smm
Strains Are Infectious and Replication
Competent %' 3%3&
D Ma
1
, H Li
2
, C Xu
1
, B Keele
3
, J Estes
3
, J LiIson
3
, I Pandrea
1
, G Shaw
2
,
B Hahn
2
, and Cristian Apetrei*
1
1
2
Univ of Pennsvlvania
Perelman Sch of Med, Philadelphia, US, and
3
Frederick Natl Lab, MD, US
250 The Number and Genetic Relatedness of Transmitted/Founder
Virus Impact Clinical Outcome in Vaginal R5 SHIV
SF162P3N

Transmission
Lily Tsai*
1
, I Tasovski
2
, AR Leda
1
, M Chin
2
, and C Cheng-Mayer
1
1
2
Temple Univ Sch
of Med, Philadelphia, PA, US
!

"#$$%&' (4*+&$,#- ./$,-01,$
HIV Compartments
251 Identification and Characterization of CD4 T Cells Actively
Transcribing HIV RNA in Peripheral Blood
Joseph Casazza*, A Vostal, D Ambrozak, B Hill, E Boritz, I Gong,
D Douek, and R Koup
Jaccine Res Ctr, NIAID, NIH, Bethesda, MD, US
252 Follicular Helper T Cells Serve as Major CD4 T Cell
Compartment for HIV-1 Infection, Replication, and Production
Matthieu Perreau*
1,2
, A-L Savoye
1,2
, E De Crignis
1,2
, J-M Corpataux
1,2
,
R Cubas
3
, E Haddad
3
, L De Leval
1
, C Graziosi
1,2
, and G Pantaleo
1,2,4
1
Lausanne Univ Hosp, Swit:erland,
2
Univ of Lausanne, Swit:erland,
3
Jaccine and Gene Therapv Inst of Florida, Port St Lucie, US, and
4
Swiss
Jaccine Res Inst, Lausanne
253 Low-level HIV Plasma Viremia Is Rarely Due to Viral
Replication, but Appears to Be Viral Expression from
Infected Cells During Systemic Inflammation
Marta Bull*
1,2
, C Mitchell
1
, S Styrchak
2
,

J Soria
3
, A LaRosa
3
,
E Ticona
3
, J McKernan-Mullin
2
, B Sorensen
1
, R Coombs
1
, and L Frenkel
1,2
1
2
Seattle Children`s Res Inst, WA, US,
and
3
Assn Civil Impacta Salud v Educacion, Lima, Peru
254 Dynamic Behavior of HIV-1 Populations in the Female
Genital Tract

Elena Dukhovlinova*
1,2
, J Anderson
1,3,4
, D Moore
2
, M Cohen
1,4
,
R Swanstrom
1,4
, and Ctr Ior HIV/AIDS Vaccine Immunology Consortium
1
Univ of North Carolina Ctr for AIDS Res,
2
Univ of North Carolina
Lineberger Comprehensive Cancer Ctr,
3
Bristol-Mvers Squibb, and
4
Univ
of North Carolina
255 HIV DNA Integration, Kinetics, and Metabolic Activity
in Macrophages and Lymphocytes in Presence/Absence of
Integrase Inhibitors
M Surdo
1
, C Orlandi
2
, A Casabianca
2
, F Di Santo
1
, I Malet
3
,
MF Cortese
1
, A-G Marcelin
3
, M Magnani
2
, C-F Perno
1,4
,
and Francesca Ceccherini-Silberstein*
1
1
Univ of Rome Tor Jergata, Italv,
2
Univ of Urbino Carlo Bo, Pesaro,
Italv,
3
Groupe Hosp Pitie-Salpetriere, UPMC Univ Paris 06, France,
and
4
INMI L Spallan:ani, Rome, Italv
256 Evidence of Long-term Persistence of Human Effector
Memory CD4
+
T Cells Using Replication-defective Integrated
HIV-1 Provirus as a Genetic Marker
Hiromi Imamichi*
1
, V Natarajan
2
, T Imamichi
2
, J Adelsberger
2
,
C Rehm
1
, and C Lane
1
1
NIAID, NIH, Bethesda, MD, US and
2
SAIC-Frederick Inc, MD, US
!

"#$$%&' (5*+&$,#- ./$,-01,$
HIV Genotypes and Phenotypes
257 Robust Phylogenetic Method to Reconstruct Dates of Infection
in HIV-1 Seroconverters from Different Risk Groups
R McGovern
1
, Z Brumme
1,2
, C Johnson
1
, R Hogg
1,2
, E Wood
1,3
, T Kerr
1,3
,
M Milloy
1
, R Harrigan
1,3
, Art Poon*
1,3
, and VANGUARD and
VIDUS/ACCESS Cohort Studies
1
2
Simon Fraser
Univ, Burnabv, Canada, and
3
Univ of British Columbia, Jancouver,
Canada
258a Increased Genetic Diversity in HIV-1 Subtype C Membrane-
proximal External Region by Pyrosequencing Is Associated
with MTCT
Li Yin*
1
, Y Cai
1
, N Veras
1
, K Chang
1
, B Gardner
1
, W Hou
1
,
K Nakamura
2
, L Kuhn
3
, G Aldrovandi
2
, and M Goodenow
1
1
Univ of Florida, Gainesville, US,
2
The Saban Res Inst Childrens Hosp
Los Angeles, CA, US, and
3
Columbia Univ, New York, NY, US
258b Viral Genotype in Subtype C Significantly Influences Plasma
Viral Load
Emma HodcroIt*
1
, E Fearnhill
2
, A Phillips
3
, D Dunn
2
, D Pillay
4
,
J HadIield
5,
A Leigh Brown
1
, and UK HIV Drug Resistance Database
1
Univ of Edinburgh, Scotland,
2
3
4
Univ Coll London, UK, and
5
Univ of
Oxford, UK
259 HIV-1 Nef Sequence and Function Evolution in Acute Infection
Martha Lewis*
1
, J de la Cruz
1
, P Frohnen
1
, H Ng
1
, E Daar
2
, and O Yang
1
1
David Geffen Sch of Med, Univ of California, Los Angeles, US and
2
LA
BioMed, Harbor UCLA Med Ctr, US
260 Reduced HIV-1 Nef Function in Acute/Early Individuals Who
Become Viremic Controllers

Xiaomei Kuang*
1
, A Le
1
, P Mwimanzi
1
, T Markle
1
, R Danroth
1
,
T Ueno
2
, T Miura
3
, B Walker
4
, Z Brumme
1,5
, M Brockman
1,5
,
and Acute HIV and Intl HIV Controllers Study Group
1
Simon Fraser Univ, Jancouver, Canada,
2
Kumamoto Univ, Japan,
3
Univ
of Nagasaki, Japan,
4
Ragon Inst of MGH, MIT, and Harvard, Boston,
MA, US, and
5
BC Ctr for Excellence in HIJ/AIDS, Jancouver, Canada
P
o
s
t
e
r

L
i
s
t
i
n
g
s
261 Genetic and Functional Compartmentalization of HIV-1 Nef
!" $%& '($
Martha Lewis*, P Frohnen, D Reed, V Iyer, J Elliott, P Anton,
and O Yang
David Geffen Sch of Med, Univ of California, Los Angeles, US
262 )!*+, -./,+$&. 0*/1 23456789 :,!$& ;(<<*&../*. 2+=&
Similar Levels of Fitness as Viral Isolates from HLA-B`57
>%*/"!? @*/A*&../*.

Maria Salgado*
1,2
, C Pohlmeyer
2
, R Buckheit III
2
, R Siliciano
2,3
,
and J Blankson
2
1
AIDS Res Inst IrsiCaixa, Inst dInvestigacio en Ciencies de la Salut
Germans Trias i Pufol, Univ Autonoma de Barcelona, Badalona, Spain,
2
Johns Hopkins Univ Sch of Med, Baltimore, MD, US, and
3
Howard
263 2-) :=/,($!/" ("B&* $%& ;&,&?$!=& @*&..(*& /0 -"$&*0&*/" !"
$!%&'

Sylvie Rato*, B Vanwalscappel, and F Mammano
INSERM U941, Paris, France
!

()**!'" ++,-'*%)& ./*%&01%*
Markers of HIV Disease Progression
264 :"B/$%&,!+, 4?$!=+$!/" 6!/1+*C&*. -"?*&+.& +0$&* 2-)5D
Acquisition, and Soluble VCAM-1 Levels at Set Point Predict
E!.&+.& @*/A*&..!/" +"B F/*$+,!$G
Susan Graham*
1,2
, N Rajwans
3
, K Tapia
1
, W Jaoko
2
, B Estambale
2
,
S McClelland
1,2
, J Overbaugh
4
, and C Liles
1,3
1
2
Univ of Nairobi, Kenva,
3
Univ of
Toronto, Canada, and
4
Fred Hutchinson Cancer Res Ctr, Seattle, WA, US
265 Association between HIV-1 Disease Status and Host
Restriction Factor Expression Profile

Mohamed Abdel-Mohsen*
1
, A Raposo
1
, D Nixon
1
, T Liegler
1
,
R Hoh
1
, J Wong
1,2
, S Deeks
1
, and S Pillai
1,2
1
2
JAMC, San Francisco, CA, US
266 High Frequencies of Polyfunctional CD8
H
IJ >&,,. !"
>%*/"!? 2-)5D -"0&?$!/" 4*& 4../?!+$&B K!$% ;,/K&* E!.&+.&
@*/A*&..!/"

Fareed Ahmad*
1
, H Hong
2
, M Jackel
1
, I-N Lu
1
, N Bhatnagar
1
,
J Eberhard
1
, B Bollmann
1
, M Ballmeier
1
, R Schmidt
1
, D Meyer-Olson
1
,
and HIV Labor
1
Hannover Med Sch, Germanv and
2
New England Primate Res Ctr,
Harvard Med Sch, Southborough, MA, US
267 Baseline CD4
H
L >&,, >/("$. >/**&,+$&. K!$% 2-)5D
Replication Rate in HLA-B`5701 Subjects with Different
M!.C /0 E!.&+.& @*/A*&..!/"

Melissa Norstrom*
1
, N Veras
2
, W Huang
3
, M Prosperi
2
, J Cook
3
,
W Hartogensis
4
, F Hecht
4
, A Karlsson
1
, and M Salemi
2
1
Karolinska Inst, Stockholm, Sweden,
2
3
Monogram Biosci Inc, South San Francisco, CA, US, and
4
San Francisco
Gen Hosp, Univ of California, US
268 Mean Asymptomatic Viral Load, Steady State Viral Load,
and CD4 Cell Count following Acute Infection as Predictors
/0 2-) E!.&+.& @*/A*&..!/"
Ashley Olson*
1
, G Touloumi
2
, R Geskus
3,4
, L Meyer
5
, M Prins
3,4
,
G Chene
6
, A De Luca
7
, D Costagliola
8
, K Porter
1
, and CASCADE
Collaboration in EuroCoord
1
2
Univ of Athens, Greece,
3
Amsterdam Publ Hlth Svc, The Netherlands,
4
Amsterdam Med Ctr,
The Netherlands,
5
INSERM U1018, Univ Paris Sud, Le Kremlin Bicetre,
France,
6
INSERM U897 and CIC-EC7, Univ Bordeaux Segalen, Ctr Hosp
Bordeaux, France,
7
Catholic Univ of the Sacred Heart, Rome, Italv, and
8
INSERM EMI 0214, Ctr Hosp Univ Pitie Salpetriere, Paris, France
269 Slow Immunological Progression in Injecting Drug Users
Infected with HIV-1 CRF07_BC in Taiwan
Sui-Yuan Chang*
1,2
, P-H Lin
2
, C-C Lai
3
, M-S Tsai
1
, J-L Yang
4
, Y-C Su
2
,
C-J Yang
5
, and C-C Hung
1,2
1
Natl Taiwan Univ Hosp, Taipei,
2
Natl Taiwan Univ Coll of Med, Taipei,
3
Kaohsiung Med Univ Hosp, Taiwan,
4
Natl Taiwan Univ Hosp, Yun-Lin
Branch, and
5
Far Eastern Memorial Hosp, Taipei, Taiwan
270 :<!$/<& :.?+<& +"B )!*(. :=/,($!/" !" $%& 2-)5D '+A '&"&
0*/1 >/"$*/,,&*. K!$% 3/"A5$&*1 I/"5<*/A*&..!/"
Ling Yue*
1
, J Okulicz
2,3
, B Agan
2
, E Hunter
1
, and V Marconi
41
Emorv Jaccine Ctr, Atlanta, GA, US,
2
Uniformed Svcs Univ of Hlth Sci,
Bethesda, MD, US,
3
Brooke Armv Med Ctr, San Antonio, TX, US, and
4
271 :,&=+$&B 3&=&,. /0 4?$!=+$&B M&A(,+$/*G L >&,,. F+G 6&
-"=/,=&B !" I/"5<*/A*&..!/" /0 2-)
H
)!*&1!? 3/"A5$&*1
I/"5<*/A*&../*.
J Gaardbo
1
, A Ronit
1
, H Hartling
1
, K Thorsteinsson
2
, H Ullum
1
, A Andersen
3
,
and Susanne Nielsen*
1
1
Rigshospitalet, Univ Hosp of Copenhagen, Denmark,
2
Hvidovre Hosp,
Univ Hosp of Copenhagen, Denmark, and
3
Univ of Southern Denmark,
Odensen
!

()**!'" +2,-'*%)& ./*%&01%*
HIV Infection Models
272 @,+.1+ )!*(. @/<(,+$!/". !" ML5;2-)
H
F+?+N(&. 4*&
E&*!=&B 0*/1 F(,$!<,& L!..(&.
Mary Kearney*
1
, C Kline
2
, E Anderson
1
, D Kordella
1
, L Smith
1
,
C Croomer
1
, J LiIson
3
, J Mellors
2
, J CoIIin
4
, and Z Ambrose
2
1
HIJ Drug Resistance Prgm, NCI-Frederick, MD, US,
2
Univ of
Pittsburgh, PA, US,
3
AIDS and Cancer Jirus Prgm, SAIC-Frederick Inc,
MD, US, and
4
273 >/**&,+$!/" /0 >%+"A&. !" $%& 6!/,/A!?+, @*/<&*$!&. /0 2-)5D
:"=&,/<& K!$% E!.&+.& @*/A*&..!/" !" + >,+B& > ;2-)
H

M%&.(. F+?+N(&
For Yue Tso*
1
, L Abrahamyan
1
, R Ruprecht
2,3
, and C Wood
1
1
Univ of Nebraska, Lincoln, US,
2
Dana-Farber Cancer Inst, Boston, MA,
US, and
3
274 Polyfunctional Plasmacytoid Dendritic Cells Redistribute to
'($ L!..(&. B(*!"A ;-) -"0&?$!/"
H Li, J Gillis, T Evans, and Keith Reeves*
New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US
275a @+$%/A&"!? ;-) -"0&?$!/" -. 4../?!+$&B K!$% :O<+".!/" /0 $%&
:"$&*!? )!*/1&
S Handley
1
, L Thackray
1
, G Zhao
1
, Rachel Presti*
1
, A Miller
2
,
K MansIield
2
, J Brenchley
3
, R Veazey
4
, D Barouch
5,6
, and H Virgin
1
1
2
New England Primate
Res Ctr, Harvard Med Sch, Southborough, MA, US,
3
NIAID, NIH,
Bethesda, MD, US,
4
Tulane Natl Primate Res Ctr, Tulane Univ Sch of
Med, Covington, LA, US,
5
Beth Israel Deaconess Med Ctr, Boston, MA,
US, and
6
275b Interferon-o Blockade during Acute SIV Infection of Rhesus
F+?+N(&. M&B(?&. L >&,, 4?$!=+$!/" +"B M&.$/*&. L >&,,
2/1&/.$+.!.
Thomas VanderIord*
1
, C Steel
2
, J Zeidan
2
, J Yu
1
, J Ahlers
2
, C Nicolette
3
,
I Tcherepanova
3
, M Cameron
2
, R-P Sekaly
2
, and G Silvestri
1
1
2
Jaccine & Gene Therapv Inst, Port St
Lucie, FL, US, and
3
Argos Therapeutics, Durham, NC, US
276 Loss and Aberrant Function of NKp44
H
-""+$& 3G1<%/!B
>&,,. !" $%& ;-)
H
Gut Are Associated with RORyt Suppression

Haiying Li*, T Evans, J Gillis, and K Reeves
New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US
277 Th17 Cells Display Defects in 1AK/STAT3 Signaling
@+$%K+G B(*!"A >%*/"!? ;-) -"0&?$!/"

Sandra Bixler* and J Mattapallil
Uniformed Svcs Univ, Bethesda, MD, US
278 ;-)
4'F
5-"0&?$&B 40*!?+" '*&&" F/"C&G. M&.</"B
to Neo Antigens and Down-regulate CD4

Molly Perkins*
1
, N Calantone
1
, S Whitted
1
, L Canary
1
, N Klatt
1
,
C Vinton
1
, P Darrah
2
, R Seder
2
, V Hirsch
1
, and J Brenchley
1
1
NIAID, NIH, Bethesda, MD, US and
2
Jaccine Res Ctr, NIAID, NIH,
Bethesda, MD, US
279 Microarray Analysis of Double-negative T Cells in Sooty
Mangabeys Demonstrates Th1-Th2-Th17-TFH Multi-
0("?$!/"+,!$G

Vasudha Sundaravaradan*
1
, R Saleem
1,2
, M Gasper
1
, A Ortiz
3
,
J Else
3
, G Silvestri
3
, J Aitchison
1,2
, and D Sodora
1
1
Seattle Biomed Res Inst, WA, US,
2
Inst of Svstems Bio, Seattle, WA, US,
and
3
280 Factors Associated with SIV Transmission in the Wild in a
I+$(*+, 2/.$ /0 ;-)

Dongzhu Ma*
1
, A Jasinska
2
, K Raehtz
1
, V Wijewardana
1
, C Schmitt
2
,
T Turner
3
, M Antonio
4
, I Pandrea
1
, N Freimer
2
, C Apetrei
1
, and Intl Consortium
1
2
Semel Inst for Neurosci
and Human Behavior, Univ of California, Los Angeles, US,
3
Facultv of
Natural and Agricultural Sci, Univ of the Free State, Bloemfontein, South
Africa, and
4
MRC Unit, Gambia, West Africa
281 3" $!$' Replication of a Transmitted Founder Clone
/0 ;-)
+A1
Recapitulates Features of Parental Swarm
!" 40*!?+" '*&&" F/"C&G. +"B @!A$+!,&B F+?+N(&.
Jan KristoII*
1
, CW Gnanadurai
2
, N Parish
3
, D Ma
1
, C Xu
1
, L Catchpole
1
,
C Apetrei
1
, B Hahn
3
, F KirchhoII
2
, and I Pandrea
1
1
2
Inst of Molecular
Jirologv, Univ of Ulm, Germanv, and
3
Univ of Pennsvlvania Perelman
Sch of Med, Philadelphia, US
Program 29
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' ()*+&$,#- ./$,-01,$
HIV and Monocytes, Macrophages, and Dendritic
Cells
282 Gene Modulation Regulated by Transcription Factors IRF3
and IRF7 during an HIV-1 Infection in Primary Human
Macrophages

Charles Joly Beauparlant*, R Allary, L Robitaille, A Droit,
J Estaquier, and J Corbeil
Univ Laval, Quebec, Canada
283 The Infectious Synapses Formed between Mature Dendritic
Cells and CD4
+
T Cells Are Independent of the Presence of
the HIV-1 Envelope Glycoprotein

Maria Rodriguez-Plata*
1
, I Puigdomenech
1
, N Izquierdo-Useros
1
,
M Puertas
1
, J Carrillo
1
, I Erkizia
1
, B Clotet
1
, J Blanco
1
, and J Martinez-Picado
1,2
1
AIDS Res Inst IrsiCaixa, Inst dInvestigacio en Ciencies de la Salut
Germans Trias i Pufol, Univ Autonoma de Barcelona, Badalona, Spain
and
2
Inst Catalana de Recerca i Estudis Avancats, Barcelona, Spain
284 Regulatory T Cell Expression Is Modulated by Dendritic
Cell Induced IDO Enzyme Activity: Implication for Clinical
Outcome in HIV
+
Patients

Mohammad-Ali Jenabian*
1
, M Patel
1
, C Kanagaratham
1
, D Radzioch
1
,
B Lebouche
1
, C Tremblay
2
, I Kema
3
, N Gilmore
1
, P Ancuta
2
, and J-P Routy
1,4
1
Res Inst of McGill Univ Hlth Ctr, Montreal, Canada,
2
Ctr Hosp Univ
de Montreal Res Ctr, Canada,
3
Univ Med Ctr, Univ of Groningen, The
Netherlands, and
4
Roval Jictoria Hosp, McGill Univ Hlth Ctr, Montreal,
Canada
285 TLR8 Ligands Inhibit HIV Infection of Macrophages
through a Vitamin D and Cathelicidin Dependent Autophagic
Mechanism
Grant Campbell*
1
and S Spector
1,2
1
Univ of California, San Diego, La Jolla, US and
2
Radv Childrens Hosp,
San Diego, CA, US
286 Restriction of HIV-1 Replication in Primary Macrophages by
Interleukin-12 and Interleukin-18 through the Up-regulation
of SAMHD1

Eduardo Pauls*, E Jimenez, A Ruiz, M Permanyer, R Pena,
B Clotet, M BoIill, and J Este
IrsiCaixa, Hosp Germans Trias i Pufol, Univ Autonoma de Barcelona,
Badalona, Spain
287 HIV-1 Infection of Macrophages Induces Transcription Factor
EB but Blocks the Fusion of Autophagosomes with Lysosomes
Inhibiting Autophagy

Huihui Tang* and S Spector
Radv Childrens Hosp and Univ of California, San Diego, La Jolla, US
288 Different Gene Expression Pattern in Mature and Immature
Dendritic Cells Is Induced by Productive HIV-1 Infection
E Calonge, J Garcia-Perez, A Munoz, and Jose Alcami*
Inst de Salud Carlos III, Madrid, Spain
289 HIV-1 Stimulates Human Monocytes to Produce BAFF
through Type I Interferon

Alejandro Gomez*
1
, M Ouellet
1
, and M Tremblay
1,2
1
Laval Univ, Ctr Hosp Univ Quebec, Infectious Disease Res Ctr, Canada
and
2
Laval Univ, Quebec, Canada
290 Tat Engagement of p38 MAPK and IRF7 Pathways Leads to
Activation of Interferon-stimulated Genes
in Antigen-presenting Cells
N Kim, S Kukkunen, MD Martinez-Viedma, and Anna Aldovini*
Boston Childrens Hosp, Harvard Med Sch, MA, US
291 A Selectively Reduced Toll-like Receptor Responsiveness and
Functional Exhaustion of Blood Plasmacytoid Dendritic Cells
in HIV-1
+
Patients
Jihong Dai*, E Jacobs, N Reilly, K Tulloch, S Hodder,
and P Fitzgerald-Bocarsly
Univ of Med and Dentistrv of New Jersev, Newark, US
292 Fc-gamma-RIII Mediated ADCC by NK Cells and Its
Regulation by Monocytes and Fc-gamma RII Is Substantially
Disturbed in Chronic HIV-1 Infection
N Bhatnagar
1
, A Fareed
1
, H Hong
2
, J Eberhard
1
, I-N Lu
1
, M Ballmeier
1
,
R Schmidt
1
, R Jacobs
1
, and Dirk Meyer-Olson*
1
1
2
New England Primate Res Ctr,
Southborough, MA, US
!

"#$$%&' (2*+&$,#- ./$,-01,$
CD8 T Cells in HIV Infection
293 Understanding the Mechanisms by Which IL-7 Down-regulates
Expression of the IL-7 Receptor Alpha-chain (CD127) in
Primary Human CD8 T Cells

Feras Al-Ghazawi*
1,2
, P Parmar
1,2
, E Faller
1,2
, S Sugden
1,2
, H Cherid
1,2
,
J Kakal
1
, A El SalIiti
1,2
, and P MacPherson
1,2,3
1
Univ of Ottawa, Canada,
2
Ottawa Hosp Res Inst, Canada, and
3
Ottawa
Hosp, Canada
294 Cytomegalovirus and HIV Infections Have Opposite Effects on
CD8
+
T Cell Differentiation and Proliferation

Sulggi Lee*
1
, E Sinclair
1
, Y Huang
1
, D Bangsberg
2
, M Lederman
3
,
F Hecht
1
, J Martin
1
, S Deeks
1
, and P Hunt
1
1
2
Massachusetts Gen Hosp and
Harvard Univ, Boston, US, and
3
Case Western Reserve Univ, Cleveland,
OH, US
295 HIV-1 Vpr Accelerates Viral Replication by Exploiting
Regulatory CD4
+
T Cells in Humanized Mice
Kei Sato*
1
, N Misawa
1
, Y Satou
1
, M Matsuoka
1
, M Ito
2
, and Y Koyanagi
1
1
Inst for Jirus Res, Kvoto Univ, Japan and
2
Central Inst for Experimental
Animals, Kanagawa, Japan
296 Impairment of Regulatory T Cell Function following HIV-1
Infection

Mathieu Angin*
1
, M King
1
, M Bhasin
2
, S Sharma
1
, T Murooka
3
,
T Mempel
3
, B Walker
1
, and M Addo
1
1
Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US,
2
Beth Israel
Deaconess Med Ctr Genomics and Proteomics Ctr, Dana-Farber/Harvard
Cancer Ctr, Boston, MA, US, and
3
Ctr for Immunologv and Inflammatorv
Diseases, Massachusetts Gen Hosp, Harvard Med Sch, Boston, US
297 Elevated Levels of T Regulatory Cells and Immune
Activation in Frail Men with and without HIV Infection
Weiying Zhang*, T Nilles, K AlthoII, and J Margolick
298 ISG15 Expression in CD8
+
T Cells Aids in the Containment of
HIV

Ana Gonzalez*
1
, W Ochieng
1
, H-H Chang
2
, A Shi
1
, H-X Liao
3
,
K Soderberg
3
, J Schmitz
1
, B Haynes
3
, and N Letvin
1
1
Ctr for Jirologv and Jaccine Res, Beth Israel Deaconess Med Ctr,
Harvard Med Sch, Boston, MA, US,
2
Childrens Hosp Informatics Prgm,
3
Human Jaccine Inst, Duke Univ
Sch of Med, Durham, NC, US
!

"#$$%&' 34*+&$,#- ./$,-01,$
Killer T Cells
299 CD4
+
Cytotoxic T Cells May Contribute to Control of HIV-1
Viremia by Eliminating Virally Infected MHC-II
+
Central
Memory CD4
+
T Lymphocytes
Antonio Valentin*, J Li, B Felber, and G Pavlakis
NCI-Frederick, MD, US
300 Stable SIV Control in the Presence of Silent Proviruses
T Nomura
1,2
, H Ishii
1,2
, N Iwamoto
1,2
, H Yamamoto
1
, and Tetsuro Matano*
1,2
1
Natl Inst of Infectious Diseases, Tokvo, Japan and
2
Univ of Tokvo, Japan
301 The Efficiency of CD8
+
T Cell-mediated Elimination of Non-
productively HIV
+
CD4
+
T Cells Is a Critical Determinant of
HIV-1 Control
H Yang
1
, R Smyth
2
, G Hancock
1
, J Mak
3
, M Davenport
4
, and Lucy Dorrell*
1
1
Univ of Oxford, UK,
2
CNRS, Strasbourg, France,
3
Deakin Univ,
Melbourne, Australia, and
4
Univ of New South Wales, Australia
302 Pre-stimulated Cytotoxic T Lymphocytes from HIV-1
+

Patients Eliminate Autologous CD4
+
T Cells Infected with
HIV-1 from Viral Latent Reservoir

Kai Deng*, L Shan, C Durand, J Blankson, and R Siliciano
303 CD8 from Elite Controllers Exhibit Comparable Antiviral
Capacity but Favorable Functional Profile Compared to
Untreated Progressors

David Shasha*, F Porichis, D Karel, O Angiuli, D KauImann,
and B Walker
304 Dissecting TCR Repertoire, Function, and Memory
Generation of Effector HIV-specific CD8 T Cells in Acute
HIV Infection
P Ngauv
1
, J Ananworanich
2,3
, F Procopio
1
, D Srinivasan
1
, C Steel
1
,
A Schuetz
3
, M deSouza
3
, N Michael
4
, J Kim
2,4
, Lydie Trautmann*
1
,
and RV254/SEARCH 010 Study Group
1
Jaccine and Gene Therapv Inst, Port St Lucie, FL, US,
2
Thai Red Cross
AIDS Res Ctr, Bangkok,
3
Armed Forces Res Inst of Med Sci, Bangkok,
Thailand, and
4
Walter Reed Armv Inst of Res, Silver Spring, MD, US
P
o
s
t
e
r

L
i
s
t
i
n
g
s
305 Antigen Exposure Triggers an Increase of the Functional
Avidity of HIV-1-specific CD8 T Cell Responses through
CDR3 Renewal
Selena Vigano*
1
, F Bellutti-Enders
1
, A-L Savoye
1
, V Rozot
1
,
C Cellerai
1
, M Cavassini
1
, S Ding
2
, P-A Bart
1
, G Pantaleo
1,3
, and A Harari
1,3
1
Lausanne Univ Hosp, Swit:erland,
2
eurovacc, Amsterdam, The
Netherlands, and
3
Swiss Jaccine Res Inst, Lausanne
306 Regulatory B Cell Frequency Correlates Positively with
Markers of HIV Disease Progression and Attenuates
Anti-HIV T Cell Responses !" $!%&'

Basile Siewe*
1
, J Stapleton
2
, J Martinson
1
, A Kesharvazian
1
,
I Pandrea
3
, A French
1,4
, P Demarais
4
, and A Landay
1
1
2
Univ of Iowa and Iowa Citv
JAMC, US,
3
Ctr for Jaccine Res, Univ of Pittsburgh, PA, US, and
4
CORE
Ctr, Stroger Hosp of Cook Countv, Chicago, IL, US
307 Specific Functional Profiles Are Linked to the Emergence of
Mutations within HLA-B`5701-restricted Epitopes

Marcus Buggert*
1
, M Norstrom
1
, M Salemi
2
, F Hecht
3
, and A Karlsson
1
1
2
and
3
308 Immune Selection in a Pigtailed Macaque Model of SIV
Central Nervous System Disease: Costs and Consequences

Sarah Beck*, S Queen, and J Mankowski
!

()**!'" +,-.'*%)& /0*%&12%*
Immune Restoration
309 Phenotypic CD8
+
T Cell Defects in Treated HIV Infection Are
Distinct from Those of Aging, Predict Mortality, and May Be
Prevented by Earlier ART

Sulggi Lee*
1
, E Sinclair
1
, Y Huang
1
, M Van Natta
2
, D Bangsberg
3
,
M Lederman
4
, F Hecht
1
, J Martin
1
, S Deeks
1
, and P Hunt
1
1
2
Johns Hopkins Univ, Baltimore,
MD, US,
3
Massachusetts Gen Hosp and Harvard Univ, Boston, US, and
4
Case Western Reserve Univ, Cleveland, OH, US
310 cART-induced Immunological Function Restoration Is
Independent of the cART Regimen and Is Not Correlated
with the Extent of CD4 Gains

Norma Rallon*
1
, B Torres
2
, A Diaz
2
, L Alos
2
, E Martinez
2
, A Leon
2
,
J Gatell
2
, V Soriano
1
, F Garcia
2
, and JM Benito
1
1
Hosp Carlos III, Madrid, Spain and
2
Hosp Clin, Univ of Barcelona, Spain
311 CD4 but Not CD4:CD8 Ratio Recovery after 14 Years
Successful HIV Suppression
Emma Devitt*
1
, JM Rodriguez
1
, S Mandalia
1,2
, and A Pozniak
1
1
Chelsea and Westminster Hosp, London, UK and
2
312 NKp44L Expression on CD4
+
T Cells Is Associated with
Impaired Immunological Recovery in HIV
+
Patients under
HAART
A Sennepin
1,2,3
, F Baychelier
1,3
, R Ho Tsong Fang
2
, C Katlama
4
, A Simon
5
,
J Crouzet
2
, V Vieillard
1,3
, and Patrice Debre*
1,3
1
INSERM UMRS 945, Paris, France,
2
Innavirvax SA, Evrv, France,
3
Unive Pierre et Marie Curie, Paris-6, France,
4
Hosp Pitie-Salpetriere,
Svc des Maladies Infectieuses, Paris, France, and
5
Hosp Pitie-Salpetriere,
Svc de Med Interne, Paris, France
313 Restoration of Cytomegalovirus-specific-CD4 with ART
Occurred Early and Was Greater in Those with More
Advanced HIV-associated Immunodeficiency

Denise Hsu*
1,2
, S Kerr
1,2
, T Iampornsin
2
, S Pett
1
, A Avihingsanon
2
,
P Thongpaeng
2
, S Ubolyam
2
, J Ananworanich
2
, A Kelleher
1
, and D Cooper
1
1
The Kirbv Inst for Infection and Immunitv in Societv, Univ of New South
Wales, Svdnev, Australia and
2
HIJNAT Res Collaboration, Thai Red
Cross AIDS Res Ctr, Bangkok
314 Poor CD4 T Cells Reconstitution in Virologically Suppressed
HIV
+
Patients on HAART: Role of CD4 Associated Immune
Correlates

Ranjini Valiathan*
1
, D Gracia
2
, and D Asthana
1
1
Univ of Miami Miller Sch of Med, FL, US and
2
Borinquen Hlth Care Ctr,
Miami, FL, US
315 Hyaluronic Acid as a Predictor of Immune Reconstitution
following ART
Ala Dababneh*
1
, N Cummins
1
, G Bren
1
, Z Temesgen
1
, D Bangsberg
2
,
and A Badley
1
1
Mavo Clin, Rochester, MN, US and
2
Massachusetts Gen Hosp, Harvard
Med Sch, Boston, US
316 The Effect of HAART-induced HIV Viral Suppression on
Markers of Immune Activation in the Multicenter AIDS
Cohort Study
Nikolas Wada*
1
, L Jacobson
1
, J Margolick
1
, E Breen
2
, and J Bream
1
1
and
2
317 sCD163 as Biomarker of Residual Innate Immune Activation
in Virologically Suppressed ART-treated Patients
Miriam Lichtner*, R Rossi, C Mascia, R Marocco, T Tieghi,
F Mengoni, G Russo, P Zuccala, C Mastroianni, and V Vullo
Sapien:a Polo Pontino Univ of Rome, Italv
318 Early Treatment Leads to a Better Profile of HIV
Inflammation Driven by Alarmin Signal Pathway
S Hue
1
, Laurent Hocqueloux*
2
, M Surenaud
1
, C Manier
1
, J Guignard
2
,
C Poillet
1
, T Prazuck
2
, C Lacabaratz
1
, and Y Levy
1
1
INSERM U955, Creteil, France and
2
Ctr Hosp Regional dOrleans, France
319 The Long-term Persistence of Monoclonal Gammopathy
in Patients on ART Is Associated with Epstein-Barr Virus
Replication

David Ouedraogo*
1,2,3
, A Makinson
4
, J-P Vendrell
1,2,3
, M-L Casanova
4
,
A De Jong
5
, N Nagot
1
, J Reynes
4
, P Van de Perre
1,3
, and E Tuaillon
1,2,3
1
INSERM U1058, Univ Montpellier 1, France,
2
Ctr Hosp Regional
Univ de Montpellier, Inst de Recherche en Biotherapies, France,
3
Ctr
Hosp Regional Univ de Montpellier, France,
4
Ctr Hosp Regional Univ
de Montpellier, UMI 233, France, and
5
Univ de Montpellier, Hosp la
Colombiere, France
!

()**!'" +3-.'*%)& /0*%&12%*
Microbial Translocation
320 Human Intestinal Defensins Inhibit Viral Replication but Are
Diminished in Chronic Untreated HIV Infection

Bjorn Corleis*, W Gostic, and D Kwon
321 Tight 1unction mRNA Expression Decreases with a Proximal
to Distal Gradient, Contributing to Colonic, Not Small
Intestinal, Permeability in HIV

Charlotte Chung* and A Levine
Case Western Reserve Univ Sch of Med, Cleveland, OH, US
322 AIDS Virus Associated Gut Epithelial Barrier Dysfunction Is
Induced by Mucosal microRNA Dysregulation

Christopher Gaulke*
1
, I Grishina
1
, M George
1
, J Fass
1
, N Joshi
1
,
J Jovel
2
, S-W Ding
2
, D Lin
1
, and S Dandekar
1
1
Univ of California, Davis, US and
2
Univ of California, Riverside, US
323 The Contribution of Intestinal Epithelial Cell Damage,
Microbial Translocation, and HIV Status to an Inflammaging
Phenotype
Amanda Steele*, E Lee, Z Dong, B Vestal, J Koeppe, and C Wilson
Univ of Colorado Anchut: Med Campus, Aurora, US
324 Immune Activation and T Cell Cycling Are Increased in
Treated HIV Infection and Inflammatory Bowel Disease;
Possible Links to Microbial Translocation
Nicholas Funderburg*, S StubbleIield-Park, H Sung, G Hardy,
B Clagett, J Ignatz-Hoover, C Harding, J Katz, M Lederman, and A Levine
325 Gut 412%'012!5515)* during HIV Infection Are Associated with
Higher CD4 and Less Microbial Translocation

Josue Perez-Santiago*
1
, S Gianella
1
, M Massanella
1
, M Karris
1
,
S Var
1
, D Patel
1
, P Jordan
1
, S Little
1
, D Richman
1,2
, and D Smith
1,2
1
2
JA San Diego Hlthcare
Svstem, CA, US
326 Changes in Stool Microbiota, Bacterial Translocation,
and Mucosal Immunity after Oral Serum-derived Bovine
Immunoglobulin Administration
David Asmuth*
1,2
, J Stombaugh
3
, Z-M Ma
4,5
, A Albanese
1
, E Hodzic
4
,
P Troia-Cancio
2
, N Flynn
2
, T Yotter
2
, C Miller
4,5
, and R Knight
3
1
JA Northern California Hosp, Mather, US,
2
Univ of California, Davis
Med Ctr, Sacramento, US,
3
Univ of Colorado, Boulder, US,
4
Univ of
California, Davis, US, and
5
Ctr for Comparative Med, Davis, CA, US
327 Interferon-y-producing y/ T Cells Are Increased in
Untreated HIV-1 Infection and Correlate with T Cell
Activation and Microbial Translocation
Stephanie Dillon*
1
, E Lee
1
, G Austin
1
, Z Dong
1
, K RuIner
1
,
S Gianella Weibel
2
, D Smith
2
, and C Wilson
1
1
Univ of Colorado Anschut: Med Campus, Aurora, US and
2
Univ of
328 Interferon-23 Production in Response to Commensal
Bacteria Is Increased in HIV-1 Infection and Is Associated
with Frequencies of Activated Monocytes
JenniIer Manuzak*, S Dillon, E Lee, and C Wilson
Univ of Colorado Anschut: Med Campus, Aurora, US
Program 31
P
o
s
t
e
r

L
i
s
t
i
n
g
s
329 Impact of Acute HIV-1 Infection on Th17/Treg Balance and
T Cell Activation in the Sigmoid Colon
Alexandra Schuetz*
1,2
, Y Phuang-Ngern
1
, R Rerknimitr
3
, I Sereti
4
,
M Robb
2
, V Ngauy
1,2
, R Dewar
5
, J Kim
2,6
, M De Souza
1,2
,
J Ananworanich
3,6,7
, and RV254/SEARCH 010 Study Team
1
Armed Forces Res Inst of Med Sci, Bangkok, Thailand,
2
US Militarv HIJ
Res Prgm, Walter Reed Armv Inst of Res, Silver Spring, MD,
3
Facultv of
Med, Chulalongkorn Univ, Bangkok, Thailand,
4
5
SAIC-Frederick Inc, MD, US,
6
SEARCH, Bangkok, Thailand, and
7
The
Thai Red Cross AIDS Res Ctr, Bangkok
330 Paucity of Nave Th17 Precursors as a Potential Cause for
Memory Th17 Deficiency in HIV
+
Individuals

Sandrina Da Fonseca*
1
, A Gosselin
1
, R-M Boulassel
2
, J-P Routy
2,3
,
N Bernard
2
, C Tremblay
1
, and P Ancuta
1
1
Ctr de Res du Ctr Hosp de lUniv de Montreal Saint Luc, Canada,
2
Roval
Jictoria Hosp, McGill Univ Hlth Ctr, Montreal, Canada, and
3
McGill
Univ, Montreal, Canada
331 Functional Dysregulation of Mucosal Th17 Cells During
HIV Infection and Treatment Is Associated with Microbial
Translocation and Immune Activation

Connie Kim*
1
, C Kovacs
2
, G Kandel
1,3,4
, S Huibner
1
, D Chege
1
,
K Shahabi
1
, E Benko
2
, M LoutIy
1,2,5
, M Ostrowski
1,3
, and R Kaul
1,4
1
Univ of Toronto, Canada,
2
Maple Leaf Med Clin, Toronto, Canada,
3
St
Michaels Hosp, Toronto, Canada,
4
Univ Hlth Network, Toronto, Canada,
and
5
Womens Coll Hosp, Toronto, Canada
!

"#$$%&' ()*+&$,#- ./$,-01,$
Immune Activation/Function in HIV Infection
332 Circulating Microparticles as Markers of Immune Activation
in Treatment-nave HIV
+
Patients
B Smit, Willem Blok*, M Van SchilIgaarde, W Terpstra,
G Van den Berk, A Leyte, and K Brinkman
OLJG Hosp, Amsterdam, The Netherlands
333 The Effect of HIV Infection on Markers of Inflammation among
Men with Known HIV Seroconversion Dates in the Multicenter
AIDS Cohort Study
Heather McKay*
1
, J Bream
1
, J Margolick
1
, O Martinez-Maza
2
, J Phair
3
,
C Rinaldo
4
, and L Jacobson
1
1
2
3
Northwestern Univ, Feinberg Sch of
Med, Chicago, IL, US, and
4
Univ of Pittsburgh Sch of Publ Hlth, PA, US
334 Increased Innate Immune Activation in HIV-1 Exposed,
Seronegative Intravenous Drug Users that Share Needles
Compared to Non-sharing IDU Controls
Costin Tomescu*
1
, P Smith
2
, D Metzger
2
, and L Montaner
1
1
The Wistar Inst, Philadelphia, PA, US and
2
Philadelphia, US
335 Soluble CD14 and IL-1ra Levels Predict the Immune
Activation Set Point in the Absence of Microbial
Translocation in Primary HIV Infection
M Chevalier
1,2
, G Petitjean
1
, C Didier
1
, C Dunyach-Remy
3,4
, P-M Girard
5
,
L Meyer
6
, J-P Lavigne
3,4
, F Barre-Sinoussi
1
, D Scott-Algara
1
,
and Laurence Weiss*
1,7,8
1
2
Univ Paris Diderot, Sorbonne Paris Cite,
France,
3
INSERM U1047, Univ Montpellier 1, UFR de Medecine, Nimes,
France,
4
Ctr Hosp Univ Caremeau, Nimes, France,
5
Hosp Saint-Antoine,
Paris, France,
6
INSERM U 1018, Univ Paris Sud, France,
7
Univ Paris
Descartes, Sorbonne Paris Cite, France, and
8
Hosp Europeen Georges
Pompidou, Paris, France
336 Multiple Imputations and Bayesian Simulations
for the Study of Immune Function in a Pediatric HIV Cohort
with High Levels of Missing Observations
Livio Azzoni*
1
, R Barbour
2
, A Violari
3
, M Cotton
4
, D Glencross
3
,
W Stevens
3
, E Papasavvas
1
, A Babiker
5
, D Gibb
5
, and L Montaner
1
1
2
3
Univ of the Witwatersrand, Johannesburg, South Africa,
4
Stellenbosch
Univ, Cape Town, South Africa, and
5
MRC, London, UK
337 Investigation of HML-2 Expression in HIV-1
+
Plasma

Neeru Bhardwaj* and J CoIIin
!

"#$$%&' (2*+&$,#- ./$,-01,$
Immune Activation, T Cell Homeostasis, and Therapy
338 Augmented Interferon Responses and Inflammation
Associated with Altered Tryptophan and Adrenal Steroid
Metabolism in HIV Patients on ART with Cocaine Use

Edana Cassol*
1,2
, V Misra
1
, S Morgello
3
, and D Gabuzda
1,2
1
Dana-Farber Cancer Inst, Boston, MA, US,
2
Harvard Med Sch, Boston,
MA, US, and
3
Mt Sinai Med Ctr, New York, NY, US
339 Transcriptional and Metabolic Pathways Link Chronic
Inflammation and Immune Failure in Treated HIV-1
Infection
JeIIrey Ahlers*
1
, R-P Sekaly
1
, M Cameron
1
, K Ghneim
1
, A Filali
1
,
M Ghannoum
2
, P Mukherjee
2
, C Shive
3
, B Rodriguez
3
, and M Lederman
3
1
Jaccine and Gene Therapv Inst-Florida, Port St Lucie, US,
2
Ctr for Med
Mvcologv and OHARA Case Mvcologv Unit, Cleveland, OH, US, and
3
340 Lower Activation in Periphery and Cervical Tissue
Gene Expression Associates with Highly Exposed HIV-1
Seronegative Female Sex Workers

Shaheed Abdulhaqq*
1,2
, C Tomescu
1
, V Tamayo
3
, L Azzoni
1
,
S Garced
3
, L Showe
1
, C Irizarry
3
, C Zorrilla
3
, and L Montaner
1
1
2
Univ of Pennsvlvania Perelman
Sch of Med, Philadelphia, US, and
3
Univ of Puerto Rico, Sch of Med,
San Juan
341 Prolonged Preservation of HIV-specific Cellular Immunity in
Recently HIV
+
Individuals Receiving Maraviroc Intensified
HAART
AI Kawana-Tachikawa*
1,2
, J Llibre
3
, I Bravo
3
, R Escrig
3
, B Mothe
1,3
,
J Miro
4
, J Gatell
4
, A Iwamoto
2
, B Clotet
1,3
, and C Brander
1
1
IrsiCaixa AIDS Res Inst, HIJACAT, Badalona, Spain,
2
Inst of Med Sci,
Univ of Tokvo, Japan,
3
Fundacio Lluita Contra La Sida, Hosp Univ
Germans Trias i Pufol, Badalona, Spain, and
4
Hosp Clin, IDIBAPS, Univ
of Barcelona, Spain
342 Clinical Impact of Altered T Cell Homeostasis in Treated HIV
+

Patients: Canadian Observational Cohort
P Ndumbi
1
, J Gillis
2
, J Raboud
2,3
, M LouIty
4
, M Klein
5
, N MachouI
6
,
C Cooper
7
, R Hogg
8,9
, A Burchell
10
, Christos Tsoukas*
1
,
and Canadian Observational Cohort Collaboration
1
McGill Univ Hlth Ctr, Montreal, Canada,
2
Univ Hlth Network, Toronto,
Canada,
3
Dalla Lana Sch of Publ Hlth, Univ of Toronto, Canada,
4
Maple
Leaf Med Clin, Toronto, Canada,
5
Montreal Chest Inst, McGill Univ Hlth
Ctr, Canada,
6
Clin Med lActuel, Montreal, Canada,
7
Ottawa Hosp, Univ
of Ottawa, Canada,
8
BC Ctr for Excellence in HIJ/AIDS, Jancouver,
Canada,
9
Facultv of Hlth Sci, Simon Fraser Univ, Burnabv, Canada,
and
10
Ontario HIJ Treatment Network, Toronto, Canada
343 Abacavir Impairs an HLA-B`5701-restricted CD8
+
T Cell
Response to an Immunodominant Epstein-Barr Virus Epitope
A Lucas
1
, V Meyer-Pannwitt
1
, E McKinnon
1
, S Burrows
2
, M Rist
2
,
S Leary
1
, M Lucas
1
, S Mallal
1,3
, and Elizabeth Phillips*
1,3,4
1
Inst for Immunologv and Infectious Diseases,
2
Queensland Inst for Med
Res,
3
Roval Perth Hosp, and
4
Sir Charles Gairdner Hosp
!

"#$$%&' (3*+&$,#- ./$,-01,$
Mucosal Factors in HIV Transmission and Infection
344 The Impact of Male Circumcision on the Penis Microbiome:
Analyses from Rakai, Uganda

Cindy Liu*
1,2,3
, B Hungate
3
, A Tobian
2,4
, D Serwadda
5
, R Lester
1
,
G Kigozi
5
, R Galiwango
5
, M Wawer
4
, R Gray
4
, and L Price
1,6
1
Translational Genomics Res Inst, Flagstaff, AZ, US,
2
Johns Hopkins Univ
3
Northern Ari:ona Univ, Flagstaff, US,
4
5
Rakai Hlth Sci Prgm, Entebbe, Uganda, and
6
George Washington Univ
Sch of Publ Hlth, Washington, DC, US
345 Enhanced Penile Skin Barrier Function in Circumcised Men
and Implications of HIV Transmission
Minh Dinh*, R Veazey, and T Hope
Northwestern Univ, Feinberg Sch of Med, Chicago, IL, US
346 Effect of Schistosomiasis Infection on HIV-1 Target Cells in
the Foreskin
Jessica Prodger*
1
, A Ssemaganda
2
, N Kiwanuka
2,3
, A Ssetaala
2
,
A Nanvubya
2
, L Nielsen
4
, P Kato
2
, and R Kaul
1
1
2
Uganda Jirus Res Inst-Intl AIDS Jaccine
Initiative, Entebbe,
3
Makerere Univ Coll of Hlth Sci, Kampala Uganda,
and
4
Intl AIDS Jaccine Initiative, New York, NY, US
347 Probing Mucosal Barrier Function and Identifying the Initial
Targets of Infection During Sexual Transmission
D Stieh
1
, D Maric
1
, K Rothwangl
1
, B BeilIuss
1
, M Anderson
1
, R Veazey
2
,
R Ruprecht
3
, F Villinger
4
, and Thomas Hope*
1
1
2
Tulane Univ, New Orleans, LA,
US,
3
Harvard Univ, Boston, MA, US, and
4
348 Differential Antibody Dependent Changes in HIV-1 Mobility
in Seminal Plasma and Cervical Mucus

Susan Schader*
1
, C Gioia
1
, S Baig
1
, E Allen
1
, E Spongberg
1
, S Allen
1
,
G Cianci
1
, D Stieh
1
, P Kiser
2
, and T Hope
1
1
Northwestern Univ, Chicago, IL, US and
2
Univ of Utah, Salt Lake Citv, US
P
o
s
t
e
r

L
i
s
t
i
n
g
s
349 Impact of Early HIV Infection on CD4
+
T Cell Subsets in the
Female Genital Tract

Lyle McKinnon*
1,2
, B Nyanga
1
, P Izulla
1
, J Kwatampora
1
, M Kimani
1
,
N Mugo
3
, J Smith
4
, O Anzala
1,5
, J Kimani
1,6
, and R Kaul
1,2
1
2
3
Kenvatta Natl Hosp,
Nairobi, Kenva,
4
5
Kenvan AIDS
Jaccine Initiative, Nairobi, and
6
Univ of Manitoba, Winnipeg, Canada
350 The Impact of HIV Infection on Foreskin T Cell Frequency
and Function: Rakai, Uganda
Jessica Prodger*
1
, R Gray
2
, G Kigozi
3
, F Nalugoda
3
, RM Galiwango
3
,
T Hirbod
4
, M Wawer
2
, D Serwadda
3
, R Kaul
1
, and Rakai Genital
Immunology Res Group
1
2
Johns Hopkins Univ Bloomberg Sch of
Publ Hlth, Baltimore, MD, US,
3
Rakai Hlth Sci Prgm, Uganda, and
4
Karolinska Inst, Stockholm, Sweden
!

"#$$%&' ()*+&$,#- ./$,-01,$
Neutralizing Antibodies and How to Stimulate Them
351 HIV-1 Genetic Diversity and the Neutralizing Antibody
Response during Primary Infection
Christoph Carter*
1
, G Wagner
1
, G Hightower
1
, L Hepler
1
, G Caballero
2
,
S Little
1
, S Kosakovsky Pond
1
, P Phung
3
, D Richman
1,2
, and D Smith
1,2
1
2
JA Hlthcare Svstem, San
Diego, CA, US, and
3
Monogram Biosci Inc, South San Francisco, CA, US
352 Characterization of Broadly Neutralizing Antibodies to HIV-1
Present in a Cohort of Long-term Non-progressors

Nuria Gonzalez*
1
, K McKee
2
, E Yuste
3
, J Mascola
2
, and J Alcami
1
1
Inst de Salud Carlos III, Madrid, Spain,
2
3
Hosp Clin, Barcelona, Spain
353 HIV-1 Cross-Clade Neutralization Evolution in Elite
Neutralizers: Association with Detectable Viremia and
Partial Restoration of B Cell Subpopulations

Carolina Ferreira*
1,2
, A Merino-Mansilla
1,2
, A Llano
2,3
, I Perez
4
,
I Crespo
5
, L Llinas
5
, F Garcia
2,4
, J Gatell
2,4
, E Yuste
1,2
,
and V Sanchez-Merino
1,2
1
Inst dInvestigacions Biomed August Pi i Sunver, Barcelona, Spain,
2
HIJACAT, Barcelona, Spain,
3
IrsiCaixa AIDS Res Inst, Hosp Germans
Trias i Pufol, Badalona, Barcelona, Spain,
4
Hosp Clin, Barcelona, Spain,
and
5
Ctr Esther Koplowit:, IDIBAPS, Barcelona, Spain
354 Adaptation of HIV-1 Envelope Glycoproteins to Selective
Pressure by Neutralizing Antibodies at the Population Level

Melanie Bouvin*
1
, M Morgand
1
, A Moreau
1
, P Jestin
2
, L Meyer
2
,
F Barin
1
, and M Braibant
1
1
INSERM U966, Univ Francois Rabelais, Tours, France and
2
CESP
INSERM U1018, Univ Paris Sud, Hosp de Bicetre, Le Kremlin-Bicetre,
France
355 X4 Virus Has Increased Resistance to Neutralization as
Compared to Co-circulating R5 Virus in HIV-1 Subtype C
Nina Lin*
1,2
, C Becerril
1
, S Moyo
3
, J Makhema
3
, R Musonda
3
, M Essex
3,4
,
S Lockman
2,3,4,5
, D Kuritzkes
2,5
, and M Sagar
2,5
1
2
US,
3
Botswana-Harvard AIDS Inst Partnership, Gaborone,
4
Harvard Sch
of Publ Hlth, Boston, MA, US, and
5
Brigham and Womens Hosp, Boston,
MA, US
356 Cleaved, Soluble HIV-1 Env Trimers Presenting Multiple
Broadly Neutralizing Antibody Epitopes
John Moore*
1
, R Sanders
1,2
, R Derking
2
, R Depetris
1
, A Cupo
1
, P Klasse
1
,
R King
3
, J-P Julien
4
, I Wilson
4
, and A Ward
4
1
2
Academic Med Ctr,
Amsterdam, The Netherlands,
3
Intl AIDS Jaccine Initiative, New York,
NY, US, and
4
The Scripps Res Inst, La Jolla, CA, US
!

"#$$%&' ((*+&$,#- ./$,-01,$
HIV Compartmentalization and Evolution on Therapy
357 Prevalence and Patterns of Residual Viremia in HIV
+

Patients on Long-term Suppressive ART
Sharon Riddler*
1
, E Aga
2
, R Bosch
2
, M Bedison
1
, B Bastow
3
, J Eron
4
,
R Gandhi
5
, J Mellors
1
, and A5276s Protocol Team
1
2
3
Social & Scientific Svstems Inc, Silver Spring, MD, US,
4
Univ of North
Carolina at Chapel Hill, US, and
5
358 In-depth Phylogenetic Analyses of HIV-1 Evolution during
Long-term Suppressive Therapy

Lina JoseIsson*
1
, N Faria
2
, S Eriksson
1
, E Sinclair
3
, W Shao
4
,
P Hunt
3
, M Somsouk
3
, S Deeks
3
, F Hecht
3
, and S Palmer
1
1
Karolinska Inst and Swedish Inst for Infectious Disease Control, Solna,
2
Rega Inst, Katholieke Univ Leuven, Belgium,
3
Francisco, US, and
4
Advanced Biomed Computing Ctr, SAIC-Frederick
Inc, NCI-Frederick, MD, US
359 Sequencing of the HIV-1 Population in Cerebrospinal Fluid
during Suppressive Therapy

Viktor Dahl*
1
, M Gisslen
2
, J Peterson
3
, W Shao
4
, S Spudich
5
,
R Price
3
, and S Palmer
1
1
2
Gothenburg, Sweden,
3
4
Advanced
Biomed Computing Ctr, SAIC-Frederick Inc, Frederick Natl Lab for
Cancer Res, MD, US, and
5
360 Wild-type Viremia >50 Copies/mL Arising on cART: Identical
Viral Sequences Imply Expansion of a Clonal Source
Elizabeth Anderson*
1
, J Spindler
1
, V Boltz
1
, W Shao
2
, T Uldrick
3
,
C Rhem
4
, M Kearney
1
, J Mellors
5
, J CoIIin
6
, and F Maldarelli
1
1
HIJ Drug Resistance Prgm, NCI-Frederick Natl Lab, MD, US,
2
Advanced Biomed Computing Ctr, SAIC-Frederick, Inc, NCI-Frederick
Natl Lab, MD, US,
3
HIJ & AIDS Malignancv Branch, NCI, Bethesda,
MD, US,
4
Lab of Immunoregulation, NIAID, Bethesda, MD, US,
5
Univ of
Pittsburgh, PA, US, and
6
361 Lack of Viral Compartmentalization in Nave and Memory
CD4
+
T Cells Subsets After 5 Years of Suppressive ART

Gabriela Khoury*
1
, A Solomon
1
, L JoseIsson
2
, F Wightman
1
,
S Palmer
2
, P Cameron
1,3
, and S Lewin
1,3
1
Monash Univ and Burnet Inst, Melbourne, Australia,
2
Swedish Inst for
Infectious Disease Control and Karolinska Inst, Solna, and
3
Alfred Hosp,
Melbourne, Australia
362 Deep Sequencing Analysis of RT-SHIV Viremia in a Non-
human Primate Model of HIV-1 Therapy: Emergence of
Novel Variants during Viral Rebound
Robert KauIIman*
1,2
, A Villalobos
2,3
, J Higgins
1
, R Schinazi
2,3
,
and T North
1,2,3
1
Univ of California, Davis, US,
2
and
3
JAMC, Decatur, GA, US
!

"#$$%&' (2*+&$,#- ./$,-01,$
Viral DNA Dynamics
363 Decay of Total HIV-1 DNA, 2-LTR Circles, and Plasma HIV-1
RNA in Patients on Long-term Suppressive ART

Guillaume Besson*
1
, E Anderson
2
, M Kearney
2
, J CoIIin
3
,
T Tanzosh
2
, C Rehm
4
, F Maldarelli
2
, and J Mellors
1
1
2
NCI-Frederick, MD, US,
3
Tufts Univ,
Boston, MA, US, and
4
NIAID, NIH, Bethesda, MD, US
364 Initial Therapy with Raltegravir Increases Clearance of
2-LTR Circles but Not Total HIV DNA
Matthew Strain*
1
, S Rought
1
, S Lada
1
, T Luong
2
, C Woelk
1
,
A Andrade
3
, D Kuritzkes
4
, D Richman
1
, and ACTG 5248
1
Univ of California, San Diego, La Jolla and JA San Diego Hlthcare
Svstem, US,
2
Univ of Michigan, Ann Arbor, US,
3
Johns Hopkins Univ,
4
365 Implications of Total, Integrated, and 2-LTR HIV DNA
Distribution Dynamics in Activated vs Resting CD4 Memory
T Cells for Eradication Strategies
Kersten Koelsch*
1,2
, J Murray
2,3
, K McBride
1,2
, Y Xu
1,2
, M Bailey
1,2
,
S Emery
2
, D Cooper
1,2
, J Zaunders
1
, A Kelleher
1,2
, and PINT Study Team
1
St Jincents Hosp, Ctr for Applied Med Res, Svdnev, Australia,
2
The
Kirbv Inst for Infection and Immunitv in Societv, Univ of New South
Wales, Svdnev, Australia, and
3
Sch of Mathematics and Statistics, Univ of
New South Wales, Svdnev, Australia
366 RT-SHIV Viral Decay Kinetics following Three- and Five-
drug cART in Rhesus Macaques
T North
1,2
, Andradi Villalobos*
1
, J Deere
2
, J Higgins
2
, P Chatterjee
1,3
,
S-J Tao
1,3
, J Kohler
1,3
, P Luciw
1,3
, and R Schinazi
1,3
1
Emorv Univ Sch of Med and Emorv Univ Ctr for AIDS Res, Atlanta, GA,
US,
2
3
Atlanta JAMC, Decatur, GA, US
!

"#$$%&' (3*+&$,#- ./$,-01,$
Infected Cell Dynamics on Therapy
367 Kinetic of Peripheral CCR6
+
T Cells in HIV
+
Nave Patients
Treated with Maraviroc-based Therapy
Silvia Nozza*
1
, D De Battista
1
, L Galli
1
, A Galli
1
, M Ripa
1,2
, L Della
Torre
1
, S Chiappetta
1,2
, G Tambussi
1
, M Malnati
1
, and A Lazzarin
1,2
1
2
Univ Jita Salute, San Raffaele Sci
Inst, Milan, Italv
368 HIV-1 Latent Infection Is Preferentially Established in a
Subset of Primary CD4
+
T Cells and Is Inhibited by Cytolytic
T-Lymphocyte Responses

Liang Shan*
1
, C Durand
1
, R Siliciano
1,2
, and J Siliciano
1
1
2
Howard
Program 33
P
o
s
t
e
r

L
i
s
t
i
n
g
s
369 Dynamics of HIV Latency and Reactivation by
Transcriptome Profiling

Julia di Iulio*
1,2
, M Munoz
1
, J Fellay
1,3
, A Telenti
1
, and A CiuIIi
1
1
Inst of Microbiologv, Lausanne Univ Hosp and Univ of Lausanne,
Swit:erland,
2
Bioinformatics and Biostats Core Facilitv, Sch of Life Sci,
Ecole Polvtech Fed de Lausanne, Swit:erland, and
3
Global Hlth Inst, Sch
of Life Sci, Ecole Polvtech Fed de Lausanne, Swit:erland
370 Whole-genome Transcriptional Profiling of CD4
T Cells Identifies Gene Expression Patterns Associated with
the Size of the Latent HIV-1 Reservoir

Hong Sun*
1,2
, M Buzon
1,3
, Z Ouyang
1
, F Pereyra
1,4
, E Rosenberg
3
,
W Hide
5
, X Yu
1
, and M LichterIeld
3
1
Ragon Inst of MGH, MIT and Harvard, Boston, MA, US,
2
No 1 Hosp
of China Med Univ, Shenvang,
3
4
Brigham and Womens Hosp, Boston, MA, US, and
5
Harvard Sch of Publ
Hlth, Boston, MA, US
!

"#$$%&' ()*+&$,#- ./$,-01,$
(see Session 15 on Mondav for corresponding Themed Discussion)
What Is Latency and What Can We Do about It?
371 Only a Small Fraction of HIV-1 Proviruses in Resting CD4
+

T Cells Can Be Induced to Produce Virions #2 3%3& with Anti-
CD3/CD28 or Vorinostat

Anthony Cillo*
1
, M Sobolewski
1
, J CoIIin
2
, and J Mellors
1
1
2
372 A Comparison of Methods Used to Measure Rectal HIV Levels
Suggests that HIV DNA Resides in Cells Other than CD4
+
T
Cells, Including CD45
+
CD13
+
Cells
Steven Yukl*
1,2
, H Hatano
2,3
, L Epling
2,3
, P Hunt
2,3
, P Li
1,2
, D Havlir
2,3
,
M Somsouk
2,3
, E Sinclair
2,3
, S Deeks
2,3
, J Wong
1,2
, and DARE
1
2
and
3
San Francisco Gen Hosp, CA, US
373 Integrated HIV DNA and Associated Histiocyte Marker
mRNA in Autopsy Samples of Non-lymphoid Tissue
Including the Central Nervous System
Benjamin Gelman*
1
, T Chen
1
, J Lisinicchia
1
, and A Rice
2
1
Univ of Texas Med Branch, Galveston, US and
2
Bavlor Coll of Med,
Houston, TX, US
374 HIV Preferentially Infects Hematopoietic Progenitor Cells
with High CD4 and Can Be Found in CD133
+
Hematopoietic
Progenitor Cells in a Subset of Optimally Treated People with
Long-term Viral Suppression

Lucy McNamara*, N Sebastian, A OnaIuwa-Nuga, J Riddell,
D Bixby, and K Collins
Univ of Michigan, Ann Arbor, US
375 Differences in Integration Site Distributions for Latent and
Expressed HIV-1 Proviruses

Scott Sherrill-Mix*, K Ocwieja, N Malani, U O`Doherty, and F Bushman
376 Histone Deacetylase Inhibitor Romidepsin Induces
HIV in CD4
+
T Cells from ART-suppressed Subjects at
Concentrations Achieved by Clinical Dosing
George Wei*
1
, V Chiang
1
, E Fyne
2
, M Balakrishnan
1
, G Stepan
1
, A Tsai
1
,
J Lalezari
3
, J Mellors
2
, R Geleziunas
1
, and T Cihlar
1
1
Gilead Sci Inc, Foster Citv, CA, US,
2
US, and
3
Quest Clin Res, San Francisco, CA, US
!

"#$$%&' (4*+&$,#- ./$,-01,$
Mechanism of HIV Latency and Reactivation
377 Dose Dependent Gene Expression Changes in Suberoylanilide
Hydroxamic Acid Treated Resting CD4 T Cells

Brian Reardon*
1
, A Singhania
2
, N Beliakova-Bethell
1
, J Zhang
2
,
V Terry
2
, C Spina
1,2
, D Richman
1,2
, and C Woelk
1,2
1
2
JA San Diego, CA, US
378 HDAC3 Is a Key Therapeutic Target for the Disruption of
Latent HIV-1 Infection
Kirston Barton*, K Keedy, N Archin, and D Margolis
379 52 3%3& Responses to Histone Deacetylase Inhibitors Using
HIV Long-terminal Repeat Integrated Sequences from HIV
+

Patients

Hao Lu*
1,2
, L Gray
1,2
, P Ellenberg
1,2
, F Wightman
1,2
, P Cameron
1,2
,
S Wesselingh
1,3
, M Churchill
1,2
, and S Lewin
1,2,4
1
Monash Univ, Melbourne, Australia,
2
3
South Australian Hlth and Med Res Inst, Adelaide, and
4
Alfred Hosp,
Melbourne, Australia
380 The Tyrosine Kinase Inhibitor Dasatinib Blocks %' 3%,-& HIV-1
Production by Primary CD4 T Cells from HIV-1
+
Patients

Manuela Pogliaghi*
1,2,3
, L Papagno
1
, C Katlama
4
, and B Autran
1
1
INSERM UMRS945, Univ Pierre and Marie Curie, Hosp Pitie-
Salpetriere, Paris, France,
2
Univ Jita-Salute, San Raffaele Sci Inst,
Milan, Italv,
3
European AIDS Clin Soc Scholarship Program, and
4
INSERM UMRS943, Univ Pierre and Marie Curie, Hosp Pitie-
Salpetriere, Paris, France
381 Toll-like Receptor 9 Agonist Treatment Decreases the
Proviral Reservoir in Peripheral Blood and Could Impact
HIV-specific Immunity in Patients on cART

Anni Winckelmann*
1
, L Munk-Petersen
1
, T Aagaard Rasmussen
1
,
J Melchjorsen
1
, D MonteIiori
2
, L Ostergaard
1
, O Schmeltz Sogaard
1
,
and M Tolstrup
1
1
Aarhus Univ Hosp, Denmark and
2
Duke Univ Med Ctr, NC, US
382 Low Activity of P-TEFb in Central Memory T Cells and
Reactivation from Latency
Vicente Planelles*
1
, L Martins
1
, M Famiglietti
1
, S Budhiraja
2
,
A Bosque
1
, and A Rice
2
1
Univ of Utah, Salt Lake Citv, US and
2
Bavlor Coll of Med, Houston, TX, US
383 Latency-reversing Agents Differentially Prime Resting
CD4
+
Cells for Recognition by HIV-specific Cytotoxic
T-Lymphocytes

Brad Jones*
1
, M Buzon
1
, M Ostrowski
2
, M LichterIeld
2
, D Irvine
1
,
and B Walker
1
1
Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US and
2
Univ of
Toronto, Canada
384 Reactivation of Latent HIV-1 in Primary Memory CD4
+

T Cells through TLR Stimulation

Camille Novis*, V Planelles, and A Bosque
Univ of Utah, Salt Lake Citv, US
385 Epigenetic Control of PRC-mediated Gene Silencing on
HIV-1 Latency
D-H Jang, K-C Kim, C-H Yoon, SY Park, H-Y Kim, SS Kim,
and Byeong-Sun Choi*
Korea Natl Inst of Hlth, Osong, Chungbuk, South Korea
386 Predicting Outcomes of Treatments to Eradicate the HIV
Latent Reservoir

Alison Hill*
1
, D Rosenbloom
1
, M Nowak
1
, and R Siliciano
2,3
1
Harvard Univ, Cambridge, MA, US,
2
3
Howard Hughes Med Inst, Baltimore, MD, US
387 Sensitive and Scalable %' 3%,-& Memory T Cell Model of HIV-1
Latency for High-throughput Screening and Identification of
Agents that Activate HIV
Helen Yu*, T Barnes, G Stepan, M Balakrishnan, K Stray, C Callebaut,
G Wei, R Geleziunas, N Pagratis, and T Cihlar
Gilead Sci Inc, Foster Citv, CA, US
!

"#$$%&' (6*+&$,#- ./$,-01,$
Novel Vaccine Strategies
388 Protection from Infection and Disease Progression after,
Respectively, Gastrointestinal and Oral Vaccinations with a
SIV DNA/rMVA/Particle Vaccine

Mariana Manrique*
1
, A Cobo-Molinos
1
, A Carville
2
, P Kozlowski
3
,
and A Aldovini
1
1
Childrens Hosp Boston and Harvard Univ, MA, US,
2
New England
Regional Primate Res Ctr, Harvard Med Sch, Southborough, MA, US,
and
3
Louisiana State Univ, New Orleans, US
389 Rescue of Myeloid Dendritic Cell Dysfunction in the Setting
of Chronic HIV-1 Infection with Recombinant, Attenuated
7%$,#-%0 8&'&19,&:#'#$ Vectors
Elizabeth Miller*
1
, M Spadaccia
1
, M Demmler
1
, P Lauer
2
,
D Brockstedt
2
, and N Bhardwaj
1
1
New York Univ Sch of Med, NY, US and
2
Aduro BioTech Inc, Berkelev,
CA, US
390 Potent Cellular Immune Responses Induced after
Therapeutic Immunization of HIV
+
Patients with
PENNVAX-B DNA Vaccine Delivered by Electroporation

Lorenzo Ramirez*
1
, T Arango
1
, D Shah
2
, M Morrow
2
, J Lee
2
,
M Naji
1
, K MaIIei
3
, M Bagarazzi
2
, P Tebas
3
, and J Boyer
1
1
2
Inovio
Pharmaceuticals, Blue Bell, PA, US, and
3
Philadelphia, US
391 Therapeutic Immunization Plus IL-2, GM-CSF, and rhGH
Improves CD4 T Cell Counts and Reduces Immune Activation
in Treated Chronic HIV-1 Infection

Anna Herasimtschuk*
1
, J Downey
1
, M Nelson
2
, G Moyle
2
,
A Jackson
2
, R Sikut
3
, M Adojaan
3
, I Stanescu
4
, F Gotch
1
, and N Imami
1
1
Imperial Coll London, UK,
2
3
FIT Biotech Ltd, Tartu, Estonia, and
4
FIT Biotech Ov, Tampere, Finland
P
o
s
t
e
r

L
i
s
t
i
n
g
s
392 A Randomized, Placebo-controlled, Double-blind, Phase I/
IIa Dose Escalation Study of Immunotherapy by VAC-3S
Directed to the gp41 3S Motif of HIV-1
Christine Katlama*
1
, O Launay
2
, R Ho Tsong Fang
3
, H Bodilis
2
, R Calin
1
,
B Autran
1
, S Gharakhanian
4
, V Vieillard
5
, J Crouzet
3
, and P Debre
6
1
Pitie-Salpetriere Hosp, Paris, France,
2
Cochin Hosp and INSERM
CIC BT505, Paris, France,
3
InnaJirJax, Evrv, France,
4
InnaJirJax,
Cambridge, MA, US,
5
INSERM UMR S945, Paris, France, and
6
Univ
Pierre and Marie Curie, Paris-6 Univ, France
393 HIV-1 Attenuation by Codon-pair Bias

Gloria Martrus*
1
, M Nevot
1
, B Clotet
1,2
, and MA Martinez
1
1
Inst de Investigacio del Sida IrsiCaixa, Badalona, Spain and
2
Lluita
contra la SIDA Fndn, Hosp Univ Germans Trias i Pufol, Badalona, Spain
!

"#$$%&' ()*+&$,#- ./$,-01,$
Gene and Adoptive Immunotherapy
394 HIV Gene Therapy: HIV-1 2&3 Gene-specific Zinc Finger
Nucleases Targeting HIV-1 Provirus in Latent Cells
Cheol-Hee Yoon*, SS Kim, SY Park, O-K Kwon, H-Y Kim, D-H Jang,
and B-S Choi
Korea Natl Inst of Hlth, Osong, Chungbuk, South Korea
395 Promoter Targeting Small RNA Suppresses HIV-1 Infection
%' 4%4&
Kazuo Suzuki*
1
, S Hattori
2
, K Marks
1
, C Ahlenstiel
1
, M Millington
3
,
M Boyd
3
, G Symonds
3
, D Cooper
1
, S Okada
2
, and A Kelleher
1
1
The Kirbv Inst, Svdnev, Australia,
2
Ctr for AIDS Res, Kumamoto, Japan,
and
3
Calimmune Inc, Svdnev, Australia
396 T Cell Receptor Transfer for Boosting HIV-1-specific T Cell
Immunity in HIV-1
+
Patients

Christiane Mummert*
1
, C HoImann
1,2
, A Huckelhoven
1
,
S Muller-Schmucker
1
, J Dorrie
1
, N SchaIt
1
, S Bergmann
1
, E Harrer
1
,
and T Harrer
1
1
Univ Hosp Erlangen, Friedrich-Alexander Univ, Germanv and
2
Univ of
California, Los Angeles, US
!

"#$$%&' (5*+&$,#- ./$,-01,$
Progressive Multifocal Leukoencephalopathy
and Other Central Nervous System Infections
398 Polymorphisms in Toll-like Receptor Genes Increase
Neurosyphilis Risk
Christina Marra*, S Sahi, L Tantalo, E Ho, T Jones, S Dunaway, and T Hawn
399 No Benefit of Mitarzapine Add-on to ART in HIV
+
Patients
with Progressive Multifocal Leukoencephalopathy
Ana Canestri*, K Protopapas, A-A Mazet, J-P Brosseau, Y TaouIik,
J-F DelIraissy, and J Gasnault
Bicetre Hosp, Le Krmlin-Bicetre, France
400 Clonal Immortalized Human Glial Cell Lines Support
Varying Levels of 1C Virus Infection Due to Differences in
Cellular Gene Expression

Michael Ferenczy*, K Johnson, and E Major
Natl Inst of Neurological Disorders and Stroke, NIH, Bethesda, MD, US
!

"#$$%&' (6*+&$,#- ./$,-01,$
Central Nervous System Penetration, ART
Intensification, and Cerebrospinal Fluid Escape
401 Low-level HIV RNA Declines over Time in Cerebrospinal
Fluid but Not in Plasma
Scott Letendre*
1
, D McClernon
2
, R Deutsch
1
, D Cookson
1
, M Cherner
1
,
M Crescini
1
, I Grant
1
, and R Ellis
1
1
Univ of California, San Diego, US and
2
bioMONTR, Research Triangle
Park, NC, US
402 Incidence, Risk Factors, and Neurocognitive Impact of
Cerebrospinal Fluid Viral Escape: Longitudinal Analysis of
the Central Nervous System HIV ART Effects Research and
HIV Neurobehavioral Research Program Cohorts

Ignacio Perez-Valero*
1,2
, S Letendre
2
, R Deutsch
2
, R Heaton
2
,
D CliIIord
3
, J McArthur
4
, S Morgello
5
, B Gelman
6
, A Collier
7
, I Grant
2
,
and CHARTER and HNRP Study Groups
1
Hosp Univ La Pa:, Madrid, Spain,
2
3
4
Johns Hopkins Univ
5
Mt Sinai Hosp, New York, NY, US,
6
Univ of Texas, Galveston, US, and
7
Univ of Washington, US
403 Maraviroc Intensification in Virally Suppressed HIV
Subjects Leads to Improvement in Neurocognitive Test
Performance and Declines in Immune Activation
Lishomwa Ndhlovu*, T Umaki, G Chew, M Agsalda, K Amina,
N Hanks, B Nakamoto, J Barbour, B Shiramizu, and C Shikuma
Univ of Hawaii, Manoa, US
404 Rates and Stability of HIV-associated Neurocognitive
Disorders among Adults on cART and Suppressed Plasma
Viral Load: Prospective Results from the Ontario HIV
Treatment Network Cohort Study
Sean Rourke*
1,2,3
, J Gill
4
, T Bekele
1
, A Carvalhal
2,3
, J McCombe
5
,
A Rachlis
2
, M Atkinson
1
, C Kovacs
2
, T Marcotte
6
, S Letendre
6
,
and OCS Cohort Study
1
Ontario HIJ Treatment Network, Toronto, Canada,
2
Univ of Toronto,
Canada,
3
St Michael`s Hosp, Toronto, Canada,
4
Univ of Alberta, Calgarv,
Canada,
5
Univ of Alberta, Edmonton, Canada, and
6
Univ of California,
San Diego, US
405 Central Nervous System Penetration Effectiveness Score Better
Correlates with Cognitive Performance of HIV
+
Patients after
Accounting for Drug Susceptibility of Plasma Virus

Massimiliano Fabbiani*
1
, P Grima
1,2
, B Milanini
1
, A Mondi
1
,
M ColaIigli
1
, R Gagliardini
1
, R Cauda
1
, MC Silveri
1
, A De Luca
1,3
,
1
1
Catholic Univ of the Sacred Heart, Rome, Italv,
2
S Caterina Novella
Hosp, Galatina, Italv, and
3
406 Protease Inhibitor Mono-therapy Is Not Associated with
a Higher Rate or a Different Pattern of Neurocognitive
Impairment than Triple Drug Therapy
Ignacio Perez-Valero*
1
, A Gonzalez-Baeza
1
, M Estebanez
1
,
N Stella-Ascariz
1
, J Mingorance
1
, C Bayon
1
, M Lagarde
2
, F Pulido
2
,
A Borobia
1
, J Arribas
1
, and PICASSO Study Group
1
Hosp Univ La Pa:, IdiPa:, Madrid, Spain and
2
Hosp Univ 12 de Octubre,
i12, Madrid, Spain
!

"#$$%&' (7*+&$,#- ./$,-01,$
ART, Neurocognitive Outcomes, and New Central
Nervous System-targeted Therapies
407 Long-term Efavirenz Use Is Associated with Worse
Neurocognitive Functioning
Scott Letendre*
1
, F Vaida
1
, D Croteau
1
, D CliIIord
2
, A Collier
3
, B Gelman
4
,
J McArthur
5
, D Simpson
6
, R Heaton
1
, I Grant
1
, and CHARTER Group
1
2
3
4
Univ of Texas Med Branch, Galveston,
US,
5
6
Mt Sinai Sch of Med,
New York, NY, US
408 Gold Nanoparticles to Improve Drug Delivery
to the Central Nervous System

Carolina Garrido*
1
, N Dahl
1
, C Simpson
2
, J Bresee
2
, D Feldheim
2
,
C Melander
3
, and D Margolis
1
1
2
Univ of Colorado, Boulder,
US, and
3
North Carolina State Univ, Raleigh, US
409 Symptoms of Autonomic Dysfunction in HIV
+
Patients
Receiving Stable ART
Dominic Chow*
1
, K Sullivan
1
, D Sletten
2
, M Kocher
1
, R Romine
1
,
B Nakamoto
1,3
, T Umaki
1
, K Kallianpur
1
, C Shikuma
1
, and P Low
2
1
Univ of Hawaii at Manoa, Honolulu, US,
2
Mavo Clin, Rochester, MN,
US, and
3
Straub Med Ctr, Honolulu, HI, US
410 Similar Cognition Outcomes after 24 Weeks for Tenofovir/
Emtricitabine + Atazanavir/Ritonavir-experienced HIV
+

Subjects or Those Simplifying to Abacavir/Lamivudine +
Atazanavir
Kevin Robertson*
1
, P MaruII
2
, D Wohl
1
, L Bhatti
3
, C Small
4
,
H Edelstein
5
, H Zhao
6
, D Margolis
6
, L Ross
6
, M ShaeIer
7
,
Ior ASSURE EPZ113734 Study Team
1
2
Cogstate Ltd, Melbourne,
Australia,
3
AIDS HlthCare Fndn, Beverlv Hills, CA, US,
4
New York
Med Coll, Jahalla, US,
5
Alameda Countv Med Ctr, Oakland, CA, US,
6
GlaxoSmithKline, Research Triangle Park, NC, US, and
7
JiiJ HlthCare,
Research Triangle Park, NC, US
411 Impact of Minocycline on Markers of Oxidative Stress
and Neuronal Injury in HIV
+
Individuals with Cognitive
Impairment
Ned Sacktor*
1
, S Miyahara
2
, S Evans
2
, G SchiIitto
3
, B Cohen
4
,
N Haughey
1
, D Graham
1
, A Nath
5
, D CliIIord
6
, and AACTG A5235 Team
1
2
Harvard Sch of
Publ Hlth, Boston, MA, US,
3
Univ of Rochester, NY, US,
4
Northwestern
Univ, Chicago, IL, US,
5
6
Washington Univ
Sch of Med, St Louis, MO, US
412 A Radiolabeled Monoclonal Antibody to gp41 Eliminates
HIV-1
+
Monocytes after Passing through a Human Blood-
Brain Barrier Model
A McFarren
1
, Dina Tsukrov*
2
, E Eugenin
3
, A Morgenstern
4
,
F BruchertseiIer
4
, S Zolla-Pazner
5,6
, M Gorny
5
, A Casadevall
2
, J Berman
2
,
and E Dadachova
2
1
Children`s Hosp at Montefiore, Bronx, NY, US,
2
Albert Einstein Coll of
Med, Bronx, NY, US,
3
Univ of Med and Dentistrv of New Jersev, Newark,
US,
4
European Commission, Joint Res Ctr, Inst for Transuranium
Elemens, Karlsruhe, Germanv,
5
New York Univ, NY, US, and
6
JAMC,
NY, US
Program 35
P
o
s
t
e
r

L
i
s
t
i
n
g
s
413 "#$% &' ()#*#+,))- .#/*#'#+,*0 12342$$#&* #* 567
8
9,0#2*0$:
;''2+0 &' <"7 14=/$
Felix Gutierrez*
1
, L Garcia
2
, S Padilla
1
, D Alvarez
3
, S Moreno
4
,
G Navarro
5
, JL Gomez-Sirvent
6
, F Vidal
7
, V Asensi
8
, M Masia
1
,
and CoRIS
1
Hosp Gen Univ de Elche, Alicante, Spain,
2
Hosp Univ Sant Joan
dÀlacant, Alicante, Spain,
3
Ctr Natl de Epidemiologia, Inst de Salud
Carlos III, Madrid, Spain,
4
Hosp Ramon v Cafal, Madrid, Spain,
5
Hosp
Parc Tauli, Sabadell, Barcelona, Spain,
6
Hosp Univ de Canarias, Santa
Cru: de Tenerife, Spain,
7
Hosp Univ Joan XXIII, Tarragona, Spain, and
8
Hosp Univ Central de Asturias, Oviedo, Spain
!

"#$$%&' ()*+&$,#- ./$,-01,$
Central Nervous System Viral Evolution and
414 Viral Signatures in HIV-1 Subtype C Tat Are Associated with
>2=4&+&/*#0#?2 6@3,#4@2*0 #* ,* 6*A#,* (&B&40

Myres Tilghman*
1
, S Deshpande
2
, J Bhattacharya
2
, M Ghate
2
,
T Marcotte
1
, D Smith
1,3
, and S Mehendale
4
1
2
Natl AIDS Res Inst, Pune,
India,
3
JA San Diego Hlthcare Svstem, La Jolla, CA, US, and
4
Natl Inst
of Epidemiologv, Chennai, India
415 Longitudinal Analysis of HIV-1 Cerebrospinal Fluid
Compartmentalization in Early Infection Detected by Deep
.2C=2*+#*/

TiIIany Yuh*
1
, J Chiarella
1
, B Reese
2
, E St John
2
, B Simen
2
,
M Mohiuddin
2
, J Peterson
3
, R Price
3
, M Kozal
1
, and S Spudich
1
1
2
454 Life Sci, Branford, CT,
US, and
3
416 (),A2D$32+#'#+ 1#''242*+2$ #* 567DE 9,0B&/2*2$#$
Demonstrated by the Studies in Humanized Mice
Santhi Gorantla*
1
, E Makarov
1
, S Adem
1
, L Wu
1
, C Wood
2
,
L Poluektova
1
, and H Gendelman
1
1
Univ of Nebraska Med Ctr, Omaha, US and
2
Univ of Nebraska-Lincoln, US
417 (&442),0#*/ >2=4&3,0B&/2*2$#$ F#0B G4,#* 6*'2+0#&* 1-*,@#+$
#* 0B2 .67
mac251
D#*'2+02A (1HDA23)202A "B2$=$ I,+,C=2 I&A2)
J$#*/ G,-2$#,* 9B-)&/2&/4,3B-

Samantha Strickland*
1
, N Veras
1
, M Prosperi
1
, T Burdo
2
, D Nolan
1
,
M Suchard
3
, K Williams
2
, and M Salemi
1
1
2
and
3
418 1#$0#*+0 "2/#&*,) (&@3,40@2*0,)#K,0#&* #* 0B2 (2*04,)
>24?&=$ .-$02@ &' ,* "L .567
8
"B2$=$ I,+,C=2 F#0B
.2?242 ;*+23B,)#0#$
K Zhuang
1
,

Ana Rachel Leda*
1
, C Harbison
2
, H Knight
2
,
S Westmoreland
2
, and C Cheng-Mayer
1
1
2
New England
Primate Res Ctr, Harvard Med Sch, Southborough, MA, US
!

"#$$%&' ((*+&$,#- ./$,-01,$
Neuropathogenesis Mechanisms
419 94&02&@#+ <*,)-$#$ &' I&)2+=),4 6*024,+0#&*$ &' 0B2
I,+4&3B,/2DA24#?2A 94&02,$2 (,0B23$#* G 1=4#*/ 567DE
6*'2+0#&* %' 2%,-&

Yisel Cantres-Rosario*
1
, M Plaud-Valentin
1
, R Quiles
2,3
,
J Perez-Laspiur
1
, Y Rodriguez
1
, S ShaIIer
4
, and L Melendez
1
1
Univ of Puerto Rico Med Sci Campus, San Juan,
2
Univ of Puerto Rico
Rio Pedras, San Juan,
3
Interamerican Univ of Puerto Rico, Bavamon,
and
4
Univ of Massachussets, Boston, US
420 52@2 MN-/2*,$2DE ">< 6$ 6*+42,$2A #* 567
8
G4,#*$ F#0B
>2=4&+&/*#0#?2 1#$&4A24$ ,*A #* 567
8
;*+23B,)#0#+ G4,#*$

Surendra Ambegaokar*
1
, A Gill
1
, C Kovacsics
1
, S Cross
1
,
B Gelman
2
, and D Kolson
1
1
2
Galveston, US
421 .=3342$$#&* &' G4,#* 52@2 MN-/2*,$2DE #* 567 6*'2+0#&*:
Possible Role in Macrophage-mediated Neurodegeneration

Alexander Gill*
1
, S Cross
1
, C Kovacsics
1
, B Gelman
2
, and D Kolson
1
1
Univ of Pennsvlvania Perelman Sch of Med, Philadelphia, US and
2
Univ
of Texas Med Branch, Galveston, US
422 HIV Infection Increases Levels of Phosphorylated eIF2u,
which Enhances Neurotoxin Production in both Macrophages
,*A <$04&+-02$
Stephanie Cross*
1
, A Gill
1
, C Kovacsics
1
, S Ambegaokar
1
, P Vance
1
,
L Kolson
1
, B Gelman
2
, and D Kolson
1
1
2
Galveston, US
423 .67 6*'2+0#&* ,*A 6*024'24&*D I&A=),02 @#+4&">< 94&'#)2$
&' I,+,C=2 <$04&+-02$

Diego Espinoza*, E Buchanan, A Moyer, J Clements, and K Witwer
424 Expression and Regulation of Host Restriction Factor
.<I51E A=4#*/ O2*0#?#4,) 6*'2+0#&* &' <$04&+-02$ ,*A
I,+4&3B,/2$

Erin Buchanan*, D Espinoza, A Moyer, J Clements, and K Witwer
425 CCL2 Enhances Microglia Outward K Current and
"2$=)0,*0 >2=4&0&N#+ <+0#?#0- ?#, 7&)0,/2D/,02A 9&0,$$#=@
Channel Kv1.3
P Xu, Jianuo Liu*, and H Xiong
426 I&43B&)&/#+ ,*A I&)2+=),4 9,0B&)&/- #* 0B2 .3#*,) (&4A &'
.67
8
I,+,C=2$

Lisa Mangus*, J Dorsey, and J Mankowski
427 PB2 uQD>#+&0#*#+ <+20-)+B&)#*2 "2+230&4 6$ J3D42/=),02A #* ,
P4,*$/2*#+ I&=$2 I&A2) '&4 567
Coral Capo-Velez*
1
, B Morales
1
, R Melendez
2
, and J Lasalde-Dominicci
1
1
Univ of Puerto Rico, San Juan and
2
Univ of Puerto Rico, Med Sci, San Juan
428 PB2 ;''2+0$ &' 92A#,04#+ .67 6*'2+0#&* &* 0B2 6*02/4#0- &' 0B2
5#33&+,@3=$
K Bradshaw
1
, K Curtis
1
, M Rollins
1
, S Graham
1
, D Jackson
1
, M M`Baye
1
,
H Carryl
1
, T Heinbockel
1
, K Abel
2
, and Mark Burke*
1
1
Howard Univ, Washington, DC, US and
2
Univ of North Carolina at
Chapel Hill, US
429 (&+,#*2 9&02*0#,02$ (,0B23$#* G .2+420#&* #* 0B2 9),$@, &'
567
8
5#$3,*#+ R&@2*

Frances Zenon*, M Plaud, V Wojna, and L Melendez
Univ of Puerto Rico Sch of Med and NeuroAIDS Prgm, Med Sci Campus
!

"#$$%&' (3*+&$,#- ./$,-01,$
Central Nervous System Inflammation and
Biomarkers of HIV-associated Neurocognitive
Disorders
430 Gender-specific Innate Responses Vary before and after the
6*#0#,0#&* &' <"P #* 6*A#?#A=,)$ F#0B (B4&*#+ 567 6*'2+0#&*
#* PB,#),*A
Bonnie Slike*
1
, V Valcour
2
, S Krebs
1
, P Sithinamsuwan
3
,
P Saengtawan
4
, A Schuetz
5
, J Kim
1
, N Michael
1
, J Ananworanich
4,6
,
M Marovich
1
, and SEARCH 011 Study Team
1
US Militarv HIJ Res Prgm, Silver Spring, MD,
2
Francisco, US,
3
Phramongkutklao Hosp, Bangkok, Thailand,
4
SEARCH
and Thai Red Cross AIDS Res Ctr, Bangkok,
5
Armed Forces Res Inst
of Med Sci, Bangkok, Thailand, and
6
Chulalongkorn Univ, Bangkok,
Thailand
431 Elevated Levels of Soluble CD40L Cause Increase in
Circulating Platelet-Monocyte Complexes: Possible Role in
567D,$$&+#,02A >2=4&D#*'),@@,0#&*

Meera Singh*
1
, D Davidson
1
, S Ramirez
2
, J Silva
1
, and S Maggirwar
1
1
Univ of Rochester Med Ctr, NY, US and
2
Temple Univ Sch of Med,
Philadelphia, PA, US
432 Elevated Cerebrospinal Fluid Inflammatory Biomarkers across
0B2 .32+04=@ &' 567 1#$2,$2 94&/42$$#&*
Sheila Keating*
1,2
, J Peterson
2
, M Gisslen
3
, J Heitman
1
, S Wu
1
,
S Spudich
4
, P Norris
1,2
, and R Price
2
1
Blood Svstems Res Inst, San Francisco, CA, US,
2
Univ of California,
San Francisco, US,
3
Univ of Gothenburg, Sweden, and
4
Yale Univ, New
Haven, CT, US
433 Novel Mannose-binding Lectin beta-Amyloid Interactions
#* 567DE
8
G4,#*: 6@3)#+,0#&*$ '&4 567D42),02A </#*/ ,*A
<)KB2#@24S$ 1#$2,$2

Dong Tran*, N Kumar, C TeodoroI, A Adame, B Gouaux, D Moore,
W Dumaop, S Michael, E Masliah, K Singh, and HIV Neurobehavioral
Res Prgm
Univ of California, San Diego, La Jolla, US
434 I&A2)#*/ 0B2 12?2)&3@2*0 &' (B4&*#+ >2=4&#*'),@@,0#&*
'&))&F#*/ G)=*0#*/ &' 94#@,4- 7#42@#, 0B4&=/B 9,40#,)
7,++#*2 94&02+0#&*
Debbie Ferguson*
1
, S Clarke
1
, C Ham
1
, A Das
2
, B Berkhout
2
, A Meiser
3
,
S Patterson
3
, N Berry
1
, and N Almond
1
1
Natl Inst for Bio Standards and Control, Potters Bar, UK,
2
Academic
Med Ctr, Univ of Amsterdam, and
3
435 CD14
8
567 1>< 942A#+0$ 567D,$$&+#,02A >2=4&+&/*#0#?2
6@3,#4@2*0 ,*A "2/#&*,) G4,#* <04&3B- #* P42,0@2*0D*,T?2
Subjects
Victor Valcour*
1
, J Ananworanich
2,3,4
, M Agsalda
5
, K Kallianpur
5
,
T Chalermchai
3
, P Sithinamsuwan
6
, S Tipsuk
3
, A Schuetz
7
, C-Y Liang
5
,
B Shiramizu
5
, and SEARCH 007 and 011 Study Groups
1
2
Chulalongkorn Univ, Bangkok,
Thailand,
3
South East Asia Res Collaboration with the Univ of Hawaii,
Bangkok, Thailand,
4
HIJNAT Res Collaboration, Bangkok, Thailand,
5
Univ
of Hawaii at Manoa, Honolulu, US,
6
Phramongkutklao Hosp, Bangkok,
Thailand, and
7
US Armed Forces Res Inst of Med Sci, Bangkok, Thailand
P
o
s
t
e
r

L
i
s
t
i
n
g
s
436 Low CD4
+
Cell Count despite Effective ART is Associated
with Elevated Monocyte Activation
and Poor Neurocognitive Performance
Alessandra Bandera*
1
, M Saresella
2
, G Lapadula
1
, A Muscatello
1
,
I Marventano
2
, S Limonta
1
, V Pastore
1
, E Cappelletti
1
, M Clerici
3
,
and A Gori
1
1
S Gerardo Hosp, Mon:a, Italv,
2
Don C Gnocchi Fndn, Milan, Italv,
and
3
437 Cerebrospinal Fluid Interferon-u Levels Inversely Correlate
with Processing and Motor Speed in HIV
+
Subjects with
Cognitive Complaints with and without HIV-associated
Neurocognitive Disorder
Albert Anderson*
1,2
, J Lennox
1,2
, D Loring
1
, and W Tyor
1
1
Emorv Univ Sch of Med, Atlanta, GA, US and
2
Gradv Hlth Svstem
Infectious Diseases Prgm, Atlanta, GA, US
438 Cerebrospinal Fluid Viral and Neurodegenerative Markers
in HIV
+
Very Late-presenters

Andrea Calcagno*
1
, C Atzori
2
, D Imperiale
2
, F Lipani
1
, S Audagnotto
1
,
G OroIino
3
, V Ghisetti
3
, G Marietti
2
, G Di Perri
1
, and S Bonora
1
1
Univ of Torino, Italv,
2
Ospedale Maria Jittoria, ASLTO2, Torino, Italv,
and
3
Ospedale Amedeo di Savoia, ASLTO2, Torino, Italv
!

"#$$%&' ()*+&$,#- ./$,-01,$
Aging and Neurocognitive Function in HIV Infection
439 Older Age and Neurocognitive Function: Multi-center AIDS
Cohort Study
Karl Goodkin*
1
, E Miller
2
, C Cox
3
, S Reynolds
3
, D Ostrow
4
, O Selnes
5
,
E Martin
6
, N Sacktor
5
, and J Becker
7
1
AIDS Hlthcare Fndn, Los Angeles, CA, US,
2
Univ of California,
Los Angeles, US,
3
Johns Hopkins Univ Bloomberg Sch of Publ Hlth,
Baltimore, MD, US,
4
Univ of Chicago, IL, US,
5
Johns Hopkins Univ Sch
of Med, Baltimore, MD, US,
6
Univ of Illinois at Chicago, US, and
7
Univ
of Pittsburgh, PA, US
440 Veterans Aging Cohort Study Index Score Is Associated with
Neurocognitive and Functional Impairment: A CHARTER
Study
D Franklin Jr
1
, R Heaton
1
, S Woods
1
, S Letendre
1
, A Collier
2
, D CliIIord
3
,
B Gelman
4
, J McArthur
5
, D Simpson
6
, Igor Grant*
1
, and CHARTER Group
1
2
3
4
Galveston, US,
5
6
Mt Sinai
Sch of Med, New York, NY, US
441 Changing Cerebrospinal Fluid Concentrations of
Neurofilament Light Chain Protein, Tau, and Amyloid
Proteins Characterize Evolving Central Nervous System
Injury in HIV-1 Infection
Julia Peterson*
1
, H Zetterberg
2
, L Hagberg
2
, S Spudich
3
, M Gisslen
2
,
and R Price
1
1
2
3
442 Prevalence of Cerebrospinal Fluid Alzheimer`s Disease-like
Profiles in Chronic Middle-aged HIV
+
Individuals
L Cysique
1,2
, J Lamoury
2
, T Hewitt
2,3
, K Taddei
4,5,6
, R Martins
4,5
, C Chew
5
,
P Price
5
, and Bruce Brew*
1,2
1
St Jincents Hosp, Svdnev, Australia,
2
Univ of New South Wales, Svdnev,
Australia,
3
Notre Dame Univ, Svdnev, Australia,
4
Edith Cowan Univ,
Australia,
5
Univ of Western Australia, Perth, and
6
Hollvwood Private
Hosp, Nedlands, Australia
443 Axonal Disturbance in Neuroasymptomatic Patients off and
on Suppressive ART: An Aging Effect of Central Nervous
System Infection?
Jan Jessen Krut*
1
, T Mellberg
1
, R Price
2
, L Hagberg
1
, D Fuchs
3
,
L Rosengren
1
, S Nilsson
4
, H Zetterberg
1,5
, and M Gisslen
1
1
Sahlgrenska Academv, Univ of Gothenburg, Sweden,
2
Univ of California,
San Francisco, US,
3
4
Chalmers Univ of Tech,
5
Univ Coll London, Inst of Neurologv, UK
444 Longitudinal Association of HIV-associated Neurocognitive
Disorders with Frailty in HIV-1
+
Men

Bryan Smith*
1
, R Skolasky
1
, F Mateen
1
, J Becker
2
, E Martin
3
, E Miller
4
,
J Margolick
5
, O Selnes
1
, N Sacktor
1
, and Multictr AIDS Cohort Group
1
2
Univ of Pittsburgh
Sch of Med, PA, US,
3
Univ of Illinois Sch of Med, Chicago, US,
4
David
Geffen Sch of Med, Univ of California, Los Angeles, US, and
5
Johns
Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD US
445 HIV and Aging: New Graph Theoretical Models of rs-fcMRI
Neuropathophysiology
Jewell Thomas*, M Brier, and B Ances
Washington Univ in St. Louis
!

"#$$%&' (2*+&$,#- ./$,-01,$
NeuroAIDS Clinical Studies
446 Neurological Characterization of HIV Controllers

Evelyn Lee*
1
, J Peterson
1
, R Walter
1
, J Javerbaum
1
, S Deeks
1
,
R Price
1
, K Robertson
2
, D MeyerhoII
1
, B Shacklett
3
, and S Spudich
4
1
2
Chapel Hill, US,
3
4
Yale Univ Sch of
Med, New Haven, CT, US
447 Neurovirological Correlation with HIV-associated
Neurocognitive Disorders and Encephalitis in a HAART-era
Cohort
Benjamin Gelman*
1
, J Lisinicchia
1
, S Morgello
2
, E Masliah
3
,
D Commins
4
, I Grant
3
, E Singer
5
, S Sherman
6
, G Gensler
6
, V Soukup
1
,
and Natl NeuroAIDS Tissue Network
1
Univ of Texas Med Branch, Galveston, US,
2
Mt Sinai Med Ctr, New
York, NY, US,
3
4
Univ of
Southern California, Los Angeles, US,
5
Univ of California, Los Angeles,
US, and
6
The EMMES Corp, Rockville, MD, US
448 Baseline CD4 Cell Count and Cardiovascular Risk Factors
Predict Cognitive Performance after 2 Years
Andrea De Luca*
1,2
, N Ciccarelli
1
, P Grima
1,3
, M ColaIigli
1
, M Fabbiani
1
,
E Baldonero
1
, A Borghetti
1
, E Tamburrini
1
, R Cauda
1
,
1
1
Catholic Univ of the Sacred Heart, Rome, Italv,
2
Univ of Siena, Italv,
and
3
S Caterina Novella Hosp, Galatina, Italv
449 Follow-up of HIV-associated Neurocognitive Disorders in the
cART Era: Neuradapt Study
Matteo Vassallo*
1,2
, B Dunais
2
, J Durant
2
, V Biscay
2
, M LaIIont
3
,
C Lebrun-Frenay
3
, J Cottalorda
2
, M Ticchioni
2
, C Pradier
2
,
P Dellamonica
2
, and Neuradapt Study Group
1
Pierre Nouveau Hosp, Cannes, France,
2
LArchet Hosp, Univ of Nice,
France, and
3
Pasteur Hosp, Univ of Nice, France
450 HIV-associated Neurocognitive Disorders in a Community
Cohort Evaluated by a New CogState Screen against a
Standardized Neuropsychological Assessment
Mark Bloch*
1
, A Carberry
1
, J Kamminga
2
, M Bailey
3
, T Vincent
1
,
D Quan
1
, B Brew
4,5
, and L Cysique
4,5
1
Holdsworth House Med Practice, Svdnev, Australia,
2
Macquarie Univ,
Svdnev, Australia,
3
Monash Univ, Melbourne, Australia,
4
Univ of New
South Wales, Svdnev, Australia, and
5
St Jincents Hosp, Svdnev, Australia
451 Trails A Test Improves Performance Characteristics of the
International HIV Dementia Scale to Identify Symptomatic
HIV-associated Neurocognitive Disorder
T Chalermchai
1
, J Ananworanich
1,2,3
, P Sithinamsuwan
4
, S Pinyakorn
1
,
D CliIIord
5
, R Paul
6
, V DeGruttola
7
, S Ratto-Kim
8
, C Shikuma
9
,
Victor Valcour*
10
, and SEARCH 007 and 011 Study Groups
1
South East Asia Res Collaboration with the Univ of Hawaii, Bangkok,
Thailand,
2
Chulalongkorn Univ, Bangkok, Thailand,
3
HIJ-NAT Res
Collaboration, Bangkok,
4
Phramongkutklao Hosp, Bangkok, Thailand,
5
Washington Univ in St Louis, MO, US,
6
Univ of Missouri, St Louis, US,
7
8
Walter Reed Armv Inst of
Res, Silver Spring, MD, US,
9
and
10
452 High Grade Liver Steatosis and Cognitive Impairment in
HIV
+
Patients
PierIrancesco Grima*
1,2
, M Fabbiani
1
, A Mondi
1
, A DÀvino
1
, S
Limiti
1
,
M ColaIigli
1
, B Milanini
1
, E Baldonero
1
, R Cauda
1
,
1
1
Catholic Univ of the Sacred Heart, Rome, Italv and
2
S Caterina Novella
Hosp, Galatina, Italv
453 Minimal Cognitive Impairment in UK HIV
+
Men Who Have
Sex with Men; Comparison with the General Population and
across Classification Systems
J McDonnell
1
, Fiona Lampe*
1
, L Haddow
1
, A Phillips
1
, L Sherr
1
,
R Gilson
1
, J Harrison
2
, A Antinori
3
, M Johnson
4
, A Rodger
1
,
and CIPHER Study Group
1
2
3
Natl Inst for
Infectious Diseases, Rome, Italv, and
4
Roval Free Hosp, London, UK
454 Progression Rates of Neuro-AIDS and Its Neuropsychological
Patterns in the cART Era
Gabriele Arendt*, E Orhan, and T Nolting
Univ of Dusseldorf, Germanv
455 Performance of Screening Tools for the Detection of
Neurocognitive Impairment in HIV Patients
Andrea Antinori*, P Balestra, P Lorenzini, R Libertone, G Cataldo,
L Giancola, C Pinnetti, and V Tozzi
INMI L Spallan:ani, Rome, Italv
Program 37
P
o
s
t
e
r

L
i
s
t
i
n
g
s
456 A Longitudinal Study of the Effects of Aging and HIV-1
Infection on Cognitive Performance

Becky Haynes*
1
, T Karren
1
, S Casey
2
, J Dunn
1
, F Zelaya
1
,
M Pitkanen
1
, R Kulasegaram
3
, G Barker
1
, and M Kopelman
1
1
Kings Coll London, Inst of Psvchiatrv, UK,
2
Acquired Brain Infurv
Ireland, Dublin, and
3
Guvs and St Thomas NHS Fndn Trust, London, UK
457 Genome-wide Association Study of Peripheral Neuropathy
with Stavudine/Didanosine: ACTG Study 384
Paul Leger*
1
, D Johnson
1
, G Robbins
2
, R ShaIer
3
, D CliIIord
4
, J Li
1
,
P McLaren
5,6
, and D Haas
1
1
Janderbilt Univ Sch of Med, Nashville, TN, US,
2
Massachusetts Gen
Hosp, Harvard Univ, Boston, US,
3
Stanford Univ, CA, US,
4
Washington
Univ Sch of Med, St Louis, MO, US,
5
Broad Inst of MIT and Harvard,
Cambridge, MA, US, and
6
Ecole Polvtechnique Federale de Lausanne,
Univ of Lausanne, Swit:erland
458 Cognitive Rehabilitation Protocol in HIV/AIDS Outpatients
with Asymptomatic Neurocognitive Impairment and Minor
Neurocognitive Disorder: Results and Clinical Applicability
A Livelli
1,2
, GianCarlo Orofno*
1
, L Pia
3
, S Carosella
1
, M Farenga
1
,
V Ghisetti
1
, A Calcagno
1,3
, and P Caramello
1
1
Amedeo of Savoia Hosp, Turin, Italv,
2
CRT, G Goria Fndn, Turin, Italv,
and
3
Univ of Turin, Italv
459 Associations between Regional Fat Deposition and
Neurocognitive Function: Multicenter AIDS Cohort Study
Jordan Lake*
1
, Q Vo
2
, L Jacobson
3
, N Sacktor
3
, W Post
3
, J Becker
4
,
F Palella
5
, A Ragin
5
, and T Brown
3
1
2
Henrv M Jackson Fndn for the
Advancement of Militarv Med, Bethesda, MD, US,
3
Johns Hopkins Univ,
Baltimore, MD, US, 4Univ of Pittsburgh, PA, US, and
5
Northwestern
Univ, Chicago, IL, US
460 Proteinuria Is Associated with Neurocognitive Impairment in
HIV
+
Subjects: ACTG Longitudinal Cohort Study
Robert Kalayjian*
1
, K Wu
2
, S Evans
2
, M Pallaki
3
, D CliIIord
4
,
and M Smurzynski
2
1
MetroHlth Med Ctr, Cleveland, OH, US,
2
Boston, MA, US,
3
Louis Stokes JAMC, Cleveland, OH, US, and
4
461a Moderate Neurocognitive Decline Can Be Detected over a
4-Month Period Using the HIV Dementia Scale

Grace Lu*
1
, L Cysique
1,2,3,4
, K SieIried
4
, B Draper
5
, and B Brew
1,3,4
1
Univ of New South Wales, St Jincents Hosp Clin Sch, Svdnev Australia,
2
Neurosci Res Australia, Svdnev,
3
St Jincents Ctr for Applied Med Res,
Svdnev, Australia,
4
St Jincents Hosp, Svdnev, Australia, and
5
Sch of
Psvchiatrv, Univ of New South Wales, Svdnev Australia
461b A Loss of Function Polymorphism in Complement Factor
H Predicts HIV-1-related Neurocognitive Impairment and
Neuroimaging Abnormalities
Kumud Singh*, F Vaida, C Fennema-Notestine, R Ellis, S Letendre,
D Franklin Jr, D Rosario, R Heaton, I Grant, and CHARTER Group
Univ of California San Diego, La Jolla, US
!

"#$$%&' ()*+&$,#- ./$,-01,$
Neuroimaging Studies
462 Dynamics of Changes in Cerebral Metabolites over 144
Weeks in HIV
+
Individuals Commencing ART
Alan Winston*
1
, R Puls
2
, S Kerr
2
, C Duncombe
3
, P Li
4
, J Gill
5
,
R Ramautarsing
5
, S Taylor-Robinson
1
, S Emery
2
, D Cooper
2
,
Ior ALTAIR Study Group
1
2
The Kirbv Inst, Svdnev, Australia,
3
HIJNAT,
Bangkok,
4
Queen Eli:abeth Hosp, Hong Kong, China, and
5
Calgarv Hlth,
Canada
463 Matrix Metalloproteinases and Relation to Brain Status in
Early HV Infection
Ann Ragin*
1
, H Du
2
, Y Gao
1
, S Li
1
, R Mahadevia
1
, C Sammet
1
, Y Wu
2
,
and L Epstein
1
1
Northwestern Univ, Chicago, IL, US and
2
NorthShore Univ Hlth Svstem,
Evanston, IL, US
464 Effects of HIV Clade B and C on Brain Volumetric
Measurements

Mario Ortega*
1
, J Joska
2
, J Heaps
3
, F Vaida
4
, A Agrawal
1
, R Paul
3
,
and B Ances
1

1
2
3
Univ of Missouri, St Louis, US, and
4
465 Altered Tryptophan Metabolism Correlates with Intrathecal
Inflammation and Cerebral Metabolites Detected by
Magnetic Resonance Spectroscopy in Primary HIV Infection
Marie Grill*
1
, J Peterson
1
, E Lee
1
, R Walter
1
, D Fuchs
2
, L Hagberg
3
,
D MeyerhoII
1
, R Price
1
, and S Spudich
4
1
2
3
Univ of Gothenburg, Sweden, and
4
466 Effects of Primary and Chronic HIV Infection on White Matter
Integrity Using Diffusion Tensor Imaging

Patrick Wright*
1
, R Fernandez
2
, D MeyerhoII
3
, R Price
3
,
K Robertson
4
, E Lee
3
, J Rutlin
1
, J Shimony
1
, S Spudich
5
, and B Ances
1
1
Washington Univ in St Louis, MO, US,
2
Univ of Puerto Rico, Rio
Piedras,
3
4
Univ of North Carolina
at Chapel Hill, US, and
5
467 Effects of HIV and Hepatitis C Co-infection on White Matter
Structural Integrity and White Matter Volumes
Jodi Heaps*
1
, P Wright
2
, B Ances
2
, D CliIIord
2
, and R Paul
1
1
Univ of Missouri-St Louis, US and
2
Washington Univ Sch of Med,
St Louis, MO, US
468 Neuroimaging Correlates of Prior Immunosuppression and
Cognitive Status in HIV
Christine Fennema-Notestine*
1
, M Taylor
1
, R Notestine
1
, T WolIson
2
,
A Gamst
1,2
, S Archibald
1
, R Theilmann
1
, R Heaton
1
, C Marra
3
, I Grant
1
,
and CHARTER Group
1
2
San Diego Supercomputer
Ctr, La Jolla, CA, US, and
3
469 Diffusion Tensor Imaging Uncovers Specific Brain
Microstructural Deficits during Chronic HIV-1 Infection of
Humanized Mice

Prasanta Dash*, J Knibbe, T Gutti, E Makarov, D Baber, S Gorantla,
L Poluektova, H Gendelman, and M Boska
!

"#$$%&' (2*+&$,#- ./$,-01,$
Human Genomics
470 Genome-Wide Association Study of Phenotypic HIV-1
Co-receptor Usage in Treatment-nave Patients from the
ACTG A5095 Trial
Timothy Henrich*
1,2
, P McLaren
1,2,3,4
, S Rao
5
, N Lin
2,6
, F Giguel
6
,
H Ribaudo
2,7
, R Gulick
8
, P de Bakker
1,2,3
, and D Kuritzkes
1,2
1
Brigham and Womens Hosp, Boston, MA, US,
2
Harvard Med Sch,
Boston, MA, US,
3
Broad Inst of Harvard and MIT, Cambridge, MA,
US,
4
Ecole Polvtechnique Federale de Lausanne and Univ of Lausanne,
Swit:erland,
5
Harvard Univ, Cambridge, MA, US,
6
Massachusetts Gen
Hosp, Boston, US,
7
Harvard Sch of Publ Hlth, Boston, MA, US, and
8
Weill Med Coll of Cornell Univ, New York, NY, US
471 Novel HLA Associations with HIV Control in a Previously
Uncharacterized Immunogenetic Context

Humberto Valenzuela-Ponce*, S Avila-Rios, M Soto-Nava,
D Garrido-Rodriguez, T Garcia-Tellez, V Quiroz-Morales,
C Garcia-Morales, R Hernandez-Juan, A Murakami-Ogasawara,
G Reyes-Teran, and Mexican HIV Molecular Epidemiology Project Group
Natl Inst of Respiratorv Diseases, Mexico Citv, Mexico
472 Increased HIV-1 Susceptibility to Human TRIM5a Could
Contribute to Controller Phenotype in Patients Expressing
HLA-B`57
C Granier
1
, Emilie Battivelli*
1
, A Venet
2
, C Lecouroux
2
, O Lambotte
3
,
C Delaugerre
1
, J-M Molina
4
, F Clavel
1
, and A Hance
1
1
INSERM U941, Hosp St Louis, Paris, France,
2
INSERM U1012, Faculte
de Med Paris-Sud, France,
3
Hosp de Bicetre, le Kremlin-Bicetre, France,
and
4
Hosp St Louis, Paris, France
473 Human MHC Gene Variants and Immune Control of HIV-1
Infection in Zambians: Findings from Fine-Mapping Using
the Immunochip

Heather Prentice*
1
, N Pajewski
2
, E Brown
1
, S Allen
3
, E Hunter
3
,
R Kaslow
1
, and J Tang
1
1
2
Wake Forest Univ, Winston-
Salem, NC, US, and
3
474 Gene Expression Profiling Identifies Genes with a Mechanistic
Role in CD4 T Cell Recovery in HIV
+
Individuals on ART

Nadejda Beliakova-Bethell*
1
, S Little
1
, P Du
2
, S Rought
2
,
D Richman
1,2
, and C Woelk
1,2
1
2
JA San Diego, CA, US
475 HLA Associations with Immunological Recovery and Drug
Toxicities in HIV-1
+
Adults
Jane O`Halloran*
1
, J Crowley
2
, M Fagan
2
, C Hickey
2
, S Stokes
2
,
A Kinsella
2
, H Tuite
1
, R Hagan
2
, and C Bergin
1
1
St Jamess Hosp, Dublin, Ireland and
2
Irish Blood Transfusion Svc,
Dublin, Ireland
476 A Paired Analysis Reveals Unexpectedly Large Numbers of
Genes Differentially Expressed in HIV
+
Individuals following
ART
Marta Massanella*
1
, A Singhania
2
, N Beliakova-Bethell
3
, J Perez-Santiago
3
,
R Pier
3
, C White
2,3
, J Blanco
1
, D Richman
2,3
, S Little
3
, and C Woelk
2,3
1
Fndn irsiCaixa-HIJACAT, Inst de Recerca en Ciencies de la Salut
Germans Trias i Pufol, Hosp Germans Trias, Univ Autonoma de
Barcelona, Spain,
2
JA San Diego Hlthcare Svstem, CA, US, and
3
Univ of
California, San Diego, La Jolla, US
P
o
s
t
e
r

L
i
s
t
i
n
g
s
477 Human KIR3DS1 Gene Has a Favorable Impact on Primary
HIV-1 Infection in Africans

Travis Porter*
1
, W Song
1
, M Price
2
, E Cormier
2
, P Amornkul
2
,
S Lakhi
2
, A Kamali
2
, R Kaslow
1
, J Gilmour
2
, J Tang
1
, and IAVI AIrican
HIV Res Network
1
Univ of Alabama at Birmingham, US and
2
Intl AIDS Jaccine Initiative,
New York, NY, US
478 The Additive Effect of Specific Activating KIR Interactions
with Putative HLA Ligands Protects from HIV Infection and
Disease Progression

Daniela Garrido-Rodriguez*, S Avila-Rios, H Valenzuela-Ponce,
T Garcia-Tellez, V Quiroz-Morales, C Garcia-Morales, M Soto-Nava,
J Vazquez-Perez, R Hernandez-Juan, and G Reyes-Teran
Natl Inst of Respiratorv Diseases, Mexico Citv, Mexico
479 Effect of KIR2D and HLA-C Alleles on Clinical Outcome
among HIV-1 CRF01_AE
+
Thais

Masahiko Mori*
1,2,3,4
, N Wichukchinda
5
, R Miyahara
1
, A Rojanawiwat
1
,
P Pathipvanich
6
, T Maekawa
1
, P Goulder
2
, M Yasunami
1
, K Ariyoshi
1,4
,
and P Sawanpanyalert
5
1
Nagasaki Univ, Japan,
2
Univ of Oxford, UK,
3
Japan Fndn for AIDS
Prevention, Tokvo,
4
Nagasaki Univ Global COE Prgm, Japan,
5
Ministrv
of Publ Hlth, Nonthaburi, Thailand, and
6
Lampang Hosp, Thailand
480 A Targeted Transcriptomic Approach Reveals HIV-1
Associated Cellular Factors Modulated by Substances of
Abuse
Ivan Tasovski*, J Purushe, and M Chin
Temple Univ Sch of Med, Philadelphia, PA, US
481 Exome Sequencing to Assess the Role for Rare Coding
Mutations in the Host Genome in HIV-1 Control
Paul McLaren*
1,2
, P Shea
3
, I Bartha
1,2
, D Goldstein
3
, and J Fellay
1,2
1
Ecole Polvtechnique Federale de Lausanne, Swit:erland,
2
Univ Hosp
Lausanne, Swit:erland, and
3
!

"#$$%&' ()*+&$,#- ./$,-01,$
Simian Viral Reservoirs
482 Discovery of Novel and Highly Divergent SIV in Three Wild
Monkey Species in Kibale National Park, Uganda
William Switzer*
1
, M Lauck
2
, A Shankar
1
, D Hyeroba
3,4
, A Tumukunde
4
,
C Chapman
4,5,6
, N Ting
7
, T Friedrich
2,8
, D O`Connor
2,8
, and T Goldberg
2,4,6,8
1
2
3
Jane Goodall
Inst, Entebbe, Uganda,
4
Kibale EcoHlth Profect, Makerere Univ Bio
Field Station, Kanvawara, Uganda,
5
6
7
Univ of Oregon, Eugene, US,
and
8
Wisconsin Natl Primate Res Ctr, Madison, US
483 Full-length Genome Analyses of Two Highly Divergent SIV
mus

Strains Isolated in Mustached Monkeys (23 1#456$) Hunted
for Bushmeat in Gabon
Florian Liegeois*
1,2
, V Boue
1,2
, C Butel
1
, P Ngari
2
, F Mouacha
1
,
B Mve Ondo
2
, L Eric
2
, M Peeters
1
, and F Rouet
2
1
UMI 233, Inst de Recherche pour le Devt and Univ of Montpellier,
France and
2
484 Gorillas in Southwest Cameroon Are the Reservoir of HIV-1
Group P Ancestors

Mirela Dàrc*
1,2
, A Ayouba
1
, A Esteban
1
, L Etienne
1
, S Locatelli
1
,
A Aghokeng
1,3
, E Delaporte
1
, EM Ngole
3
, and M Peeters
1
1
UMI 233, IRD and Univ of Montpellier 1, France,
2
Univ Federal do Rio
de Janeiro, Bra:il, and
3
Profet PRESICA and IMPM/CREMER, Yaounde,
Cameroon
485 Non-Invasive Follow-up of SIV
cpz+,,
Infection in Wild-living
Chimpanzees in Northeast Gabon

Vanina Boue*
1,2
, F Liegeois
1,2
, AP Okouga
2
, S Locatelli
1
, C Butel
1
,
P Ngari
2
, E Delaporte
1
, M Peeters
1
, and F Rouet
2
1
UMI 233, Inst de Recherche pour le Devt and Univ of Montpellier,
France and
2
486 Expanded Screening for Simian Foamy Virus in New World
Primates Identifies 2 Novel Simian Foamy Virus in Tamarin
and Uakari Monkeys from Brazil

Claudia Muniz*
1
, A Santos
1
, H Jia
2
, L Troncoso
1
, L Faria
1
,
A Augusto
3
, L Fedullo
3
, A Pissinatti
4
, M Soares
1,5
, and W Switzer
2
1
Univ Federal do Rio de Janeiro, Bra:il,
2
3
Fndn
Rio-Zoo, Rio de Janeiro, Bra:il,
4
Ctr de Primatologia do Rio de Janeiro,
Bra:il, and
5
Prgm de Oncovirologia, Inst Nacional de Cancer, Rio de
Janeiro, Bra:il
487 Co-infection of Wild African Primates with SIV and Simian
Hemorrhagic Fever Viruses
Tony Goldberg*
1,2,3
, M Lauck
2
, W Switzer
4
, D Hyeroba
3
, A Tumukunde
3
,
J Kuhn
5
, C Chapman
6
, N Ting
7
, T Friedrich
1,2
, and D O`Connor
1,2
1
2
Wisconsin Natl Primate Res Ctr,
Madison, US,
3
Kibale EcoHlth Profect, Makerere Univ Bio Field Station,
Kanvawara, Uganda,
4
5
IRF-Frederick, NIH, Fort
Detrick, MD, US,
6
Sch of Environment, McGill Univ, Montreal, Canada,
and
7
Univ of Oregon, Eugene, US
!

"#$$%&' (7*+&$,#- ./$,-01,$
Mining Sequence Data to Understand
Transmission and Disease
488 The Global Transmission Network of HIV-1

Joel Wertheim*
1
, A Leigh Brown
2
, L Hepler
1
, S Mehta
1
,
D Richman
1,3
, D Smith
1,3
1
1
2
and
3
JA San Diego Hlthcare Svstem, CA, US
489 Frequent HIV Introductions into Communities Sustain Local
Epidemics in Rural Rakai, Uganda

Mary Grabowski*
1
, J Lessler
1
, A Redd
2
, O Laeyendecker
2,3
,
J Kagaayi
4
, T Lutalo
4
, M Wawer
1,4
, D Serwadda
4,5
, T Quinn
2,3
, R Gray
1,4
,
and Rakai Hlth Sci Prgm
1
2
Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US,
3
Johns
Hopkins Univ Sch of Med, Baltimore, MD, US,
4
Rakai Hlth Sci Prgm,
Entebbe, Uganda, and
5
Makerere Univ Sch of Med, Kampala, Uganda
490 Dynamics of Non-B HIV Transmission in the UK

Manon Ragonnet-Cronin*
1
, S Lycett
1
, E HodcroIt
1
, S Hue
2
,
E Fearnhill
3
, D Dunn
3
, V Delpech
4
, A Leigh Brown
1
, and UK Collaborative
Group on HIV Drug Resistance
1
2
3
London, UK, and
4
Hlth Protection Agencv, London, UK
491 Defining HLA Genotypes from Bulk HIV Sequences
A Kreimer
1
, M ShaeIer
2
, N PIeiIer
1
, V Tan
1
, P Goulder
3
, M John
4
, Z Brumme
5
,
E Hunter
2
, D Heckerman
1
, Jonathan Carlson*
1
, and Intl and Southern
AIrica HIV Assn Collaboratives
1
2
3
Univ of Oxford, UK,
4
Murdoch Univ, Australia, and
5
Simon Fraser Univ,
Burnabv, Canada
492 Whole Genome Sequencing of HIV
+
African Americans with
Rapid Disease progression or Long-term Non-progression
Amy Weintrob*
1,2
, K Pelak
3
, R Thomas
2
, P Ehrenberg
2
, P Shea
3
,
J Okulicz
1
, A Ganesan
1
, B Agan
1
, N Michael
2
, and D Goldstein
3
1
Uniformed Svcs Univ Infectious Disease Clin Res Prgm, Bethesda, MD,
US,
2
Militarv HIJ Res Prgm, Bethesda, MD, US, and
3
Duke Univ Ctr for
Human Genome Jariation, Durham, NC, US
493 Exome Sequencing of Elite and Rapid HIV Progressors:
Results from the Exploratory Pilot of the UK HIV Genomics
Consortium

Deepti Gurdasani*
1,2
, C Scott
1
, E Young
1,2
, K Porter
3
, P Kellam
1,4
,
M Sandhu
1,2
, and UK HIV Genomics Consortium
1
Wellcome Trust Sanger Inst, Cambridge, UK,
2
Univ of Cambridge, UK,
3
4
!

"#$$%&' (8*+&$,#- ./$,-01,$
Transmission Clusters
494 Multiple Patterns of Transmission of HIV-1 B Subtype
in Italy Detected by a Nationwide Large-scale Phylogeny

Alessia Lai*
1
, M Franzetti
1
, M Prosperi
2
, G Sterrantino
3
, F Saladini
4
,
B Bruzzone
5
, M Zazzi
4
, M Ciccozzi
6
, C Balotta
1
, and A Deluca
7
1
L Sacco Hosp, Univ of Milan, Italv,
2
Univ of Florida, Coll of Med,
Emerging Pathogens Inst, US,
3
Infectious Diseases of Careggi, Florence,
Italv,
4
Univ of Siena, Italv,
5
Lab of Hvgiene, San Martino Hosp, Italv,
6
Italian Inst of Hlth, Rome, and
7
495 HIV Transmission Patterns among Immigrant Latinos
Illuminated by the Integration of Phylogenetic and Migration
Data
Ann Dennis*
1
, S Hue
2
, S Napravnik
1
, D Pasquale
1
, L Hightow-Weidman
1
,
J Sebastian
3
, D Pillay
2
, and J Eron
1
1
2
and
3
Lab Corp of America, Research Triangle Park, NC, US
496 Improving the Sensitivity of Molecular Epidemiology Using
Ultra-deep Sequencing

Lance Hepler*
1
, G Wagner
1
, S Little
1
, D Richman
1,2
, J Wertheim
1
,
S Mehta
1
, D Smith
1,2
1
1
2
Svstem, CA, US
497 Chronic Infections Drive HIV Transmission Networks among
High-risk Populations
Philip Chan*
1
, A Huang
1
, M Salemi
2
, M Prosperi
2
, M Reitsma
1
,
and R Kantor
1
1
Brown Univ, Providence, RI, US and
2
Univ of Florida, Gainesville, US
Program 39
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' ()*+&$,#- ./$,-01,$
HIV Subtypes: Epidemiology and Disease
Progression
498 CRF01_AE Subtype Is Associated with Faster Disease
Progression in Chinese HIV-1 Sexually Infected Patients
Y Li
1
, Y Han
1
, J Xie
1
, L Gu
2
, L Li
3
, W Li
4
, H Wang
1
, T Ishida
2
,
A Iwamoto
2
, Taisheng Li*
1
, on behalI oI CACT0810 Group
1
Peking Union Med Coll Hosp, Beifing, China,
2
Univ of Tokvo, Japan,
3
Beifing Inst of Microbio and Epi, China, and
4
Beifing Youan Hosp,
Capital Med Univ, China
499 HIV-1 Subtype and Disease Progression in Seroincident HIV
Infections among MSM in Thailand

Wanna Leelawiwat*
1
, F Mueanpai
1
, O Kongpechsatit
1
, S Pattanasin
1
,
W Chonwattana
1
, A Sriporn
1
, S Chaikummao
1
, F van Griensven
2
,
and M Curlin
3
1
2
AJRAM Corp, Miami, FL, US, and
3
500 Subtypes and Risk Behaviors among Incident HIV Cases in
the Bangkok MSM Cohort Study, 2006-2012

Caitlin Lam*
1
, T Holtz
2,3
, W Leelawiwat
2
, P Mock
2
, W Chonwattana
2
,
W Wimonsate
2
, A Varangrat
2
, W Thienkrua
2
, A Chitwarakorn
4
,
and M Curlin
2,3
1
Emorv Univ Sch of Publ Hlth, Atlanta, GA, US,
2
Thailand Ministrv of
Publ Hlth-CDC Collaboration, Nonthaburi,
3
and
4
Thailand Ministrv of Publ Hlth, Nonthaburi
501 Emergence of a New Circulating B/CRF02/G Recombinant
Form Spreading in France
Marie Leoz*
1
, C Charpentier
2
, C Delaugerre
3
, M Wirden
4
, V Lemee
1
,
and JC Plantier
1
1
CHU Charles Nicolle, Rouen, France,
2
CHU Bichat Claude Bernard,
Paris, France,
3
CHU St Louis, Paris, France, and
4
CHU Pitie Salpetriere,
Paris, France
502 Molecular Epidemiology Study of HIV-1 Outbreak among
Intravenous Drugs Users in Athens Metropolitan Area: A
Longitudinal Study
Dimitrios Paraskevis*
1
, G Nikolopoulos
2
, M Malliori
3
, J Kremastinou
2
,
and A Hatzakis
1
1
Natl Retrovirus Reference Ctr, Univ of Athens Med Sch, Greece,
2
Hellenic Ctr for Disease Control and Prevention, Athens, Greece,
and
3
Org Against Drugs, Athens, Greece
503 HIV-1 Genetic Variants in Vladivostok, Russia

Vita Laga*
1
, E Kazennova
1
, A Vasilyev
1
, I Lapovok
1
, A Kuz`mina
2
,
Y Mikryukova
2
, A Aleksashkina
2
, and M Bobkova
1
1
DI Ivanovskv Inst of Jirologv, Moscow, Russian Federation and
2
Regional AIDS Ctr, Jladivostok, Russian Federation
504 High-throughput DNA Sequencing Is a Powerful Tool
to Analyze Dual and Multiple HIV Infections: Its First
Application to the Study in DRC
Eiji Ido*
1
, S Karhemere
2
, M Ebengho
3
, S Nakamura
4
, T Nakaya
5
,
J BrandIul
6
, J Barnor
6
, W AmpoIo
6
, S Yamaoka
1
, and J-J Muyembe
2
1
Tokvo Med and Dental Univ, Japan,
2
Natl Inst of Biomed Res, Kinshasa,
Democratic Republic of the Congo,
3
AMO-Congo, Mbandaka,
4
Inst of
Microbial Diseases, Osaka Univ, Japan,
5
Kvoto Prefectural Univ, Japan,
and
6
Noguchi Memorial Inst for Med Res, Univ of Ghana, Accra
505 New Insights into HIV-1 Group O Diversity
Marie Leoz*
1
, F Damond
2
, J KIutwah
3
, JC Plantier
1
,
and French RES-O Network
1
CHU Charles Nicolle, Rouen, France,
2
CHU Bichat Claude Bernard,
Paris, France, and
3
Ctr Pasteur du Cameroun, Yaounde
!

"#$$%&' (2*+&$,#- ./$,-01,$
Within-patient Diversity Compartmentalization,
Dual Infection, and Recombination
506 Migratory Pathways of HIV-1 during the Natural History of
Intra-patient Infection Identify Targets for HIV Eradication

Nazle Veras*
1
, A Lowe
1
, M Salemi
1
, J Sleasman
2
, and M Goodenow
1
1
Univ of Florida, Gainesville, US and
2
Univ of South Florida, Tampa, US
507 Genetic Analysis of HIV Genomic DNA Sequences from
Phenotypic and Antigen-specific CD4
+
T Cell Subsets

Eli Boritz*
1
, B Hill
1
, M Rolland
2
, and D Douek
1
1
Jaccine Res Ctr, NIAID, NIH, Bethesda, MD, US and
2
US Militarv HIJ
Res Prgm, Silver Spring, MD
508 Global Haplotype Reconstruction of Gag-Pol HIV-1 Genomes
in Mixed Populations

Francesca Di Giallonardo*
1,2
, M Rey
3
, A TopIer
4
, S Prabhakaran
3
,
Y Duport
1
, M Kuenzli-Gontarczyk
5
, H Gunthard
1
, N Beerenwinkel
4,6
,
V Roth
3
, and K Metzner
1
1
Univ Hosp Zurich, Univ of Zurich, Swit:erland,
2
Life Sci Zurich Grad Sch,
Univ of Zurich, Swit:erland,
3
Univ of Basel, Swit:erland,
4
ETH Zurich,
Basel, Swit:erland,
5
Functional Genomics Ctr Zurich, Univ of Zurich, ETH
Zurich, Swit:erland, and
6
SIB Swiss Inst of Bioinformatics, Basel
509 The Interplay and Influence of Point Mutations, Recombination,
and Pseudoknots in HIV-1 gp120 RNA Secondary Structures
Susanna Lamers*
1
, D Nolan
2
, S Strickland
2
, and M Salemi
2
1
Bioinfoexperts, LLC, Thibodaux, LA, US and
2
Univ of Florida,
Gainesville, US
510 High Rates of Intraclade HIV-1 Dual Infection among MSM
in San Diego

Gabriel Wagner*
1
, M Pacold
2
, S Kosakovsky Pond
1
, G Caballero
3
,
D Richman
1,3
, S Little
1
, and D Smith
1,3
1
2
Life Technologies, Foster Citv, CA,
US, and
3
JA Hlthcare Svstem, San Diego, CA, US
!

"#$$%&' ((*+&$,#- ./$,-01,$
New Approaches to ARV Drug Delivery
512a Improved Biodistribution, Pharmacokinetics, and ARV
Responses for Folate-targeted Nanoformulated ART

Pavan Puligujja*, H Gendelman, L Kendrick, N Smith, S Balkundi,
U Roy, R Veerubhotla, J McMillan, and X Liu
512b Development of Small Magnetite ARV Nanoparticles for
Targeted Drug Delivery to Viral Reservoirs

Dongwei Guo*, T Li, J McMillan, M Boska, X Liu, and H Gendelman
513 Enhanced Pharmacological Properties of Efavirenz
Formulated as Solid Drug Nanoparticles
P Martin
1
,

Neill Liptrott*
1
, T McDonald
1
, M Giardiello
1
, P Roberts
1
,
P Curley
1
, D Smith
2
, M Siccardi
1
, S Rannard
1
, and A Owen
1
1
2
Univ of Northumbria, Newcastle Upon Tvne, UK
!

"#$$%&' 344*+&$,#- ./$,-01,$
ARV Pharmacogenetics: Metabolism, Drug
Interactions, and Response
514 Prediction of Etravirine Pharmacogenetics Using a
Physiologically Based Pharmacokinetic Approach

Marco Siccardi*, A Olagunju, P Curley, J Hobson, S Khoo, D Back,
and A Owen
Univ of Liverpool, UK
515 Pharmacokinetics of Etravirine According to CYP2C9 and
CYP2C19 Metabolizer Status: a Meta-analysis of Phase I Trials
Thomas Kakuda*
1
, S Nijs
2
, G van Hoecke
2
, F Tomaka
1
, and R Hoetelmans
2
1
Janssen Res & Devt, LLC, Titusville, NJ, US and
2
Janssen Infectious
Diseases BJBA, Beerse, Belgium
516 Differential Induction of Efavirenz Metabolism by Rifampin
without and with Isoniazid in Healthy Volunteers with
CYP2B6 516GG and TT Genotypes
Lawrence Lee*
1,2
, GH Soon
1,2
, N Chew
2
, L Else
3
, A Amara
3
, and S Khoo
3
1
Natl Univ of Singapore,
2
Natl Univ Hlth Svstem, Singapore, and
3
Univ of
Liverpool, UK
517 Identification of Isoniazid as a Potent Inhibitor of CYP2A6-
mediated Efavirenz 7-hydroxylation in CYP2B6`6
Genotyped Human Liver Microsomes
M Court
1
, F Almutairi
1
, D Greenblatt
1
, S Duan
1
, K Klein
2
, U Zanger
2
,
and Awewura Kwara*
3,4
1
Tufts Univ Sch of Med, Boston, MA, US,
2
Dr Margarete Fischer-
Bosch Inst of Clin Pharmacologv, Stuttgart, Germanv,
3
Miriam Hosp,
Providence, RI, US, and
4
Warren Alpert Med Sch of Brown Univ,
Providence, RI, US
518 Relationship between CYP2B6 Haplotype and Virologic
Response to Efavirenz-containing Regimens in Port-au-
Prince, Haiti
David Haas*
1
, P Severe
2
, M-A Juste
2
, J Pape
2,3
, and D Fitzgerald
2,3
1
2
GHESKIO Ctrs,
Port-au-Prince, Haiti, and
3
Weill Cornell Med Coll, New York, NY, US
519 Proposed Host Pharmacogenetic Polymorphisms Predict
Laboratory Abnormalities, but Not Early Treatment
Discontinuation in Patients Receiving HAART

Chanson Brumme*
1
, C Chui
1
, JE Min
1
, W Dong
1
, G Colley
1
, B Yip
1
,
and R Harrigan
1,2
1
BC Ctr for Excellence in HIJ/AIDS, Jancouver, Canada and
2
Facultv of
Med, Univ of British Columbia, Canada
P
o
s
t
e
r

L
i
s
t
i
n
g
s
520 Genome-wide Association Study of Atazanavir
Pharmacokinetics and Indirect Hyperbilirubinemia

Daniel Johnson*
1
, C Venuto
2
, E Daar
3
, G Morse
4
, P Sax
5
, M Fischl
6
,
A Collier
7
, P McLaren
8,9
, M Ritchie
10
, D Haas
1
, and ACTG
1
2
Univ of Rochester, NY,
US,
3
Los Angeles Biomed Res Inst at Harbor-UCLA Med Ctr, Torrance,
CA, US,
4
Univ at Buffalo, SUNY, US,
5
Brigham and Womens Hosp,
Boston, MA, US,
6
Univ of Miami Miller Sch of Med, FL, US,
7
Univ of
8
Broad Inst of MIT and Harvard, Cambridge,
MA, US,
9
Ecole Polvtech Federale de Lausanne, Univ of Lausanne,
Swit:erland, and
10
Pennsvlvania State Univ, Univ Park, US
!

"#$$%&' ()(*+&$,#- ./$,-01,$
ARV Drug Exposure, Safety, and Efficacy
521 Efavirenz Pharmacokinetics Are Independently Associated
with Virologic Failure in Diverse-Resource Limited Settings
Adriana Andrade*
1
, G Baheti
2
, L Smeaton
3
, M Yang
3
, N Kumarasamy
4
,
T Flanigan
5
, J Hakim
6
, K Klingman
7
, T Campbell
8
, C Fletcher
2
, and ACTG
5175 Team
1
2
Univ of Nebraska Med Ctr,
Omaha, US,
3
Statistical and Data Analvsis Ctr, Harvard Sch of Publ Hlth,
Boston, MA, US,
4
YR Gaitonde Ctr for AIDS Res and Ed, Chennai, India,
5
Miriam Hosp, Providence, RI, US,
6
7
NIAID,
8
Univ of Colorado Denver, Aurora, US
522 Common Conditions-Age, Low BMI, Renal Impairment,
Ritonavir Use-Increase Tenofovir Exposure in a Large
Unselected Cohort of HIV
+
Women
S Baxi
1
, R Greenblatt
1
, P Bacchetti
1
, K Anastos
2
, C Ponath
1
, M Cohen
3
,
H MinkoII
4
, S Gange
5
, Monica Gandhi*
1
, and Womens Interagency
HIV Study
1
2
Albert Einstein Coll of Med,
Bronx, NY, US,
3
Stroger Cook Countv Hosp, Chicago, IL, US,
4
SUNY
Downstate Med Ctr, Brooklvn, US, and
5
Johns Hopkins Univ Bloomberg
Sch of Publ Hlth, Baltimore, MD, US
523 Factors Associated with Tenofovir-related Adverse Events
and Drug Exposure in HIV
+
Patients
Cristina Gervasoni*, P Meraviglia, S Landonio, S Baldelli, S Fucile,
L Castagnoli, E Clementi, M Galli, A Riva, and D Cattaneo
Luigi Sacco Hosp, Milan, Italv
524 Evaluation of Glomerular Function, Renal Blood Flow, and
Exposure-safety Relationship following Administration of
EVG/COBI/FTC/TDF
Srini Ramanathan*, Y-P Liu, H Wang, A Plummer, M Fordyce,
L Zhong, F Jin, A Cheng, J Szwarcberg, and B Kearney
Gilead Sci, Inc, Foster Citv, CA, US
!

"#$$%&' ()2*+&$,#- ./$,-01,$
ARV Pharmacokinetics: New Assays, Drugs, and
Special Populations
525 Tenofovir Diphosphate in Dried Blood Spots in HIV
-
vs HIV
+

Individuals
Jose Castillo-Mancilla*
1
, J Rower
1
, J-H Zheng
1
, A Meditz
1
, E Gardner
2
,
K McAllister
1
, B Klein
1
, J Kiser
1
, L Bushman
1
, and P Anderson
1
1
Univ of Colorado-AMC, Aurora, US and
2
Denver Hlth Med Ctr, CO, US
526 Nevirapine Levels in Saliva Measured by Thin Layer
Chromatography and Self-reported Adherence in Patients on
ART
Eva Muro*
1,2
, L George
1
, W Dolmans
3
, D Burger
3,4
, and E Kisanga
1,2
1
Kilimanfaro Christian Med Univ Coll, Moshi, Tan:ania,
2
Kilimanfaro
Clinical Res Inst, Moshi, Tan:ania,
3
Inst for Infection, Inflammation and
Immunitv, Nifmegen, The Netherlands, and
4
Radboud Univ Med Ctr,
Nifmegen, The Netherlands
527 Safety, Tolerability, and Pharmacokinetics of Single and
Multiple Doses of MK-1439, a Novel HIV NNRTI, in Healthy
Subjects
Matt Anderson*
1
, J Gilmartin
1
, M Robberechts
1
, I De Lepeleire
1
,
L van Bortel
2
, M DockendorI Fallon
1
, Y Guo
1
, J Wagner
1
, and J Butterton
1
1
Merck Sharp & Dohme, Corp, Whitehouse Station, NJ, US and
2
Drug
Res Unit, Ghent, Belgium
528 Pharmacokinetic Study of Raltegravir in HIV
+
Patients with
End Stage Liver Disease: LIVERAL ANRS 148 Study
C Barau
1
, J Braun
2
, C Vincent
2
, S Haim-Boukobza
3,4
, J-M Molina
5,6
,
P Miailhes
7,8
, J-P Aboulker
2
, J-C Duclos-Vallee
3,9
, A-M Taburet
1
,
Elina Teicher*
1,3
, and ANRS 148 Study Group
1
Bicetre Hosp, Le Kremlin-Bicetre, France,
2
INSERM SC10-US019,
Jillefuif, France,
3
Paul-Brousse Hosp, Jillefuif, France,
4
INSERM U785,
Jillefuif, France,
5
St Louis Hosp, Paris, France,
6
Paris JII Univ, France,
7
Croix-Rousse Hosp, Lvon, France,
8
INSERM U1052, Lvon, France, and
9
CHB UMR-S 785, Jillefuif, France
529 Tenofovir Alafenamide Pharmacokinetics in Renal Impairment:
Potential for Administration without Dose Adjustment
Srini Ramanathan*
1
, J Custodio
1
, M Fordyce
1
, W Garner
1
, M Vimal
1
,
G Klein
2
, K Farbakhsh
3
, P Pergola
4
, A Cheng
1
, and B Kearney
1
1
Gilead Sci, Inc, CA, US,
2
APEX GmbH, Munich, Germanv,
3
DaJita Clin Res,
Minneapolis, Minnesota, US, and
4
Renal Assoc, PA, San Antonio, Texas, US
!

"#$$%&' ()3*+&$,#- ./$,-01,$
Compartment Penetration of ARV
530 Protein-free Efavirenz Is Equivalent in Cerebrospinal Fluid
and Blood Plasma: Applying the Law of Mass Action to
Predict Protein-free Drug Concentration

Lindsay Avery*, N Sacktor, J McArthur, and C Hendrix
531 Single and Multiple Dose Dolutegravir Pharmacokinetics in
the Genital Tract and Colorectum of HIV
-
Men and Women
Benjamin Greener*
1
, J Adams
1
, K Patterson
2
, H Prince
2
, C Sykes
1
,
M Wai
1
, J Dumond
1
, N Shaheen
2
, M Cohen
2
, and A Kashuba
1,2
1
Univ of North Carolina at Chapel Hill Eshelman Sch of Pharmacv, US
and
2
Univ of North Carolina at Chapel Hill Sch of Med, US
532 Gene and Protein Expression of Drug Transporters in Vaginal,
Cervical, and Rectal Tissues: Implications for Drug Disposition
in HIV Prevention
Melanie Nicol*
1
, Y Fedoriw
1
, M Mathews
1
, J Micheli
2
, D Kroetz
2
,
and A Kashuba
1
1
Univ of North Carolina at Chapel Hill, US and
2
Univ of California,
San Francisco, US
!

"#$$%&' ()4*+&$,#- ./$,-01,$
ARV Drug Interactions
533 5' 6%,-& Induction of Influx and Efflux Transporters and
Cytochrome P450 3A4 in Human Hepatocytes by Rifampicin,
Rifabutin, and Rifapentine

Beth Williamson*
1
, K Dooley
2
, D Back
1
, and A Owen
1
1
2
534 Pharmacokinetic Interactions Between BMS-663068,
Prodrug of the HIV-1 Attachment Inhibitor BMS-626529,
and Ritonavir or Ritonavir-boosted Atazanavir
L Zhu, C Hwang, V Shah, M Hruska, P Hu, B Vakkalagadda, M Furlong,
X Xu, G Hanna, and Richard Bertz*
Bristol-Mvers Squibb, Princeton, NJ, US
535 Dolutegravir Has No Effect on Pharmacokinetics of Methadone
or Oral Contraceptives with Norgestimate and Ethinyl Estradiol
I Song
1
, S Mark
1
, J Borland
1
, S Chen
1
, T Wajima
2
, A Peppercorn
1
,
and Stephen Piscitelli*
1
1
GlaxoSmithKline, Research Triangle Park, NC, US and Mississauga,
Canada and
2
Shionogi and Co, Ltd, Osaka, Japan
536 Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-
sparing Regimen Raltegravir plus Nevirapine in HIV-1
+
Patients

Chiara Montrucchio*
1
, A Calcagno
1
, M LanzaIame
2
, G Cenderello
3
,
M Simiele
1
, MC Tettoni
1
, P Bigliano
1
, A DÀvolio
1
, G Di Perri
1
,
and S Bonora
1
1
2
GB Rossi Univ Hosp, Jerona, Italv, and
3
San
Martino Hosp Genoa, Univ of Genoa, Italv
537 Absence of a Significant Pharmacokinetic Interaction
between the Hepatitis C Virus Protease Inhibitor Boceprevir
and HIV-1 NNRTI Rilpivirine
Elizabeth Rhee*, H-P Feng, F Xuan, W Lin, C Smith, Y Zhu,
and J Butterton
Merck & Co, Inc, Whitehouse Station, NJ, US
538 Steady-State Plasma and Intracellular Ribavirin
Concentrations Are Not Significantly Altered by Abacavir
Co-administration in Hepatitis C Virus Infected Patients
Adriana Andrade*
1
, C Hendrix
1
, E Fuchs
1
, C Radebaugh
1
,
M Sulkowski
1
, L Bushman
2
, M Ray
2
, and J Kiser
2
1
Johns Hopkins Univ, Baltimore, MD, US and
2
Univ of Colorado Denver,
Aurora, US
539 Pharmacokinetics of Two Doses of Raltegravir in
Combination with Rifampin in HIV-TB Co-infected Patients,
an ANRS 12 180 Reflate TB Sub-study
H Sauvageon
1
, B Grinsztejn
2
, V Arnold
3
, V Veloso
2
, C Vorsatz
2
, JH Pilotto
4
,
C Grondin
3
, G Chene
3
, Anne-Marie Taburet*
5
, and J-M Molina
1,6
1
Hosp St Louis, Paris, France,
2
IPEC, Fiocru:, Rio de Janeiro, Bra:il,
3
4
Hosp Geral de Nova Iguacu,
Bra:il,
5
Hosp Bicetre, Kremlin-Bicetre, France, and
6
Univ Paris Diderot,
Paris, France
Program 41
P
o
s
t
e
r

L
i
s
t
i
n
g
s
551 Early Hospitalization and Mortality in Patients Starting ART
in Rural Kenya: the Kericho Clinic-based ART Diagnostic
Evaluation (CLADE) Trial
Eunice Obiero*
1
, P Yegon
2
, A Aoko
2
, R Langat
2
, J Maswai
2
, J Tarus
2
,
M Bii
2
, M Omondi
3
, F Sawe
2,4
, and D ShaIIer
2,4
1
Kenva Ministrv of Med Svcs, Kericho,
2
Kenva Med Res Inst/Walter Reed
Profect, Kericho,
3
Kenva Med Res Inst/Walter Reed Profect, Kisumu, and
4
US Militarv HIJ Res Prgm, Bethesda, MD
552 Association Between Early Virologic Response and
Immunologic Outcomes in Raltegravir-treated Patients
Christos Tsoukas*
1
, A Rodgers
2
, H Teppler
2
, R Leavitt
2
, B-Y Nguyen
2
,
and P Sklar
2
1
McGill Univ, Montreal, Canada and
2
Merck Sharp & Dohme, Corp,
Whitehouse Station, NJ, US
553 96-week Efficacy and Safety of Elvitegravir/Cobicistat/
Emtricitabine/Tenofovir DF - Subgroup Analyses by
Baseline HIV-1 RNA and CD4 Cells
Andrew Zolopa*
1
, J Rockstroh
2
, C Orkin
3
, H-J Stellbrink
4
, S Walmsley
5
,
D Cooper
6
, L Zhong
7
, M Fordyce
7
, M Rhee
7
, and J Szwarcberg
7
1
Stanford Univ, Palo Alto, CA, US,
2
Univ of Bonn, HIJ-Outpatient Clin,
Bonn, Germanv,
3
Barts and the London NHS Trust, UK,
4
ICH Studv Ctr,
Hamburg, Germanv,
5
Univ Hlth Network, Toronto Gen Hosp, Canada,
6
St
Jincent`s Hosp, Svdnev, Australia, and
7
554 Dolutegravir Treatment Response and Safety by
Key Subgroups in Treatment-nave HIV
+
Individuals
Cynthia Brinson*
1
, S Walmsley
2
, K Arasteh
3
, M Gorgolas
4
,
L Schneider
5
, F RaIIi
6
, C Brennan
7
, K Pappa
7
, S Almond
8
, C Granier
9
,
and Extended SPRING-2 and SINGLE Study Teams
1
Central Texas Clin Res, Austin, US,
2
Univ Hlth Network, Toronto,
Canada,
3
EPIMED/Jivantes Auguste-Jiktoria-Klinikum, Berlin,
Germanv,
4
Fndn Jimene: Dia:, Madrid, Spain,
5
Internistische Praxis,
Fuerth, Germanv,
6
Univ of Nantes, France,
7
GlaxoSmithKline, Research
Triangle Park, NC, US,
8
GlaxoSmithKline, Mississauga, Canada, and
9
GlaxoSmithKline, Stocklev Park, UK
555 Maraviroc Intensification of cART in Patients with Suboptimal
Immunological Recovery Does Not Increase CD4 Count: A
48-week, Placebo-controlled Trial
Steven van Lelyveld*
1
, J Drylewicz
1
, C Richter
2
, R Soetekouw
3
,
J Prins
4
, K Brinkman
5
, JW Mulder
6
, M Nijhuis
1
, K Tesselaar
1
,
A Hoepelman
1
, and MIRS Study Group
1
Univ Med Ctr Utrecht, The Netherlands,
2
Rifnstate Hosp, Arnhem, The
Netherlands,
3
Kennemer Gasthuis, Haarlem, The Netherlands,
4
Academic
Med Ctr, Amsterdam, The Netherlands,
5
On:e Lieve Jrouwe Gasthuis,
Amsterdam, The Netherlands, and
6
Slotervaart Hosp, Amsterdam, The
Netherlands
556 Pharmacogenetics-based Schedule Adjustment of Unboosted
Atazanavir Associated with Tenofovir/Emtricitabine: A
Randomized Controlled Study (REYAGEN)
SteIano Bonora*
1
, O Vigano
2
, A Calcagno
1
, J Cusato
1
, M LanzaIame
3
,
A Trentalange
1
, A DÀvolio
1
, M Galli
2
, S Rusconi
2
, and G Di Perri
1
1
2
Univ of Milan, Italv, and
3
GB Rossi Hosp, Jerona,
Italv
557 Baseline Characteristics and Acceptance of Regimens
Recommended by an Expert Panel in ACTG A5241
OPTIONS, a Randomized Salvage HIV Therapy Trial
Karen Tashima*
1
, K Mollan
2
, L Na
2
, R Gandhi
3
, K Klingman
4
,
C Fichtenbaum
5
, A Andrade
6
, V Johnson
7
, J Eron
8
, and R Haubrich
9
1
Miriam Hosp, Alpert Med Sch of Brown Univ, Providence, RI, US,
2
Ctr
for Biostatistics in AIDS Res, Harvard Sch of Publ Hlth, Boston, MA, US,
3
4
DAIDS, NIAID, NIH, Bethesda,
MD, US,
5
Univ of Cincinnati, OH, US,
6
Johns Hopkins Univ, Baltimore,
MD, US,
7
Birmingham JAMC and Univ of Alabama at Birmingham Sch
of Med, US,
8
Univ of North Carolina at Chapel Hill, US, and
9
Univ of
558 Efficacy of Different ARV Approaches after Virologic Failure
on First-line Ritonavir-boosted Protease Inhibitor Regimens
Yu Zheng*
1
, M Hughes
1
, S Lockman
1
, M Hosseinipour
2
, T Campbell
3
,
R Salata
4
, R Gulick
5
, E Daar
6
, C Benson
7
, and J Currier
8
1
2
Chapel Hill, US,
3
Univ of Colorado Denver, Aurora, US,
4
Case Western
Reserve Univ, Cleveland, OH, US,
5
Weill Med Coll, Cornell Univ, New
York, NY, US,
6
Los Angeles Biomed Res Inst at Harbor-UCLA Me Ctr,
Torrance, CA, US,
7
8
Univ of
California, Los Angeles, US
559 More Treatment Failures among Men in a Prospective
Randomized NNRTI vs b-PI Trial in Nave HIV-1
+
Patients in
a Resource-Limited Setting
Nathan Clumeck*
1
, M Claude
2
, K Kabamba
1
, S Matanda
2
, D Vaira
3
,
C Necsoi
1
, D Kadiebwe
2
, C Milolo
2
, J Ilunga
2
, and L Kapend
2
1
St-Pierre Univ Hosp Brussels, Belgium,
2
Lubumbashi Network and
PNMLS, Democratic Republic of the Congo, and
3
CHU Liege, Belgium
!

"#$$%&' ()*+,&$-#. /0$-.12-$
New ARV Agents
540 Tenofovir Alafenamide (GS-7340) Is Not a Substrate for
Renal Organic Anion Transporters (OAT) and Does Not
Exhibit OAT-dependent Cytotoxicity
Rujuta Bam*, S Yant, and T Cihlar
541 Kinetic Mechanism of (-)--D-Dioxolane-Adenosine Inhibition
of Wild-type and Mutant HIV-1 Reverse Transcriptase
Robert Domaoal*
1
, M Detorio
1
, C Montero
1
, L Bondada
1
, S Amiralaei
1
,
T Nie
1
, E Anandarajah
1
, S Coats
2
, and R Schinazi
1
1
Emorv Univ and JAMC, Decatur, GA, US and
2
RFS Pharma, LLC,
Tucker, GA, US
542 Homology Models of the Attachment Inhibitor BMS-626529
Bound to gp120 Suggests a Unique Mechanism of Action
David Langley*, R Kimura, P Sivaprakasam, N Zhou, I Dicker,
T Wang, J Kadow, N Meanwell, and M Krystal
Bristol-Mvers Squibb Res and Devt, Wallingford, CT, US
543 Identification and Characterization of X4 HIV-1 Env-specific
Antibodies for Diagnostic/Therapeutic Applications
Svenja Weiss*
1
, R Duerr
1
, M Hust
2
, J Este
3
, C Kuecherer
4
, R Schmidt
5
,
and U Dietrich
1
1
Georg-Spever-Haus, Inst for Biomed Res, Frankfurt am Main, Germanv,
2
Tech Univ Braunschweig, Germanv,
3
Irsi Caixa, Univ Barcelona, Spain,
4
Robert-Koch Inst, Berlin, Germanv, and
5
Hannover Med Sch, Germanv
544 New HIV-1 Entry Inhibitors Identified by Selectivity Analysis
of a High-Throughput Chemical Screen

Alon Herschorn*
1
, G Christopher
1
, V Misra
1
, D Flood
2
, and J Sodroski
1,3,4
1
Dana-Farber Cancer Inst and Harvard Med Sch, Boston, MA, US,
2
Inst
of Chemistrv and Cell Bio, Harvard Med Sch, Boston, MA, US,
3
Harvard
4
Harvard, Boston, MA, US
545 Coupling HIV-1 Nef to a Host Cell Kinase Enables High-
Throughput Screening for Direct Antagonists of Nef
Function
Lori Emert-Sedlak*
1
, P Narute
1
, S Shu
1
, H Shi
1
, N Yanamala
1
,
JJ Alvarado
1
, J Lazo
1,2
, J Yeh
1
, P Johnston
1,3
, and T Smithgall
1
1
2
Univ of Jirginia,
Charlottesville, US, and
3
Univ of Pittsburgh Sch of Pharmacv, PA, US
546 Development of a Bimolecular Fluorescence Complementation
Assay for Small Molecule Inhibitors of HIV-1 Nef Dimerization

Jerrod Poe*, L Vollmer, A Vogt, and T Smithgall
Univ of Pittsburgh Sch of Med, PA, US
547 Mut101 Integrase-LEDGF Inhibitor Impairs HIV-1 Replication
at Two Different Steps, Integration and Production of Infectious
Virions after Integration
E Le Rouzic
1
, D Bonnard
1
, S Chasset
1
, J-M Bruneau
1
, F Chevreuil
1
,
F Le Strat
1
, S Emiliani
2
, B Ledoussal
1
, F Moreau
1
, and Richard Benarous*
1
1
BIODIM Mutabilis, Romainville, France and
2
INSERM, Paris, France
548 2-Hydroxyisoquinoline-1,3(2H, 4H)diones, Novel Inhibitors
of the HIV Integrase Catalytic Activity with a High Barrier to
Resistance
Frauke Christ*
1
, B Desimmie
1
, J Demeulemeester
1
, V Suchaud
2
,
O Taltynov
1
, C Lion
2
, F Bailly
2
, S Strelkov
1
, P Cotelle
2
, and Z Debyser
1
1
2
Univ of Lille, France
!

"#$$%&' ()3+,&$-#. /0$-.12-$
Randomized Trials of ART: A Potpourri
549 A Randomized Trial of Time-limited ART in Acute and Early
HIV Infection
Joseph Margolick*
1
, L Apuzzo
1
, J Singer
2
, H Wong
2
, T Lee
2
, M LoutIy
3
,
A Rachlis
4
, P El-Helou
5
, H Tossonian
6
, and B Conway
7
1
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD,
US,
2
Canadian Trials Network, Jancouver,
3
Maple Leaf Clin, Toronto,
Canada,
4
Sunnvbrook Clin, Toronto, Canada,
5
McMaster Univ Sch
of Med, Hamilton, Canada,
6
Downtown Infectious Diseases Clin,
Jancouver, Canada, and
7
Univ of British Columbia, Jancouver, Canada
550 Acceptance of ART in the Delay Arm after Notification of
Interim Study Results: Data from HPTN 052
J Batani
1
, T Brum
2
, G Calvet
3
, P Dusara
4
, S Dhayarkar
5
, Theresa Gamble*
6
,
X Li
7
, RA Lira
8
, M Maliwichi
9
, M McCauley
10
, and HPTN 052 Study Team
1
2
Hosp Geral de Nova Iguacu, Rio de
Janeiro, Bra:il,
3
Inst de Pesquisa Clin Evandro Chagas, Fiocru:, Rio de
Janeiro, Bra:il,
4
Botswana Harvard AIDS Inst, Gaborone,
5
Natl AIDS
Res Inst, Pune, India,
6
FHI 360, Durham, NC, US,
7
Fred Hutchinson
Cancer Res Ctr, Seattle, WA, US,
8
Hosp Nossa Senhora da Conceicao,
Porto Alegre, Bra:il,
9
UNC Profect, Lilongwe, Malawi, and
10
FHI 360,
Washington, DC, US
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' ()*+,&$-#. /0$-.12-$
ART: Too Early or Too Late? Or Better Late than Never!
560 Kinetics of Resting Memory B Cells in Nave HIV
+
Patients
Treated during Primary and Chronic HIV Infection

Marco Ripa*, S Pensieroso, S Nozza, L Galli, G Scarlatti,
and G Tambussi
San Raffaele Sci Inst, Milan, Italv
561 Predictors of Virologic Suppression in Persons Who Start
ART during Primary HIV Infection
Maile Karris*
1
, Y-T Kao
1
, F Vaida
1
, C Spina
1,2
, D Richman
1,2
, S Little
1,2
,
and D Smith
1,2
1
2
Svstem, CA, US
562 Early Intermittent ART in HIV
+
Patients with CD4 >500/
mm
3
: Results of the ANRS 141 TIPI Trial
Lionel Piroth*
1
, L Moinot
2
, P Yeni
3
, J Reynes
4
, P-M Girard
5
,
X Anglaret
2
, A Taieb
2
, B Autran
6
, C Rouzioux
7
, C Fagard
2
, and ANRS 141
TIPI Trial Study Group
1
Hosp Bocage, Univ de Bourgogne, Difon, France,
2
INSERM U897, Univ
Bordeaux, France,
3
Hosp Bichat-Claude Bernard, Paris, France,
4
Hosp
Gui De Chauliac, Montpellier, France,
5
Hosp St-Antoine, Paris, France,
6
Hosp Pitie-Salpetriere, Paris, France, and
7
Hosp Necker, Paris, France
563 The Long-term Effects on CD4 Counts of Initiating Treatment
in Very Early Compared to Chronic HIV Infection
Frederick Hecht*
1
, W Hartogensis
1
, S Saha
1
, S Little
2
, M Markowitz
3
,
J Margolick
4
, B Walker
5
, V Jain
1
, C Pilcher
1
, P Bacchetti
1
, and Acute
InIection Early Disease Res Prgm
1
2
Diego, US,
3
Aaron Diamond AIDS Res Ctr, New York, NY, US,
4
Johns
Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US, and
5
564 Laboratory-defined Toxicities when Starting cART
at High CD4 Counts: The UK Collaborative HIV Cohort Study

Sophie Jose*
1
, S Fidler
2
, C Sabin
1
, and UK Collaborative HIV Cohort
Study
1
Univ Coll London, UK and
2
St Marvs Hosp, London, UK
565 Evaluation of Chloroquine Administration on CD4 Recovery
and Immune Activation in HIV
+
Subjects Receiving ART

Mohammad-Ali Jenabian*
1
, M Patel
1
, C Kanagaratham
1
, D Radzioch
1
,
P Ancuta
2
, I Kema
3
, R Thomas
4
, J Singer
5
, J Angel
6
, and J-P Routy
7
1
Res Inst of McGill Univ Hlth Ctr, Montreal, Canada,
2
CHUM Res Ctr,
Montreal, Canada,
3
Univ Med Ctr, Univ of Groningen, The Netherlands,
4
Lactuel Med Clin, Montreal, Canada,
5
CIHR Canadian HIJ Trials
Network, Jancouver,
6
Ottawa Hosp Res Inst, Canada, and
7
Roval
Jictoria Hosp, McGill Univ Hlth Ctr, Montreal, Canada
566 Maraviroc + Raltegravir Dual Therapy in Aviremic HIV
+

Patients with Lipodystrophy: Results from the ROCnRAL
Agence Nationale de la Recherche 157 Study
Christine Katlama*
1
, L Assoumou
1
, M-A Valantin
1
, C Duvivier
2
,
C Soulie
1
, L Chablais
1
, G Pialoux
3
, P Mercie
4
, G Peytavin
5
, A-G Marcelin
1
,
and ANRS 157 Study Group
1
INSERM U943, Paris JI Pitie Salpetriere Univ Hosp, France,
2
Inst
Pasteur Paris, Necker Hosp, France,
3
Tenon, Paris JI Univ, France,
4
INSERM U897 Hosp St-Andre, Bordeaux, France, and
5
Bichat Univ
Hosp, Paris, France
567 Maraviroc + Darunavir/ritonavir Once Daily Exhibits Rapid
Early Viral Decay: Results of the Viral Dynamics Sub-study
of MIDAS
BabaIemi Taiwo*
1
, D Lu
2
, S Swindells
3
, B Berzins
1
, P Ryscavage
4
,
J Lalezari
5
, J Castro
6
, O Adeyemi
7
, D Kuritzkes
2
, J Eron
8
, and MIDAS
Study Team
1
2
Harvard Univ, Cambridge, MA,
US,
3
Univ of Nebraska, Omaha, US,
4
Univ of Marvland, Baltimore, US,
5
Quest Clin Res, San Francisco, CA, US,
6
Univ of Miami, FL, US,
7
CORE
Ctr, Chicago, IL, US, and
8
568 Contribution of AIDS and Non-AIDS Deaths to Lower Life
Expectancy of ART-treated HIV
+
Individuals Compared with
the General Population
Margaret May*
1
, A MocroIt
2
, J Guest
3
, H Crane
4
, P Reiss
5
,
A dArminio MonIorte
6
, P Labarga
7
, J-C Wasmuth
8
, S Ingle
1
, R Hogg
9,10
,
and ART Cohort Collaboration
1
Univ of Bristol, UK,
2
Univ Coll London Med Sch, UK,
3
Atlanta JAMC,
Decatur, GA, US,
4
Univ of Washington Sch of Med, Seattle, US,
5
Univ
of Amsterdam, The Netherlands,
6
Univ of Milan, Italv,
7
Hosp Carlos III,
Madrid, Spain,
8
Rheinische Friedrich-Wilhelms-Univ Bonn, Germanv,
9
BC Ctr for Excellence in HIJ/AIDS, Jancouver, Canada, and
10
Simon
Fraser Univ, Burnabv, Canada
!

"#$$%&' ()3+,&$-#. /0$-.12-$
ART: Host and Viral Determinants of Outcome
569 European Mitochondrial Haplogroups Are Associated with
CD4
+
T Cell Recovery in HIV
+
Patients on cART
M Guzman-Fulgencio
1
, Juan Berenguer*
2
, A Fernandez-Rodriguez
1
,
D Micheloud
2
, M GarciaAlvarez
1
, MA Jimenez-Sousa
1
, JM Bellon
2
,
J Cosin
2
, T Aldamiz-Echevarria
2
, and S Resino
1
1
Natl Ctr of Microbio, Inst de Salud Carlos III, Mafadahonda, Madrid,
Spain and
2
Hosp Gen Univ Gregorio Maranon, Madrid, Spain
570 Impact of HIV
+
Patient`s Obesity on Immuno-virological
Response and ARV Pharmacokinetics
MP Le
1
, K Champenois
2
, C Charpentier
1
, R Landman
1
, V Joly
1
, P Yeni
1
,
D Descamps
1
, Y Yazdanpanah
1
, and Gilles Peytavin*
1
1
APHP, EA4409 Univ Paris 7 Diderot, Bichat-Claude Bernard Hosp,
France and
2
Equipe Atip/Avenir INSERM U738, Univ Paris 7 Diderot,
France
571 Weight Change at 1 Month of ART Is Associated with
Subsequent Mortality and Morbidity among a Tanzanian
HIV
+
Adult Cohort
Christopher SudIeld*
1
, S Isanaka
1
, F Mugusi
2
, S Aboud
2
, M Wang
1
,
G Chalamilla
3
, and W Fawzi
1
1
2
Muhimbili Univ of Hlth
and Allied Sci, Dar es Salaam, Tan:ania, and
3
Mgmt and Devt for Hlth,
Dar es Salaam, Tan:ania
572 Effect of HIV-1 Subtypes on Virological and Immunological
Response to Initial cART: A European Multicohort Study
Linda Wittkop on behalI oI EuroCoord-CHAIN Subtype Project Team
INSERM U897-Epidemiologie-Biostatistique, Univ Bordeaux and Univ
Hosp, France
573 Can the Veterans Aging Cohort Study Index Improve Clinical
1udgment?
Amy Justice*
1,2
, J Tate
1,2
, S Brown
3,4
, C Gibert
5,6
, M Rodriguez-
Barradas
7,8
, D Rimland
9,10
, K Akgun
1,2
, and K Bryant
11
1
2
JA Connecticut Hlthcare Svstem,
West Haven, US,
3
James J Peters JAMC, New York NY, US,
4
Mt Sinai
Sch of Med, New York, NY, US,
5
George Washington Univ Sch of Med,
Washington, DC, US,
6
Washington DC JAMC, US,
7
Bavlor Coll of Med,
Houston TX, US,
8
Michael E DeBakev JAMC, Houston, TX, US,
9
Emorv
Univ Sch of Med, Atlanta, GA, US,
10
Atlanta JAMC, GA, US, and
11
Natl
Inst on Alcohol Abuse and Alcoholism, Bethesda, MD, US
574 Plasma HIV DNA Is the Major Driver of Virological Failure
to Protease Inhibitor-boosted Mono-therapy
Adriana Ammassari*, I Abbate, P Lorenzini, G Rozera, S Ottou,
C Pinnetti, A Amendola, M Zaccarelli, A Antinori, and MR Capobianchi
Natl Inst for Infectious Disease L Spallan:ani, Rome, Italv
575 A Low HIV DNA Level in Peripheral Blood Mononuclear
Cells at ART Interruption Predicts a Higher Probability of
Maintaining Plasma Viral Load <400 Copies/mL
L Assoumou
1,2
, L Weiss
3,4
, C Piketty
3
, M Burgard
5
, A Melard
5
, J-M Ragnaud
6
,
P-M Girard
7
, D Costagliola
1,2
, Christine Rouzioux*
4,5
, and ANRS 116
SALTO Study Group
1
INSERM U943, Paris, France,
2
UPMC Univ Paris 06, UMR S 943,
France,
3
AP-HP Hosp Europeen Georges Pompidou, Paris, France,
4
Univ Rene Descartes Paris 05, France,
5
AP-HP Hosp Necker Paris,
France,
6
Hosp Pellegrin, Bordeaux, France, and
7
AP-HP Hosp
St-Antoine, Paris, France
576 Viremia Copy-years as a Measure of Viral Load Burden
and Associated Mortality Risk among ART Patients:
1ohannesburg, South Africa

Alana Brennan*
1,2
, M Maskew
2
, I Sanne
2,3
, and M Fox
1,2,4
1
2
Sch of Clin Med,
Facultv of Hlth Sci, Univ of the Witwatersrand, Johannesburg, South
Africa,
3
Right to Care, Johannesburg, South Africa, and
4
Boston Univ Sch
of Publ Hlth, MA, US
577 Mortality of Treated HIV-1
+
Individuals according to Viral
Subtype in Europe and Canada: ART Cohort Collaboration
Margaret May*
1
, M Gill
2
, R Harrigan
3
, M Klein
4
, P Reiss
5
, A MocroIt
6
,
A dArminio MonIorte
7
, R Zangerle
8
, M Cavassini
9
, J Sterne
1
, and ART
Cohort Collaboration
1
2
Univ of Calgarv, Canada,
3
BC Ctr for Excellence
in HIJ/AIDS and Univ of British Columbia, Jancouver, Canada,
4
McGill
Univ, Montreal, Canada,
5
Univ of Amsterdam, The Netherlands,
6
Univ
Coll London Med Sch, UK,
7
8
Innsbruck Med Univ,
Austria, and
9
Ctr Hosp Univ Jaudois, Lausanne, Swit:erland
Program 43
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' ()*+,&$-#. /0$-.12-$
ART: Care and Adherence
578 Outcomes for HIV
+
Patients Receiving Care at Multiple HIV
Clinics
Baligh Yehia*
1
, A Schranz
1
, F Momplaisir
2
, S Keller
1
, R Gross
1
,
J Metlay
1
, and K Brady
3
1
2
Temple
Univ Sch of Med, Philadelphia, PA, US, and
3
Philadelphia Dept of Publ
Hlth AIDS Activities Coordinating Office, PA, US
579 Virological Response in Patients, Who for Economic Reasons
Were Changed from Atripla to a Multi-tablet cART Regimen
F Engsig
1
, J GerstoIt
1
, Marie Helleberg*
1
, G Kronborg
2
, L Mathiesen
2
,
1
Copenhagen Univ Hosp, Rigshospitalet, Denmark and
2
Copenhagen Univ
Hosp, Hvidovre, Denmark
580 Food Insecurity and HIV Treatment Outcomes in a
Longitudinal Study of Homeless and Marginally Housed HIV
+

Individuals: San Francisco
Sheri Weiser*
1
, K Yuan
2
, D Guzman
1,3
, E Frongillo
4
, E Riley
1
,
D Bangsberg
5,6,7
, and M Kushel
2
1
2
Sch of Med, Univ of California,
San Francisco, US,
3
San Francisco Gen Hosp, CA, US,
4
Arnold Sch of
Publ Hlth, Univ of South Carolina, Columbia, US,
5
Massachusetts Gen
Hosp Ctr for Global Hlth, Boston, US,
6
Harvard, Boston, MA, US, and
7
581 Care Engagement and Viral Suppression in Comprehensive
HIV Care Coordination Clients: Baseline Characteristics and
Pre- and Post-enrollment Outcomes
M Irvine
1
, S Chamberlin
1
, R Robbins
2
, J Myers
1
, X Yang
2
, G Harriman
1
,
S Braunstein
1
, F Laraque
1
, B Mitts
1
, and Denis Nash*
2
1
New York Citv Dept of Hlth and Mental Hvgiene, NY, US and
2
CUNY
Sch of Publ Hlth at Hunter Coll, New York, NY, US
582 Long-term Adherence to ART: Republic of Georgia

Nikoloz Chkhartishvili*
1
, L Sharvadze
1,2
, O Chokoshvili
1
,
P Gabunia
1
, and T Tsertsvadze
1,2
1
Infectious Diseases, AIDS and Clin Immunologv Res Ctr, Tbilisi, Georgia
and
2
Tbilisi State Univ, Georgia
583 Associations of Self-reported and Prescription-based
Adherence with Viral Suppression in 5 HIV Cohort Studies
Suzanne Ingle*
1
, T Glass
2
, H Crane
3
, R Hogg
4
, J Gill
5
, A Ammassari
6
,
M Mugavero
7
, J Tate
8
, N Turner
1
, J Sterne
1
, and ART Cohort
Collaboration
1
2
Univ of Basel, Swit:erland,
3
Univ of Washington,
Seattle, US,
4
Simon Fraser Univ, Burnabv, Canada,
5
Univ of Calgarv,
Canada,
6
INMI, L Spallan:ani, Rome, Italv,
7
Univ of Alabama at
Birmingham, US, and
8
Yale Univ Sch of Med and Publ Hlth and JA
Connecticut Hlthcare Svstem, New Haven, US
584 30-Day Hospital Readmission Rate Is Nearly Doubled in
Persons Living with HIV vs HIV
-
Persons
Stephen Berry*
1
, K Gebo
1
, R Moore
1
, and J Fleishman
2
1
2
Agencv for
Hlthcare Res and Qualitv, Rockville, MD, US
!

"#$$%&' (()+,&$-#. /0$-.12-$
Tropism Testing/Maraviroc Resistance
585 Field Validation of RECall for Automated Genotypic
Tropism Testing

Christian Pou*
1,2,3
, R Bellido
1,2,3
, M Casadella
1,2,3
, T Puig
1,2,3
, B Clotet
1,2,3,4
,
R Harrigan
5
, and R Paredes
1,2,3,4
1
IrsiCaixa Inst for AIDS Res, Badalona, Catalonia, Spain,
2
Hosp Germans
Trias i Pufol, Badalona, Catalonia, Spain,
3
Univ Autonoma de Barcelona,
Cerdanvola del Jalles, Catalonia, Spain,
4
Fnd Lluita Contra la SIDA,
Badalona, Catalonia, Spain, and
5
BC Ctr for Excellence in HIJ/AIDS,
Jancouver, Canada
586 Does HIV-1 Proviral DNA Envelope Sequence Predict Trofile
Co-receptor Usage upon Treatment Interruption?
Elizabeth White*
1
, M Balamane
1
, K Henry
2
, H Valdez
3
, D Margolis
4
,
D Skiest
5
, P Tebas
6
, D Katzenstein
1
, and ACTG NWCS 303 Team
1
2
Hennepin Countv Med Ctr, Minneapolis, MN,
US,
3
Pfi:er Inc, New York, NY, US,
4
Univ of North Carolina at Chapel
Hill, US,
5
Tufts Univ Sch of Med, Springfield, MA, US, and
6
Univ of
Pennsvlvania, Philadelphia, US
587 Absence of Genotype/Phenotype Correlations to Predict
Primary Resistance of R5-tropic HIV-1 to Maraviroc
Pierre Delobel*
1,2
, M Cazabat
1,2
, A Saliou
1
, M Requena
1,2
, S Raymond
1,2
,
B Marchou
2
, P Massip
2
, and J Izopet
1,2
1
INSERM UMR1043, Toulouse, France and
2
Toulouse Univ Hosp, France
588 A Common Mechanism of Clinical HIV-1 Resistance to
Maraviroc despite Divergent Resistance Levels and Lack of
Common gp120 Resistance Mutations

Renee Duncan*
1
, M Roche
1
, H Salimi
1,2
, J Sterjovski
1
, M Moore
1
,
B Lee
3
, M Westby
4
, R Payne
5
, M Churchill
1,2
, and P Gorry
1,2,6
1
2
Monash Univ, Clavton, Australia,
3
David Geffen Sch of Med, Univ of California, Los Angeles, US,
4
Pfi:er
Global Res and Devt, Sandwich, UK,
5
Univ of Svdnev, Australia, and
6
Univ of Melbourne, Australia
589 Impact of Maraviroc-resistant and Low CCR5-adapted
Mutations Induced %' 3%-.& Passage on Sensitivity to Anti-Env
Neutralizing Antibodies
Kazuhisa Yoshimura*
1,2
, S Harada
1
, S Boonchawalit
2
, and S Matsushita
2
1
AIDS Res Ctr, Natl Inst of Infectious Diseases, Tokvo, Japan and
2
Ctr for
AIDS Res, Kumamoto Univ, Japan
!

"#$$%&' (((+,&$-#. /0$-.12-$
HIV Drug Resistance: Trends and Emergence
590 Trends in Darunavir Resistance-associated Mutations and
Phenotypic Resistance: US, 2006 to 2012
Erkki Lathouwers*
1
, C Kambili
2
, M Haddad
3
, A Paquet
3
, S De Meyer
1
,
and B Baugh
4
1
Janssen Infectious Diseases BJBA, Beerse, Belgium,
2
Janssen Res and
Devt, LLC, Titusville, NJ, US,
3
Monogram Biosci, South San Francisco,
CA, US, and
4
Janssen Therapeutics, Titusville, NJ, US
591 Characterization of Resistance to Integrase Strand Transfer
Inhibitors among Clinical Specimens:
US, 2009-2012
Christopher Hurt*
1
, J Sebastian
2
, C Hicks
3
, and J Eron
1
1
2
Lab Corp of America,
Research Triangle Park, NC, US, and
3
592 15 Years after the Introduction of ART in Senegal: Virological
Response and Risk of Resistance in the Agence Nationale de
Recherches sur le Sida 1215 Cohort

Assane DiouI*
1
, P De Beaudrap
2
, M Thiam
3
, C Toure-Kane
3
,
N Ngom-Gueye
4
, N Vidal
2
, S Mboup
3
, I Ndoye
5
, PS Sow
4
, E Delaporte
2
,
and ANRS 1215 Study Group
1
Ctr Regional de Recherche et Formation sur le JIH/SIDA, Univ Cheikh
Anta Diop, Dakar, Senegal,
2
Inst de Recherche pour le Devt, Univ de
Montpellier 1, France,
3
Hosp Le Dantec, Dakar, Senegal,
4
CHU de Fann,
Dakar, Senegal, and
5
Multisectorial AIDS Prgm, Dakar, Senegal
593 Population-based Monitoring of HIV Drug Resistance
Emerging on Treatment and Associated Factors in Sentinel
ART Sites: Namibia
J Gweshe
1
, A Jonas
1
, A Shiningavamwe
2
, T Desta
3
, G Hunt
4
, H Sheehan
5
,
K Lau
5
, A Trotter
5,6
, M Jordan
5,6
, and Steven Hong*
5,6
1
Republic of Namibia Ministrv of Hlth and Social Svcs, Windhoek,
2
Namibia Inst of Pathologv, Windhoek,
3
WHO, Klein Windhoek, Namibia,
4
Natl Inst of Communicable Diseases, Johannesburg, South Africa,
5
Tufts
Univ Sch of Med, Boston, MA, US, and
6
Tufts Med Ctr, Boston, MA, US
594 Rapid Increase in the Frequency of Wild-type HIV-1 Drug
Resistance Reports among ART-experienced Patients: UK
David Dolling*
1
, M Nelson
2
, A Schwenk
3
, D Churchill
4
, D Pillay
5
,
D Dunn
1
, and UK HIV Drug Resistance Database and UK Collaborative
HIV Cohort Study
1
2
Chelsea and Westminster Hosp,
London, UK,
3
North Middlesex Univ Hosp NHS Trust, London, UK,
4
Brighton and Sussex Univ Hosp NHS Trust, Brighton, UK, and
5
Univ
Coll London, UK
595 Baseline HIV Drug Resistance Is Independently Associated
with Virologic Failure: Multi-national Prospective
Evaluation of ARV in Resource-limited Settings Study,
ACTG A5175
Rami Kantor*
1
, L Smeaton
2
, S Vardhanabhuti
2
, S Tripathi
3
,
M Morgado
4
,

S Saravanan
5
, C Wallis
6
, S Hudelson
7
, T Campbell
8
,
S Eshleman
7
, on behalI oI A5175 Study Investigators
1
Brown Univ, Providence, RI, US,
2
Harvard Univ, Boston, MA, US,
3
Natl
AIDS Res Inst, Pune, India,
4
Oswaldo Cru: Inst, Rio de Janeiro, Bra:il,
5
YRG CARE, Chennai, India,
6
Lancet Labs, Johannesburg, South Africa,
7
8
Univ of Colorado Denver,
Aurora, US
596 Emergent Drug Resistance from the HIV-1 Phase 3
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil
Fumarate Studies through Week 96
Kirsten White*, M Abram, R Kulkarni, M Rhee, M Fordyce,
J Szwarcberg, and M Miller
Gilead Sci, Inc, Foster Citv, CA, US
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' (()*+&$,#- ./$,-01,$
Detecting and Interpreting HIV Drug Resistance
597 A Sensitive and Single-tube Detection Assay for Identifying
HIV-1 Drug-resistance Mutations Associated with Pre-
Exposure Prophylaxis
Guoqing Zhang*
1
, H Guo
1
, J DeVos
1
, I Lorenzana de Rivera
2
, I Zulu
3
,
N Wadonda-Kabondo
4
, C Ndongmo
3
, J Nkengasong
1
, F Gao
5
, and C Yang
1
1
2
Natl Autonomous Univ of Honduras,
Tegucigalpa,
3
CDC-Zambia, Lusaka,
4
CDC-Malawi, Lilongwe, and
5
Duke
Univ Med Ctr, Durham, NC, US
598 HIV-2 EU-supporting Standardized HIV-2 Drug Resistance
Interpretation in Europe
Charlotte Charpentier*
1
, R Camacho
2
, J Ruelle
3
, R Kaiser
4
, J Eberle
5
,
A Pironti
6
, M Stuermer
7
, F Brun-Vezinet
1
, D Descamps
1
, and M Obermeier
6
1
Hosp Bichat-Claude Bernard, Paris, France,
2
Univ Nova de Lisboa,
Portugal,
3
Univ Catholique de Louvain, Brussels, Belgium,
4
Univ of
Cologne, Germanv,
5
Ludwig Maximilian Univ Munich, Germanv,
6
Med
Labor Dr Berg, Berlin, Germanv, and
7
Johann Wolfgang Goethe-Univ
Hosp, Frankfurt, Germanv
599 The Individualized Genetic Barrier Predicts Treatment
Response in a Large Cohort of HIV-1
+
Patients
N Beerenwinkel
1
, H Knotzsch
1
, P KnupIer
1
, V von Wyl
2
, S Yerly
3
, J Boni
4
,
T Klimkait
5
, V Aubert
6
, Huldrych Gunthard*
2
, and Swiss HIV Cohort Study
1
ETH Zurich, Basel, Swit:erland,
2
Univ Hosp Zurich, Swit:erland,
3
Univ
Hosp Geneva, Swit:erland,
4
5
Univ of Basel,
Swit:erland, and
6
Ctr Hosp Univ Jaudois, Lausanne, Swit:erland
600 Genotype, Phenotype, and Susceptibility to New Drugs among
Subtype C-infected 1
st
-line Failure Patients
Anne Derache*
1
, C Wallis
2
, J Bartlett
3
, E Aga
4
, M Norton
5
,
K Klingman
6
, W Stevens
7
, D Katzenstein
1
, and ACTG5230 Team
1
2
3
4
Statistical Data Analvsis Ctr
at Harvard Univ, Cambridge, MA, US,
5
Abbott Labs, Abbott Park,
IL, US,
6
DAIDS, NIAID, NIH, Bethesda, MD, US, and
7
Univ of the
Witswatersrand, Johannesburg, South Africa
601 Low-level HIV Viremia and Drug Resistance
Alejandro Gonzalez-Serna*
1
, JE Min
1
, C Woods
1
, J Li
2
, R Harrigan
1
,
and L Swenson
1
1
2
Brigham
and Womens Hosp, Harvard Med Sch, Boston, MA, US
!

"#$$%&' ((2*+&$,#- ./$,-01,$
Innovation in Measuring Viral Nucleic Acids
602 Comparison of Different US Food and Drug Administration-
cleared Plasma HIV-1 RNA Assay Platforms for Determination
of Virologic Failure Endpoints: An ACTG Analysis
Christina Lalama*
1
, C Jennings
2
, V Johnson
3,4
, R Coombs
5
, J McKinnon
6
,
J Bremer
2
, B Cobb
7
, G Cloherty
8
, H Ribaudo
1
, and J Mellors
9
1
2
Rush Univ Med Ctr,
Chicago, IL, US,
3
Birmingham JAMC, AL, US,
4
Univ of Alabama at
Birmingham Sch of Med, US,
5
6
Henrv
Ford Hosp, Detroit, MI, US,
7
Roche Diagnostics, Pleasanton, CA, US,
8
Abbott Molecular, Des Plaines, IL, US, and
9
603 Residual Viremia Detected by Single Copy Plasma HIV RNA
Assay as an Early Predictor of Virologic Failure
John McKinnon*
1
, C Lalama
2
, S Riddler
3
, R Haubrich
4
, M Hughes
2
,
D Vagrattian
3
, and J Mellors
3
1
Henrv Ford Hosp, Detroit, MI, US,
2
MA, US,
3
Univ of Pittsburgh, PA, US, and
4
Diego, US
604 Refining Approaches to Viral Load Monitoring Using Dried
Blood Spots
Carole Wallis*
1
, E Aga
2
, H Ribaudo
2
, C Chevallier
3
, K Klingman
4
,
W Stevens
5
, N Kumarasamy
6
, J Bartlett
7
, D Katzenstein
8
, and A5230 Team
1
2
Statistical Data Analvsis
Ctr, Harvard Sch of Publ Hlth, Boston, MA, US,
3
Clinton Hlth Access
Initiative, Papua New Guinea,
4
5
Univ of
the Witwatersrand, Johannesburg, South Africa,
6
YRG Care, Joluntarv
Hlth Svcs, Chennai, India,
7
Duke Univ Med Ctr, Durham, NC, US, and
8
Stanford Univ, CA, US
605 Assessment of Treatment Efficacy with Virological and
Pharmacological Evaluations on Capillary Dried Blood Spots
in HIV
+
Patients Enrolled in a West African Cohort
M Daou
1,2
, M Le
3
, B Madougou
1,2
, C Delaugerre
4
, T Maillard
4
, G Peytavin
3
,
E Adehossi
1
, M Saidou
1
, E Rouveix
2,5
, and Pierre de Truchis*
2,5
1
Hosp Natl, Niamev, Niger,
2
Gip-ESTHER Niger, France,
3
Hosp Bichat
Claude Bernard APHP, Paris, France,
4
Hosp St Louis, APHP, Paris,
France, and
5
GH A Pare-R Poincare, Garches, France
606 Dried Blood Spots for HIV-1 Viral Load and Drug Resistance
Monitoring in HAART-treated Patients from Africa and
Asia: The Agence de Nationale de Recherche sur le Sida
12235 Study
Ahidjo Ayouba*
1
, M Monleau
1
, S Eymard-Duvernay
1
, A Dagnra
2
,
D Kania
3
, N Ngo-Giang-Huong
4
, C Toure-Kane
5
, L Truong
6
, M-L Chaix
7
,
A Aghokeng
8
, and ANRS 12235 Study Group
1
IRD and Univ de Montpellier 1, France,
2
BIOLIM, FMMP/UL, Lome,
Togo,
3
Ctr Mura:, Bobo-Dioulasso, Burkina Faso,
4
Chiang Mai Univ,
Thailand,
5
Hosp Le Dantec, Dakar, Senegal,
6
Inst Pasteur, Ho Chi Minh
Citv, Jietnam,
7
Hosp Necker, Paris, France, and
8
CREMER/IMPM/IRD,
Yaounde, Cameroon
607 Evaluation of Point-of-Care Nucleic Acid Testing for HIV
Viral Load and Early Infant Diagnosis in Primary Health
Clinics: Mozambique
Ilesh Jani*
1
, B Meggi
1
, A Vubil
1
, N Sitoe
1
, N Bhatt
1
, O Tobaiwa
2
,
J Quevedo
2
, O Loquiha
3
, J Lehe
2
, and T Peter
2
1
Inst Nacional de Saude, Maputo, Mo:ambique,
2
Clinton Hlth Access
Initiative, Maputo, Mo:ambique, and
3
Univ Eduardo Mondlane, Maputo,
Mo:ambique
608 Use of Finger-prick Dried Blood Spots for Quantifying HIV-1
Viral Load, a Diagnostic Accuracy Study: Thyolo, Malawi
Carol MetcalI*
1
, E Fajardo
1
, P Pannus
2
, L Trevino
3
, I Panunzi
2
,
T Ellman
1
, R Coulborn
2
, A Kamiza
4
, R Mbewa
5
, and P Chaillet
6
1
Medecins Sans Frontieres, Cape Town, South Africa,
2
Medecins Sans
Frontieres, Thvolo, Malawi,
3
Medecins Sans Frontieres, Blantvre,
Malawi,
4
Malawi Ministrv of Hlth, Thvolo,
5
Malawi Ministrv of Hlth,
Lilongwe, and
6
Medecins Sans Frontieres, Brussels, Belgium
609 Performance of a Novel Internal Competitive Fly-gene
Control for an HIV-1 RNA Assay Quantifying Viral Load in
Different Biological Fluids
Eric Ramos*, M Chang, J Ortega, G Daza, E Goecker, S Harb,
J Dragavon, and R Coombs
610 Real-time Polymerase Chain Reaction Evaluation of Seminal
HIV Viral Load
Roberto Rodriguez-Diaz*
1
, E Mendez-Hernandez
1
, M Flores-Hernandez
1
,
E Mendoza-Guadarrama
1
, L Rojo-Gutierrez
2
, C Hernandez-Martinez
1
,
and L Soto-Ramirez
1
1
Inst Nacional de Ciencias Med v Nutricion Salvador Zubiran, Mexico
Citv, Mexico and
2
Hosp Med Sur, Mexico Citv, Mexico
611 Pooled Nucleic Acid Testing to Identify ART Failure during
HIV Infection in a Tertiary Teaching Hospital: Seoul, South
Korea
H Kim
1
, NS Ku
1
, SB Kim
1
, SJ Jeong
1
, SH Han
1
, JM Kim
1
, D Smith
2
,
and Jun Yong Choi*
1
1
AIDS Res Inst, Yonsei Univ Coll of Med, Seoul, Korea and
2
Univ of
California, San Diego, La Jolla, US
612 Efficiency of HIV-1 Pooled Viral Load Testing to Reduce the
Cost of Monitoring ART in a Resource-limited Setting: Rural
Malawi
Pieter Pannus*
1
, E Fajardo
1
, C MetcalI
1
, L Trivino
2
, D Garone
2
,
R Coulborn
2
, H Bygrave
1
, T Ellman
1
, M Murowa
3
, and R Mwenda
4
1
Medecins Sans Frontieres, South African Med Unit, Cape Town, South
Africa,
2
Medecins Sans Frontieres, Thvolo, Malawi,
3
Ministrv of Hlth,
District Mgmt Office, Thvolo, Malawi, and
4
Ministrv of Hlth, DDTSS,
Lilongwe, Malawi
613 The Clinical and Economic Impact of Point of Care CD4
Testing in Resource-limited Settings
Emily Hyle*
1
, I Jani
2
, J Lehe
3
, R Wood
4
, A Su
1
, J Quevedo
3
, E Losina
1,5,6
,
I Bassett
1,5
, T Peter
3
, and R Walensky
1,5,6
1
Med Practice Evaluation Ctr, Massachusetts Gen Hosp, Boston, US,
2
Inst
Nacional da Saude, Maputo, Mo:ambique,
3
Clinton Hlth Access Initiative,
Maputo, Mo:ambique,
4
Desmond Tutu HIJ Fndn, Univ of Cape Town,
South Africa,
5
and
6
!

"#$$%&' ((3*+&$,#- ./$,-01,$
Transmitted Drug Resistance
614 Origin of Minority Drug-resistant HIV-1 Variants in Primary
HIV-1 Infection
Karin Metzner*, A Scherrer, B Preiswerk, B Joos, V von Wyl, C Leemann,
D Braun, C Grube, H Kuster, H Gunthard, and Swiss HIV Cohort Study
Univ Hosp Zurich, Univ of Zurich, Swit:erland
615 Trends in Genotypic Resistance Testing Use and Results
among ARV-nave Patients in the HIV Outpatient Study
Kate Buchacz*
1
, B Young
2,3
, F Palella
4
, C Armon
5
, J Brooks
1
,
and HIV Outpatient Study Investigators
1
2
Apex Familv Med and Res, Denver, CO,
US,
3
Intl Assn of Phvsicians in AIDS Care, Washington, DC, US,
4
Northwestern Univ Sch of Med, Chicago, IL, US, and
5
Cerner Corp,
Jienna, JA, US
Program 45
P
o
s
t
e
r

L
i
s
t
i
n
g
s
616 Resistance Mutations in ARV-nave Patients at an Urban
Immigrant HIV Clinic
Rachel Chasan*
1
, K Sigel
1
, J Karimjee
2
, and C Salama
1,2
1
2
Elmhurst Hosp Ctr,
New York, NY, US
617 HIV Molecular Epidemiology and Transmitted Drug
Resistance Surveillance: Mesoamerican Region
Claudia Garcia-Morales*
1
, S Avila-Rios
1
, D Tapia-Trejo
1
,
C Mejia-Villatoro
2
, J Pascale
3
, G Porras-Cortes
4
, R Mendizabal
2
, Y Zaldivar
3
,
B Hernandez
4
, G Reyes-Teran
1
, and HIV Molecular Epidemiology and TDR
Surveillance in the Mesoamerican Region Study Group
1
Inst Nacional de Enfermedades Respiratorias, Mexico Citv, Mexico,
2
Hosp Roosevelt, Guatemala,
3
Inst Conmemorativo Gorgas, Panama,
and
4
Hosp Metropolitano, Managua, Nicaragua
618 Clinical, Virological, and Phylogenetic Characterization of
a Transmitted Reverse Transcriptase Multi-resistant HIV-1
Outbreak in Southern Spain
Isabel Viciana*
1
, N Chueca
2
, A del Arco
3
, F Tellez
4
, F Jarilla
5
,
JD Colmenero
6
, F Gardia
2
, and J Santos
1
1
Hosp Jirgen de la Jictoria, Malaga, Spain,
2
Hosp San Cecilio, Granada,
Spain,
3
Hosp Costa del Sol, Marbella, Spain,
4
Hosp de la Linea, Cadi:,
Spain,
5
Hosp de Antequera, Malaga, Spain, and
6
Hosp Carlos Hava,
Malaga, Spain
619 Trends in Transmitted Drug Resistance and Subtype
Distribution in 2007-2011: Spanish Cohort of ARV-nave
Adults
S Monge
1
, M Alvarez
2
, V Guillot
2
, P Viciana
3
, C Rodriguez
4
, S Perez-Elias
5
,
JL Gomez-Sirvent
6
, D Dalmau
7
, M Rivero
8
, Federico Garcia*
2
,
and CORIS Resistance Study Group
1
Ctr Nacional de Epidemiologia, CoRIS, Madrid, Spain,
2
HU San Cecilio,
Granada, Spain,
3
HU Jirgen del Rocio, Sevilla, Spain,
4
Ctr Sandoval,
Madrid, Spain,
5
HU Ramon v Cafal, Madrid, Spain,
6
HU Canarias,
Spain,
7
Mutua Terrassa, Spain, and
8
HU Navarra, Spain
!

"#$$%&' (()*+&$,#- ./$,-01,$
Drug Resistance Mutational Pathways and Subtype
Associations
620 CD4 Mimic Small Compounds, NBD-556 and Its Analogues
Bind at 3 Amino Acid Positions in the gp120 CD4 Cavity
Shigeyoshi Harada*
1
, S Boonchawalit
1,2
, T Narumi
3
, H Tamamura
3
,
S Matsushita
2
, and K Yoshimura
1,2
1
Natl Inst of Infectious Diseases, Tokvo, Japan,
2
Kumamoto Univ, Japan,
and
3
Tokvo Med and Dental Univ, Japan
621 A Novel Pathway of Resistance to NRTI at Codon 65 of HIV-1
Reverse Transcriptase (K65E)
S Fourati
1,2
, C Charpentier
3,4
, D Armenia
5
, L Morand-Joubert
1,6,7
,
M Wirden
1,2
, A Artese
8
, F Ceccherini-Silberstein
5
, D Descamps
3,4
,
V Calvez
1,2,6
, and Anne-Genevieve Marcelin*
1,2,6
1
INSERM UMR S-943, Paris, France,
2
Hosp Pitie-Salpetriere, Paris,
France,
3
Hosp Bichat Claude Bernard, Paris, France,
4
Univ Paris
Diderot, Paris, France,
5
Univ of Tor Jergata, Rome, Italv,
6
Univ Pierre
and Marie Curie, Paris, France,
7
Hosp St-Antoine, Paris, France, and
8
Univ Catan:aro Magna Graecia, Italv
622 2' 3%,-& Accumulation of Drug Resistance Mutations in
Subtype B and C Chimeric Infectious Clones Selected with
Tenofovir and Didanosine
Rodrigo Cunha*
1
, C Abreu
1
, V Mabombo
1
, A Sousa
1
, M Nijhuis
2
,
D de Jong
2
, R Brindeiro
1
, and A Tanuri
1
1
Federal Univ of Rio de Janeiro, Bra:il and
2
Univ Med Ctr Utrecht,
The Netherlands
623 Varying Effects of the Integrase G118R-linked Mutations
on Susceptibility to Integrase Inhibitors in Different HIV-1
Subtypes
Peter Quashie*
1,2
, T Mesplede
1
, Y Han
1
, H-T Xu
1
, B Spira
1
, R Sloan
1
,
T Veres
1
, M Wainberg
1,2
, and B Brenner
1
1
McGill Univ AIDS Ctr, Ladv Davis Inst-Jewish Gen Hosp, Montreal,
Canada and
2
McGill Univ, Montreal, Canada
624 Subtype-specific Effects of the H51Y and R263K Mutations
Selected %' 3%,-& with Dolutegravir on Integrase Activity and
Viral Fitness

Thibault Mesplede*, P Quashie, N Osman, Y Han, D Singhroy,
A Sabbah, M Charabati, B Spira, and M Wainberg
McGill Univ AIDS Ctr, Montreal, Canada
!

"#$$%&' ((4*+&$,#- ./$,-01,$
Advances in Sequencing and Analysis
625 Rapid Sequencing of HIV-1 Genomes as Single Molecules
from Simple and Complex Samples
Michael Brown*
1
, Y Guo
1
, M SchaeIer
2
, W Kilembe
3
, S Allen
2
,
E Hunter
2
, and E Paxinos
1
1
Pacific Biosci, Menlo Park, CA, US,
2
and
3
Zambia Emorv HIJ Res Profect, Lusaka
626 Impact of Experimental Conditions on the Utility of Primer
ID Tagging for Next-generation HIV Sequencing

Richard Liang*
1
, T Mo
1
, W Dong
1
, G Lee
1
, L Swenson
1
,
R McCloskey
1
, C Woods
1
, C Brumme
1
, R Harrigan
1,2
, and A Poon
1,2
1
2
Univ of
British Columbia, Jancouver, Canada
627 Accurately Identifying Low-frequency Variation in Viral
Deep-sequencing Data by Leveraging Signal from Temporal
Sampling

John Archer*
1
, A Rambaut
2,3
, and D Robertson
1
1
Univ of Manchester, UK,
2
Inst of Evolutionarv Bio, Univ of Edinburgh,
UK, and
3
Fogartv Intl Ctr, NIH, US
628 Use of 4 Next-generation Sequencing Platforms to Determine
HIV-1 Co-receptor Tropism

John Archer*
1
, J Weber
2
, K Henry
3
, R Gibson
3
, L Lee
4
, E Paxinos
4
,
E Arts
3
, D Robertson
1
, L Mimms
5
, and M Quinones-Mateu
3,6
1
Univ of Manchester, UK,
2
Inst of Organic Chemistrv and Biochemistrv,
Prague, C:ech Republic,
3
Case Western Reserve Univ, Cleveland, OH,
US,
4
5
Quidel Corp, San Diego,
CA, US, and
6
Univ Hosp Translational Lab, Univ Hosp Case Med Ctr,
Cleveland, OH, US
629 An Evaluation of Phylogenetic Methods for Reconstructing
Transmitted HIV Variants Using Longitudinal Clonal HIV
Sequence Data

Rosemary McCloskey*
1
, R Liang
1
, R Harrigan
1
, Z Brumme
2
,
and A Poon
1
1
2
Simon
Fraser Univ, Burnabv, Canada
!

"#$$%&' ((5*+&$,#- ./$,-01,$
Detecting HIV Infection
630 Reduction of HIV Window Period by 4
th
Generation HIV
Combination Tests
Mark Manak*
1
, LA Eller
2
, J Malia
3
, M De Souza
4
, K Shikuku
5
, C Lueer
1
,
A Taylor
6
, N Michael
3
, M Robb
2
, and S Peel
3
1
Mbeve Med Res Prgm, Tan:ania,
2
US Militarv HIJ Res Prgm, Henrv
M Jackson Fndn for the Advancement of Militarv Med, Rockville, MD,
3
US Militarv HIJ Res Prgm, Walter Reed Inst of Res, Silver Spring, MD,
4
AFRIMS, Bangkok, Thailand,
5
Walter Reed Profect, Keicho, Kenva, and
6
Makerere Univ Walter Reed Profect, Kampala, Uganda
631 Performance of Determine HIV-1/2 Ag/Ab Combo Test to
Detect Acute Infections in a High-prevalence Cross-sectional
Population: Swaziland
Yen Duong*
1
, Y Mavengere
2
, J Manjengwa
2
, D Sibandze
3
, J Chang
1
,
LM Emel
4
, J Justman
2
, R Jason
1
, G Bicego
5
, B Parekh
1
, and SHIMS Study
Team
1
2
Intl Ctr for AIDS Care and Treatment, Columbia
Univ, New York, NY, US,
3
Ministrv of Hlth, Mbabane, Swa:iland,
4
Statistical Ctr for HIJ/AIDS Res and Prevention, Seattle, WA, US,
and
5
CDC, Mbabane, Swa:iland
632 HIV Combination Antigen/Antibody Testing Detects a High
Proportion of Acute HIV Infections and Improves HIV
Diagnostic Yield: 3 Regions of the US
Philip Peters*
1
, E Westheimer
2
, N Moss
3
, C Gay
4,5
, B Tsoi
2
, M Pandori
3
,
L Hightow-Weidman
4,5
, L Hall
6
, P Patel
1
, and STOP Study Group
1
2
New York Citv Dept of Hlth and Mental
Hvgiene, NY, US,
3
San Francisco Dept of Publ Hlth, CA, US,
4
Univ of
North Carolina at Chapel Hill, US,
5
North Carolina Dept of Publ Hlth
Collaboration, Raleigh, US, and
6
633 Evaluation of HIV-1 Antigen/Antibody Combination Assay
Performance: Taiwan
Chun-Kai Chang*
1
, P-H Lin
1
, S-Y Ho
2
, S-Y Chang
1,2
, C Kao
3
,
and J-Y Yang
3
1
Natl Taiwan Univ Coll of Med, Taipei,
2
Natl Taiwan Univ Hosp, Taipei,
and
3
Ctr for Disease Control, Taiwan
634 A Novel Acute HIV Infection Staging System Based on 4th
Generation Enzyme Immunoassay
Jintanat Ananworanich*
1,2,3,4
, J Fletcher
1,2
, S Pinyakorn
1,2,3
,
FV Griensven
2
, T Pankam
2
, R Trichaviroj
5
, P Phanuphak
1,2,3
, N Chomont
6
,
J Kim
1,5,7
, M de Souza
5
1
SEARCH, Bangkok, Thailand,
2
The Thai Red Cross AIDS Res Ctr,
Bangkok,
3
4
Facultv of Med, Chulalongkorn
Univ, Bangkok, Thailand,
5
Armed Forces Res Inst of Med Sci, Bangkok,
Thailand,
6
Jaccine and Gene Therapv Inst, Port St Lucie, FL, US, and
7
US Militarv HIJ Res Prgm, Rockville, MD
635 Streamlining HIV Testing during Pre-exposure Prophylaxis
Use: Lessons from the Pre-exposure Prophylaxis Initiative
Trial
Juan Guanira*
1
, T Liegler
2
, R Hance
3
, D Glidden
2
, and R Grant
2,3
1
Investigaciones Med en Salud, Lima, Peru,
2
Univ of California,
San Francisco, US, and
3
Gladstone Inst, San Francisco, CA, US
P
o
s
t
e
r

L
i
s
t
i
n
g
s
636 Challenges and Missed Opportunities in the Diagnosis of
Acute HIV
Suzanne McCluskey*
1
, S Heath
2
, and K Bar
3
1
2
Univ of Alabama at Birmingham,
US, and
3
Univ of Pennsvlvania Perelman Sch of Med, Philadelphia, US
!

"#$$%&' (()*+&$,#- ./$,-01,$
Hepatic Injury and Fibrosis
637 Does Persistent Hepatitis C Viremia Lead to Advanced Liver
Fibrosis Progression Early after Acute Hepatitis C Infection
in HIV Co-infection?

Christoph Boesecke*
1
, T Reiberger
2
, S Mauss
3
, H-J Stellbrink
4
,
M MandorIer
2
, M Nelson
5
, S Bhagani
6
, M-A Valantin
7
, P Ingiliz
8
,
J Rockstroh
1
, and NEAT Study Group
1
Bonn Univ Hosp, Germanv,
2
Med Univ of Jienna, Austria,
3
Ctr for HIJ
and Hepatogastroenterologv, Dusseldorf, Germanv,
4
ICH Studv Ctr,
Hamburg, Germanv,
5
6
7
AP-HP, Hosp La Pitie Salpetriere,
Paris, France, and
8
MIB, Berlin, Germanv
638 Incidence and Progression to Cirrhosis of Hepatitis C Virus
Superinfection in Persons Living with HIV
Massimo Puoti*
1
, P Lorenzini
2
, E Girardi
2
, A Cozzi-Lepri
3
, A Gori
4
,
C Mastroianni
5
, G Rizzardini
6
, G Mazzarello
7
, A Antinori
2
,
A dÀrminio MonIorte
8
, and Icona Fndn Study Group
1
Niguarda Ca Granda Hosp, Milan, Italv,
2
Natl Inst of Infectious Disease
La::aro Spallan:ani, Rome, Italv,
3
Hampstead Coll Univ Coll London,
UK,
4
San Gerardo de Tintori Hosp, Mon:a, Italv,
5
La Sapien:a Rome
Univ Polo Pontino, Latina, Italv,
6
Luigi Sacco Hosp, Milan, Italv,
7
San
Martino Hosp, Genova, Italv, and
8
639 Circulating MicroRNA as Marker for Liver Injury in HIV
+

Individuals
E Anadol
1
, K Tack
1
, C Schwarzer-Zander
1
, N ElIimova
2
, C Boesecke
1
,
J-C Wasmuth
1
, T Sauerbruch
1
, J Rockstroh
1
, M Odenthal
2
,
and Jonel Trebicka*
1
1
Univ of Bonn, Germanv and
2
Univ of Cologne, Germanv
640 Proteomic Fingerprinting in Hepatitis C Virus Mono- and
HIV-1/Hepatitis C Virus Co-infection Reveals Plasma
Biomarkers Prognostic of Fibrosis

Carlos Enrique Melendez-Pena*
1
, C Santamaria
1
,
B Conway
2
, C Cooper
3
, B Segatto
1
, B Ward
1
, M Ndao
1
, M Klein
1
,
and Canadian Co-inIection Cohort Study Group
1
McGill Univ Hlth Ctr, Montreal, Canada,
2
Univ of British Columbia,
3
Univ of Ottawa at the Ottawa Hosp, Canada
641 Increased Risk of ARV Drug Discontinuation among Patients
with High Hyaluronic Acid, a Marker of Liver Fibrosis

Daniel Grint*
1
, L Peters
2
, J Rockstroh
3
, J Lundgren
2
, S De Wit
4
,
V Mitsura
5
, B Kynsz
6
, C Pedersen
7
, O Kirk
2
, A MocroIt
1
, and EuroSIDA
1
2
3
Univ of Bonn,
Germanv,
4
St-Pierre Hosp, Brussels, Belgium,
5
Gomel State Med Univ,
Belarus,
6
Med Univ, Wroclaw, Poland, and
7
Odense Univ Hosp, Denmark
642 Circulating Tissue Factor Expression Is Associated with
Advanced Fibrosis in Hepatitis C and HIV/Hepatitis C Virus
Co-infection
Aimee Hodowanec*
1,2
, R Lee
3
, K Brady
2
, W Gao
4
, S Kincaid
1
, J Plants
2
,
M Bahk
1
, A Landay
2
, N Mackman
3
, and G Huhn
1,2
1
Ruth M Rothstein CORE Ctr, Chicago, IL, US,
2
Rush Univ Med Ctr,
Chicago, IL, US,
3
4
Univ
of Illinois at Chicago, US
643 Apoptosis and Oxidative Stress Are Associated with Liver
Disease Progression in HIV/Hepatitis C Virus Co-Infection
Marianna Baum*
1
, K Sherman
2
, S Martinez
1
, D-H Shin
1
, D Jayaweera
3
,
P Greer
1
, S Williams
1
, M Parsons
1
, J Martinez
1
, and A Campa
1
1
Florida Intl Univ, Miami, US,
2
Univ of Cincinnati, OH, US, and
3
Univ of
Miami, FL, US
644 Marijuana Smoking and Progression to Liver Fibrosis,
Cirrhosis, and End-stage Liver Disease in HIV/Hepatitis C
Virus Co-infected Individuals

Laurence Brunet*
1
, E Moodie
1
, J Young
2
, M Tyndall
3
, M Hull
4
,
C Cooper
3,5
, S Walmsley
6
, J Gill
7
, M Potter
2
, M Klein
1,2
, and Canadian
Co-inIection Cohort Study
1
2
McGill Univ Hlth Ctr, Montreal,
Canada,
3
Univ of Ottawa, Canada,
4
BC Ctr for Excellence in HIJ/AIDS,
Jancouver, Canada,
5
Ottawa Hosp, Canada,
6
and
7
Southern Alberta HIJ Clinic, Calgarv, Canada
645 HIV Virologic Rebounds but Not Blips Predict Liver Fibrosis
Progression in ARV-treated HIV/Hepatitis C Virus Co-infected
Patients
Curtis Cooper*
1
, K Rollet
2
, C Vasquez
1
, M Potter
2
, J Gill
3
, N Pick
4
,
S Walmsley
5
, M Tyndall
1
, M Klein
2
, and Canadian Co-inIection Cohort
Study Investigators
1
Univ of Ottawa, Ottawa Hosp Res Inst, Canada,
2
McGill Univ, Montreal,
Canada,
3
Univ of Calgarv, Canada,
4
Univ of British Columbia, Canada,
and
5
Univ of Toronto, Canada
646 Predictors for the Presence of Liver Fibrosis among Hepatitis C
Virus and HIV/Hepatitis C Virus-infected Patients: Thailand
Reshmie Ramautarsing*
1,2
, P Tangkijvanich
3
, S Jirajariyavej
4
,
S Chittmittrapap
3
, T Apornpong
1
, P Chaihong
1
, S Ubolyam
1
,
W Khowidhunkit
3
, K Ruxrungtham
1,3
, and A Avihingsanon
1,3
1
HIJNAT Res Collaboration, Bangkok, Thailand,
2
Amsterdam Inst for
Global Hlth and Devt, The Netherlands,
3
King Chulalongkorn Memorial
Hosp, Bangkok, Thailand, and
4
Thaksin Hosp, Bangkok, Thailand
647 Hepatic Fibrosis and Immune Phenotypes Vary by Hepatitis
C Virus Viremia in HIV Infection: A Women`s Interagency
HIV Study
Seema Desai*
1
, J Dodge
2
, A Landay
1
, M Glesby
3
, P Latham
4
,
M Villacres
5
, A French
6
, N Amali
2
, R Greenblatt
2
, and M Peters
2
1
2
Francisco, US,
3
Weill Cornel Med Coll, New York, NY, US,
4
George
Washington Univ, Washington, DC, US,
5
Univ of Southern California,
Los Angeles, US, and
6
Stroger Hosp Cook Countv, Chicago, IL, US
648 The Effect of Hepatic Fibrosis and Hepatitis C Virus Viremia
on Serum Inflammatory Mediators in HIV Infection: The
Women`s Interagency HIV Study
Sheila Keating*
1,2
, J Dodge
1
, P Norris
1,2
, A French
3
, M Glesby
4
, B Edlin
5
,
P Latham
6
, N Ameli
1
, R Greenblatt
1
, M Peters
1
, and Women`s Interagency
HIV Study
1
2
Blood Svstems Res Inst, San
Francisco, CA, US,
3
Stroger Hosp of Cook Countv, Chicago, IL, US,
4
5
SUNY Downstate, Brooklvn,
US, and
6
649 ARV-induced Very Low Density Lipoprotein Apolipoprotein
Increases Are Associated with Change in Hepatitis C Viral
Load in HIV/Hepatitis C Virus Co-infected Individuals
Susanna Naggie*
1
, K Patel
1
, J Guyton
1
, L-Y Yang
1
, S Chow
1
, M Kang
2
,
V Johnson
3
, A Muir
1
, M Sulkowski
4
, and C Hicks
1
1
Duke Univ, Durham, NC, US,
2
3
Univ
of Alabama at Birmingham and Birmingham JAMC, US, and
4
Johns
Hopkins Univ, Baltimore, MD, US
650 Association of LDLR Haplotypes with Hepatitis C Virus
Viral Load and Sustained Virological Response in HIV
Patients Co-infected with Hepatitis C Virus Genotypes 1-4
Antonio Caruz*
1
, K Neukam
2
, A Rivero-Juarez
3
, L-M Real
2
, F-J Marquez
1
,
A Camacho
3
, P Barreiro
4
, V Soriano
4
, A Rivero
3
, and J Pineda
2
1
Univ de Jaen, Spain,
2
Hosp Univ de Jalme, Sevilla, Spain,
3
Hosp Univ
Reina Sofia, Cordoba, Spain, and
4
Hosp Carlos III, Madrid, Spain
651 HIV
+
Status, Low Income, and Active Hepatitis C Virus
Infection are Associated with Shorter Leukocyte Telomere
Length in a Cohort of HIV
+
and HIV
-
Adults
DeAnna Zanet*
1
, A Thorne
2
, B Sattha
1
, E Maan
3
, I Gadawski
1
,
M Murray
1,3,4
, J Singer
1,2
, D Money
1,3,4
, N Pick
1,3,4
, H Cote
1,4
,
and CIHR Emerging Team in HIV Therapy and Aging
1
Univ of British Columbia, Jancouver, Canada,
2
CIHR Canadian HIJ
Trials Network, Jancouver,
3
Oak Tree Clin, Jancouver, Canada,
and
4
Women`s Hlth Res Inst, Jancouver, Canada
!

"#$$%&' ((2*+&$,#- ./$,-01,$
Laboratory Assessment and Imaging of Hepatic
Injury
652 Inter-observer Concordance in Controlled Attenuation
Parameter Measurement, a Novel Tool for the Assessment of
Hepatic Steatosis
Eva Recio*
1
, K Neukam
1
, C CiIuentes
1
, M Mancebo
1
, J Macias
1
,
C Almeida
1
, N Merchante
1
, J Mira
1
, A Rivero-Juarez
2
, and J Pineda
1
1
Hosp Univ de Jalme, Seville, Spain and
2
Maimonides Inst for Biomed
Res, Hosp Univ Reina Sofia, Cordoba, Spain
653 Acoustic Radiation Force Impulse Imaging: An Attractive
New Procedure for Liver Fibrosis Measurement in HIV/
Hepatitis C Virus Co-infected Patients
N Frulio, J Asselineau, M HessamIar, F Maire, P Perez, J Delaune,
M-A Vandenhende, V De Ledinghen, H Trillaud, and Philippe Morlat*
Univ Hosp, Bordeaux, France
654 Assessment of Liver Fibrosis by Transient Elastography
in Patients with HIV and Hepatitis B Virus Co-infection:
Nigeria

Oche Agbaji*
1
, P Ugoagwu
1
, R Murphy
2
, C Thio
3
, C Ani
1
, C OkaIo
1
,
M Auwal
1
, E Wallender
4
, and C Hawkins
2
1
Jos Univ Teaching Hosp, Nigeria,
2
3
Johns Hopkins Univ, Baltimore MD, US, and
4
Janderbilt Univ Med Ctr,
Nashville, TN, US
655 Liver Stiffness Predicts Liver-related Complications and
Mortality in HIV/Hepatitis C Virus Co-infected patients
Jose Vicente Fernandez-Montero*, P Barreiro, E Vispo, P Labarga,
C Sanchez-Parra, M Arredondo, and V Soriano
Program 47
P
o
s
t
e
r

L
i
s
t
i
n
g
s
656 Comparison of Transient Elastography and Hepatic Gradient
Venous Pressure for Predicting Liver Complications or
Death in Patients with Hepatitis C Virus Cirrhosis
Leire Perez-Latorre*
1,2
, M Sanchez-Conde
1,2
, JM Bellon
2
, P Miralles
1,2
,
D Rincon
1,2
, JC Lopez
1,2
, J Cosin
1,2
, R Banares
1,2,3
, and J Berenguer
1,2
1
Hosp Gregorio Maranon, Madrid, Spain,
2
Inst de Investigacion Sanitaria
Gregorio Maranon, Madrid, Spain, and
3
CIBEREHD, Spain
657 Worse Clinical and Immunological Outcomes Associated
with Hepatitis C Virus Infection in HIV Elite Controllers
Mohammad Sajadi*, R RedIield, and R Talwani
Inst of Human Jirologv, Baltimore, MD, US
658 Prognostic Utility of Transient Elastography in HIV
+
Patients
with Liver Cirrhosis
Maria Luisa Montes Ramirez*
1
, MA Von Wichmann
2
, J Miro
3
,
C Quereda
4
, C Tural
5
, E Ortega
6
, J Berenguer
7
, J Sanz
8
, A Hernando
9
,
J Arribas
1
, and GESIDA-CIRROSIS Study Group
1
Hosp Univ La Pa:, IdiPa:, Madrid, Spain,
2
Hosp de Donostia, San
Sebastian, Spain,
3
Hosp Clin-IDIBAPS, Univ of Barcelona, Spain,
4
Hosp
Ramon v Cafal, Madrid, Spain,
5
Hosp Germans Trials v Pufol, Badalona,
Spain,
6
Hosp Univ Gen de Jalencia, Spain,
7
Hosp Univ Gregorio
Maranon, Madrid, Spain,
8
Hosp Univ Principe de Asturias, Madrid,
Spain, and
9
Hosp 12 de Octubre, Univ Europea de Madrid, Spain
659 Association of HIV Mono-infection and HIV/Hepatitis C
Virus Co-infection with Liver Fibrosis Measured by Indirect
Markers Aspartate Aminotransferase to Platelet Ratio Index
and FIB-4 and Transient Elastography
Phyllis Tien*
1,2
, R Scherzer
1,2
, R Bailony
1
, M Plankey
3
, M Peters
1
,
G Huhn
4
, and Women`s Interagency HIV Study
1
2
3
Georgetown Univ Med Ctr, Washington, DC, US, and
4
Stroger Hosp and
Rush Univ, Chicago, IL, US
660 The Cirrhosis Risk Score Implication in Fibrosis Prediction
among HIV/Hepatitis C Virus Co-infected Patients
A Fernandez-Rodriguez
1
, Juan Berenguer*
2
, MA Jimenez-Sousa
1
,
M Guzman-Fulgencio
1
, D Micheloud
2
, JC Lopez
2
, E Alvarez
2
, JM Bellon
2
,
P Miralles
2
, and S Resino
1
1
Natl Ctr for Microbio, Mafadahonda, Madrid, Spain and
2
Hosp Gen Univ
Gregorio Maranon, Madrid, Spain
661 Comparison of Viral Load Assays for the Quantification of
Hepatitis C Virus Genotype 1 in the Setting of Low Viremic
Samples
P Braun
1
, F Wiesmann
1
, A Berger
2
, R Kaiser
3
, G Naeth
1
, R Ehret
4
,
and Heribert Knechten*
1
1
PZB Aachen, Germanv,
2
Inst of Jirologv, Frankfurt, Germanv,
3
Inst of
Jirologv, Cologne, Germanv, and
4
Med Lab Berg, Berlin, Germanv
662 Sensitive Detection of Minor Variants and Viral Haplotypes
Using Single-molecule, Real-time Sequencing
A Sethuraman
1
, Y Guo
1
, M Brown
1
, J Toma
2
, A Newton
2
, W Huang
2
,
M Sugiyama
3
, C Petropoulos
2
, M Mizokami
3
, and Ellen Paxinos*
1
1
2
Monogram Biosci, South San
Francisco, CA, US, and
3
Res Ctr for Hepatitis and Immunologv, Natl Ctr
for Global Med, Ichikawa, Japan
!

"#$$%&' ()*+,&$-#. /0$-.12-$
Hepatitis E Virus
663 Seroepidemiology and Genotyping of Hepatitis E Virus
among MSM in the Era of cART: Taiwan
Chien-Ching Hung*, S-Y Chang, Z-Y Yang, W-C Liu, C-H Wu,
and P-J Chen
Natl Taiwan Univ Hosp and Natl Taiwan Univ Coll Med, Taipei
664 Chronic Hepatitis E Causes Rapid Progression to Liver
Cirrhosis in HIV Infection which Can Be Reversed by
Treatment with Ribavirin

Karin Neukam*
1,2
, P Barreiro
3
, J Echevarria
4
, J Macias
1
, P Labarga
3
,
A Avellon
4
, M Parra-Sanchez
1
, N Merchante
1
, V Soriano
3
, and J Pineda
1
1
Hosp Univ de Jalme, Seville, Spain,
2
Roval Free Hosp, London,
UK,
3
Hosp Carlos III, Madrid, Spain, and
4
Inst de Salud Carlos III,
Mafadahonda, Spain
!

"#$$%&' ()(+,&$-#. /0$-.12-$
Hepatitis B Virus
665 Virologic/Serologic Outcomes in HIV/Hepatitis B Virus
Co-infected, Hepatitis B Virus Treatment-nave on Mono-
and Dual- Hepatitis B Virus Therapy: ACTG Longitudinal
Linked Randomized Trials
M Kang
1
, K Hollabough
1
, V Pham
2
, S Koletar
3
, K Wu
1
, M Smurzynski
1
,
and Judith Aberg*
2
1
2
New York Univ Sch of Med,
NY, US, and
3
Ohio State Univ Med Ctr, Columbus, US
666 Quantification of Hepatitis B Envelope Antigen at Month 24
Is an Accurate Predictor of Long-term Hepatitis B Envelope
Antigen Loss in HIV/Hepatitis B Virus Co-infected Patients
Treated with Tenofovir

Anders Boyd*
1
, S Maylin
2
, C Lascoux-Combe
2
, P Miailhes
3
,
J Gozlan
4
, C Delaugerre
2
, P-M Girard
1,4,5
, and K Lacombe
1,4,5
1
INSERM UMR-S707, France,
2
Hosp St-Louis, AP-HP, Paris, France,
3
Hosp Croix-Rousse, Hospices Civils de Lvon, France,
4
Hosp St-Antoine,
AP-HP, Paris, France, and
5
UPMC, Paris JI, France
667 History of Lamivudine Predicts Lower Likelihood of
Hepatitis B Viral Suppression on Tenofovir in HIV/Hepatitis
B Virus Co-infected Patients: The Centers for AIDS Research
Network of Integrated Clinical Systems Cohort
Nina Kim*
1
, C Rodriguez
1
, S Van Rompaey
1
, H Crane
1
, M Saag
2
,
J Eron
3
, J Martin
4
, M Kitahata
1
, and Ctr Ior AIDS Res Network oI Clinical
Integrated Systems
1
2
3
4
Francisco, US
668 Intensification with Pegylated Interferon during Treatment
with Tenofovir in HIV/Hepatitis B Virus Co-infected Patients

Anders Boyd*
1
, P Miailhes
2
, S Maylin
3
, J Gozlan
4
,
C Lascoux-Combe
3
, C Delaugerre
3
, P-M Girard
1,4,5
, and K Lacombe
1,4,5
1
INSERM UMR-S707, France,
2
Hosp Croix-Rousse, Hospices Civils de
Lvon, France,
3
Hosp St-Louis, AP-HP, Paris, France,
4
Hosp St-Antoine,
AP-HP, Paris, France, and
5
UPMC, Paris JI, France
669 Additional Pegylated Interferon in HBeAg
+
HIV Co-infected
Patients on cART Including Tenofovir: The ANRS HB01
EMVIPEG Study
Patrick Miailhes*
1
, M Maynard-Muet
1
, F Carrat
2
, C Lascoux-Combe
3
,
D Rey
4
, P Sogni
5
, S Pol
5
, P Cacoub
6
, F Zoulim
1
, and L Piroth
7
1
Hospices Civils de Lvon, INSERM U1052, Croix-Rousse Hosp, Lvon,
France,
2
UMRS-707, Univ Paris 6 et INSERM, Sante Publique, APHP,
Paris, France,
3
St-Louis Hosp, APHP, Paris, France,
4
Hosp Univ, HIJ
Infection Ctr, Strasbourg, France,
5
Univ Paris Descartes, INSERM
U1016, APHP, Cochin Hosp, Paris, France,
6
La Pitie-Salpetriere Hosp,
CNRS UMR 7087, Pierre et Marie Curie Univ, Paris, France, and
7
CHU
Difon and Univ of Burgundv, France
670 Brief ARV Interruptions Do Not Increase the Risk of Liver
Flares in Hepatitis B Virus/HIV Co-infected Individuals on
Dual-active Treatment
Huw Price*
1
, D Dunn
2
, D Pillay
1
, T Zachary
3
, T Vudriko
4
, C Kityo
3
,
P Munderi
4
, J Hakim
5
, C Gilks
6
, R Gilson
1
, and DART Virology Group
1
2
MRC, London, UK,
3
Joint Clin Res Ctr,
Kampala, Uganda,
4
MRC/UJRI, Entebbe, Uganda,
5
Univ of Zimbabwe
Clin Res Ctr, Harare, and
6
671 Key Patterns of Mutations in Hepatitis B Virus S Open
Reading Frame Are Involved in Mechanisms Underlying
Levels of Serum Hepatitis B Virus DNA %' 3%3&
C Mirabelli
1
, V Cento
1
, C Alteri
1
, R Salpini
1
, M Surdo
1
, M Pollicita
1
,
C Gori
2
, A Bertoli
1
, C-F Perno
1
, and Valentina Svicher*
1
1
Univ of Tor Jergata Rome, Italv and
2
Natl Inst for Infectious Diseases L
Spallan:ani, Rome, Italv
672 Treatment of Hepatitis Delta with TenofovirLamivudine/
Emtricitabine in HIV Patients-Effect on Hepatitis D Virus
RNA, Hepatitis B Surface Antigen, Transaminases, and Liver
Fibrosis
Rocio Sierra-Enguita*
1
, Z Plaza
1
, V Soriano
1
, MD Gonzalez
1
, JM Benito
1
,
A Aguilera
2
, A Mena
3
, J Pedreira
2
, L Martin-Carbonero
1
, and E Poveda
1
1
Hosp Carlos III, Madrid, Spain,
2
Hosp Conxo-CHUS, Santiago de
Compostela, Spain, and
3
Hosp Univ A Coruna, Spain
673 Seroepidemiology of Hepatitis D Virus Infection among HIV
+

Patients with Hepatitis B Virus Co-infection: Taiwan
Sui-Yuan Chang*
1,2
, S-M Wu
2
, Y-C Su
2
, S-F Chang
2
, W-C Liu
1
,
C-H Wu
1
, and C-C Hung
1,2
1
Natl Taiwan Univ Hosp, Taipei and
2
Natl Taiwan Univ Coll Med, Taipei
!

"#$$%&' ())+,&$-#. /0$-.12-$
Hepatitis C Virus Treatment Today and Tomorrow
675 Telaprevir, Pegylated Interferon, and Ribavirin Combination
Therapy for Chronic Hepatitis C Virus Genotype 1 in Hepatitis
C Virus/HIV Co-infected Patients: Early Response and Viral
Resistance
Kenneth Sherman*
1
, D Bartels
2
, M Bsharat
2
, R Rubin
2
, T KieIIer
2
,
and M Sulkowski
3
1
Univ of Cincinnati Coll of Med, OH, US,
2
Jertex Pharmaceuticals Inc,
Cambridge, MA, US, and
3
Johns Hopkins Univ Sch of Med, Baltimore,
MD, US
P
o
s
t
e
r

L
i
s
t
i
n
g
s
676 Triple Combination Therapy for Hepatitis C with Telaprevir
Exhibits Higher Early Antiviral Potency than with
Boceprevir Regardless HIV Status
Jose Miguel Benito*
1
, K Bichoupan
2
, V Soriano
1
, I Maida
3
, A Branch
2
,
C Sanchez
1
, N Rallon
1
, A Aguilera
4
, P Barreiro
1
, and D Dieterich
2
1
2
Mt Sinai Hosp, New York, NY, US,
3
Univ
of Sassari, Italv, and
4
Hosp de Conxo, Santiago de Compostela, Spain
677 Risk of Anemia in HIV/Hepatitis C Virus Co-infected Patients
Treated with Telaprevir-based Hepatitis C Virus Therapy
Jay Kostman*, J Gilmore, A Binkley, K Lynn, R Bahirwani, B Appolo,
L Sinese, R Reddy, and V Lo Re
Perelman Sch of Med of the Univ of Pennsvlvania, Philadelphia, US
678 Telaprevir Combination Treatment in Hard-to-treat African
American, Null Responder G1 Chronic Hepatitis C Patients:
Early Data from the OUTLOOK Study
Steven Flamm*
1
, E Martin
2
, A Muir
3
, N Shores
4
, L JeIIers
5
, S Harrison
6
,
R Reddy
7
, and M Friedman
2
1
2
Jertex Pharmaceuticals Inc,
Cambridge, MA, US,
3
Duke Clinical Res Inst, Durham, NC, US,
4
Tulane
Univ Hlth Sci Ctr, New Orleans, LA, US,
5
South Florida JA Fndn for Res
and Ed, Miami, US,
6
San Antonio Militarv Med Ctr-Brooke Armv Med Ctr,
Fort Sam Houston, TX, US, and
7
679 On-treatment Responses to Telaprevir-based Hepatitis C
Treatment Are Similar in HIV/Hepatitis C Virus Co-infected
and Hepatitis C Virus Mono-infected Patients
Valerie Martel-LaIerriere*
1
, S Brinkley
2
, K Bichoupan
1
, S Posner
1
,
A Stivala
1
, P Perumalswami
1
, T Schiano
1
, M Sulkowski
2
, D Dieterich
1
,
and A Branch
1
1
2
John Hopkins Univ,
Baltimore, MD, US
680 Treatment of HIV/Hepatitis C Virus G2/3 Co-infection in 556
Treatment-nave Patients: Sustained Virologic Response in
Field Practice
R Bruno
1
, Paola Nasta*
2
, A Capetti
3
, V Ravasio
4
, M Galli
3
, E Raise
5
,
A Caputo
5
, C Iannacone
6
, and M Puoti
7
1
Fndn IRCCS Policlin San Matteo, Pavia, Italv,
2
Brescia Hosp, Italv,
3
Univ Hosp Luigi Sacco, Milan, Italv,
4
Riuniti Hosp, Bergamo, Italv,
5
DellAngelo Hosp, Mestre, Italv,
6
Roche Spa, Mon:a, Italv, and
7
SPARC
Consulting, Milan, Italv
681 Treatment of Chronic Hepatitis C May Improve Clinical
Outcomes Despite Lack of Sustained Virological Response in
HIV/ Hepatitis C Virus Co-infected Patients
Pablo Labarga*, JV Fernandez, E Vispo, JM Benito, N Rallon,
C Sanchez, I Perez, C Garcia-Delgado, P Barreiro, and V Soriano
682 Does Choice of HIV Therapy Impact Overall Sustained
Virological Response Rates in HIV/Hepatitis C Virus
Co-infected Individuals?
SteIan Mauss*
1
, A Baumgarten
2
, T Lutz
3
, B Bieniek
4
, S Koeppe
5
,
M Freiwald
5
, U Alshuth
6
, R Goesseringer
6
, and J Rockstroh
7
1
Ctr for HIJ and Hepatogastroenterologv, Duesseldorf, Germanv,
2
MIB,
Berlin, Germanv,
3
Infektiologikum, Frankfurt, Germanv,
4
Practice
Citv Ost, Berlin, Germanv,
5
Private Practice, Berlin, Germanv,
6
Roche
Pharma AG, Germanv, and
7
Universittsklinikum Poliklinik, Bonn,
Germanv
683 Effect of Detectable HIV RNA at Baseline on the Response
to Treatment with Pegylated Interferon and Ribavirin in
Patients Co-infected with HIV and Hepatitis C Virus
T Aldamiz
1
, Juan Berenguer*
1
, F Zamora
2
, M Von Wichmann
3
,
M Crespo
4
, M Tellez
5
, J Sanz
6
, H Esteban
7
, JM Bellon
1
, J Gonzalez
2
,
and GESIDA 3603 and 5006 Study Groups
1
Hosp Gen Univ Gregorio Maranon, Madrid, Spain,
2
Hosp Univ La Pa:,
Madrid, Spain,
3
Hosp de Donostia, San Sebastian, Spain,
4
Hosp Jall
dHebron, Barcelona, Spain,
5
Hosp Clin de San Carlos, Madrid, Spain,
6
Hosp Principe de Asturias, Alcala de Henares, Spain, and
7
Fndn SEIMC/
GESIDA, Madrid, Spain
684 Single Nucleotide Polymorphisms at Multiple Genes Predict
Response to Pegylated Interferon + Ribavirin and Modify the
Effect of Interleukin 28B Genotype

Karin Neukam*
1,2
, A Caruz
3
, P Barreiro
4
, A Rivero-Juarez
5
, D Merino
6
,
M Marquez
7
, E Perez-Navarro
1
, V Soriano
4
, A Rivero
5
, and J Pineda
1
1
2
3
Univ of Jaen, Spain,
4
5
Hosp Univ Reina
Sofia, Cordoba, Spain,
6
Hosp Juan Ramon Jimene:, Huelva, Spain, and
7
Hosp Univ Jirgen de la Jictoria, Malaga, Spain
685 Favorable !"#$% Genotypes Are Associated with Spontaneous
Clearance but Not Aboriginal Ancestry in Canadian HIV/
Hepatitis C Virus Co-infected Individuals
Nasheed Moqueet*
1
, J Young
1
, C Lisle
2
, R Carter
2
, M Klein
1
,
and Canadian Co-inIection Cohort
1
McGill Univ, Montreal, Canada and
2
Bav Area Genetic Lab, Hamilton,
Canada
686 Variations in Convertase Subtilisin/Kexin Type 9 Gene Are
Associated with Response to Therapy against Hepatitis C
Virus Genotype 3 Infection

Karin Neukam*
1,2
, A Rivero-Juarez
3
, A Caruz
4
, P Labarga
5
, M Marquez
6
,
L Real
1
, R Herrero
4
, A Rivero
3
, V Soriano
5
, and J Pineda
1
1
2
3
Hosp
Univ Reina Sofia, Cordoba, Spain,
4
Univ of Jaen, Spain,
5
Hosp Carlos III,
Madrid, Spain, and
6
Hosp Univ Jirgen de la Jictoria, Malaga, Spain
687 Baseline Plasma Lipopolysaccharide Predicts Sustained
Virological Response in HIV/Hepatitis C Virus Co-infected
Patients Treated with Pegylated Interferon-alpha/Ribavirin
Jessica Nystrom*, J Stenkvist, P Nowak, J Svard, O Weiland,
and A Sonnerborg
Karolinska Inst, Stockholm, Sweden
688 Interferon-stimulated Gene Expression Is a Better Predictor of
Treatment Response than IL28B Genotype in HIV/Hepatitis C
Virus Co-infected Patients

Norma Rallon*
1
, L Lpez-Fernndez
2
, C Restrepo
1
, M Garcia
2
,
V Soriano
1
, and JM Benito
1
1
Hosp Carlos III, Madrid, Spain and
2
Hosp Gregorio Maranon, Madrid,
Spain
689 Elevated Hepatitis C Virus Anti-Core Antibody and Tissue-
like Memory B Cells Predict Relapse in HIV/Hepatitis C
Virus Patients Treated with Pegylated Interferon+Ribavirin

Ashton ShaIIer*
1
, A Kohli
2
, E Meissner
1
, B Santich
1
, E Funk
1
,
P Burbelo
1
, M Polis
1
, S Moir
1
, S Kottilil
1
, and H Masur
1
1
NIH, Bethesda, MD, US and
2
SAIC-Frederick, Inc, Frederick Natl Lab
for Cancer Res, MD, US
690 Acute and Chronic Immune Biomarker Changes after
Pegylated Interferon+Ribavirin Treatment in HIV/Hepatitis
C Virus Co-infected Patients
Mamta Jain*
1
, B Adams-Huet
1
, R Bedimo
1,2
, L Kushner
3
, D Terekhova
1
,
and M Holodniy
3,4
1
Univ of Texas Southwestern, Dallas, US,
2
North Texas JAMC, Dallas, US,
3
JA Palo Alto Hlth Care Svstem, CA, US, and
4
691 CD4 Increase Induced by Long-term cART in ARV-nave
HIV
+
and HIV/Hepatitis C Virus Co-infected Patients: The
PISCIS Cohort
A Esteve
1
, Jose Miro*
2
, C Campbell
1
, A Gallois
1
, D Podzamczer
1
,
C Tural
3
, J Murillas
4
, F Segura
5
, C CiIuentes
6
, J Casabona
1
, and PISCIS
Study Group
1
CEEISCAT, Badalona, Spain,
2
Hosp Clin-Idibaps, Univ de Barcelona,
Spain,
3
Fndn Lluita contra la Sida, Fndn irsicaixa, Hosp Univ Germans
Trias i Pufol, Univ Autonoma de Barcelona, Badalona, Spain,
4
Hosp Son
Espases de Mallorca, Palma de Mallorca, Spain,
5
Corp Sanitaria Univ
Parc Tauli, Univ Autonoma de Barcelona, Sabadell, Spain, and
6
Hosp
Son Llat:er, Palma de Mallorca, Spain
692 A Randomized, Double-blind, Phase 1b Study of the Hepatitis
C Virus Entry Inhibitor ITX5061 in Treatment-nave,
Hepatitis C Virus Mono-infected Adults: ACTG A5277
Mark Sulkowski*
1
, M Kang
2
, R Matining
2
, D Wyles
3
, V Johnson
4
,
G Morse
5
, V Amorosa
6
, D Bhattacharya
7
, F Wong-Staal
8
, M Glesby
9
,
and A5277 Protocol Team
1
2
Boston, MA, US,
3
4
Birmingham
JAMC and Univ of Alabama at Birmingham Sch of Med, US,
5
Univ
at Buffalo, the State Univ of New York, US,
6
Philadelphia, US,
7
8
iTherX, San
Diego, CA, US, and
9
Weill Med Coll of Cornell Univ, New York, NY US
!

'())*+, -#./0+)1(2 34)12561)
Hepatitis C Virus Resistance and Virology
693 High-resolution Primer ID Sequencing of Hepatitis C Virus
NS3 Protease Reveals Less Diversity and Dissimilar Pre-
existing Resistance-associated Variants in Co- vs Mono-
infected Subjects
Cassandra Jabara*, F Hu, C Jones, P Menezes, M Fried, J Eron,
R Swanstrom, and S Lemon
694 Replication Capacity and Susceptibility to Telaprevir of the
T54S Resistant Variant Is Modulated by Other Hepatitis C
Virus NS3 Mutations
Sandrine Ortiou*
1
, J-Y Servais
1
, D Perez-BercoII
1
, J Fritz
1,2
, D Vaira
3
,
J Delwaide
4
, V Arendt
1,5
, T Staub
5
, J-C Schmit
1,5
, and C Devaux
1
1
CRP-Sante, Luxembourg,
2
Univ of Luxembourg,
3
Univ of Liege, Belgium,
4
Univ Hosp of Liege, Belgium, and
5
CHL, Luxembourg
695 Hepatitis C Virus NS3/4A Quasi-species Diversity in Acute
Hepatitis C Infection in HIV Co-infected Patients
M Nevot
1
, C Boesecke
2
, M Parera
1
, C Andres
1
, B Revollo
3
, C Tural
3
,
B Clotet
1,3
, J Rockstroh
2
, Miguel Angel Martinez*
1
,
and NEAT Study Group
1
Fndn irsiCaixa, Badalona, Spain,
2
Bonn Univ Hosp, Germanv,
and
3
Fndn Lluita contra la Sida, Badalona, Spain
Program 49
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' ()*+,&$-#. /0$-.12-$
Innate Immunity and Hepatitis C Virus
696 Intra- and Extra-Hepatic Correlates of Plasma Viral
Clearance in Patients with Chronic Hepatitis C Virus
Genotype 1 Treated with GS-7977 and Ribavirin

Eric Meissner*
1
, A Osinusi
1,2
, H Wang
3
, L Heytens
3
, A Nelson
1
,
M Polis
1
, H Masur
3
, W Symonds
4
, A Fauci
1
, and S Kottilil
1
1
2
SAIC-Frederick, MD, US,
3
Clinical
Ctr, NIH, Bethesda, MD, US, and
4
697 Augmentation of Interferon Signaling by Nitazoxanide in
HIV/Hepatitis C Virus Co-infected Subjects: An Exploratory
Analysis from the ACTG A5269 Trial

Yu-Jin Lee*
1
, A Osinusi
1,2
, M Kang
3
, T Umbleja
3
, V Amorosa
4
,
S Kottilil
1
, M Peters
5
, and ACTG5269 Study Group
1
2
SAIC-Frederick Inc, MD, US,
3
Harvard Sch of
4
JAMC, Philadelphia, PA, US, and
5
Univ of
California, San Francisco, US
698 Natural Killer KIR3DS1 Is Closely Associated with Hepatitis
C Virus Viral Clearance and Sustained Virological Response
in HIV/Hepatitis C Virus Co-infected Patients
Antonio Rivero-Juarez*
1
, R Gonzalez
1
, A Camacho
1
,
B Manzanares-Martin
1
, A Caruz
2
, A Martinez-Peinado
1
,
L Martinez-Duenas
1
, J Pineda
3
, J Pena
1
, and A Rivero
1
1
Inst Maimonides de Investigacion Biomed de Cordoba, Hosp Reina Sofia de
Cordoba, Spain,
2
Univ de Jaen, Spain, and
3
Hosp de Jalme, Seville, Spain
699 Effective Inhibition of Hepatitis C Virus Replication
by Natural Killer Cells Is Associated with Spontaneous
Clearance of Acute Hepatitis C in HIV
+
Patients
Pavlos Kokordelis*
1
, B Kramer
1
, C Boesecke
1
, C Korner
1
, E Voigt
2
,
P Ingiliz
3
, A Glassner
1
, U Spengler
1
, J Rockstroh
1
, and J Nattermann
1
1
Dept of Internal Med I, Bonn, Germanv,
2
Praxis Theisen, Wiesel and Joigt,
Cologne, Germanv, and
3
Med Ctr for Infectious Diseases, Berlin, Germanv
700 Impaired NKG2D- and NKp46-mediated Anti-fibrotic Natural
Killer Cell Activity May Be Involved in Faster Liver Fibrosis
Progression in HIV/Hepatitis C Virus Co-infected Patients

Andreas Glassner*, P Kokordelis, M Eisenhardt, B Kramer, F Wolter,
C Korner, C Boesecke, J Rockstroh, U Spengler, and J Nattermann
Univ of Bonn, Germanv
701 HIV-associated Down-regulation of the Activating Natural
Killer Cell Receptor NKp46 Might Affect Susceptibility to
and Natural Course of Hepatitis C Virus Infection
Benjamin Kramer*
1
, P Kokordelis
1
, S Diegeler
1
, A Glassner
1
, M Eisenhardt
1
,
P Ingiliz
2
, C Boesecke
1
, U Spengler
1
, J Rockstroh
1
, and J Nattermann
1
1
2
Med Ctr for Infectious Diseases, Berlin,
Germanv
702 Co-stimulation via CD27 Stimulates Anti-Hepatitis C Virus
Activity of Natural Killer Cells and May Be Involved in
Spontaneous Clearance of Acute Hepatitis C in HIV
+
Patients

Marianne Eisenhardt*
1
, A Glaessner
1
, P Kokordelis
1
, B Kraemer
1
,
F Wolter
1
, E Voigt
2
, C Boesecke
1
, U Spengler
1
, J Rockstroh
1
,
and J Nattermann
1
1
2
Ctr Theisen, Wiesel, and Joigt, Cologne,
Germanv
703 Effect of Early Viral Kinetics on Interferon-y Inducible
Protein-10 in Patients Given an All-Oral Anti-Hepatitis C
Virus Regimen

JenniIer Lin*
1
, F Habersetzer
2
, M Rodriguez-Torres
3
, M Paulson
4
,
Y Zhu
4
, M Subramanian
4
, J McHutchison
4
, M Sulkowski
5
, D Wyles
1
,
and R Schooley
1
1
2
Univ Hosp Strasbourg,
France,
3
Fndn de Investigacion de Diego, San Juan, Puerto Rico,
4
Gilead
Sci, Inc, Foster Citv, CA, US, and
5
Baltimore, MD, US
!

"#$$%&' ()3+,&$-#. /0$-.12-$
Hepatitis C Virus Epidemiology and Clinical Outcomes
704 Most Incident Hepatitis C Virus Infections among HIV
+

Persons in a Contemporary Cohort Are Not Acquired
Parenterally
Lynn Taylor*
1
, T Bush
2
, P Patel
2
, K Henry
3
, L Conley
2
, J Hammer
4
,
N Onen
5
, C Carpenter
1
, and J Brooks
2
1
Brown Univ, Providence, RI, US,
2
3
Hennepin
Countv Med Ctr, Minneapolis, MN, US,
4
Denver Infectious Diseases
Consultants, CO, US, and
5
705 Acute Hepatitis C Virus Infection in Studies of Elvitegravir/
Cobicistat/Emtricitabine/Tenofovir DF (Stribild) and
Cobicistat for Initial HIV-1 Therapy
Erin Quirk*, H Graham, H Liu, and J Szwarcberg
Gilead Sci Inc, Foster Citv, CA, US
706 Acute Hepatitis C Virus Infection in Young Adults
Carrie Jennings* and K Sherman
Univ of Cincinnati Coll of Med, UC Hlth, OH, US
707 Location on HIV Phylogeny Is Indicative of the Risk of
Hepatitis C Virus Co-infection

Roger Kouyos*
1,2
, A Rauch
3
, V Aubert
4
, S Yerly
5
, J Boni
1
,
T Klimkait
6
, B Ledergerber
1,2
, H Gunthard
1,2
, and Swiss HIV Cohort Study
1
2
Univ Hosp Zurich, Swit:erland,
3
Univ of
Bern, Swit:erland,
4
Ctr Hosp Univ Jaudois, Lausanne, Swit:erland,
5
Univ
Hosp Geneva, Swit:erland, and
6
Univ of Basel, Swit:erland
708 Hepatitis C Virus Re-infections in HIV
+
MSM: Evidence for
Partial Protective Immunity
X Thomas
1
, B Grady
2
, J van der Meer
1
, F Lambers
2
, M Prins
1,2
,
M van der Valk
2
, S Rebers
1
, R Molenkamp
1
, Janke Schinkel*
1
,
on behalI oI MOSAIC Study Group
1
Academic Med Ctr, Amsterdam, The Netherlands and
2
Publ Hlth Svc,
Amsterdam, The Netherlands
709 Trends in Prevalence of Hepatitis C Virus among the HIV
+

Population: Spain
Sergio Serrano-Villar*
1
, P Sobrino-Vegas
2
, M Riera
3
, JA Iribarren
4
,
I Santos
5
, R Rubio
6
, L Munoz
7
, B Clotet
8
, J del Amo
2
, S Moreno
1
,
and CoRIS
1
Hosp Univ Ramon v Cafal, Madrid, Spain,
2
Ctr Nacional de
Epidemiologia, Inst de Salud Carlos III, Madrid, Spain,
3
Hosp Univ Son
Espases, Palma, Spain,
4
Hosp Univ de Donostia, San Sebastian, Spain,
5
Hosp Univ de la Princesa, Madrid, Spain,
6
Hosp Univ Doce de Octubre,
Madrid, Spain,
7
Hosp Univ San Cecilio, Granada, Spain, and
8
Hosp Univ
Germans Trias i Pufol, Badalona, Spain
710 Prevalence of Hepatitis C Virus Infection in US Hispanics/
Latinos: Results from the NHANES
2007-2010 and HCHS/SOL Studies
Mark Kuniholm*
1
, M Jung
1
, J Everhart
2
, S Cotler
3
, G Heiss
4
,
G McQuillan
5
, B Thyagarajan
6
, M Youngblood
4
, R Kaplan
1
, and G Ho
1
1
Albert Einstein Coll of Med, Bronx, NY, US,
2
Natl Inst of Diabetes
and Digestive and Kidnev Diseases, NIH, Bethesda, MD, US,
3
Univ
of Illinois, Chicago, US,
4
5
CDC, Hvattsville, MD, US, and
6
Univ of Minnesota Med Ctr, Fairview,
Minneapolis, US
711 Diversity of Hepatitis C Virus Infection among HIV
+
Injection
Drugs Users in India: Implications for HIV and Hepatitis C
Virus Treatment
Sunil Solomon*
1,2,3
,

S Shanmugam
2
, A Srikrishnan
2
, S Iqbal
2
,
C Vasudevan
2
, M Kumar
2
, D Persaud
1
, S Solomon
2
, S Ray
1
, and S Mehta
3
1
2
YRG CARE,
Chennai, India, and
3
Baltimore, MD, US
712 Identifying Priorities for Improving Hepatitis C Virus Care
in the Era of Directly Acting Antiviral Therapy
Benjamin Linas*
1,2
, D Barter
1
, J LeII
3
, S Assoumou
1
, A Kim
4
,
and B Schackman
3
1
2
Boston Univ Sch of Publ Hlth, MA, US,
3
Weill
Cornell Med Coll, New York, NY, US, and
4
Massachusetts Gen Hosp,
Boston, US
713 Using an HIV Primary Care Model for the Treatment of
Hepatitis C

Lucas Hill*, C Ballard, B Colwell, D Wyles, F Torriani, W Mathews,
and E Cachay
714 A Test, Treat, and Retain Combination Strategy for Elimination
of Hepatitis C Virus Transmission: A Mathematical Model
Viviane Lima*
1
, B Nosyk
1
, M Krajden
2
, M Hull
1
, T Kerr
1
, E Wood
1
,
E Yoshida
3
, Z Wu
4
, and J Montaner
1
1
2
BC Ctr
for Disease Control, Jancouver, Canada,
3
4
Natl Ctr for AIDS/STD Control and Prevention,
Chinese Ctr for Disease Control and Prevention, Beifing
715 The Effect of Hepatitis C Virologic Clearance on Cardiovascular
Disease Biomarkers in HIV/Hepatitis C Virus Co-infection

Kara Chew*
1
, L Hua
2
, D Bhattacharya
1
, A Butt
3,4
, R Chung
5
,
J Andersen
2
, and J Currier
1
1
2
Harvard
Sch of Publ Hlth, Boston, MA, US,
3
US,
4
Sheikh Khalifa Med Citv, Abu Dhabi, United Arab Emirates, and
5
Harvard Med Sch, Massachusetts Gen Hosp, Boston, US
716 Coronary Heart Disease Risk by Framingham Risk Score in
Hepatitis C Virus and HIV/Hepatitis C Virus

Kara Chew*
1
, D Bhattacharya
1
, K McGinnis
2
, J Currier
1
, and A Butt
3,4
1
2
JA
Pittsburgh Hlthcare Svstem, PA, US,
3
US, and
4
Sheikh Khalifa Med Citv, Abu Dhabi, United Arab Emirates
717 Methamphetamine Promotes Cardiac Dysfunction in
Genetically Engineered Hepatitis C Virus Mice

Rebecca Torres*, E Fields, C Koczor, R Russ, T Ludaway,
K Jackson, Q Qin, and W Lewis
P
o
s
t
e
r

L
i
s
t
i
n
g
s
718 Hepatitis C Co-infection and the Risk of Chronic Kidney Disease
in HIV
+
Individuals: Does Hepatitis C Viremia Matter?
Gregory Lucas*, Y Jing, M Sulkowski, A Abraham, M Atta, D Fine,
R Moore, M Estrella, and North American AIDS Cohort Collaboration
on Res and Design oI IeDEA
719 Trends and Patterns of Healthcare Utilization among
Hepatitis C Virus, HIV, and HIV/Hepatitis C Virus
Co-infected Veterans: Understanding the Burden of Disease
Shereen Katrak*
1,2
, L Park
2
, C Woods
1,2
, A Muir
1
, C Hicks
1
, and S Naggie
1,2
1
Duke Univ, Durham, NC, US and
2
Durham JAMC, NC, US
720 Impact of Hepatitis Serostatus on Hospitalization Rates and
Reasons for Admission in a Multi-center Cohort of Persons
Living with HIV in the USA
Trevor Crowell*, K Gebo, A Balagopal, S Berry, and HIV Res Network
721 Hepatitis C Virus Infection and Severe Sepsis Are Associated
with a Higher Risk of Death among HIV
+
Patients Admitted
at Intensive Care Units
Jose Medrano*
1,2
, A Alvaro-Meca
3
, A Boyer
4
, D Gruson
4
, H Rue
5
,
E Fernandez
6
, and S Resino
7
1
Hosp Univ de Araba, Jitoria-Gastei:, Spain,
2
Facultad de Med-UDM
Araba, Univ del Pais Jasco,
3
Univ Rev Juan Carlos, Alcorcon, Spain,
4
Ctr Hosp Univ Pellegrin, Bordeaux, France,
5
Norwegian Univ of Sci and
Tech, Trondheim,
6
Hosp Infanta Sofia, San Sebastian de los Reves, Spain,
and
7
Inst de Salud Carlos III, Mafadahonda, Spain
722 Chronic Hepatitis C Infection Is Independently Associated
with Mortality in a Cohort of HIV
+
Patients with Alcohol
Problems

Daniel Fuster*
1
, D Cheng
1,2
, E Quinn
3
, D Nunes
1
, R Saitz
1
, J Samet
1
,
and J Tsui
1
1
2
Boston Univ Sch
of Publ Hlth, MA, US, and
3
Data Coordinating Ctr, Boston Univ Sch of
Publ Hlth, MA, US
723 Predictors of Mortality among US Veterans with HIV and
Hepatitis C Virus Co-infection

Sebhat Erqou*
1
, A Mohanty
1
, and A Butt
2
1
Univ of Pittsburgh Med Ctr, PA, US and
2
Univ of Pittsburgh Sch of Med,
PA, US
724 Incidence of Hepatocellular Carcinoma in HIV
+
Patients and
Risk in HIV/Hepatitis C Virus Co-infected Patients after
Sustained Virological Response: Spain
Nicolas Merchante*
1
, E Merino
2
, C Tural
3
, J Lopez-Aldeguer
4
, F Jover
5
,
A Rivero-Juarez
6
, M Delgado-Fernandez
7
, MJ Galindo
8
, A Romero-
Palacios
9
, and J Pineda
1
1
Hosp Univ de Jalme, Sevilla, Spain,
2
Hosp General Univ de Alicante,
Spain,
3
Hosp Germans Trias i Pufol, Badalona, Spain,
4
Hosp Univ
v Politecnico La Fe, Jalencia, Spain,
5
Hosp Clin Univ de San Juan,
Alicante, Spain,
6
Hosp Univ Reina Sofia, Cordoba, Spain,
7
Hosp Regional
Carlos Hava, Malaga, Spain,
8
Hosp Clin de Jalencia, Spain, and
9
Hosp
Univ de Puerto Real, Cadi:, Spain
725 Clinical Presentation and Follow-up of Idiopathic Portal
Hypertension in HIV
+
Patients
O Marin
1
, P Miralles
2
, M Montes
2
, C Quereda
3
, M Tellez
4
, J Sanz
5
,
C Barros
6
, A Carrero
1
, and Juan Berenguer*
1
1
Hosp Gen Univ Gregorio Maranon, Madrid, Spain,
2
Hosp Univ La Pa:,
Madrid, Spain,
3
Hosp Ramon v Cafal, Madrid, Spain,
4
Hosp Clin de San
Carlos, Madrid, Spain,
5
Hosp Principe de Asturias, Alcala de Henares,
Spain, and
6
Hosp Univ de Mostoles, Spain
!

"#$$%&' ()*+,&$-#. /0$-.12-$
Hepatic Failure and Transplantation
726 Liver Retransplantation in HIV
+
Patients: A Multicenter and
Multinational Cohort Study
J Miro
1
,

Fernando Aguero*
1
, P Stock
2
, P Grossi
3
, J Rockstroh
4
,
K Agarwal
5
, C Garzoni
6
, LA Barcan
7
, F Maltez
8
, A Rimola
1
,
and FIPSE/NIH HIVTR/NEAT023 Investigators
1
Hosp Clin-IDIBAPS, Univ of Barcelona, Spain,
2
Francisco, US,
3
Univ of Insubria, Circolo Hosp and Macchi Fndn, Jarese,
Italv,
4
Univ of Bonn, Germanv,
5
Kings Coll Hosp Fndn Trust/Kings Hlth
Partners, London, UK,
6
Clin Luganese, Swit:erland,
7
Hosp Italiano,
Buenos Aires, Argentina, and
8
Hosp Currv Cabral, Lisbon, Portugal
727 Risk of Decompensation of Cirrhosis among HIV/Hepatitis
C Virus Co-infected Individuals with Advanced Fibrosis:
Implications for the Timing of Therapy against Hepatitis C
Virus
Juan Macias*
1
, A Camacho
2
, M von Wichmann
3
, L Lopez-Cortes
4
,
E Ortega
5
, C Tural
6
, MJ Rios
7
, D Merino
8
, F Tellez
9
, and J Pineda
1
1
2
Hosp Univ Reina Sofia, Cordoba,
Spain,
3
Hosp Donostia, San Sebastian, Spain,
4
Hosp Univ Jirgen del
Rocio, Seville, Spain,
5
Hosp Gen Univ de Jalencia, Spain,
6
Hosp Univ
Germans Trias i Pufol, Barcelona, Spain,
7
Hosp Univ Jirgen Macarena,
Seville, Spain,
8
Complefo Hosp de Huelva, Spain, and
9
Hosp de La Linea
de la Concepcion, Cadi:, Spain
728 Determinants of Hepatic Decompensation in ARV-treated
HIV/Hepatitis C Virus Co-infected Patients
Vincent Lo Re*
1,2
, M Kallan
1
, J Tate
3,4
, R Localio
1
, J Lim
3,4
, M Goetz
5
,
A Butt
6
, S Brown
7
, J Kostman
1
, A Justice
3,4
, and Veterans Aging Cohort Study
1
2
Philadelphia JAMC, PA, US,
3
JA
Connecticut Hlthcare Svstem, West Haven, US,
4
Yale Univ, New Haven, CT,
US,
5
6
Univ of Pittsburgh
Sch of Med, PA, US, and
7
James J Peters JAMC, New York, NY, US
729 When to Start ART in the Post-transplant Period in HIV
+

Patients
Mrianna Menozzi*, S Cocchi, M Codeluppi, E Garlassi, S Zona,
R Montalti, N De Ruvo, F Di Benedetto, GE Gerunda, and G Guaraldi
Modena and Reggio Emilia Univ, Modena, Italv
!

"#$$%&' ()3+,&$-#. /0$-.12-$
Emergence and Persistence of HPV-associated
730 AIDS-defining Cancers in Switzerland 1985-2011: Separating
the Effects of Age and Period
F Schoni-AIIolter
1
, L Elzi
2
, R Weber
3
, A Calmy
4
, A Bregenzer
5
,
M Cavassini
6
, H Furrer
7
, G CliIIord
8
, M Egger
1
, Olivia Keiser*
1
,
1
2
3
Univ Hosp
Zurich, Swit:erland,
4
Geneva Univ Hosp, Swit:erland,
5
Cantonal Hosp
St Gallen, Swit:erland,
6
Univ Hosp Lausanne, Swit:erland,
7
Univ Hosp
Bern, Swit:erland, and
8
Intl Agencv for Res on Cancer
731 Incidence of AIDS-defining and Non-AIDS-defining Cancers
following Expansion of ART: Botswana 2003-2008
Scott Dryden-Peterson*
1,2,3
, H Medhin
4
, G Seage
2
, M Pusoentsi
4
,
S El-Halabi
4
, T Rebbeck
5
, G Suneja
5
, M Mmalane
3
, M Essex
2,3
,
and S Lockman
1,2,3
1
Brigham and Women`s Hosp, Boston, MA, US,
2
Harvard Sch of Publ
Hlth, Boston, MA, US,
3
Botswana Harvard AIDS Inst Partnership,
Gaborone,
4
Botswana Ministrv of Hlth, Gaborone, and
5
Univ of
Pennsvlvania, Philadelphia, US
732 Frequent Detection of Human Papillomavirus before and
after Initiation of ART among HIV
+
Women: Uganda

Anne Rositch*
1
, P Gravitt
1,2
, A Tobian
1,3
, K Newell
4
, T Quinn
3,5
,
D Serwadda
6
, P Ssebbowa
6
, V Kiggundu
6
, R Gray
1,6
, and S Reynolds
3,5
1
2
Perdana Univ Grad Sch of Med, Serdang, Malavsia,
3
Johns Hopkins
Univ Sch of Med, Baltimore, MD, US,
4
Frederick Natl Lab for Cancer
Res, MD, US,
5
6
Rakai Hlth Sci
Prgm, Entebbe, Uganda
733 HPV Genotype Impacts T Cell Activation and Cervical
Cellular Infiltrates Irrespective of Lesion Grade in ART-
suppressed Human Papillomavirus/HIV-1 Co-infected
Women
Emmanouil Papasavvas*
1
, D Glencross
2,3
, N Mayisela
4
, T Omar
2
,
A-L Williamson
5,6
, M Siminya
4
, X Yin
1
, Q Liu
1
, C Firnhaber
2,4
,
and L Montaner
1
1
2
3
Natl Hlth Lab Svc, Johannesburg, South
Africa,
4
5
Univ of Cape Town,
South Africa, and
6
Natl Hlth Lab Svc, Cape Town, South Africa
734 Human Papillomavirus, Cervical Neoplasia, and Invasive
Cancer in Women with HIV-2 Infection in the ART Era:
Senegal
S Hawes
1
, Q Feng
1
, S Ba
2
, M Toure
1,2
, M-P Sy
2
, F Traore
2
, R Smith
1
,
N Kiviat
1
, PS Sow
1,2
, GeoIIrey Gottlieb*
1
, and UW-Dakar HIV-2 Study
Group
1
2
Ctr Hosp Univ de Fann, Univ
Cheikh Anta Diop de Dakar, Senegal
735 Anal Human Papillomavirus Infection in HIV
+
Patients:
Prevalence, Incidence, and Predictors of High-risk Human
Papillomavirus Infection

Alberto Borghetti*
1
, P Cattani
2
, G Maria
3
, M Sanguinetti
2
,
S DÒnghia
2
, R Santangelo
2
, S Marchetti
2
, R Cauda
1
, A De Luca
1,4
,
1
1
Inst of Clin Infectious Diseases, Catholic Univ of Sacred Heart, Rome,
Italv,
2
Inst of Microbiologv, Catholic Univ of Sacred Heart, Rome, Italv,
3
Inst of Clin and Surgical Therapv, Catholic Univ of Sacred Heart, Rome,
Italv, and
4
736 The Effect of Protease Inhibitors on the Incidence of HIV-
associated Squamous Cell Carcinoma of the Anus

Pamela Mbang*
1
, M Kowalkowski
2
, and E Chiao
1,2
1
Bavlor Coll of Med, Houston, TX, US and
2
Houston Hlth Svcs Res and
Devt Ctr of Excellence, Michael E DeBakev JAMC, TX, US
737 Prevalence and Genotypes of Human Papillomavirus at
Penile and Perianal Sites among HIV
+
and HIV
-
MSM
Han-Zhu Qian*
1
, Y Hu
2
, L Yin
1
, Y Ruan
2
, Y Shao
2
, and S Vermund
1
1
Janderbilt Univ, Nashville, TN, US and
2
Natl Ctr for STD/AIDS Control
and Prevention of China CDC, Beifing
Program 51
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' ()*+,&$-#. /0$-.12-$
HIV-associated Malignancies: Miscellaneous
738 Incidence of Kaposi Sarcoma in South Africa in the ART
Era: Prospective Multi-cohort Study
J Bohlius
1
, F Valeri
1
, M Maskew
2
, H Prozesky
3
, C Chimbetete
4
,
P Lumano-Mulenga
5
, D Garone
6
, Matthias Egger*
1
,
and Intl Epidemiologic Databases to Evaluate AIDS Southern AIrica
1
2
Univ of the Witwatersrand, Johannesburg,
South Africa,
3
Univ of Stellenbosch, Cape Town, South Africa,
4
Newlands
Clin, Harare, Zimbabwe,
5
Ctr for Infectious Diseases and Res in Zambia,
Lusaka, and
6
Medecins Sans Frontieres, South Africa
739 The Role of Interleukin-6 and Interleukin-6 Receptorin
Multicentric Castleman`s Disease: Frequency of
Polymorphisms and Functional Implications

Salvinia Mletzko*
1
, A Rai
1
, S Westrop
1
, N Imami
1
, Y Shahrabi
1
,
J Williams
2
, M Jones
2
, F Gotch
1
, and M Bower
1
1
Imperial Coll, Chelsea and Westminster Hosp, London, UK and
2
MRC
Clinical Sci Ctr, Imperial Coll, Hammersmith Hosp, London, UK
740 Prognosis in HIV
+
Patients with Non-small Cell Lung Cancer
Keith Sigel*
1
, K Crothers
2
, K KrauskopI
1
, R Dubrow
3
, J Jao
1
, C Sigel
4
,
and J Wisnivesky
1
1
2
Univ of Washington Sch of
Med, Seattle, US,
3
Yale Univ Sch of Med and Publ Hlth, New Haven, CT,
US, and
4
Memorial Sloan-Kettering Hosp, New York, NY, US
741 Lung Cancer Screening Indicators in HIV
+
Patients
K Chen
1
, S Olender
2
, and Noga Shalev*
2
1
Ben Gurion Univ, Israel and
2
Columbia Univ Med Ctr, New York, NY, US
742a Prior HIV Testing in Newly Diagnosed Black Cancer Patients:

Mazvita Sengayi*
1
, C Babb
2
, and M Urban
2
1
NHLS Natl Cancer Registrv and Res and Intl Epidemiological Databases
to Evaluate AIDS, Johannesburg, South Africa and
2
NHLS/MRC Cancer
Epidemiologv Res Group, Johannesburg, South Africa
742b Cancer Risk and Use of Protease Inhibitor- or NNRTI-based
cART: The D:A:D Study
Mathias Bruyand*
1
, L Ryom
2
, L Shepherd
3
, P Reiss
4
, S de Wit
5
,
A dÀrminio MonIorte
6
, M Rickenbach
7
, A Phillips
3
, J Lundgren
8
,
C Sabin
3
, and D:A:D Study Group
1
INSERM, ISPED, Ctr INSERM U897-Epidemiologie-Biostatistique,
CHU de Bordeaux, COREJIH Aquitaine, France,
2
Copenhagen HIJ
Prgm, Univ of Copenhagen, Facultv of Hlth Sci, Denmark,
3
Res Dept
of Infection and Population Hlth, UCL, London, UK,
4
Academic Med
Ctr, Univ of Amsterdam, The Netherlands,
5
CHU Saint-Pierre, Dept
of Infectious Diseases, Brussels, Belgium,
6
Dipartimento di Med,
Chirurgia e Odontoiatria, Clin di Malattie Infettive e Tropicali, A:ienda
Ospedaliera-Polo Univ San Paolo, Milan, Italv,
7
Inst for Social and
Preventive Med, Univ of Lausanne, Swit:erland, and
8
Copenhagen HIJ
Prgm, Univ of Copenhagen, Facultv of Hlth Sci and Epidemiklinikken
M5132, Copenhagen Univ Hosp/Rigshospitalet, Denmark
742c Serum-free Testosterone Predicts Human Papillomavirus
Type 16/18 Infection in a Cohort of MSM
Dorothy Wiley*
1
, T Brown
2
, X Li
3
, S Young
4
, R Cranston
5
, G D`Souza
3
,
L Jacobson
3
, O Martinez-Maza
6
, E Seaberg
3
, R Detels
7
, and MultiCtr AIDS
Cohort Study
1
Univ of California, Los Angeles, Sch of Nursing, US,
2
Johns Hopkins
Univ, Sch of Med, Baltimore, MD, US,
3
Sch of Publ Hlth, Baltimore, MD, US,
4
Tricore Reference Labs, Univ of
New Mexico, Albuquerque, US,
5
6
Univ of
California, Los Angeles AIDS Inst and David Geffen Sch of Med, US,
and
7
Univ of California, Los Angeles Jonathan and Karen Fielding Sch
of Publ Hlth, US
!

"#$$%&' ()3+,&$-#. /0$-.12-$
HIV-associated Malignancies: Lymphoma
743 A Novel Prognostic Model for HIV
+
Diffuse Large B Cell
Lymphoma
Chun Chao*
1
, M Silverberg
2
, O Martinez-Maza
3,4
, D Abrams
5
, R Haque
1
,
H Zha
6
, L-H Chen
1
, L Xu
1
, M Chi
1
, and J Said
3
1
Kaiser Permanente Southern California, Pasadena, US,
2
Kaiser
Permanente Northern California, Oakland, US,
3
David Geffen Sch of
Med, Univ of California, Los Angeles, US,
4
Sch of Publ Hlth, Univ
of California, Los Angeles, US,
5
San Francisco Gen Hosp and Univ
6
Los Angeles Med Ctr, Kaiser
Permanente Southern California, US
744 Protease Inhibitor- vs Non-Protease Inhibitor-based ART in
HIV
+
Patients with Hodgkin Lymphoma Receiving Adriamyc
in+Bleomycin+Vinblastine+Dacarbazine Chemotherapy
Karim Ibrahim* and S Milliken
St Jincents Hosp, Svdnev, Australia
745 Hodgkin Lymphoma Is Almost as Prevalent as Non-Hodgkin
Lymphoma in HIV
+
Patients with Sustained Viral Suppression
and Limited Immune Deficiency
Christian HoIImann*
1
, D Gillor
2
, G Behrens
3
, A Stoehr
4
, J van Lunzen
5
,
M Hentrich
6
, M Hensel
7
, J Thoden
8
, C Wyen
2
, and G Fatkenheuer
2
1
ICH, Hamburg, Germanv,
2
Univ Hosp of Cologne, Germanv,
3
Med Sch
of Hannover, Germanv,
4
ifi Hamburg, Germanv,
5
Univ Hosp Eppendorf,
Hamburg, Germanv,
6
Hosp Harlaching, Munich, Germanv,
7
Mannheim
Oncologv Ctr MOP, Germanv, and
8
Univ Hosp Freiburg, Germanv
746 Role of PI3K/AKT/mTOR Pathway in AIDS-related Diffuse
Large B Cell Lymphoma and Kaposi Sarcoma
Sara Browne*, J Diaz-Perez, H-Y Wang, H Li, E Reid, and S VandenBerg
!

"#$$%&' (45+,&$-#. /0$-.12-$
Cardiovascular Disease: Predicting Risk and
Monitoring Outcomes
747 Projecting 10-Year, 20-Year, and Lifetime Risks of
Cardiovascular Disease in HIV
+
Individuals in the US:
Competing Risks and Premature Aging
Elena Losina*
1,2,3,4
, B Linas
4,5
, E Hyle
1,3
, C Rusu
4
, F Noubary
4
,
B Berkowitz
4
, P Sax
1,2
, M Weinstein
6
, R Walensky
1,2,3,4
, and K Freedberg
1,3,4,5
1
2
Brigham and
3
4
5
6
748 Improvements in Short-term Mortality following Myocardial
Infarction: The Data Collection on Adverse events of Anti-
HIV Drugs Study
Caroline Sabin*
1
, L Ryom
2
, M Law
3
, W El-Sadr
4
, O Kirk
2,5
, M Bruyand
6
,
P Reiss
7
, C Pradier
8
, B Ledergerber
9
, J Lundgren
2,5
, and D:A:D Study
1
2
3
The Kirbv
Inst, Univ of New South Wales, Svdnev, Australia,
4
Intl Ctr for AIDS
Care and Treatment Prgms, Columbia Univ and Harlem Hosp, New
York, NY, US,
5
6
Univ
of Bordeaux, ISPED, Ctr INSERM U897-Epidemiologie-Biostatistique,
France,
7
8
Ctr
Hosp Univ, Nice, France, and
9
Univ Hosp Zurich, Swit:erland
749 ST2 and NT-proBNP Are Associated with Cardiac
Dysfunction and Mortality in HIV
+
Individuals
Eric Secemsky*
1
, R Scherzer
2
, E Nitta
2
, A Wu
2
, D Lange
2
, S Deeks
2
,
J Martin
2
, J Snider
3
, P Ganz
2
, and P Hsue
2
1
2
Francisco, US, and
3
Critical Diagnostics, San Diego, CA, US
750 The Risk of and Survival with Preserved vs Reduced Ejection
Fraction Heart Failure by HIV Status
Matthew Freiberg*
1
, C-C Chang
1
, KA Oursler
2,3
, J Gottdiener
4
, S Gottlieb
4
,
A Warner
5
, D LeaI
5
6,7
, S Felter
8
, A Butt
1,9
,
and VACS Project Team
1
2
Baltimore JAMC, MD, US,
3
Univ of Marvland Sch of Med, Baltimore, US,
4
Univ of Marvland Med
Ctr, Baltimore, US,
5
6
7
Michael E DeBakev JAMC,
Houston, TX, US,
8
JA Pittsburgh Hlthcare Svstem, PA, US, and
9
Sheikh
Khalifa Med Citv, Abu Dhabi, United Arab Emirates
751 Emergency Medical Service Utilization and Reperfusion
Times among HIV
+
Individuals Presenting with ST-elevation
Myocardial Infarction

Mark Dela Cruz*
1
, K Thomas
1
, D Brenner
1
, A Kulkarni
2
, J McCabe
3
,
P Hsue
1
, P Ganz
1
, and S Waldo
1
1
2
Massachusetts Gen Hosp,
Boston, US, and
3
Brigham and Women`s Hosp, Boston, MA, US
!

"#$$%&' (4(+,&$-#. /0$-.12-$
Endothelial Dysfunction in HIV Infection
752 Early Changes in Adhesion Molecules Expression and
Endothelial Function in Patients Initiating ART with
Atazanavir or Lopinavir
Alessandra Bandera*
1
, D Trabattoni
2
, N Squillace
1
, A Muscatello
1
,
F Calascibetta
2
, A Maloberti
3
, C Giannattasio
3
, V Marcandalli
1
, M Clerici
2
,
and A Gori
1
1
S Gerardo Hosp, Mon:a, Italv,
2
3
Milan-Bicocca
Univ, Milan, Italv
753 Nadir CD4 Count and Elevated ADMA Are Associated with
Endothelial Dysfunction in HIV
+
Individuals
R Parikh
1
, R Scherzer
1
, C GrunIeld
1
, E Nitta
1
, A Leone
2
, J Martin
1
, S Deeks
1
,
P Ganz
1
, and Priscilla Hsue*
1
1
2
Oxonon BioAnalvsis,
Emervville, CA, US
P
o
s
t
e
r

L
i
s
t
i
n
g
s
754 Endothelial Dysfunction in HIV Infection Results from
Interactions between Endothelial Cells and Activation/
Inflammation Biomarkers
Mariola Lopez*
1
, M Masia
2
, J San Roman
3
, S Padilla
2
, E Vispo
1
,
V Estrada
4
, P Parra
1
, JM Benito
1
, F Gutierrez
2
, and V Soriano
1
1
2
Gen Univ Hosp, Elche, Spain,
3
Rev
Juan Carlos Univ, Madrid, Spain, and
4
Clin San Carlos Hosp, Madrid,
Spain
755 Pentoxifylline neither Reduces Systemic Inflammation
nor Improves Endothelial Function in HIV
+
Persons Not
Receiving ART
Samir Gupta*
1
, D Mi
1
, M Dube
2
, C Saha
1
, R Johnson
1
, J Stein
3
,
M Clauss
1
, K Mather
1
, Z Desta
1
, and Z Liu
1
1
Indiana Univ Sch of Med, Indianapolis, US,
2
Univ of Southern California
Keck Sch of Med, Los Angeles, US, and
3
Univ of Wisconsin Sch of Med
and Publ Hlth, Madison, US
756 HIV Elite Controllers Have Lower Asymmetric
Dimethylarginine and Improved Endothelial Function as
Compared to Individuals with Treated and Suppressed HIV
R Parikh
1
, R Scherzer
1
, C GrunIeld
1
, E Nitta
1
, A Leone
2
, J Martin
1
, S Deeks
1
,
P Ganz
1
, and Priscilla Hsue*
1
1
2
Oxonon BioAnalvsis,
Emervville, CA, US
!

"#$$%&' ()*+,&$-#. /0$-.12-$
Vascular Imaging and Subclinical Atherosclerosis
757 HIV and Coronary Artery Calcium Score: Comparison of
Hawaii Aging with HIV Cardiovascular Study and the Multi-
Ethnic Study of Atherosclerosis
Dominic Chow*
1
, J Barbour
1
, L Ndhlovu
1
, P Norris
2,3
, R Young
4
,
R Kronmal
4
, M BudoII
5
, N Valcour
1
, C-Y Liang
1
, C Shikuma
1
,
and Multi-ethnic Study oI Atherosclerosis AC 388
1
2
Blood Svstems Res Inst, San
Francisco, CA, US,
3
4
Univ of
Washington, Seattle, US, and
5
Los Angeles Biomed Res Inst, CA, US
758 Elite Controllers and Coronary Plaque in the Multicenter
AIDS Cohort Study
Wendy Post*
1,2
, L Jacobson
2
, C Coley
2
, S Grinspoon
3
, F Palella
4
,
L Kingsley
5
, M Witt
6
, T Brown
1
, M BudoII
6
, and J Margolick
2
1
2
Johns Hopkins
3
Massachusetts
4
5
Univ of
Pittsburgh, PA, US, and
6
Harbor UCLA, US
759 Retention of Surface CD14 Expression on Monocyte Subsets
Associated with Lower Carotid Artery Intima-media
Thickness in HIV
+
Adults
Jason Barbour*
1
, E Jalbert
1
, D Chow
1
, H Hodis
2
, L Nagamine
1
, T Seto
1,3
,
N Parikh
1,3
, C-Y Liang
1
, L Ndhlovu
1
, and C Shikuma
1
1
Univ of Hawaii Manoa, US,
2
Univ of Southern California, Los Angeles,
US, and
3
Queen`s Med Ctr, Honolulu, HI, US
760 Adiponectin Is Associated with Subclinical Coronary
Atherosclerosis: Multicenter AIDS Cohort Study
1
, W Post
1,2
, X Li
2
, L Jacobson
2
, F Palella
3
,
J Margolick
2
, L Kingsley
4
, M Witt
5
, M BudoII
5
, T Brown
1,2
,
and Multictr AIDS Cohort Study
1
2
Johns Hopkins
3
Northwestern
Univ Feinberg Sch of Med, Chicago, IL, US,
4
and
5
761 C-Reactive Protein Predicts 96-week Carotid Intima Media
Thickness Progression in HIV
+
Adults Nave to ART
Corrilynn Hileman*
1,2
, C Longenecker
2,3
, T Carman
2,3
, D Labbato
3
,
N Storer
3
, V Tangpricha
4
, and G McComsey
2,3
1
MetroHlth Med Ctr, Cleveland, OH, US,
2
Case Western Reserve Sch of
Med, Cleveland, OH, US,
3
Univ Hosp Case Med Ctr, Cleveland, OH, US,
and
4
762 Adipokines, Asymmetric Dimethylarginine, and Subclinical
Vascular Disease in HIV
+
Patients on ART
Chris Longenecker*
1,2
, W Dunn
2
, Y Jiang
2
, S Debanne
2
, and G McComsey
1,2
1
Univ Hosp Case Med Ctr, Cleveland, OH, US and
2
Case Western
Reserve Univ, Cleveland, OH, US
763 Ambulatory Arterial Stiffness Index and 24-hour Pulse
Pressure in HIV Infection: Results of a Nationwide Cross-
sectional Study
Giuseppe Vittorio De Socio*
1
, P Maggi
2
, G Madeddu
3
, G Parruti
4
,
G Penco
5
, G OroIino
6
, B Menzaghi
7
, M Franzetti
8
, P BonIanti
9
, G Schillaci
10
,
and CISAI Study Group
1
Santa Maria della Misericordia Hosp, Perugia, Italv,
2
Univ of Bari,
Italv,
3
Univ of Sassari, Italv,
4
Pescara Hosp, Italv,
5
Galliera Hosp,
Genoa, Italv,
6
Amedeo di Savoia Hosp, Turin, Italv,
7
Busto Arsi:io Hosp,
Italv,
8
9
Man:oni Hosp, Lecco, Italv, and
10
Univ of
Perugia, Italv
!

"#$$%&' ())+,&$-#. /0$-.12-$
Statin Use and HIV: How Sweet Is It?
764 Statin Therapy and Mortality in HIV
+
Individuals: A Danish
Nationwide Population-based Cohort Study

Line Rasmussen*
1
, G Kronborg
2
, C Larsen
3
, C Pedersen
1
, J GerstoIt
4
,
and N Obel
4
1
Odense Univ Hosp, Denmark,
2
Copenhagen Univ Hosp, Hvidovre,
Denmark,
3
Aarhus Univ Hosp, Skefbv, Denmark, and
4
Copenhagen Univ
Hosp, Rigshospitalet, Denmark
765 Impact of Statin Exposure on Mortality and Non-AIDS
Complications in HIV Patients on HAART
Henning Drechsler*
1,2
, S Zhang
2
, N MaalouI
2
, J Cutrell
2
, P Tebas
3
,
and R Bedimo
1,2
1
JA North Texas Hlth Care Svstem, Dallas, US,
2
Univ of Texas Southwestern
Med Ctr, Dallas, US, and
3
766 Association between Statin Use and Type-2 Diabetes Mellitus
Occurrence among HIV-1
+
Patients Receiving ART

Vincenzo Spagnuolo*
1
, L Galli
1
, A Poli
1
, S Salpietro
1
, N Gianotti
1
,
P Piatti
1
, C Vinci
1
, E Carini
1
, A Lazzarin
1,2
, and A Castagna
1
1
2
Univ Jita-Salute San Raffaele,
Milan, Italv
767 Statin Use Is Associated with Incident Diabetes Mellitus among
Patients in the HIV Outpatient Study
Kenneth Lichtenstein*
1
, R Debes
2
, K Wood
2
, S Bozzette
2,3
, K Buchacz
4
,
J Brooks
4
, and HIV Outpatient Study Investigators
1
Natl Jewish Hlth, Denver, CO, US,
2
3
4
!

"#$$%&' ()3+,&$-#. /0$-.12-$
Dyslipidemia: Risks, Pathogenesis, and Treatment
768 Influence of Age on Survival, Immune Recovery, and Changes
in Lipid Parameters among HIV
+
Patients Receiving ART
Enju Liu*
1
, D Spiegelman
1
, G Chalamilla
2
, M Njelekela
3
, C Hawkins
4
,
E Aris
2
, L Hirschhorn
5
, N Li
1
, C Armstrong
6
, and W Fawzi
1
1
2
Dar es Salaam, Tan:ania,
3
Muhimbili Univ of Hlth and Allied Sci, Dar es
Salaam, Tan:ania,
4
Northwestern Univ, Feinberg Sch of Med, Chicago,
IL, US,
5
6
Beth Israel Deaconess
Med Ctr, Boston, MA, US
769 Dyslipidemia in HIV
+
Patients Receiving Protease Inhibitors
Ezetimibe+Fenofibrate vs Pravastin.
A Randomized, Prospective, Controlled, Pilot Study
AM Grandi
1
, E Nicolini
2
, L Rizzi
2
, S Caputo
2
, F Annoni
1
, AM Cremona
1
,
C Marchesi
2
, AM Maresca
1
, and Paolo Grossi*
1
1
Univ of Insubria, Jarese, Italv and
2
Ospedale di Circolo, Jarese, Italv
770 Modulation of Liver X Receptor and Genes Involved in
Cholesterol Metabolism by ARV Drugs
Federica Gnudi*
1,2
, M De Luca
1,2
, M Biasin
1,2
, G Rizzardini
1
, M Clerici
2
,
D Trabattoni
1,2
, and S Piconi
1
1
Hosp L Sacco Milan, Italv and
2
771 10 of HIV
+
Men Who Are Not Taking Statins Should Be
Anne Monroe*
1
, M Zikusoka
1
, W Fu
2
, L Jacobson
2
, M Witt
3
, F Palella
4
,
L Kingsley
5
, W Post
1
, and T Brown
1
1
2
Johns Hopkins
3
Los Angeles
Biomed Res Inst at Harbor UCLA Med Ctr, Torrance, CA, US,
4
Northwestern Univ, Feinberg Sch of Med, Chicago, IL, US, and
5
Univ of
Pittsburgh Grad Sch of Pub Hlth, PA, US
772 Bilirubin Changes Are Not Associated with Lipid Changes
in Patients Starting Atazanavir/Ritonavir- or Darunavir/
Ritonavir-containing Therapy
Esteban Martinez*
1
, D Podzamczer
2
, P Domingo
3
, E Negredo
4
,
F Gutierrez
5
, J Portilla
6
, E Ribera
7
, J Murillas
8
, J Arribas
9
, J Gatell
1
,
and ATADAR Study Group
1
Hosp Clin-IDIBAPS and Univ of Barcelona, Spain,
2
Hosp Univ de
Bellvitge and Univ of Barcelona, LHosp de Llobregat, Spain,
3
Hosp de
Sant Pau and Univ Autonoma de Barcelona, Spain,
4
Hosp Germans Trias
i Pufol and Luita contra la SIDA Fndn, Badalona, Barcelona, Spain,
5
Hosp Univ de Elche and Univ Miguel Hernande:, Alicante, Spain,
6
Hosp Gen Univ de Alicante, Spain,
7
Hosp Univ Jall dHebron and Univ
Autonoma de Barcelona, Spain,
8
Hosp Univ Son Espases, Palma de
Mallorca, Spain, and
9
Hosp Univ La Pa:, Madrid, Spain
Program 53
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' ()*+,&$-#. /0$-.12-$
Risk Prediction, Risk Factors, Biomarkers, and
Outcomes
773 The Veterans Aging Cohort Study Index Predicts Mortality
in a Young, Healthy HIV
+
Population Starting HAART
I Bebu
1
, J Tate
2
, O Mesner
1
, G Macalino
1
, D Rimland
1
, A Ganesan
1
,
A Weintrob
1
, A Justice
2
, and Brian Agan*
1
1
Infectious Disease Clin Res Prgm, Uniformed Svcs Univ of the Hlth Sci,
Bethesda, MD, US and
2
Yale Univ and the JA Hlthcare Svstem, West
Haven, CT, US
774 Framingham Risk Score and Cardiovascular Risk Profiles in
HIV
+
Patients and HIV
-
Controls Differ by Sex
SteIan Esser*
1
, T Neumann
1
, B BokhoI
2
, L Eisele
2
, B Schwarz
1
,
V HolzendorI
3
, R Erbel
1
, K-H Joeckel
2
, D SchadendorI
1
, N Reinsch
1
,
and HIV-HEART Study Group and Heinz NixdorI Recall Study Group
1
Univ Hosp Essen, Germanv,
2
Inst for Med Informatics, Biometrv and
Epidemiologv, Univ Hosp Essen, Germanv, and
3
Univ of Leip:ig, Clin
Trial Ctr, Germanv
775 Cigarette Smoking among HIV
+
Adults in Care: Medical
Monitoring Project, US, 2009
Rennatus Mdodo*, E Frazier, C Mattson, M Sutton, J Brooks,
and J Skarbinski
776 Hypertension Prevalence and Framingham Risk Scores in a
Large HIV
+
Cohort: Mildmay Uganda Cohort

Farrah Mateen*
1
, S Kanters
2
, A Funk
3
, E Kyegonza
3
, and E Mills
4
1
2
Jancouver, Canada,
3
Mildmav Uganda, Kampala, and
4
Univ of Ottawa,
Canada
777 Prevalence of Obesity in a Nationally Representative Sample
of HIV
+
Adults Receiving Medical Care in the US: Medical
Monitoring Project, 2009
Angela Thompson-Paul*, S Wei, C Mattson, and J Skarbinski
778 High Prevalence and Severity of Pulmonary Emphysema Is
Associated with Cardiovascular Morbidity
Giovanni Guaraldi*
1
, G Besutti
1
, R Scaglioni
1
, A Santoro
1
, S Zona
1
,
E Garlassi
1
, G Ligabue
1
, D Sin
2,3
, J Leipsic
2,3
, and P Man
2,3
1
Modena and Reggio Emilia Univ, Modena, Italv,
2
British Columbia
Univ, James Hogg Res Ctr, Jancouver, Canada, and
3
St Pauls Hosp,
Jancouver, Canada
779 Lipoprotein-associated Phospholipase A2 and Cardiovascular
Disease Risk in HIV: A Balance of Pro-Inflammatory and
Anti-Thrombotic Effects
Allison Ross Eckard*
1
, C Longenecker
2,3
, Y Jiang
2
, S Debanne
2
,
D Labbato
2,3
, N Storer
2,3
, and G McComsey
2,3
1
Emorv Univ Sch of Med and Childrens Hlthcare of Atlanta, GA, US,
2
Case Western Reserve Univ, Cleveland, OH, US, and
3
Univ Hosp Case
Med Ctr, Cleveland, OH, US
780 Significant Elevations in Interleukin-6 Levels as a Predictor
of All-cause Mortality among Adults Receiving cART in
Botswana: Results from a Clinical Trial

Bethan McDonald*
1,2
, S Moyo
2
, L Gabaitiri
3
, S Gaseitsiwe
1,2
,
H Bussmann
2
, J Koethe
4
, J Makhema
2
, R Marlink
1,2
, W Wester
2,4
,
and M Essex
1,2
1
2
Botswana-Harvard
AIDS Inst Partnership, Gaborone,
3
Univ of Botswana, Gaborone,
and
4
Janderbilt Univ Sch of Med, Nashville, TN, US
781 HIV Infection and Risk of Venous Thromboembolism

Pashtoon Kasi*
1
, A Mohanty
1
, S Erqou
1
, K McGinnis
2
, K Crothers
3
,
K Corey
4,5
, R Chung
4,5
, M Freiberg
2
, and A Butt
2,6
1
Univ of Pittsburgh Med Ctr, PA, US,
2
US,
3
4
US,
5
6
Sheikh Khalifa Med Citv,
Abu Dhabi, United Arab Emirates
782 Effect of HIV Seroconversion and ART Initiation on Multiple
Biomarkers of Organ Function

Kaku Armah*
1
, J Lim
2
, V Lo Re
3
, J Baker
4
, R Tracy
5
, A Butt
2,6
,
B Agan
7,8
, D Rimland
9,10
, A Justice
11,12
, M Freiberg
2
, and VACS Project Team
1
Univ of Pittsburgh Grad Sch of Publ Hlth, PA, US,
2
Univ of Pittsburgh
Sch of Med, PA, US,
3
Univ of Pennsvlvania Sch of Med, Philadelphia,
US,
4
Univ of Minnesota Med Sch, Minneapolis, US,
5
Univ of Jermont,
Burlington, US,
6
Sheikh Khalifa Med Citv, Abu Dhabi, United Arab
Emirates,
7
Infectious Disease Clin Res Prgm, Bethesda, MD, US,
8
Uniformed Svs Univ of the Hlth Sci, Bethesda, MD, US,
9
Emorv Univ
Sch of Med, Atlanta, GA, US,
10
JAMC, Atlanta, GA, US,
11
JA Connecticut
Hlth Care Svstem and Med Ctr, West Haven, CT, US, and
12
Yale Univ Sch
of Med, New Haven, CT, US
!

"#$$%&' ()3+,&$-#. /0$-.12-$
Microbial Translocation Measurement and
Associations
783 Background Subtraction in the Limulus Amebocyte Assay
May Underestimate Lipopolysaccharide Levels in Those with
the Greatest Microbial Translocation

Helen Byakwaga*
1,2
, P Hsue
2
, E Sambrano
2
, E Sinclair
2
, Y Huang
2
,
R Tracy
3
, T Burdo
4
, J Martin
2
, C GrunIeld
2
, and P Hunt
2
1
2
US,
3
Univ of Jermont, Burlington, US, and
4
Boston Coll, MA, US
784 Association of Intestinal Dysbiosis with Microbial
Translocation and Inflammation in Chronic HIV Infection
Gretchen Volpe*
1,2
, C DuIIalo
1
, D Dinh
1
, S Bhalchandra
1
, M Mwamburi
2
,
A Kane
1,2
, H Ward
1,2
, and C Wanke
1,2
1
Tufts Med Ctr, Boston, MA, US and
2
785 Microbial Translocation, Inflammation, and Soluble and
Cellular Immune Activation Biomarkers and HAART
Outcomes in Resource-limited Settings
A Balagopal
1
, D Asmuth
2
, L Smeaton
3
, N Gupte
1
, V Franco
1
, J Hakim
4
,
R Pollard
2
, T Campbell
5
, D Thomas
1
, Amita Gupta*
1
, Ior ACTG5175
and NWCS319 Study Group
1
2
Univ of California, Davis,
Sacramento, US,
3
4
Univ of
Zimbabwe, Harare, and
5
Univ of Colorado Denver, US
786 Asymmetric and Symmetric Dimethylarginine Are
Associated with Plasma Lipopolysaccharide, Low Nadir CD4
Count, and Future Hypertension in HIV
+
Individuals
I Manner
1
, M Baekken
1
, I Os
1,2
, O Oektedalen
1
, D Kvale
1,2
, I SeljeIlot
1,2
,
and Marius Troseid*
1
1
Oslo Univ Hosp, Norwav and
2
Univ of Oslo, Norwav
787 Safety and Tolerability of Crofelemer 125 mg for Treating
Non-infectious Diarrhea in HIV
+
Individuals: Results from
Double-blind and Open-label Studies
Rodger MacArthur*
1
, T Hawkins
2
, S Brown
3
, A LaMarca
4
, P Golden
5
,
R Rolleri
5
, E Bortey
5
, C Paterson
5
, and W Forbes
5
1
Wavne State Univ, Detroit, MI, US,
2
Southwest CARE, Santa Fe, NM,
US,
3
AIDS Res Alliance, Los Angeles, CA, US,
4
Therafirst Med Ctr, Ft
Lauderdale, FL, US, and
5
Salix Pharmaceuticals, Inc, Raleigh, NC, US
!

"#$$%&' ()4+,&$-#. /0$-.12-$
Inflammatory Biomarkers, Microparticles,
and Clinical Outcomes in HIV
788 Inflammatory Cytokines and Mortality in a Cohort of HIV
+

Patients with Alcohol Problems

Daniel Fuster*
1
, D Cheng
1,2
, E Quinn
3
, K Armah
4
, R Saitz
1
,
M Freiberg
5
, J Samet
1
, and J Tsui
1
1
2
Boston Univ Sch
of Publ Hlth, MA, US,
3
Data Coordinating Ctr, Boston Univ Sch of Publ
Hlth, MA, US,
4
Univ of Pittsburgh Grad Sch of Publ Hlth, PA, US, and
5
789 Tissue Factor Microparticles among HIV
+
Persons Are Reduced
with ART and Associated with D-dimer Levels after Treatment
Jason Baker*
1,2
, K Huppler Hulsiek
1
, R BradIord
3
, R Prosser
1,2
, R Tracy
4
,
and N Key
3
1
2
Hennepin Countv Med Ctr,
Minneapolis, MN, US,
3
and
4
Univ of Jermont, Burlington, US
790 Soluble Markers of Inflammation and Coagulation, but Not
T Cell Activation, Predict Non-AIDS-defining Events during
Suppressive ART
Allan Tenorio*
1
, E Zheng
2
, R Bosch
2
, S Deeks
3
, B Rodriguez
4
, S
Krishnan
2
, P Hunt
3
, C Wilson
5
, M Lederman
4
, A Landay
1
, and ACTG
1
2
Boston, MA, US,
3
San Francisco Gen Hosp and Univ of California, San
Francisco, US,
4
Case Western Reserve Univ Sch of Med, Cleveland, OH,
US, and
5
Univ of Colorado Hosp, Aurora, US
791 Inflammation and Coagulation Markers Are Predictive of
Anemia in ARV-treated HIV Disease

Alvaro Borges*
1
, J Weitz
2
, G Collins
3
, J Baker
3,4
, Y Levy
5
, R Davey
6
,
A Phillips
7
, J Neaton
3
, J Lundgren
1
, S Deeks
8
, Ior INSIGHT SILCAAT
Study Group
1
Copenhagen HIJ Prgm and Rigshospitalet, Denmark,
2
Thrombosis
and Atherosclerosis Res Inst, Hamilton, Canada,
3
Univ of Minnesota,
Minneapolis, US,
4
5
Assistance Publ-Hosp de Paris, INSERM U955, Univ Paris 12, Creteil,
France,
6
7
Univ Coll London Med Sch,
UK, and
8
P
o
s
t
e
r

L
i
s
t
i
n
g
s
792 Osteoprotegerin and Receptor Activator of Nuclear Factor
Kappa Ligand Are Associated with Subclinical Coronary
Atherosclerosis: Multicenter AIDS Cohort Study
1
, W Post
1,2
, X Li
2
, L Jacobson
2
, F Palella
3
,
J Margolick
2
, L Kingsley
4
, M Witt
5
, M BudoII
5
, T Brown
1,2
, and Multictr
AIDS Cohort Study
1
2
Johns Hopkins
3
Northwestern Univ
Feinberg Sch of Med, Chicago, IL, US,
4
Univ of Pittsburgh Grad Sch of
Publ Hlth, PA, US, and
5
!

"#$$%&' ()*+,&$-#. /0$-.12-$
ART Effects: Monocyte and T Cell Activation
793 The Prognostic Capacity of CD8 T Cell Activation during
Effective ART Is Attenuated by Age
Judith Lok*
1
, P Hunt
2
, A Collier
3
, C Benson
4
, M Witt
5
, A Luque
6
,
S Deeks
2
, and R Bosch
1
1
2
Francisco, US,
3
Univ of Washington Sch of Med, Seattle, US,
4
Univ of
California, San Diego, US,
5
David Geffen Sch of Med, Univ of California,
Los Angeles, US, and
6
Univ of Rochester Med Ctr, NY, US
794 Soluble CD14 Declines in Virologically Suppressed Women
Switching from Protease Inhibitor or NNRTI to Raltegravir:
The Women, Integrase, and Fat Accumulation Trial
Jordan Lake*
1
, G McComsey
2
, T Hulgan
3
, C Wanke
4
, A Mangili
4
,
S Walmsley
5
, S Boger
6
, S Stramotas
1
, and J Currier
1
1
2
Case Western Reserve Univ,
Cleveland, OH, US,
3
Janderbilt Univ, Nashville, TN, US,
4
Tufts Univ,
Boston, MA, US,
5
Univ of Toronto, Canada, and
6
Med Univ of South
Carolina, Charleston, US
795 Activated Proinflammatory Monocytes Are Consistently
Elevated in Patients on Protease Inhibitor Mono-therapy
B Torres, M Plana, A Guardo, A Leon, L Leal, M Laguno,
A Gonzalez-Cordon, J Mallolas, J Gatell, and Felipe Garcia*
Hosp Clin, Barcelona, Spain
!

"#$$%&' ()3+,&$-#. /0$-.12-$
ART Effects: Gene Expression and Cellular Function
796 Autophagy Inhibition by HIV Drugs Contributes to Toxicity
in Hepatocytes and Adipocytes
Metodi Stankov*
1
, D Panayotova-Dimitrova
2
, M Leverkus
2
, F Vondran
1
,
R BauerIeind
1
, A Binz
1
, R Schmidt
1
, and G Behrens
1
1
2
Mannheim Clin of Univ of
Heidelberg, Germanv
797 Differential Subcutaneous Adipose Tissue Gene Expression
Pattern with 1
st
-line Treatment Containing either Efavirenz
or Lopinavir/ritonavir
Lander Egana-Gorrono*
1
, E Martinez
2
, M Lonca
2
, T Escriba
1
, P Domingo
3
,
J Fontdevila
2
, F Vidal
4
, E Negredo
5
, J Gatell
1,2
, and M Arnedo
1
1
AIDS Res Unit, Barcelona, Spain,
2
Hosp Clin, Barcelona, Spain,
3
Hosp
de la Santa Creu i Sant Pau, Barcelona, Spain,
4
Hosp Univ de Tarragona
Joan XXIII, Spain, and
5
Fndn lluita contra la SIDA, Hosp Germans Trias
i Pufol, Badalona, Spain
!

"#$$%&' (45+,&$-#. /0$-.12-$
Frailty: From Mice to Men and Women
798 Zidovudine Worsens Exercise Performance in Aged
Transgenic AIDS Mice %' 6%6&: Insights into Age-related
Changes in Patients Treated with NRTI

Rebecca Torres*, T Ludaway, E Fields, R Russ, and W Lewis
799 Some HIV Protease Inhibitors and HIV Proteins Induce
Senescence and Differentially Alter Cell Fate of Human Bone
Marrow Mesenchymal Stem Cells

Carine Beaupere*
1
, S Hernandez-Vallejo
1
, J Capeau
1,2
, and C Lagathu
1
1
INSERM UMRS938, UPMC, Paris, France and
2
APHP, Hosp Tenon,
Paris, France
800 Frailty and Circulating Markers of Inflammation in HIV
+

and HIV
-
Men in the Multi-center AIDS Cohort Study
Joseph Margolick*
1
, O Martinez-Maza
2
, L Jacobson
1
, J Lopez
1
, X Li
1
,
J Phair
3
, C Rinaldo
4
, and J Bream
1
1
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD,
US,
2
David Geffen Sch of Med and Fielding Sch of Publ Hlth, Univ of
California, Los Angeles, US,
3
Northwestern Univ Feinberg Sch of Med,
Chicago, IL, US, and
4
Univ of Pittsburgh Grad Sch of Publ Hlth, PA, US
801 Fall Frequency and Associated Factors among Men and
Women with or at Risk for HIV Infection
Todd Brown*
1
, G Springer
1
, H Cohen
2
, C Cox
1
, H HoIIman
3
, M Yin
4
,
and M Plankey
5
1
2
Bavlor Coll of Med, Houston,
TX, US,
3
4
Columbia Univ, New York, NY, US,
and
5
802 Impaired Physical Function and Frailty Are Associated with
Cytomegalovirus Immunoglobulin G Antibody Concentration
in Middle-aged Adults with HIV
Kristine Erlandson*, A Allshouse, R Rapaport, C Jankowski,
S MaWhinney, W Kohrt, C Wilson, and T Campbell
Univ of Colorado-Anschut: Med Campus, Aurora, US
803 Association of Cytomegalovirus Immunoglobulin-G with
Markers of Incomplete CD4 T Cell Recovery in Long-term
Virologically Suppressed HIV
+
Individuals
J Blanco
1
, M Massanella
1,2
, E Garcia
1
, E Gomez
1
, D Giles
3
, M Bernado
3
,
J Puig
4
, E Negredo
4
, B Clotet
1,4
, and Cecilia Cabrera*
1
1
Irsicaixa Fndn, Badalona, Barcelona, Spain,
2
Diego, US,
3
Biokit, LLica dAmunt, Barcelona, Spain, and
4
Fndn LLuita
contra la Sida, Badalona, Barcelona, Spain
!

"#$$%&' (4(+,&$-#. /0$-.12-$
Diabetes, Metabolic Syndrome, and Vitamin D
Deficiency
804 Risk of Incident Diabetes Associated with Weight Gain after
cART Initiation
Melissa Herrin*
1
, J Tate
1,2
, M Freiberg
3
, J Chang
3
, K Crothers
4
,
C Gibert
5
, D LeaI
6
, D Rimland
7,8
9,10
, and A Justice
1,2
1
2
JA Connecticut Hlthcare Svstem, West
Haven, US,
3
4
Univ of Washington
Sch of Med, Seattle, US,
5
Washington DC JAMC, US,
6
Greater Los
Angeles JA Hlthcare Svstem, CA, US,
7
Emorv Univ Sch of Med, Atlanta,
GA, US,
8
Atlanta JAMC, GA, US,
9
and
10
Michael E DeBakev JAMC, Houston, TX, US
805 ART Modifies the Genetic Effect of Known Type 2 Diabetes-
associated Risk Variants in the Women`s HIV Interagency
Study

Melissa Frasco*
1
, W Mack
1
, K Anastos
2
, M Cohen
3
, S Gange
4
,
D GustaIson
5
, C Lui
6
, P Tien
7
, and CL Pearce
1
1
Univ of Southern California, Los Angeles, US,
2
Montefiore Med Ctr
and Albert Einstein Coll of Med, Bronx, NY, US,
3
Stroger Hosp and
Rush Univ, Chicago, IL, US,
4
Johns Hopkins Univ Bloomberg Sch of
Publ Hlth, Baltimore, MD, US,
5
SUNY Downstate Med Ctr, Brooklvn,
US,
6
Georgetown Univ Sch of Med, Washington, DC, US, and
7
Univ of
806 Prevalence and Predictors of Metabolic Abnormalities and
Metabolic Syndrome in South African Women with Acute
and Early HIV-1 Subtype C Infection
Magdalena Sobieszczyk*
1,2
, L Werner
1
, N Garrett
1
, K Mlisana
1,3
,
A Feinstein
2
, N Naicker
1
, C Gray
4
, C Williamson
4
, S Abdool Karim
1,2
,
and CAPRISA002 Acute HIV InIection Study Team
1
Ctr for the AIDS Prgm of Res in South Africa, Univ of KwaZulu-Natal,
Durban,
2
3
Natl Hlth Lab Svcs,
Durban, South Africa, and
4
Inst of Infectious Diseases and Molecular
Med, Univ of Cape Town, South Africa
807 1, 25-Dihydroxyvitamin Levels Remain Normal in HIV
+

Women with Hypovitaminosis D on Efavirenz: Data from the
Women`s Interagency HIV Study
Oluwatoyin Adeyemi*
1
, B Livak
1
, P Tien
2
, A Sharma
3
, M Glesby
4
,
E Golub
5
, M Villacres
6
, M Young
7
, and M Cohen
1
1
CORE Ctr, Cook Countv Hlth and Hosp Svstem, Chicago, IL, US,
2
Univ of
3
SUNY Downstate Med Ctr, Brooklvn, US,
4
Weill Cornell Univ, New York, NY, US,
5
Sch of Publ Hlth, Baltimore, MD, US,
6
Univ of Southern California, Los
Angeles, US, and
7
!

"#$$%&' (47+,&$-#. /0$-.12-$
Renal Disease: Diagnosis, Predictors, and Drugs
808 A Comparison of Estimated Glomerular Filtration Rates
Using Cockcroft-Gault and the Chronic Kidney Disease
Epidemiology Collaboration Estimating Equations
Amanda MocroIt*
1
, L Ryom
2
, P Reiss
3
, B Ledergerber
1
, A dÀrminio
MonIorte
4
, J Gatell
5
, S de Wit
6
, M Beniowski
7
, J Lundgren
2,8
, O Kirk
2,8
,
and EuroSIDA in EuroCOORD
1
Univ Hosp Zurich, Swti:erland,
2
Univ of Copenhagen, Denmark,
3
4
Istituto
Di Clinica Malattie Infettive e Tropicale, Milan, Italv,
5
Hosp Clin i
Provincial, Barcelona, Spain,
6
St-Pierre Hosp, Brussels, Belgium,
7
Osrodek Diagnostvki i Terapii AIDS, Chor:ow, Poland, and
8
Rigshospitalet, Copenhagen, Denmark
Program 55
P
o
s
t
e
r

L
i
s
t
i
n
g
s
809 Prevalence of Chronic Kidney Disease among HIV
+
Adults in
Care in the US: Medical Monitoring Project, 2009
Shikha Garg*, C Furlow-Parmley, E Frazier, and J Skarbinski
810 Predictors of Advanced Chronic Kidney Disease and End-
stage Renal Disease in HIV
+
Persons: D:A:D

Lene Ryom*
1
, A MocroIt
2
, O Kirk
1,3
, W El-Sadr
4
, M Ross
5
, P Reiss
6
,
S De Wit
7
, P Morlat
8
, C Fux
9
, J Lundgren
1,3
, and D:A:D Study Group
1
Copenhagen HIJ Prgm, Univ of Copenhagen, Facultv of Hlth and
Med Sci, Denmark,
2
3
Epidemiklinikken M5132,
4
Intl Ctr for AIDS Care
and Treatment Prgms, Columbia Univ and Harlem Hosp, New York, NY,
US,
5
6
Academic Med Ctr, Univ
of Amsterdam, The Netherlands,
7
CHU St-Pierre, Brussels, Belgium,
8
Univ Bordeaux Segalen, INSERM U 897, CHU de Bordeaux, France,
and
9
Clin for Infectious Diseases and Hosp Hvgiene, Kantonsspital
Aarau, Swit:erland
811 Long-term Changes in Renal Parameters in ART-nave
Subjects Randomized to Abacavir/Lamivudine or Tenofovir/
Emtricitabine with Atazanavir/ritonavir or Efavirenz:
ACTG A5224s,
a Sub-study of A5202
Samir Gupta*
1
, D Kitch
2
, C Tierney
2
, P Sax
3
, E Daar
4
, L Szczech
5
, P Tebas
6
,
B Ha
7
, K Melbourne
8
, G McComsey
9
, and ACTG A5224s Study Team
1
2
Boston, MA, US,
3
Brigham and Womens Hosp, Harvard Med Sch,
Boston, MA, US,
4
Los Angeles Biomed Res Inst at Harbor-UCLA Med
Ctr, Torrance, CA, US,
5
PPD, LLC, Research Triangle Park, NC, US,
6
7
GlaxoSmithKline, Research
Triangle Park, NC, US,
8
Gilead Sci, Foster Citv, CA, US, and
9
Case
Western Reserve Univ, Cleveland, OH, US
812 Urinary 2 Microglobulin and u1 Microglobulin Are Useful
Screening Tools for Tenofovir-induced Kidney Tubulopathy:
A Diagnostic Accuracy Study
Takeshi Nishijima*
1,2
, T Shimbo
1
, H Komatsu
3
, M Takano
1
, J Tanuma
1
,
K Tsukada
1
, K Teruya
1
, H Gatanaga
1,2
, Y Kikuchi
1
, and S Oka
1,2
1
Natl Ctr for Global Hlth and Med, Tokvo, Japan,
2
Ctr for AIDS Res,
Kumamoto, Japan, and
3
Saku Central Hosp, Nagano, Japan
813 Reversibility of Tenofovir-associated Decline in Kidney
Function

Sophie Jose*
1
, L Hamzah
2
, L Campbell
2
, D Nitsch
3
, R Jones
4
,
C Sabin
1
, F Post
2
, and UK CHIC
1
2
Kings Coll London, UK,
3
London Sch of
Hvgiene and Tropical Med, UK, and
4
Chelsea and Westminster Hosp,
London, UK
814 Tenofovir Is Associated with an Increased Risk and Faster
Progression of Renal Impairment amongst HIV
+
Patients:
India

Sanjay Pujari*
1
, C Smith
2
, A Makane
1
, M Youle
3
, M Johnson
3
,
and S Bhagani
3
1
Inst of Infectious Diseases, Pune, India,
2
and
3
Roval Free London Fndn Trust, UK
815 5-Year Evolution of Creatinine Clearance in HIV-1
+
Adults
Initiating Tenofovir- vs Zidovudine-containing HAART:
Thailand
Gonzague Jourdain*
1,2,3
, L Harrison
1
, P Kantipong
4
, T Cressey
1,2,3
,
M Techapornroong
5
, G Halue
6
, S Banchongkit
7
, M Lallemant
1,2,3
,
N Ngo-Giang-Huong
1,2,3
, C Bowonwattanuwong
8
, and Prgm Ior HIV
Prevention and Treatment
1
Inst de Recherche pour le Devt, Marseille, France,
2
Harvard Sch of
3
Associated Med Sci, Chiang Mai Univ,
Thailand,
4
Chiangrai Prachanukroh Hosp, Thailand,
5
Prapokklao Hosp,
Chantaburi, Thailand,
6
Phavao Provincial Hosp, Thailand,
7
Ravong
Hosp, Thailand, and
8
Chonburi Regional Hosp, Thailand
816 Renal Function and Outcomes of Tenofovir-containing ART:
Zambia
Lloyd Mulenga*
1
, A Mwango
2
, P Musonda
1
, M-A Davies
3
,
A Mweemba
4
, A Calmy
5
, J Stringer
1
, O Keiser
6
, B Chi
1
, G Wandeler
6,7
,
and IeDEA-Southern AIrica
1
Ctr for Infectious Disease Res in Zambia,
2
Zambian Ministrv of Hlth,
3
4
Univ Teaching Hosp, Lusaka,
Zambia,
5
Univ Hosp Geneva, Swit:erland,
6
and
7
Univ Hosp Bern, Swit:erland
!

"#$$%&' ()*+,&$-#. /0$-.12-$
Bone Loss: Risk Factors and Pathogenesis
817 HIV Is an Independent Predictor of Lower Bone Mineral
Density in HIV
+
Subjects Compared to HIV
-
Subjects

AoiIe Cotter*
1,2
, C Sabin
3
, S Simelane
1
, A Macken
1
, B Rogers
1
,
E Kavanagh
2
, J Brady
2
, P Mallon
1,2
, and HIV UPBEAT Study Group
1
HIJ Molecular Res Group, Sch of Med and Med Sci, Univ Coll Dublin,
Ireland,
2
Mater Misericordiae Univ Hosp, Dublin, Ireland, and
3
Univ
Coll London, UK
818 Lower Peak Bone Mass and Abnormal Trabecular and
Cortical Microarchitecture in Men Infected with HIV Early
in Life
Michael Yin*
1
, E Broun
1
, J Shah
1
, M Foca
1
, N Neu
1
, J Nelson
1
, D Bell
1
,
A Zhang
1
, M Ueno
2
, and S Arpadi
1
1
Columbia Univ Med Ctr, New York, NY, US and
2
Georgetown Univ Sch
of Med, Washington, DC, US
819 Lack of Predictive Ability of Bone Turnover Markers for
Change in Bone Mineral Density in Middle-aged HIV
+
and
HIV
-
Women
Anjali Sharma*
1
, P Flom
2
, E Schoenbaum
3
, and C Rosen
4
1
SUNY Downstate Med Ctr, Brooklvn, US,
2
Peter Flom Consulting, New
York, NY, US,
3
Albert Einstein Coll of Med, Bronx, NY, US, and
4
Maine
Med Ctr Res Inst, Scarborough, US
820 Fracture Risk among HIV
+
Medicare Beneficiaries
Amy Warriner*, W Smith, J Curtis, K Saag, and E Delzell
Univ of Alabama at Birmingham, US
821 B Cell Dysregulation Promotes HIV-induced Bone Loss
Kehmia Titanji*
1
, A Vunnava
1
, A Sheth
1
, J Lennox
1
, N Weitzmann
1,2
,
and I OIotokun
1
1
Emorv Univ, Atlanta, GA, US and
2
Atlanta JAMC, Decatur, GA, US
!

"#$$%&' ())+,&$-#. /0$-.12-$
ART and Bone Disease
822 Bone Mineral Density and Prevalence of Asymptomatic
Vertebral Fractures in HIV
+
Patients on cART

Daria Gotti*, M Gianizza, T Porcelli, L Albini, E Foca, F Castelli,
A Giustina, and E Quiros-Roldan
Univ of Brescia, Italv
823 Lower Baseline CD4 Is Associated with Greater Loss of Bone
Mineral Density after ART Initiation
Philip Grant*
1
, D Kitch
2
, G McComsey
3
, M Dube
4
, R Haubrich
5
,
J Huang
5
, S Riddler
6
, P Tebas
7
, A Zolopa
1
, and T Brown
8
1
2
3
Case Western, Cleveland, OH, US,
4
Univ of Southern California, Los
Angeles, US,
5
6
Univ of Pittsburgh, PA,
US,
7
Univ of Pennsvlvania, Philadelphia, US, and
8
Johns Hopkins Univ,
Baltimore, MD, US
824 Multicenter Randomized Study to Assess Changes in HIV
Subjects with Low Bone Mineral Density after Switching
from Tenofovir to Abacavir: OsteoTDF Study
Eugenia Negredo*
1
, P Domingo
2
, N Perez-Alvarez
1,3
, M Gutierrez
2
,
J Puig
1
, J Munoz
2
, G Mateo
2
, A Bonjoch
1
, E Redondo
2
, and B Clotet
4
1
Lluita contra la Sida Fndn, Germans Trias i Pufol Univ Hosp, Badalona,
Spain,
2
Santa Creu i Sant Pau Hosp, Barcelona, Spain,
3
Univ Politecnica
de Catalunva, Barcelona, Spain, and
4
Irscaixa Fndn, Germans Trias i
Pufol Univ Hosp, Badalona, Spain
825 Change in Lean Body Mass and Association with Bone
Mineral Density Change in Subjects Randomized to Abacavir/
Lamivudine or Tenofovir/Emtricitabine with Atazanavir/
Ritonavir or Efavirenz: ACTG A5224s
Kristine Erlandson*
1
, D Kitch
2
, C Tierney
2
, P Sax
3
, E Daar
4
, P Tebas
5
,
K Melbourne
6
, B Ha
7
, N Jahed
8
, and G McComsey
9
1
Univ of Colorado-Anschut: Med Campus, Aurora, US,
2
Harvard Sch of
3
Brigham and Women`s Hosp, Harvard Med
Sch, Boston, MA, US,
4
Los Angeles Biomed Res Inst at Harbor-UCLA
Med Ctr, Torrance, CA, US,
5
6
Gilead Sci, Foster Citv, CA, US,
7
GlaxoSmithKline, Research Triangle,
NC, US,
8
Social & Scientific Svstems, Inc, Silver Spring, MD, US, and
9
826 Changes in Bone Biomarkers in Randomized Studies of ARV
Combinations in HIV
-
Volunteers

AoiIe Cotter*
1,2
, C Sabin
3
, J Brady
2
, B Rogers
1
, D Cooper
4,5
, A Carr
4
,
P Mallon
1,2
, and SAMA001 and SAMA002 Study Groups
1
HIJ Molecular Res Group, Sch of Med and Med Sci, Univ Coll Dublin,
Ireland,
2
Mater Misericordiae Univ Hosp, Dublin, Ireland,
3
Univ Coll
London Med Sch, UK,
4
St Jincents Hosp, Svdnev, Australia, and
5
Kirbv
Inst, Univ of New South Wales, Svdnev, Australia
827 25-Hydroxy Vitamin D and Bone Mineral Density Increased
with Intermittent ART vs Continuous ART: Strategies for
Management of ART Body Composition Sub-study
Daniel Nixon*
1
, B Grund
2
, H Wand
3
, A Carr
3,4
, D Duprez
2
, J Hoy
5
,
N Mueller
6
, M Roediger
2
, J-P Viard
7
, F Rhame
2
, and INSIGHT SMART
Study Team
1
Jirginia Commonwealth Univ, Richmond, US,
2
Univ of Minnesota,
Minneapolis, US,
3
Univ of New South Wales, Svdnev, Australia,
4
St
Jincent s Hosp, Svdnev, Australia,
5
Alfred Hosp and Monash Univ,
Melbourne, Australia,
6
Hosp Zurich, Swit:erland, and
7
Hosp Hotel Dieu,
Paris, France
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' ()*+,&$-#. /0$-.12-$
TB: Incidence, Risk Factors, and Outcomes
828 HIV Infection and Multidrug-resistant TB: 2 Overlapping
Epidemics
M Zignol, D Falzon, and Haileyesus Getahun*
WHO, Geneva, Swit:erland
829 High Prevalence of Mycobacteremia and Associated
Mortality among HIV
+
Smear-negative TB Suspects: Uganda

Lydia Nakiyingi*
1
, W Ssengooba
2
, O Mbabazi
1
, J Sempa
1
,
D Armstrong
3
, M Holshouser
3
, M Joloba
2
, J Ellner
4
, S Dorman
3
,
and Y Manabe
1,3
1
Infectious Diseases Inst, Makerere Univ Coll of Hlth Sci, Kampala,
Uganda,
2
Makerere Univ Coll of Hlth Sci, Kampala, Uganda,
3
Johns
Hopkins Univ Sch of Med, Baltimore, MD, US, and
4
Boston Med Ctr,
Boston Univ Sch of Med, MA, US
830 Body Mass Index and Advanced WHO Clinical Stage Are
Predictors of TB Incidence among Patients on HAART in
Botswana: Results from a Clinical Trial
Simani Gaseitsiwe*
1
, V Maiswe
1
, S Moyo
1
, H Bussmann
1
, W Wester
2
,
R Musonda
1
, M Mmalane
1
, J Makhema
1
, R Marlink
3
, and M Essex
3
1
Botswana Harvard AIDS Inst Partnership, Gaborone,
2
Janderbilt Univ
Sch of Med, Janderbilt Inst for Global Hlth, Nashville, TN, US, and
3
Harvard Sch of Publ Hlth AIDS Inst, Boston, MA, US
831 The Burden of TB among Patients Dying with HIV/AIDS while
on ART: Western Kenya
Fatuma Some*
1,2,3
, A Gardner
1,2,4,5
, A Mwangi
1,2
, D Chumba
1,2
,
M Karoney
3
, P Koskei
3
, I Maulid
3
, K Kenina
3
, and A Siika
1,2,3
1
Academic Model Providing Access to Hlthcare, Eldoret, Kenva,
2
Moi Univ Sch of Med, Eldoret, Kenva,
3
Moi Univ Clin Res Ctr, Eldoret,
Kenva,
4
Alpert Med Sch of Brown Univ, Providence, RI, US, and
5
Indiana
Univ Sch of Med, US
832 Early Mortality following Initiation of ART in Rural South
Africa: The Contribution of Existing Co-morbidities

Portia Mutevedzi*
1,2
, R Lessells
1,3
, and M-L Newell
1,4
1
Africa Ctr for Hlth and Population Studies, Univ of KwaZulu-Natal,
Somkhele, South Africa,
2
3
London Sch of Hvgiene
and Tropical Med, UK, and
4
Univ Coll London Inst of Child Hlth, UK
833 Malnutrition Predicts Treatment Outcome and Death in
South African Multidrug-resistant TB/HIV Co-infected
Children
Robert Hicks*
1,2
, N Padayatchi
2
, S Shah
1
, A WolI
1
, L Werner
2
,
B Sunkari
3
, and M O`Donnell
1,2
1
2
CAPRISA, Durban,
South Africa, and
3
King George J Hosp, Svdenham, South Africa
834 High Risk of Early Mortality among Persons Suspected of
TB: South Africa
Kerrigan McCarthy*
1,2
, K Fielding
3
, A Grant
3
, V Chihota
1
, B Ndlazi
1
,
S Mngcozelo
1
, L Vezi
1
, D Mametja
4
, W Stevens
5
, G Churchyard
1,2,3
,
and XTEND Investigators and Collaborators
1
The Aurum Inst, Johannesburg, South Africa,
2
3
London Sch of Hvgiene and Tropical Med,
UK,
4
Natl Dept of Hlth, Tshwane, South Africa, and
5
Natl Hlth Lab Svcs,
835 Predictors of Mortality and Loss to Follow-up during TB
Treatment in a High HIV Prevalence Setting

Dominique Pepper*
1
, M Schomaker
2
, R Wilkinson
2
, V DeAzevedo
3
,
and G Maartens
2
1
Univ of Mississippi Med Ctr, Jackson, US,
2
Univ of Cape Town,
South Africa, and
3
Citv Hlth, Cape Town, South Africa
836 TB Mycobacteremia as a Cause of Severe Sepsis in HIV
+

Patients: Lusaka, Zambia
Ben Andrews*
1,2
, L Muchemwa
2
, S Lakhi
2,3
, A Kruuner
4,5
, P Seidenberg
6
,
J Mwaba
3
, D Heimburger
1
, and G Bernard
11
Janderbilt Univ, Nashville, TN, US,
2
Univ of Zambia Sch of Med,
Lusaka,
3
Univ Teaching Hosp, Lusaka, Zambia,
4
Ctr for Infectious
Disease Res in Zambia, Lusaka,
5
and
6
Univ of New Mexico, Albuquerque, US
837 Undiagnosed Infectious TB in Adult Home Deaths: South
Africa
Neil Martinson*
1,2
, T Omar
3
, M Rakgokong
1
, E Moroe
1
, L Lebina
1
,
and E Variava
4
1
Perinatal HIJ Res Unit, Univ of the Witwatersrand, Johannesburg,
South Africa,
2
Johns Hopkins Univ Ctr for TB Res, Baltimore, MD,
US,
3
Natl Hlth Lab Svc and Univ of the Witwatersrand, Johannesburg,
South Africa, and
4
Klerksdorp-Tshepong Hosp Complex and Univ of the
Witwatersrand, Matlosana, South Africa
!

"#$$%&' ()3+,&$-#. /0$-.12-$
TB Diagnostics
838 Quantitative Xpert MTB/RIF and the Role of HIV among a
Cohort of TB Suspects: South Africa
Colleen Hanrahan*
1
, K Selibas
2
, B Cunningham
2
, C Deery
2
, L Scott
2
,
W Stevens
2,3
, I Sanne
2
, and A Van Rie
1
1
Univ of North Carolina Gillings Sch of Global Publ Hlth, Chapel Hill,
US,
2
Univ of the Witwatersrand, Johannesburg, South Africa, and
3
Natl
Hlth Lab Svcs, Johannesburg, South Africa
839 Use of Rapid Molecular Testing of Sputum to Predict Cases
of Drug-resistant TB among HIV Co-infected Patients: South
Africa
A Campbell
1
, James Brust*
1,2
, T Mthiyane
3
, K Mlisana
4,5
,
T van der Merwe
6
, I Master
7
, S Lachman
8
, S Shah
1,2
, and N Gandhi
9
1
2
Montefiore Med Ctr, Bronx,
NY, US,
3
MRC, Durban, South Africa,
4
Natl Hlth Lab Svc, Johannesburg,
South Africa,
5
Univ of KwaZulu-Natal, Durban, South Africa,
6
Church
of Scotland Hosp, Tugela Ferrv, South Africa,
7
King George J Hosp,
8
Murchison Provincial Hosp, Port Shepstone,
South Africa, and
9
840 2 Rapid Line Probes for Diagnosis of TB, Isoniazid and
Rifampin Resistance in HIV
+
TB Suspects in High HIV/TB
Prevalence Resource-limited Settings
Anne Luetkemeyer*
1
, M Kendall
2
, X Wu
2
, MC Lourenco
3
,
S Swindells
4
, C Ganoza
5
, D Havlir
1
, B Grinsztejn
3
, I Sanne
6
, C Firnhaber
6
,
and AACTG A5255 Study Group
1
San Francisco Gen Hosp and Univ of California, San Francisco, US,
2
3
Fndn Oswaldo Cru:,
Rio de Janeiro, Bra:il,
4
Univ of Nebraska Med Ctr, Omaha, US,
5
Assn Civil Impacta Salud v Educacion, Lima, Peru, and
6
Univ of the
Witswatersrand, Johannesburg, South Africa
841 Diagnosing TB in Those Hardest to Diagnose:
Urine Lipoarabinomannan for Suspects of Disseminated and
Extrapulmonary TB
Annelies Van Rie*
1
, E Jong
2
, M Mkhwanazi
3
, and I Sanne
2,3
1
2
Johannesburg, South Africa, and
3
Right to Care, Johannesburg,
South Africa
!

"#$$%&' ()4+,&$-#. /0$-.12-$
TB Screening Strategies: Diagnostics New and Old
and Latent TB Treatment
842 A Prospective, Clinic-based Study of a Urine Lipoarabinomannan
Test for Pulmonary or Extrapulmonary TB among HIV
+
Adults:
South Africa

Paul Drain*
1,2
, E Losina
1,2
, S Coleman
3
, J Giddy
4
, D Ross
5
, G Parker
4
,
J Katz
2
, R Walensky
1,2
, K Freedberg
1
, and I Bassett
1
1
2
Boston, MA, US,
3
Boston Univ, MA, US,
4
McCord Hosp, Durban, South
Africa, and
5
St Marvs Hosp, Durban, South Africa
843 Diagnostic Accuracy of Novel Sputum and Urine Assays
for HIV-associated TB: Correlation with C-reactive Protein
Concentration and Mortality Risk

Andrew KerkhoII*
1,2
, R Wood
2
, M Vogt
2
, and S Lawn
2,3
1
George Washington Univ, Washington, DC, US,
2
Desmond Tutu HIJ
Ctr, Cape Town, South Africa, and
3
London Sch of Hvgiene and Tropical
Med, UK
844 Sequencing of Drug Resistant 562&012-#.%78 -70#.279&$%$
Samples from a Cohort of Patients in a TB Hospital:
Gauteng, South Africa
Lynsey Isherwood*
1
, N Kushner
2
, F Conradie
1,3
, D Fallow
2
, R Louw
4
,
C Veldsman
5
, A Axcell
6
, P Diniso
1,7
, Y Nkosi
3
, and A Duse
1,7
1
2
Univ of Med
and Dentistrv of New Jersev, US,
3
Right to Care, Johannesburg, South
Africa,
4
Si:we Tropical Diseases Hosp, Johannesburg, South Africa,
5
Hain Lifescience SA Ptv Ltd, Johannesburg, South Africa,
6
Natl Inst of
Communicable Diseases, Johannesburg, South Africa, and
7
Natl Hlth Lab
Svc, Johannesburg, South Africa
845 TB Screening among Botswana`s Tebelopele Voluntary
Counseling and Testing Clients
Andrew Voetsch*
1
, S Lanje
1
, M Boima
2
, P Loeto
1
, G Machao
3,4
,
L Manthe
2
, K Molosiwa
2
, S Motsisi
2
, and R Ncube
4
1
CDC, Gaborone, Botswana,
2
Tebelopele Joluntarv Counseling and
Testing Ctr, Gaborone, Botswana,
3
Intl Training and Ed Ctr for Hlth,
Gaborone, Botswana, and
4
Ministrv of Hlth, Gaborone, Botswana
846 Diagnostic Delays Associated with Xpert MTB/RIF Assay in
a Centralized Laboratory for Pulmonary TB among HIV
+

Adults: South Africa
Gabriel Cohen*
1
, P Drain
2,3
, F Noubary
2
, C Cloete
4
, K Nixon
4
, G Parker
4
,
and I Bassett
2
1
New York Univ Sch of Med, NY, US,
2
US,
3
Brigham and Womens Hosp, Boston, MA, US, and
4
McCord Hosp,
Durban, South Africa
Program 57
P
o
s
t
e
r

L
i
s
t
i
n
g
s
847 Improving TB Screening and Isoniazid Preventative Therapy
in an HIV Clinic in Addis Ababa, Ethiopia

Sandra Zaeh*
1
, R Kempker
1
, E Stenehjem
1
, H Blumberg
1
,
I OIotokun
1
, and A Tenna
2
1
2
Addis Ababa Univ Sch of
Med, Ethiopia
848 Genetic Diversity of !"#$%&#'()*+, '+%()#+.$/*/ among HIV
+

and HIV Patients: Nigeria, Kenya, and South Africa

Marie BalliI*
1
, L Fenner
1
, A Abimiku
2
, J Obasanya
3
, J Carter
4
,
B Pederson
4
, L-G Bekker
5
, K Middelkoop
5
, M Egger
1
, S Gagneux
6
,
and Intl Epidemiologic Databases to Evaluate AIDS
1
Inst of Social and Preventive Med, Univ of Bern, Swit:erland,
2
Inst of
Human Jirologv, Nigeria,
3
Natl TB and Leprosv Training Ctr, Zaria,
Nigeria,
4
USAID AMPATH, Eldoret, Kenva,
5
Desmond Tutu HIJ Ctr,
Inst of Infectious Disease and Molecular Med, Univ of Cape Town,
South Africa, and
6
Swiss Tropical and Publ Hlth Inst and Univ of Basel
849 Diagnostic Value of Percutaneous Liver Biopsy in HIV
+

Patients with Fever of Unknown Origin in the HAART Era

Surasak Wiboonchutikul*
1
, W Manosuthi
1
, B Kowadisaiburana
1
,
and S Sungkanuparph
2
1
Bamrasnaradura Infectious Diseases Inst, Minister of Publ Hlth,
Nonthaburi, Thailand and
2
Facultv of Med, Ramathibodi Hosp, Mahidol
Univ, Bangkok, Thailand
850 Hypersensitivity Reactions among Persons Receiving 3 Months
Regimen of Rifapentine + Isoniazid for Treatment of Latent
Tuberculosis Infection
Margarita Villarino*
1
, R Moro
1
, A Borisov
1
, F Adkinson
2
, E Phillips
3
,
G Shepherd
4
, C Ho
1
, S Weis
5
, T Sterling
6
, and TB Trials Consortium
1
2
3
Murdoch Univ, Australia,
4
New York Presbvterian/Weil Cornell Hosp,
NY, US,
5
Univ of North Texas Hlth Sci Ctr, Forth Worth, US, and
6
Janderbilt Univ, Nashville, TN, US
851 Evaluation of Symptom-based Screening for TB among
People Living with HIV in the Era of ART: Eastern Cape,
South Africa

Faiz Ahmad Khan*
1
, S Verkuijl
2
, F Chikwava
2
, R Ntumy
2
, and A Howard
1
1
Intl Ctr for AIDS Care and Treatment Prgms, Columbia Univ, New York,
NY, US and
2
Intl Ctr for AIDS Care and Treatment Prgms, Columbia
Univ, Pretoria, South Africa
852 Community-based Intensified Case Finding Targeting
Household Contacts of TB and HIV Patients: Urban South
Africa
Christopher Deery*
1
, C Hanrahan
2
, K Selibas
1
, J Bassett
3
, I Sanne
4
,
and A Van Rie
2
1
Clinical HIJ Res Unit, Johannesburg, South Africa,
2
Univ of North
Carolina Gillings Sch of Global Publ Hlth, Chapel Hill, US,
3
Witkoppen
Hlth and Welfare Ctr, Johannesburg, South Africa, and
4
Right to Care,
!

0(//*$1 23456$/'() 7%/')&#'/
The ART of TB Treatment
853 Efficacy and Safety of Raltegravir vs Efavirenz for the
Treatment of HIV/TB Patients: 48-Week Results of the
ANRS 12 180 Reflate TB Trial
Beatriz Grinsztejn*
1
, N De Castro
2
, V Arnold
3
, V Veloso
1
, JH Pilotto
4
,
C Brites
5
, C Vorsatz
1
, C Grondin
3
, G Chene
3,6
, and J-M Molina
2
1
IPEC, Fiocru:, Rio de Janeiro, Bra:il,
2
Hosp St-Louis, Univ Paris
Diderot, Paris France,
3
4
Hosp
Geral de Nova Iguacu, Bra:il,
5
Hosp Univ Pr Edgar Santos, Salvador,
Bra:il, and
6
CHU de Bordeaux, France
854 Completion Rate and Viro-Immunological Response to
Combined TB/HIV Treatment: Results from the RIFART
Study
Alberto Matteelli*
1
, AC Carvalho
1
, A Apostoli
1
, C Tinelli
2
, L Scudeller
2
,
I El Hamad
3
, S Bonora
4
, E Girardi
5
, A Gori
6
, and C Mussini
7
1
Univ of Brescia, Italv,
2
IRCCS San Matteo Pavia, Italv,
3
Spedali Civili of
Brescia, Italv,
4
5
IRCCS Spallan:ani, Rome, Italv,
6
7
Univ of Modena, Italv
855 Efficacy and Safety of Nevirapine- vs Efavirenz-based
ART in TB/HIV Patients in Burkina Faso: A Clinical and
Pharmacokinetic Study
Alberto Matteelli*
1
, AC Carvalho
1
, S Kouanda
2
, N Saleri
1
,
G Ouedraogo
2
, A Roggi
1
, P Villani
3
, M Regazzi
3
, L Monno
4
,
and S Diagbouga
2
1
Inst of Infectious and Tropical Diseases, Univ of Brescia, Italv,
2
Natl TB
Prgm, Ministrv of Hlth, Burkina Faso,
3
IRCCS, San Matteo, Pavia, Italv,
and
4
Clin of Infectious Diseases, Univ of Bari, Italv
856 Mortality Risk Factors in TB/HIV Co-infected Patients: Sub-
study of A5221
Alejandro Sanchez*
1
, X Zhang
2
, D Havlir
3
, A Luetkemeyer
3
,
J Kumwenda
4
, I Sanne
5
, P Ive
5
, and F Sattler
1
1
Univ of Southern California, Los Angeles, US,
2
Harvard Sch of Publ
3
4
Univ
of Malawi Coll of Med, Blantve, and
5
857 Early Clinical, Radiographic, and Bacteriologic Response to
Thrice-weekly Compared to Daily Anti-TB Treatment among
HIV
+
TB Patients

Narendran Gopalan*
1
, RK Santhanakrishnan
1
, V Perumal
1
,
M Aravind Menon
1
, N Gomathi
1
, S Lakshmanan
1
, C Chokalingam
2
,
S Rathinam
3
, C Suresh
1
, and S Swaminathan
1
1
Natl Inst for Res in Tuberculosis, Chennai, India,
2
Govt Hosp of Thoracic
Med, Tambaram, Chennai, and
3
Govt Stanlev Hosp, Chennai, India
858 Intensive Phase Bacillary Elimination Rate Predicts Clinical
Outcome in HIV
+
and HIV
-
Malawian Adults with Smear-
positive Pulmonary TB

Derek Sloan*
1,2,3
, H Mwandumba
1,2
, C Guwende
1
, G Chipungu
2
,
A Butterworth
1,2
, J Dutton
3
, R Heyderman
1,2
, E Corbett
1,2
, S Khoo
3
,
and G Davies
1,2,3
1
Malawi-Liverpool-Wellcome Trust Clin Res Prgm,
2
Coll of Med,
Univ of Malawi, and
3
Univ of Liverpool, UK
!

0(//*$1 23896$/'() 7%/')&#'/
Mechanisms of Immune Reconstitution
859 Early ART after Cryptococcal Meningitis Increases
Cerebrospinal Fluid Macrophage Activation and Aberrant Th2
Responses in a Multisite Randomized Trial
James Scriven*
1,2
, J Rhein
3,4
4
, M von Hohenberg
4
,
G Linder
4
, M RolIes
4
, D Williams
3,4
, D Meya
3,4,5
, G Meintjes
2
, D Boulware
4
,
1
2
Africa,
3
4
Univ of Minnesota,
Minneapolis, US, and
5
860 Impact of TB-associated Immune Reconstitution
Inflammatory Syndrome on T Cell Activation and
Reconstitution in Highly Immunosuppressed HIV/TB
Co-infected Patients Starting ART
V Haridas
1
, P Pean
2
, L Jasenosky
1
, Y Madec
3
, D Laureillard
4
, L Borand
2
,
O Marcy
5
, T Sok
5
, X Blanc
6
, and Anne GoldIeld*
1,5
1
Prgm in Cellular and Molecular Med, Childrens Hosp, Boston, MA,
US,
2
Inst Pasteur du Cambodge, Phnom Penh, Cambodia,
3
Inst Pasteur,
Paris, France,
4
ANRS, Ho Chi Minh Citv, Jietnam,
5
Cambodian Hlth
Committee, Phnom Penh, and
6
Bicetre Hosp Assistance Publ-Hosp de
Paris, France
861 (: ;*;$ Interferon Gamma Release Assay Responses to
Cryptococcal Capsule Antigen Predict Outcomes of Death
or Immune Reconstitution Inflammatory Syndrome after
Cryptococcal Meningitis

Darin Wiesner*
1
, A Akamps
2
, J Rhein
1,3
, D Williams
1,3
, D Meya
1,2,3
,
P Bohjanen
1
, K Nielsen
1
, D Boulware
1
, and Cryptococcal Optimal ART
Timing Trial
1
2
Makerere Univ, Kampala,
Uganda, and
3
862 Biomarkers of CD4
+
T Cell Activation in HIV
+
Patients
Developing !"#$%&#'()*+, '+%()#+.$/*/-associated Immune
Reconstitution Inflammatory Syndrome
Lisa Chakrabarti*
1
, C Boucherie
2
, F Bugault
1
, M-C Cumont
1
,
C Roussillon
2
, G Breton
3
, O Patey
4
, L Richert
2
, G Chene
2,5
, O Lortholary
6
,
and ANRS 129 BKVIR-CYTOK Substudy Group
1
2
3
Hosp de La Pitie-Salpetriere, Paris, France,
4
Hosp Jilleneuve
St-Georges, France,
5
CHU de Bordeaux, France, and
6
Univ Paris
Descartes, Hosp Necker Enfants Malades, APHP, Paris, France
!

0(//*$1 2<=56$/'() 7%/')&#'/
Cryptococcal Infections
863 Performance of the Cryptococcal Antigen Lateral Flow
Assay as a Diagnostic and Prognostic Tool for Cryptococcal
Meningitis
Taseera Kabanda*
1
, C Muzoora
1
, M Siedner
2
, and D Boulware
3
1
Mbarara Univ, Uganda,
2
and
3
Univ of Minnesota, Minneapolis, US
864 No Association of Cryptococcal Antigenemia with Death or
Loss to Follow Up among HIV Patients: Ethiopia

Christopher Smitson*
1
, A Tenna
2
, M Tsegaye
3
, A ShiIeraw
4
,
A AseIIa
4
, H Blumberg
1
, and R Kempker
1
1
2
Addis Ababa Univ, Ethiopia,
3
All Africa
Leprosv, TB and Rehabilitation Training Ctr, Addis Ababa, Ethiopia, and
4
Armaeur-Hansen Res Inst, Addis Ababa, Ethiopia
865 6*#>*& Secretory Protein Exhibits Antifungal and Antibiofilm
Activity against ?&1@*@& and ?)"A'$#$##+/, the Most Common
Fungal Pathogens in HIV Patients
J Chandra, P Mukherjee, Mahmoud Ghannoum*,
and OHARA/ACTG Mycology Unit
P
o
s
t
e
r

L
i
s
t
i
n
g
s
866 Prevalence of Fluconazole Resistance in !"#$%&'&''()
+,&-&"./+) Isolates from HIV
+
Patients in Kampala, Uganda

Beatrice Achan*
1
, D Boulware
2
, D Meya
1,2,3
, K Nielsen
2
,
1
2
Univ of Minnesota, Minneapolis,
US, and
3
!

0,))1&+ 23245&)%," 67)%"/'%)
Herpes Zoster
867 Incidence of Herpes Zoster among HIV
+
Patients on ART in
1ohannesburg, South Africa-Whom Should We Vaccinate?
K Shearer
1
, M Maskew
1
, T Ajayi
2
, P Majuba
3
, I Sanne
1,3
,
and Matthew Fox*
1,2,4
1
Sch of Clin Med, Facultv of Hlth Sci, Univ of the Witwatersrand,
2
Ctr for Global Hlth and Devt, Boston Univ,
MA, US,
3
Right to Care, Johannesburg, South Africa, and
4
Sch of Publ
Hlth, Boston Univ, MA, US
868 Acyclovir Prophylaxis Reduces the Incidence of Herpes
Zoster among HIV
+
Individuals:
Results of a Randomized Clinical Trial
Ruanne Barnabas*
1
, J Baeten
1
, J Lingappa
1
, K Thomas
1
, J Hughes
1
,
S Delany-Moretlwe
2
, G Gray
2
, A Ronald
3
, A Wald
1
, C Celum
1
, and
Partners in Prevention HSV/HIV Transmission Study Team
1
2
3
Univ of Manitoba, Winnipeg, Canada
!

0,))1&+ 23845&)%," 67)%"/'%)
CytomegalovirusHost Pathogen Interactions
869 Predictive Value of Antigenemia Assay in the Diagnosis of
Cytomegalovirus Gastrointestinal Diseases
Yohhei Hamada*
1
, N Nagata
2
, K Teruya
1
, H Gatanaga
1
, Y Kikuchi
1
,
and S Oka
1
1
AIDS Clin Ctr, Natl Ctr for Global Hlth and Med, Tokvo, Japan and
2
Natl Ctr for Global Hlth and Med, Tokvo, Japan
870 Characterization of the Exhaustive Phenotype between HIV-
1- and CMV-specific CD8
+
T Cells Reveals Distinct Immune
Reconstitution Potential
Nathali Grageda*
1
, S Westrop
1
, M Nelson
2
, C Burton
1
, G Rosignoli
1
,
S Mandalia
1,2
, A Jackson
2
, G Moyle
2
, and N Imami
1
1
Imperial Coll London, UK and
2
Chelsea and Westminster Hosp, London, UK
!

0,))1&+ 23945&)%," 67)%"/'%)
Syphilis: Not Gone, Not Forgotten
871 The Increase in Syphilis Cases in the HIV Natural History
Study Is Attributable in Part to Repeat Infections
Anuradha Ganesan*
1,2
, O Mesner
1
, C Olsen
1,3
, C Bradley
1,3
, J Maguire
1,4
,
M Bavaro
1,5
, A Weintrob
1,2
, J Okulicz
1,3
, G Macalino
1
, B Agan
1
, and IDCRP
HIV/STI Working Group
1
Infectious Disease Clin Res Prgm, Uniformed Svcs Univ, Bethesda,
MD, US,
2
Walter Reed Natl Militarv Med Ctr, Bethesda, MD, US,
3
San
Antonio Militarv Med Ctr, TX, US,
4
Naval Med Ctr Portsmouth, JA, US,
and
5
Naval Med Ctr San Diego, CA, US
872 Comparison of Effectiveness of 1 Dose vs 3 Doses of
Benzathine Penicillin in the Treatment of Early Syphilis in
HIV
+
Patients
Chia-Jui Yang and Taiwan HIV InIection and Syphilis Study Group
Far Eastern Memorial Hosp, New Taipei Citv, Taiwan
873 Factors Associated with Biologic False Positive Rapid Plasma
Reagin Serologies in a Longitudinal Cohort of HIV
+
Persons
Ikwo Oboho*, K Gebo, R Moore, and K Ghanem
!

0,))1&+ 23:45&)%," 67)%"/'%)
Opportunistic Infections and Other Novel Pathogens
874 ;..&+)1/ <&,"1=>/??1/+/ )$@ +&A@B a Novel Dimorphic
Human Fungus Causing Disseminated Infection among
Immunocompromized Hosts:
South Africa

Chris Kenyon*
1
, K Bonorchis
1
, C Corcoran
2
, H Vismer
3
, M Van Wyk
2
,
C BamIord
1
, R Colebunders
4
, A Bornman
3
, M Mendelson
1
, and N Govender
5
1
2
Ampath Natl Reference Lab,
Centurion, South Africa,
3
Natl Mvcologv Reference Lab, Bristol, UK,
4
Inst
for Tropical Med, Antwerp, Belgium, and
5
Natl Inst for Communicable
Diseases, Johannesburg, South Africa
875 Development of a Taqman Real-time Polymerase Chain
Reaction Assay for Rapid Detection of 5,+1'1CC1(. ./"+,--,1
Infection

Ha Hien*
1
, T Thanh
1
, N Thu
1
, N Cuc
2
, N Lan
2
, N Hoa
1
, C Shikuma
3
,
J Farrar
1
, J Day
1
, and T Le
1,3
1
Oxford Univ Clin Res Unit, Jietnam,
2
Hosp for Tropical Diseases, Ho
Chi Minh Citv, Jietnam, and
3
Hawaii Ctr for AIDS, Univ of Hawaii at
Manoa, Honolulu
876 Prevalence of Malaria and Bacteremia in Ambulatory,
Febrile, and/or Anemic HIV
+
Mozambican Adults:
A Prospective Observational Study
Paula Brentlinger*
1
, W Silva
1
, E Valverde
1
, M Buene
1
, L Morais
1
,
M da Rocha
2
, J Azarate Jahar
3
, and T Moon
1
1
Friends in Global Hlth, Quelimane, Mo:ambique,
2
District Directorate
of Hlth, Namacurra, Mo:ambique, and
3
District Directorate of Hlth,
Inhassunge, Mo:ambique
877 HIV-associated Salivary Gland Disease: Identification of a
Potentially Treatable Etiologic Agent
L JeIIers, R Burger-Calderon, and JenniIer Webster-Cyriaque*
!

0,))1&+ 23345&)%," 67)%"/'%)
Vaccines: TB, Pneumococcus, and Influenza
878 Safety and Immunogenicity of AERAS-402 in HIV
+
, BCG-
vaccinated Adults with CD4
+
Lymphocyte Counts >350 Cells/
mm
3

Gavin Churchyard*
1,2
, B Landry
3
, M Snowden
3
, R Pandian
3
,
M Douoguih
4
, and T Evans
3
1
Aurum Inst, Johannesburg, South Africa,
2
3
Aeras, Rockville, MD, US, and
4
Crucell,
Leiden, The Netherlands
879 Baseline Frequency of Nave (Directly) and Terminally
Differentiated (Inversely) T Cells Is Associated with
Seroprotection after H1N1 Vaccination

Lorenzo Ramirez*
1
, P Tebas
2
, A Daniel
1
, I Frank
2
, and J Boyer
1
1
Univ of Pennsvlvania Perelman Sch of Med, Philadelphia, US and
2
Univ
of Pennsvlvania, Philadelphia, US
880 Immunogenicity and Safety of 13-Valent Pneumococcal
Conjugate Vaccine in HIV
+
Adults with Prior 23-Valent
Pneumococcal Polysaccharide Vaccination
Marshall Glesby*
1
, C Brinson
2
, R Greenberg
3
, J Lalezari
4
, D Scott
5
,
B Schmoele-Thoma
6
, A Gurtman
5
, R Natuk
5
, M Patton
7
, and W Watson
8
1
2
Central Texas Clin Res,
LLC, Austin, US,
3
Univ of Kentuckv Med Ctr, Lexington, US,
4
Quest Clin
Res, San Francisco, CA, US,
5
Pfi:er, Inc, Pearl River, NY, US,
6
Pfi:er
Pharma GmbH, Berlin, Germanv,
7
Pfi:er, Inc, Maidenhead, UK, and
8
Pfi:er, Inc, Collegeville, PA, US
!

0,))1&+ 23D45&)%," 67)%"/'%)
HIV Shedding and Impact of Infection on Immune
Cells in Women
881 Cervico-vaginal HIV-1 Shedding in Women Taking ART:
Burkina Faso, a Longitudinal Study
A Low
1
, I Konate
2
, Nicolas Nagot*
3
, H Weiss
1
, D Kania
2
, P Vickerman
1
,
M Segondy
3
, N Meda
2
, P van de Perre
3
, P Mayaud
1
, and Yerelon Study Group
1
2
Ctr Mura:, Bobo-
Dioulasso, Burkina Faso, and
3
Univ Montpellier-1, France
882 Cyclic Changes in HIV Shedding from the Female Genital
Tract during the Menstrual Cycle
Marcel Curlin*
1
, W Leelawiwat
2
, E Dunne
1
, W Chonwattana
2
, P Mock
2
,
F Mueanpai
2
, S Thep-Amnuay
3
, S Whitehead
1,2
, and J McNicholl
1
1
2
Thailand Ministrv of Publ Hlth-Ctrs for Disease
Control and Prevention Collaboration, Nonthaburi, and
3
Independent
Consultant
883 Metagenomic Characterization of the Vaginal Microbiome in
HIV
+
Women Using Culture Independent Methods
Daljeet Mahal*
1
, B Chaban
2
, A Albert
3
, L Vicol
4
, E Wagner
3
, J Hill
2
,
S Hemmingsen
2,5
, N Pick
4
, D Money
1,3
, and Vogue Study Group
1
2
Univ of Saskatchewan,
Saskatoon, Canada,
3
Women`s Hlth Res Inst, Jancouver, Canada,
4
Oak
Tree Clin, Jancouver, Canada, and
5
Plant Biotech Inst, Saskatoon, Canada
884 HIV Target Cells in the Genital Mucosa in Patients with
Female Genital Schistosomiasis
Elisabeth Kleppa*
1,2
, V Ramsuran
3,4
, S Zulu
5
, GH Karlsen
6
, K Lillebo
1,2
,
M Taylor
5
, M Onsrud
1
, SG Gundersen
7,8
, E Kjetland
1,5
, and T Ndungù
5
1
Oslo Univ Hosp, Norwav,
2
Univ of Oslo, Norwav,
3
Cancer Inflammation
Prgm, Frederick, MD, US,
4
Ragon Inst of MGH, MIT and Harvard Univ,
Charlestown, MA, US,
5
6
Aarhus Univ, Denmark,
7
Sorlandet Hosp, Kristiansand, Norwav, and
8
Univ of Agder, Kristiansand, Norwav
Program 59
P
o
s
t
e
r

L
i
s
t
i
n
g
s
885 The Impact of Valacyclovir on Systemic Immune Activation and
Regulatory T Cell Frequencies in Herpes Simplex Virus Type
2-infected, HIV
-
Women
Tae Joon Yi*
1
, S Kumar
1
, B Shannon
1
, L Chieza
2
, M Saunders
2
,
W Tharao
2
, S Huibner
1
, and R Kaul
1
1
Univ of Toronto, Canada and
2
Womens Hlth in Women`s Hands,
Toronto, Canada
!

"#$$%&' ()*+,&$-#. /0$-.12-$
Hepatitis C Virus Testing in Women
886 High-risk Human Papillomavirus Testing using Real-time
Polymerase Chain Reaction on Urine Compared to Vaginal
Swabs in Women Infected with HIV
V Rabier, Y-M Vandamme, Jean-Marie Chennebault*, P Fialaire,
P Abgueguen, S Rehaiem, S Fanello, E Pichard, F Lunel-Fabiani,
and A Ducancelle
Univ Hosp, Angers, France
887 6-Month Follow-up of Visual Inspection with Acetic Acid and
Immediate Cryotherapy among HIV
+
Women: Western Kenya
Orango Omenge*
1
, P Itsura
1
, T Liu
2
, H Mabeya
1
, A ChristoIIersen-Deb
1,3
,
S Washington
4
, and S Cu-Uvin
2
1
Moi Teaching and Referral Hosp/Moi Univ Sch of Med, Eldoret, Kenva,
2
Brown Univ/The Miriam Hosp, Providence, RI, US,
3
Univ of Toronto,
Canada, and
4
Albert Einstein Univ, NY, US
!

"#$$%&' ()3+,&$-#. /0$-.12-$
HIV Risk Factors, Prevalence, and Barriers to Care
888 South African Women with Recent Pregnancy RarelyKnow
Partner`s HIV Status: Implications for Interventions
Targeting Serodiscordant Couples
Lynn Matthews*
1
, D Bangsberg
1
, C MilIord
2
, N Mosery
2
, R Greener
2
,
A Kaida
3
, C Psaros
1
, S SaIren
1
, and J Smit
2
1
2
and
3
889 Pregnancy Intentions and Reproductive Behaviors in HIV
+

and HIV
-
Women: US

Chinenye Ugoji*
1
, H Watts
2
, M Young
3
, M Cohen
4
, R Karim
5
,
R Wright
6
, D Cohan
7
, H MinkoII
8
, and E Golub
9
1
2
and Human Devt, Rockville, MD, US,
3
Georgetown Univ Med Ctr,
Washington, DC, US,
4
Stroger Hosp and Rush Univ, Chicago, IL, US,
5
Ctr for Hlth Professions, Univ of Southern California, Los Angeles, US,
6
Albert Einstein Coll of Med and Montefiore Med Ctr, New York, NY, US,
7
8
Maimonides Med Ctr and SUNY
Downstate, New York, NY, US, and
9
Johns Hopkins Univ Bloomberg Sch
of Publ Hlth, Baltimore, MD, US
890 Changes in Sexual Risk Behavior: Mombasa Cohort, 1993-2007
Susan Graham*
1,2
, J Raboud
3,4
, W Jaoko
2
, K Mandaliya
5
, S McClelland
1,2
,
and A Bayoumi
3,6
1
2
3
Univ of
Toronto, Canada,
4
Univ Hlth Network, Toronto, Canada,
5
PathCare,
Mombasa, Kenva, and
6
St Michaels Hosp, Toronto, Canada
891 The Tide Has Finally Turned -Declining HIV Prevalence
among Young Antenatal Women, 15-29 Years: Botswana
Antenatal Sentinel Surveillance, 1992-2011
Madisa Mine*
1,2
, S Moyo
2
, K Makhaola
1,2
, and T Gaolathe
2
1
Natl Hlth Lab, Gaborone, Botswana and
2
Botswana Harvard AIDS Inst
Partnership, Gaborone
892 Barriers to HIV Care for Women of Color Living in the
US South and Co-morbidity, Social Support, and Self-
determination
M Toth
1
, Byrd Quinlivan*
1
, and L Messer
2,3
1
2
Portland State Univ, OR,
US, and
3
893 Women Released from 1ail Experience Suboptimal HIV
Treatment Outcomes Compared to Men: Results from a
Multi-center Study
Jaimie Meyer*
1,2
, A Zelenev
1
, J Wickersham
1
, C Williams
3
, P Teixiera
4
,
and F Altice
1,2
1
2
Yale Univ Sch of Publ Hlth,
New Haven, CT, US,
3
Univ of Illinois at Chicago Sch of Publ Hlth, US,
and
4
New York Citv Dept of Hlth and Mental Hvgiene, NY, US
894 Endogenous Reproductive Hormone Concentrations and
HIV Infection in African Women
Sufa Dadabhai*
1
, W Clarke
2
, B Makanani
3
, F Taulo
3
, N Kumwenda
1
,
J Sun
1
, S Schools
2
, A Breaud
2
, J Kumwenda
3
, and T Taha
1
1
2
Johns Hopkins Univ Med Inst, Baltimore, MD, US, and
3
Coll of Med,
Univ of Malawi, Blantvre
!

"#$$%&' ()4+,&$-#. /0$-.12-$
Family Planning: Unintended Pregnancy and Unmet
Need
895 Periconception HIV Risk Behavior among Men and Women
Reporting Serodiscordant Partners: KwaZulu-Natal, South
Africa
Lynn Matthews*
1
, D Bangsberg
1
, C MilIord
2
, N Mosery
2
, R Greener
2
,
A Kaida
3
, C Psaros
1
, S SaIren
1
, and J Smit
2
1
2
and
3
896 Predictors of Unplanned Pregnancies among Women Living
with HIV: US
Lisa Rahangdale*
1
, S Cohn
2
, R Stewart
3
, J Levison
4
, G Lazenby
5
,
M Badell
6
, M Nguyen
6
, M KempI
7
, M Sturdevant
7
, P Ellis
8
, and HIV
and OB Pregnancy Ed Study
1
2
Northwestern Univ Feinberg
Sch of Med, Chicago, IL, US,
3
Univ of Texas Southwestern Med Ctr,
Dallas, US,
4
5
Med Univ of South
Carolina, US,
6
7
Univ of Alabama at
Birmingham, US, and
8
Louisiana State Univ, Baton Rouge, US
897 Trends in Contraceptive Use and Choice of Contraceptive
Method in a Rural South African Population-based Cohort
during the ART Era, 2005-2011
Nuala McGrath*
1,2
, J Eaton
3
, and M-L Newell
2,4
1
2
Population Studies, KwaZulu-Natal, South Africa,
3
Imperial Coll London,
UK, and
4
Inst of Child Hlth, Univ Coll London, UK
898 Unmet Need for Family Planning, Contraceptive Failure,
and Unintended Pregnancy among Women Living with HIV
Infection: Zimbabwe
Sandra McCoy*
1
, R Buzdugan
1
, L Ralph
1
, A Mushavi
2
, A Mahomva
3
,
C Watadzaushe
4
, J Dirawo
4
, C Frances
4,5
, and N Padian
1
1
2
Ministrv of Hlth and Child Welfare,
Harare, Zimbabwe,
3
Eli:abeth Glaser Pediatric AIDS Fndn, Harare,
Zimbabwe,
4
Ctr for Sexual Hlth and HIJ Res, Harare, Zimbabwe, and
5
!

"#$$%&' (56+,&$-#. /0$-.12-$
HIV in Peri- and Post-menopause
899 Increased Hot Flash Severity and Burden among
Perimenopausal HIV
+
Women
Sara Looby*
1
, H JoIIe
1
, J ShiIren
1
, I Corless
2
, A Rope
1
, M Pedersen
1
,
and S Grinspoon
1
1
2
Massachusetts Gen Hosp Inst
of Hlth Professions, Charlestown, US
900 Comparison of Tenofovir Plasma Concentrations in Post-
menopausal vs Pre-menopausal HIV
+
Women
Cristina Gervasoni*, P Meraviglia, S Landonio, C Impagnatiello,
M Galli, G Rizzardini, A Riva, and D Cattaneo
Luigi Sacco Hosp, Milan, Italv
901 Differences by Age for Women`s Response to Initial HAART:
Meta-analysis of Clinical Trials Submitted to the US Food
and Drug Administration, 2000-2010
J Yan, G Soon, S Zhou, M Min, K Chan-Tack, Kimberly Struble*,
J Murray, and D Birnkrant
Ctr for Drug Evaluation and Res, FDA, Silver Spring, MD, US
902 Impaired Antibody Response to Influenza Vaccine Is
Associated with the Activation Status of Peripheral T
Follicular Helper Cells in Post-menopausal Women
Anita Parmigiani*, M Alcaide, M Fischl, and S Pahwa
!

"#$$%&' (5(+,&$-#. /0$-.12-$
HIV Testing and ARV Drug Resistance during
Pregnancy
903 Timing of HIV Tests during Pregnancy in Rural Uganda and
Risk of Undiagnosed Infection at Birth
F Tabu
1
, K MacLeod
1,2
, and

Mark Siedner*
3
1
2
Mersev Deanerv Hosp, Liverpool,
UK, and
3
Massachusetts Gen Hosp Ctr for Global Hlth, Boston, US
904 HIV Testing among Commercially Insured Pregnant
Women: US, 2009-2010
Allan Taylor*
1
, M Furtado
1,2
, L Hall
1,3
, and S Nesheim
1
1
2
Dvnamics Res Corp, Andover, MA, US,
and
3
P
o
s
t
e
r

L
i
s
t
i
n
g
s
905 High Rates of Baseline ARV Resistance among HIV
+

Pregnant Women: Rio de 1aneiro, Brazil
MD Teixeira
1
, E Santos
1
, MI Gouvea
1
, Esau Joao*
1
, N Yeganeh
2
,
L Ceci
1
, F Lattanzi
1
, ML Cruz
1
, LC Sidi
1
, and K Nielsen-Saines
2
1
Hosp dos Servidores do Estado, Rio de Janeiro, Bra:il and
2
David Geffen
Sch of Med, Univ of California, Los Angeles, US
!

"#$$%&' ()*+,&$-#. /0$-.12-$
ART, Viral Suppression, and MTCT
906 MTCT Continues to Decline in the UK and Ireland: 2007-2011
C Townsend,

Laura Byrne*, C Thorne, M Cortina-Borja,
C Peckham, and P Tookey
Univ Coll London Inst of Child Hlth, UK
907 Is Intrapartum Prophylaxis for MTCT Still Useful
in the HAART Era?

Nelly Briand*
1
, J Warszawski
1,2
, A Faye
3,4
, J Le Chenadec
1
,
C DollIus
5
, J-P Teglas
1
, R Tubiana
6
, C Rouzioux
7
, L Mandelbrot
1,4,8
,
S Blanche
7
, and ANRS EPF Study Group
1
INSERM U1018, CESP, Le Kremlin-Bicetre, France,
2
Univ Paris-Sud,
AP-HP, Hosp Bicetre, Le Kremlin Bicetre, France,
3
AP-HP, Hosp Robert
Debre, Paris, France,
4
Univ Paris 7, France,
5
AP-HP, Hosp Trousseau,
Paris, France,
6
AP-HP, Hosp Pitie Salpetriere, INSERM, U943, Paris,
France,
7
AP-HP, Hosp Necker-Enfants Malades, Univ Paris Descartes,
Paris, France, and
8
AP-HP, Hosp Louis Mourier, Colombes, France
908 Detectable Viral Load at Delivery in HIV
+
Women
on cART and Virologically Suppressed Antenatally
Deborah Money*
1,2,3
, J van Schalkwyk
1,2,3
, N Pick
1,2
, A Alimenti
2
,
T Chaworth-Musters
1
, E Wagner
3
, A Albert
3
, E Maan
2
, M Murray
1,2,3
,
K Tullock
1,2
, and Oak Tree Clin Res Group
1
2
Oak Tree Clin, BC
Women`s Hosp, Jancouver, Canada, and
3
Women`s Hlth Res Inst,
Jancouver, Canada
909 Trends and Factors Associated with Virological Failure
among Women Conceiving on cART: Western Europe
Heather Bailey*, C Townsend, M Cortina-Borja, C Thorne,
and European Collaborative Study in EuroCoord
910 Differential Characteristics of HIV
+
Pregnant Women by
Mode of HIV Acquisition: An Observational Study at an
Urban Hospital
Martina Badell*, A Kachikis, L Haddad, ML Nguyen, and M Lindsay
!

"#$$%&' ()3+,&$-#. /0$-.12-$
ARV Strategies, MTCT, and HIV-free Survival
911 Impact of the WHO`s Option B PMTCT Strategy on
Population HIV-free Survival: A Community Survey in
Kafue, Zambia
Benjamin Chi*
1,2
, N Chintu
2
, P Musonda
2,3
, M Gartland
2
, S Mulenga
2
,
M Lembalemba
4
, M Bweupe
5
, E Turnbull
2
, E Stringer
1,2
, and J Stringer
1,2
1
2
Ctr for Infectious Disease
Res in Zambia, Lusaka,
3
Univ of East Anglia, Norwich, UK,
4
Kafue
District Hlth Mgmt Team, Zambia, and
5
Ministrv of Hlth, Lusaka, Zambia
912 Towards Elimination of Breastfeeding Transmission by
Infant Peri-exposure Prophylaxis: Results of ANRS 12174
Trial Using Boosted Lopinavir or Lamivudine in Africa
Thorkild Tylleskar*
1
, N Nagot
2
, C Kankasa
3
, N Meda
4
, J Tumwine
5
,
A Aku
6
, M Mwiya
3
, G Ndeezi
5
, R Vallo
2
, P Van de Perre
2
, and ANRS
12174 Study Group
1
Univ of Bergen, Norwav,
2
INSERM U1058 and Univ Montpellier 1,
France,
3
4
Univ de Ouagadougou,
Burkina Faso,
5
Makerere Univ, Kampala, Uganda, and
6
Univ of the
Western Cape, Cape Town, South Africa
913 ARV Management of Antenatal and Natal HIV Infection in
Dodoma Region, Tanzania: 6-Month Longitudinal Outcome
of Antiretroviral Management of Antenatal and Natal HIV
Infection Study
Francesco Vairo*
1
, Z Chaula
2
, and AMANI Study Group
1
Natl Inst for Infectious Diseases L Spallan:ani, Rome, Italv and
2
Dodoma
Regional Referral Hosp, Tan:ania
!

"#$$%&' ()4+,&$-#. /0$-.12-$
PMTCT Implementation: Barriers and Program
Innovations
914 Barriers to Participation in Early Infant Diagnosis and
Treatment of HIV: Malawi
Elizabeth Cromwell*
1
, A Dow
1
, Q Dube
2
, D Low
3
, and A Van Rie
1
1
2
Malawi-Liverpool-Wellcome
Trust Clinical Res Prgm, Queen Eli:abeth Central Hosp, Blantvre, and
3
Univ of Washington Sch of Med, Seattle, US
915 Adaptation of Immunization`s Reaching Every District
Approach Improves Uptake of and Retention in PMTCT
Services: Bondo District, Kenya
Lynn Kanyuuru*
1
, M Kabue
1
, I Malonza
1
, L Archer
1
, K Curran
2
,
T Adamu
3,4
, and T Jacobs
5
1
Jhpiego/Maternal and Child Hlth Integrated Prgm, Nairobi, Kenva,
2
Jhpiego, Baltimore, MD, US,
3
Jhpiego/Maternal and Child Hlth
Integrated Prgm, Baltimore, MD, US,
4
Sch of Publ Hlth, Baltimore, MD, US, and
5
USAID, Washington, DC, US
916 Uganda`s Innovative Interventions in PMTCT Produce
Dramatic Gains in Linkage and Retention of HIV
+
Pregnant
Women and Their HIV-exposed Children
GodIrey Esiru*
1
, J Grosz
2
, L Nabitaka
1
, and V Narayan
2
1
Ministrv of Hlth, Kampala, Uganda and
2
Clinton Hlth Access Initiative,
Kampala, Uganda
917 The Cost-effectiveness of Point-of-Care CD4 Testing in
Antenatal Care in South Africa
Andrea Ciaranello*
1
, L Myer
2
, S Christensen
1,3
, K Kelly
1
, K Daskilewicz
2
,
K Doherty
1
, L-G Bekker
4
, T Hou
1
, K Freedberg
1,5
, and R Walensky
1,5,6
1
Massachusetts General Hosp, Boston, MA, US,
2
Univ of Cape Town
Sch of Public Health and Familv Medicine, Cape Town, South Africa,
3
Amherst College, Amherst, MA, US,
4
Univ of Cape Town Desmond Tutu
HIJ Centre, Cape Town, South Africa,
5
Harvard Univ Ctr for AIDS Res,
Boston, MA, US, and
6
!

"#$$%&' ()5+,&$-#. /0$-.12-$
Pregnancy Complications among HIV
+
Women
918 Gestational Diabetes in HIV
+
and HIV
-
Pregnant Women:
Cameroon
JenniIer Jao*
1
, J Wisnivesky
1
, R Van Dyke
2
, M GeIIner
3
, E Nshom
4
,
D Palmer
4
, P Tih
4
, D LeRoith
1
, E Abrams
5
, and R Sperling
1
1
2
Tulane Univ Hlth Sci Ctr,
New Orleans, LA, US,
3
Univ of Southern California Keck Sch of Med,
Los Angeles, US,
4
Cameroon Baptist Convention Hlth Svcs, Bamenda,
and
5
Intl Ctr for AIDS Care and Treatment Prgm, Columbia Univ,
New York, NY, US
920 Vitamin D Inadequacy in HIV
+
Women on HAART Is
Not Associated with Morbidity, Mortality, or Growth
Impairment of Uninfected Infants: Botswana
Kathleen Powis*
1,2,3
, W Fawzi
2
, L Smeaton
2
, M Hughes
2
, S Lockman
2,3,4
,

A Ogwu
3
, S Moyo
3
, J Makhema
3
, M Essex
2,3
, and R Shapiro
5
1
2
Boston, MA, US,
3
Botswana-Harvard AIDS Inst Partnership, Gaborone,
4
Brigham and Womens Hosp, Botson, MA, US, and
5
Beth Israel
Deaconess Med Ctr, Boston, MA, US
!

"#$$%&' ())+,&$-#. /0$-.12-$
PMTCT: Maternal and Child Health Outcomes
921 Post-ARV Outcomes among Women Who Received Triple-
ARV Regimens from Pregnancy to Weaning as PMTCT:
Kenya, 2003-2009
Timothy Minniear*
1,2
, S Girde
3
, F Angira
4
, L Mills
2,4
, C Zeh
2,4
, P Peters
2
,
R Masaba
4
, R Lando
4
, T Thomas
2
, and A Taylor
2
1
Epidemic Intelligence Svc, CDC, Atlanta, GA, US,
2
Div of HIJ/AIDS
Prevention, CDC, Atlanta, GA, US,
3
CDC Information Mgmt Svcs, ICF
Intl, Atlanta, GA, US, and
4
Kenva Med Res Inst/CDC Res and Publ Hlth
Collaboration, Kisumu
922 Maternal ART for the Prevention of Breastfeeding
Transmission in Malawi: Maternal and Infant Outcomes 2
Years after Delivery
Marina Giuliano*
1
, M Andreotti
1
, G Liotta
2,3
, H Jere
3
, J-B Sagno
3
,
R Amici
1
, MC Marazzi
4
, S Vella
1
, L Palombi
2,3
, and S Mancinelli
2,3
1
Istituto Superiore di Sanita, Rome, Italv,
2
Univ of Tor Jergata, Rome,
Italv,
3
DREAM Prgm, Communitv of S Egidio, Blantvre, Malawi, and
4
LUMSA Univ, Rome, Italv
923 Abacavir and Lamivudine Exposure during Pregnancy and
Birth Outcomes: Data from the ARV Pregnancy Registry
Vani Vannappagari*
1,2
, J Albano
3
, H Tilson
2
, C Gee
3
, A Gandhi
2
,
N Koram
1
, and C Ryan
3
1
GlaxoSmithKline, Research Triangle Park, NC, US,
2
Univ of North
Carolina at Chapel Hill, US, and
3
INC Res, Raleigh, NC, US
Program 61
P
o
s
t
e
r

L
i
s
t
i
n
g
s
924 Adverse Fetal Outcomes in HIV-1
+
Women Who Received
either NNRTI- or Protease Inhibitor-based Therapy for
PMTCT
R Masaba
1
, C Zeh
2
, S Girde
3
, C BorkowI
4
, R Ndivo
1
, I Nyangau
1
,
K Achola
1
, T Thomas
2
, and Shirley Lee Lecher*
4
1
Kenva Med Res Inst, Kisumu,
2
CDC, Kisumu, Kenva,
3
ICF Intl, Atlanta,
GA, US, and
4
925 Pregnancy Outcomes in HIV
+
Women with Advanced
Maternal ( Age 35 Years)
Giuseppina Liuzzi*
1
, C Pinnetti
1
, E Tamburrini
2
, M Ravizza
3
,
A Vigano
4
, A degli Antoni
5
, G Guaraldi
6
, A Maccabruni
7
, M Floridia
8
,
and Italian Group on Surveillance on ART in Pregnancy
1
Natl Inst for Infectious Diseases La::aro Spallan:ani, Rome, Italv,
2
Catholic Univ, Rome, Italv,
3
S Paolo Hosp, Milan, Italv,
4
Luigi Sacco
Hosp, Univ of Milan, Italv,
5
A:ienda Ospedaliera di Parma, Italv,
6
Univ
of Modena and Reggio Emilia, Modena, Italv,
7
IRCCS S Matteo, Pavia,
Italv, and
8
Istituto Superiore di Sanita, Rome, Italv
926 Safety of !" $%&'o and Neonatal ARV Exposure: Effects on
Cognitive and Academic Outcomes in
HIV-exposed, Uninfected Children at Age 5-13 Years
Molly Nozyce*
1
, Y Huo
2
, P Williams
2
, S Kapetanovic
3
, R Hazra
4
,
S Nichols
5
, S Hunter
6
, K Rich
6
, G Seage
2
, P Sirois
7
, and Pediatric
HIV/AIDS Cohort Study
1
Jacobi Med Ctr, Bronx, NY, US,
2
MA, US,
3
Natl Inst of Mental Hlth, NIH, Washington, DC, US,
4
Natl Inst
of Child Hlth and Human Devt, NIH, Washington, DC, US,
5
Univ of
6
Univ of Chicago, IL, US, and
7
Tulane Univ
Sch of Med, New Orleans, LA, US
!

(&))!*" +,-./*)%&' 01)%'23%)
Breast Feeding and Prevention of Postnatal MTCT
927 Predictors of Early Breastfeeding Cessation among HIV
+

Women in the Mma Bana Study, Botswana

Anthony Ogwu*
1,2
, S Moyo
1
, D Kitch
2
, J Leidner
2
, K Powis
1,2
,
S Lockman
1,2,3
, J Makhema
1,2
, M Pagano
2
, M Essex
1,2
, and R Shapiro
1,2,4
1
Botswana-Harvard AIDS Inst, Gaborone,
2
Boston, MA, US,
3
Brigham & Womens Hosp, Boston, MA, US, and
4
Beth
Isreal Deaconess Med Ctr, Boston, MA, US
928 Challenges Reported by HIV
+
Mothers Administering Long-
term Nevirapine Syrup to Their Infants at Home: Mulago
Hospital, Uganda

Joyce Namale Matovu*
1
, Z Namukwaya
1
, M Mubiru
1
, E Musingye
1
,
M Kyarimpa
1
, A Kakande
1
, S Kamya
1
, P Musoke
1
, M Kamya
2
,
and MG Fowler
1,3
1
Makerere UnivJohns Hopkins Univ Res Collaboration, Kampala,
Uganda,
2
Mulago Mbarara Teaching Hosp Joint AIDS Prgm, Kampala,
Uganda, and
3
Johns Hopkins Med Inst, Baltimore, MD, US
929 Daily Infant Nevirapine through 6 Months of Life
for PMTCT: Adherence and Nevirapine Exposure

Jim Aizire*
1
, E Capparelli
2
, C Herron
3
, E Brown
3
, A Desmond
4
,
S Eshleman
5
, B Maldonado
6
, K Manji
7
, MG Fowler
5
, M Mirochnick
8
,
and HPTN 046 Study Team
1
Makerere Univ-Johns Hopkins Univ Res Collaboration, Kampala,
Uganda,
2
3
Fred Hutchinson Cancer
Res Ctr, Seattle, WA, US,
4
CAPRISA, Nelson R Mandela Sch of Med,
5
Johns Hopkins Univ
6
Stanford Univ Sch of Med, CA, US,
7
Muhimbili Univ of Hlth and Allied Sci, Dar es Salaam, Tan:ania, and
8
930 Role of Intestinal Mucosal Integrity in HIV Transmission
to Infants through Breastfeeding: the Breastfeeding,
Antiretrovirals, and Nutrition Study
Athena Kourtis*
1
, C Ibegbu
2
, J Wiener
1
, C King
1
, G Tegha
3
, D Kamwendo
3
,
V Flax
4
, D Kayira
3
, C van der Horst
4
, D Jamieson
1
, and BAN Study Team
1
2
3
UNC Profect,
Lilongwe, Malawi, and
4
!

(&))!*" +,4./*)%&' 01)%'23%)
ARV Pharmacokinetics during Pregnancy and
Breast Feeding
931 A Comparison of the Pharmacokinetics of Maraviroc during
Pregnancy and Postpartum

Angela Colbers*
1
, B Best
2
, J Wang
3
, A Stek
4
, C Hidalgo Tenori
5
,
D Hawkins
6
, G Taylor
7
, E Capparelli
2
, D Burger
1
, M Mirochnick
8
,
on behalI oI PANNA Network and IMPAACT P1026
1
2
Univ of California,
San Diego, US,
3
Ctr for Biostatistics in AIDS Res, Harvard Sch of Publ
4
Univ of Southern California Keck Sch of Med, Los
Angeles, US,
5
Hosp Univ Jirgen de las Nieves Granada, Spain,
6
Chelsea
and Westminster Hosp, London, UK,
7
Imperial Coll Hlthcare NHS Trust,
London, UK, and
8
932 Therapeutic Levels of Lopinavir in Late Pregnancy, and
Abacavir Passage into Breast Milk: Mma Bana Study,
Botswana
R Shapiro
1,2,3
, S Rossi
4
,

Anthony Ogwu*
3
, M Moss
4
, J Leidner
1
,
S Lockman
1,3,5
, S Moyo
3
, J Makhema
1,3
, M Essex
1,3
, and E Capparelli
4
1
2
Beth Israel Deaconess Med
Ctr, Boston, MA, US,
3
Botswana-Harvard Partnership, Gaborone,
4
Univ
of California, San Diego, US, and
5
Brigham and Womens Hosp, Boston,
MA, US
933 Exposure of Breastfed Infants to Maternal Efavirenz from
Breast Milk

Adeniyi Olagunju*
1,2
, A Amara
2
, J Tjia
2
, M Siccardi
2
, J Oyigboja
3
,
O Bolaji
1
, S Khoo
2
, and A Owen
2
1
Obafemi Awolowo Univ, Ile-Ife, Nigeria,
2
Univ of Liverpool, UK,
and
3
Ctr for Clin Res, Nigeria
934 Effect of Seven Days Phenytoin on Pharmacokinetics of
and Resistance to Single-dose Nevirapine for Perinatal HIV
Prevention: A Randomized Pilot Study

Catherine Chunda*
1
, Q Fillekes
2
, E Muro
3
, M Thomason
4
,
S Aitken
5
, E Kisanga
3
, C Kankasa
1
, D Gibb
4
, S Walker
4
, and D Burger
2
1
2
Radboud Univ Nifmegen Med
Ctr, The Netherlands,
3
Kilimanfaro Christian Med Coll, Moshi, Tan:ania,
4
5
Utrecht Univ Med Ctr, The
Netherlands
!

(&))!*" +,5./*)%&' 01)%'23%)
ARV Regimens and Safety during Pregnancy
935 A Randomized Controlled Trial to Assess Safety,Tolerability,
and Peripartum Viral Load of Increased Lopinavir/Ritonavir
Dose in Pregnancy
Simone BonaIe*, J Senise, D Costa, MJ Vaz, A Castelo,
and Nucleo de Patologias InIecciosas da Gestacao
Federal Univ of Sao Paulo, Bra:il
936 Incidence and Management of Adverse Events to Nevirapine
in Pregnancy in a Resource-constrained Setting
Francesca Bisio*
1
, E Schenone
1
, S Grignolo
1
, A Calzi
1
, M Guaitolini
1
,
DR Giacobbe
1
, G Masini
1
, I Bitari
2
, B Bruzzone
3
, and C Viscoli
1,3
1
Univ of Genoa, Italv,
2
Armv Hosp, Pointe Noire, Republic of Congo,
and
3
IRCSS AOU San Martino-IST, Genoa, Italv
!

(&))!*" +-6./*)%&' 01)%'23%)
Incidence and Prevention of PMTCT-associated
Drug Resistance
937 Zidovudine-resistance Mutations Detected by Pyrosequencing
in Women Treated with Zidovudine Monotherapy for PMTCT
Scott Olson*
1
, N Ngo-Giang-Huong
2
, I Beck
3
, R Hall
1
, R Bumgarner
1
,
W Deng
1
, J Mullins
1
, R Van Dyke
4
, G Jourdain
2
, and L Frenkel
1,3
1
2
Inst de Recherche pour le Devt UMI
174-PHPT, Chiang-Mai, Thailand,
3
Seattle Childrens Res Inst, WA, US,
and
4
Tulane Univ Sch of Med, New Orleans, LA, US
938 Effect of Short-course Maternal ARV Regimens
after Single-dose Nevirapine on HIV-1 Transmission and
Drug Resistance in Infants: ACTG A5207
Jane Hitti*
1
, E Halvas
2
, L Zheng
3
, F Taulo
4
, J Kabanda
5
, H Sprenger
6
,
K Klingman
7
, E Chan
3
, D McMahon
2
, J Mellors
2
, and ACTG A5207
Protocol Team
1
2
3
Harvard
4
Queen Eli:abeth Central Hosp,
Blantvre, Malawi,
5
Joint Clin Res Ctr, Kampala, Uganda,
6
Frontier Sci
Tech and Res Fndn, Amherst, NY, US, and
7
Therapeutics Res Prgm,
DAIDS, NIH, Bethesda, MD, US
!

(&))!*" +-+./*)%&' 01)%'23%)
New HIV Infections among Children in the US
939 Non-US Birth among Children <13 Years of Age Diagnosed
with HIV Infection: US, 33 States and 2 Dependent Areas,
2001-2010
Steven Nesheim*
1
, L Linley
1
, S Whitmore
1
, T Kajese
2
, H Shericka
2
,
L Fitz Harris
2
, M Lampe
1
, and A Taylor
1
1
2
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' ()*+,&$-#. /0$-.12-$
ART Initiation and Immune Reconstitution
Inflammatory Syndrome among Infants and Children
940 Severe Immunodeficiency in Children Starting ART in Low-,
Middle- and High-income Countries
D Avila
1
, K Patel
2
, B Chi
3
, K Wools-Kaloustian
4
, V Leroy
5
, A Sohn
6
,
C Chimbetete
7
, R Hazra
8
, Matthias Egger*
1,9
, and M-A Davies
9
1
Inst of Social and Preventive Med, Univ of Bern, Swit:erland,
2
Harvard
3
Ctr for Infectious Disease Res in
Zambia, Lusaka,
4
5
French
Natl Inst for Hlth and Med Res, Univ Bordeaux,
6
TREAT Asia, Fndn for
AIDS Res, Bangkok, Thailand,
7
Newlands Clin, Harare, Zimbabwe,
8
Natl
Inst of Child Hlth and Human Devt, NIH, Bethseda, MD, US, and
9
Univ
of Cape Town, South Africa
941 Impact of Routine Early Infant Diagnosis and Early ART in
HIV
+
Malawian Infants at Community Health Centers
Anna Dow*
1
, Q Dube
2
, R Heyderman
2
, and A Van Rie
1
1
Univ of North Carolina Gillings Sch of Global Publ Hlth, Chapel Hill,
US and
2
Malawi-Liverpool-Wellcome Trust Clinical Res Prgm, Queen
Eli:abeth Central Hosp, Blantvre
942 Low Incidence of TB and Bacille Calmette Guerin Immune
Reconstitution Inflammatory Syndrome in South African
Children: Results of a Prospective Cohort Study
Annelies Van Rie*
1
, S Sawry
2
, A Richardson
1
, S DeLong
1
,
N Mahomed
3
, D Murdoch
2
, and H Moultrie
2
1
2
Wits Reproductive Hlth and
HIJ Inst, Johannesburg, South Africa, and
3
943 Dermatologic Immune Reconstitution Inflammatory
Syndrome vs Immune Status in Children Receiving
Treatment from a Community Outreach Program
Anne Bagenda*
1,2
, M Mboowa
1
, and J Mbabazi
3,4
1
Intl Hlth Sci Univ, Kampala, Uganda,
2
Makerere Coll of Hlth Sci,
Kampala, Uganda,
3
Mulago Natl Referral Hosp, Kampala, Uganda,
and
4
Intl Hosp Kampala, Uganda
!

"#$$%&' ()3+,&$-#. /0$-.12-$
ART Strategies and Outcomes among Children
944 Mortality and Long-Term Virologic Outcomes in Children
and Infants Treated with Lopinavir/ritonavir-based
Therapy: Panama
D Estripeaut
1
, Jonathan Mosser*
2
, M Doherty
2
, W Acosta
2
, H Shah
2
,
E Castano
1
, K Luciani
1
, J Pascale
3
, R Bollinger
2
, and K Page
2
1
Hosp del Nino, Panama Citv, Panama,
2
3
Inst Conmemorativo Gorgas de Estudios de la
Salud, Panama Citv, Panama
945 Growth among HIV
+
Children Receiving ART: Dar es
Salaam, Tanzania
Ramadhani Mwiru*
1,2
, D Spiegelman
1
, C Duggan
1,3
, G Seage
1
, H Semu
4
,
G Chalamilla
1,2
, R Kisenge
5
, and W Fawzi
1
1
2
Dar es Salaam, Tan:ania,
3
Boston Childrens Hosp, MA, US,
4
Ministrv of
Hlth and Social Welfare, Dar es Salaam, Tan:ania, and
5
Muhimbili Univ
of Hlth and Allied Sci, Dar es Salaam, Tan:ania
946 Weight and Height as Predictors of Clinical Progression and
Immunological Failure following HAART in a Cohort of
HIV
+
Children: Asia
Azar Kariminia*
1
, N Durier
2
, G Jourdain
3,4,5
, S Saghayam
6
, T Nguyen
7
,
and D Kumarawati
8
1
Univ New South Wales, Svdnev, Australia,
2
TREAT Asia/amfAR-Fndn
for AIDS Res, Bangkok, Thailand,
3
4
Harvard
5
Inst de Recherche pour le Devt UMI
174, Paris, France,
6
YRG CARE, Chennai, India,
7
Children`s Hosp 2, Ho
Chi Minh Citv, Jietnam, and
8
Sanglah Hosp, Bali, Indonesia
947 Treatment Simplification in HIV
+
Children and Adolescents

Talia Sainz*
1
, M Santos
1
, B Jimenez
2
, S Jimenez de Ory
1
, J Saavedra
1
,
D Blazquez Gamero
3
, JT Ramos
4
, MI de Jose
5
, MJ Mellado
6
,
ML Navarro
1
, and Madrid Cohort oI HIV-inIected Children and
Adolescents, Integrated in CORISPE
1
2
Hosp Infanta Sofia, Madrid,
Spain,
3
Hosp 12 de Octubre, Madrid, Spain,
4
Hosp de Getafe, Madrid,
Spain,
5
Hosp La Pa:, Madrid, Spain, and
6
948 Characteristics and Management of HAART Failure among
Perinatally HIV
+
Children and Adolescents: US
Lee Fairlie*
1
, B Karalius
2
, K Patel
2
, R Van Dyke
3
, G Siberry
4
, G Seage
2
, A
Agwu
5
, H Mendez
6
, R Hazra
4
, A Wiznia
7
, and PHACS Team and IMPAACT
1
Wits Reproductive Hlth Inst, Facultv of Hlth Sci, Univ of the
Witwatersrand, South Africa,
2
Ctr for Biostatistics in AIDS Res, Harvard
Sch of Publ Hlth, Boston, US,
3
Tulane Univ Hlth Sci Ctr, New Orleans,
LA, US,
4
Pediatric, Adolescent and Maternal AIDS Branch, Natl Inst of
Child Hlth and Human Devt, NIH, Bethesda, MD, US,
5
Johns Hopkins
Univ Sch of Med, Baltimore, MD, US,
6
SUNY Downstate, Brooklvn, NY,
US, and
7
Jacobi Med Ctr/Familv Based Svcs, Bronx, NY, US
!

"#$$%&' ()4+,&$-#. /0$-.12-$
Cost and Cost-effectiveness of ART and Monitoring
949 Within-trial Cost-effectiveness Analysis of Clinically-driven vs
Laboratory and Clinical Monitoring for 1206 African Children
on ART: The AntiRetroviral Research for Watoto Trial
Paul Revill*
1
, T Mabugu
2
, F Mirimo
3
, K Nathoo
2
, P Mugyenyi
4
,
P Musoke
5,6
, P Munderi
3
, D Gibb
7
, S Walker
1
, M Sculpher
1
,
and ARROW Study Team
1
Univ of York, UK,
2
3
Uganda Jirus Res Inst,
Entebbe,
4
5
Makerere Univ,
Kampala, Uganda,
6
Paediatric Infectious Diseases Clin, Kampala,
Uganda, and
7
MRC Clin Trials Unit, London, UK
950 Time in Care and Resource Utilization Prior to ART
Initiation for Pediatric Patients: Zambia
Hari Iyer*
1
, C Scott
1,2
, D Bwalya
1
, J Kasimba
1
, K McCoy
2
,
G Meyer-Rath
2,3,4
, C Moyo
5
, C Bolton-Moore
6,7
, B Larson
2,8
, and S Rosen
2,3,4
1
Zambia Ctr for Applied Hlth Res and Devt, Lusaka,
2
Ctr for Global Hlth
and Devt, Boston Univ, MA, US,
3
Hlth Economics and Epidemiologv
Res Office, Johannesburg, South Africa,
4
5
Zambian Ministrv of Hlth, Lusaka,
6
Univ
of North Carolina at Chapel Hill, US,
7
Ctr for Infectious Disease Res in
Zambia, Lusaka, and
8
Boston Univ Sch of Publ Hlth, MA, US
!

"#$$%&' ()5+,&$-#. /0$-.12-$
HIV Drug Resistance in Children and Youth
951 Pre-treatment Drug Resistance Mutations among HIV
+

Children < 2 Years of Age Who Failed or Missed PMTCT:
Louise Kuhn*
1
, G Hunt
2
, K Technau
3
, A Coovadia
3
, V Black
3
, L Morris
2
,
E Abrams
1
, and Finding InIants with HIV Disease and Evaluating
Resistance Study Group
1
2
Natl Inst of Communicable
Diseases, Johannesburg, South Africa, and
3
Rahima Moosa Mother and
Child Hosp, Univ of the Witwatersrand, Johannesburg, South Africa
952a High-level Resistance to Didanosine Observed in South
African Children Failing an Abacavir- or Stavudine-based
1
st
-Line Regimen
Kim Steegen*
1
, L Levin
2
, I Ketseoglou
1
, M Bronze
1
,
M Papathanasopoulos
1
, S Carmona
1,3
, and W Stevens
1,3
1
2
Right to Care,
3
Natl Hlth Lab Svcs, Johannesburg,
South Africa
952b Major HIV Drug Resistance Mutations in ARV-nave
Adolescents and Young Adults: New York City
Christina Gagliardo*
1
, L Saiman
1
, J Birnbaum
2
, A Radix
3
, M Foca
1
,
J Nelson
1
, M Yin
1
, A Brozovich
1
, E West
1
, and N Neu
1
1
Columbia Univ Med Ctr, New York, NY, US,
2
SUNY Downstate Med Ctr,
Brooklvn, NY, US, and
3
Callen-Lorde Communitv Hlth Ctr, New York,
NY, US
!

"#$$%&' ()6+,&$-#. /0$-.12-$
Co-infections among HIV-infected and -exposed
Children
953 Early TB Infection among HIV-1-exposed Kenyan Infants
Lisa Cranmer*
1,2
, M Kanyugo
3
, S Jonnalagada
1
, B Lohman-Payne
1
,
E Maleche-Obimbo
3
, D Wamalwa
3
, B Richardson
1
, B Sorensen
1
,
and G John-Stewart
1

1
2
Seattle Childrens Hosp, WA, US,
and
3
Univ of Nairobi, Kenva
954 Incidence of Malaria in HIV
+
Children on Pediatric ART:
Cote dÌvoire, International Epidemiologic Databases to
Evaluate AIDS, 2004-2009
A Mounkala Harouna
1
, Madelaine Amorissani-Folquet*
2
, T Eboua
3
,
S Desmonde
1
, E Aka
4
, K Kouadio
5
, B Kouakou
5
, P CoIIie
6
, V Leroy
1
,
and IeDEA Pediatric West AIrican Study Group
1
Univ Bordeaux, ISPED, Ctr INSERM U897, France,
2
Univ Cocodv,
Cocodv Univ Hosp, Abidfan, Cote dIvoire,
3
Yopougon Univ Hosp, Abidfan,
Cote dIvoire,
4
CePReF-Enfant, ACONDA, Abidfan, Cote dIvoire,
5
CIRBA,
Abidfan, Cote dIvoire, and
6
Ctr MTCT-plus, Abidfan, Cote dIvoire
955 Hepatitis C in HIV
+
Patients: Brazil
Denise Pacola*, M Della Negra, Y Ching Lian, W Queiroz, and C Roberio
Inst Infectologia Emilio Ribas, Sao Paulo, Bra:il
956 Dynamics of Epstein-Barr Virus in HIV-1
+
Children: Uganda

Maria RaIIaella Petrara*
1
, M Penazzato
1,2
, W Massavon
2
,
S Nabachwa
3
, M Nannyonga
3
, A Mazza
4
, K Gianesin
1
, M Zanchetta
5
,
C Giaquinto
1,2
, and A De Rossi
1,5
1
Univ of Padova, Italv,
2
Tukula Fenna Profect,
3
Nsambva Home Care,
Kampala, Uganda,
4
Hosp of Cles, Italv, and
5
Inst Oncologico Jeneto-
IRCCS, Padova, Italv
Program 63
P
o
s
t
e
r

L
i
s
t
i
n
g
s
!

"#$$%&' ())*+&$,#- ./$,-01,$
HIV and ART-related Complications and Treatment
in Children and Youth
957 Mortality among HIV
+
Children with Cancer in South
Africa: A Pilot Linkage Study
M Maskew
1
, Julia Bohlius*
2
, C SteIan
3
, A Davidson
4
, N Maxwell
1
,
B Eley
4
, H Prozesky
5
, M Egger
2
, and M-A Davies
1
1
2
Inst of Social and Preventive Med,
3
Univ of Stellenbosch, South Africa,
4
Red
Cross War Memorial Childrens Hosp, Cape Town, South Africa, and
5
Tvgerberg Hosp, Cape Town, South Africa
958 Neurocognitive Function in HIV Vertically Infected Children
and Adolescents
P Martos
1
, E Sanchez
2
, A Noguera-Julian
1
, J Lledo
3
, A Mur
3
,
and Claudia Fortuny*
1
1
Hosp Sant Joan de Deu, Univ de Barcelona, Spain,
2
Univ Ramon Llull,
Barcelona, Spain, and
3
Hosp del Mar, Univ Autonoma de Barcelona, Spain
959 Pubertal Onset in HIV
+
Children in the Era of cART
P Williams
1
, M Abzug
2
, Denise Jacobson*
1
, J Wang
1
, R Van Dyke
3
,
R Hazra
4
, K Patel
1
, L DiMeglio
5
, J Oleske
6
, M GeIIner
7
, and IMPAACT
219C and Pediatric HIV/AIDS Cohort Study Teams
1
2
Univ of Colorado Sch of
Med, Denver, US,
3
Tulane Univ Sch of Med, New Orleans, LA, US,
4
Natl
Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US,
5
Indiana
Univ Sch of Med, Indianapolis, US,
6
New Jersev Med Sch, Newark, US,
and
7
Childrens Hosp Los Angeles, CA, US
960 Incidence of Lipodystrophy Syndrome in a European Cohort
of HIV
+
N Alam
1
, M Cortina-Borja
1
, T Goetghebuer
2
, M Marczynska
3
, A Vigano
4
,
Claire Thorne*
1
, and European Paediatric HIV and Lipodystrophy
Study in EuroCoord
1
2
Ctr Hosp Univ St Pierre, Brussels, Belgium,
3
Med Univ of Warsaw, Poland, and
4
961 Evaluation of Ventricular Function in HIV
+
Pediatric and
Adolescent Patients: The Use of Speckle Tracking
M Alvarez Fuente
1
, Talia Sainz*
1
, JT Ramos Amador
2
, C Medrano
3
,
D Blazquez Gamero
3
, MI de Jose
4
, MJ Mellado
5
, ML Navarro
1
,
P Rojo Conejo
1
, and MA Munoz
1
1
2
Hosp de Getafe, Madrid,
Spain,
3
4
Hosp La Pa:, Madrid,
Spain, and
5
962 Hypertension in HIV
+
Sam Chatterton-Kirchmeier*
1
, R Chakraborty
2
, A Camacho-Gonzalez
2
,
and D Batisky
2
1
2
Emorv Univ, Atlanta,
GA, US
963 Renal Function in Perinatally HIV
+
Children from Latin
America and the Caribbean: NICHD International Site
Development Initiative Study
Cristina HoIer*
1
, R Harris
2
, R Oliveira
1
, T de Abreu
1
, F Kakehasi
3
,
JH Pilotto
4
, N Pavia Ruz
5
, M Krauss
2
, R Hazra
6
, and NISDI Pediatric
Study Group 2012
1
Inst de Puericultura e Pediatria Martagao Gesteira, Rio de Janeiro,
Bra:il,
2
Westat, Rockville, MD, US,
3
Uviv Federal de Minas Gerais, Belo
Hori:onte, Bra:il,
4
Hosp Geral Nova de Iguacu, Bra:il,
5
Hosp Infantil de
Mexico Federico Gome:, Mexico Citv, and
6
Natl Inst of Child Hlth and
Human Devt, NIH, Bethesda, MD, US
964 Low Bone Mineral Density in Vertically HIV
+
Adolescents:
Inflammation, Immune Activation, and HIV-related Factors
B Jimenez
1
,

Talia Sainz*
2
, L Diaz
2
, ML Navarro
2
, MI Gonzalez-Tome
3
,
MJ Mellado
4
, MI de Jose
5
, P Rojo
3
, JT Ramos
6
, MA Munoz-Fernandez
2
,
and Madrid Cohort oI HIV-inIected Children and Adolescents, Integrated
in CORISPE
1
Hosp Infanta Sofia, Madrid, Spain,
2
Hosp Gregorio Maranon, Madrid,
Spain,
3
4
Hosp Carlos III, Madrid,
Spain,
5
Hosp La Pa:, Madrid, Spain, and
6
Hosp de Getafe, Madrid, Spain
965 Vitamin D
3
Supplementation (4000 or 7000 IU/d) in Botswana
Children and Adults with HIV
A SteenhoII
1,2,3,4
, J Schall
2
, B Seme
1
, M Marape
5
, I Tsimako
1
, M Tolle
5
,
M Nnyepi
4
, L Mazhani
4
, Richard Rutstein*
2,3
, and V Stallings
2,3
1
Botswana-UPenn Partnership, Gaborone,
2
Childrens Hosp of
Philadelphia, PA, US,
3
Perelman Sch of Med at the Univ of Pennsvlvania,
Philadelphia, US,
4
Univ of Botswana, Gaborone, and
5
Botswana-Bavlor
Childrens Clin Ctr of Excellence, Gaborone
!

"#$$%&' ()2*+&$,#- ./$,-01,$
Characteristics of Youth with HIV
966 Preservation of Nave CD4 and CD8 T Lymphocytes 15 Years
or More after Perinatal HIV Infection: Agence Nationale de
Recherche sur le SIDA EP38-IMMIP Study
S Blanche
1
, D Scott-Algara
2
, J Le Chenadec
3
, V Avettand-Fenoel
1
,
N Bouallag
3
, C Rouzioux
1
, J-P Viard
4
, C DollIus
5
, J Warsawski
3,6
,
and Florence Buseyne*
2
1
Univ Paris Descartes, Hosp Necker, Paris, France,
2
Inst Pasteur, Paris,
France,
3
INSERM U1018, Le Kremlin-Bicetre, France,
4
Hosp de lHotel-
Dieu, Paris, France,
5
Hosp Trousseau, Paris, France, and
6
Univ Paris
Sud, Le Kremlin-Bicetre, France
967 Direct Determination of Elevated Nave CD4
+
T Cell
Diversity Decades after Perinatal HIV-1 Infection
Christian Aguilera-Sandoval*
1
, O Yang
1
, N Jojic
2
, M Belzer
3
,
J Church
3
, and P Krogstad
1
1
Geffen Sch of Med, Univ of California, Los Angeles Med Ctr, US,
2
Microsoft Inc, US, and
3
Childrens Hosp and Keck Sch of Med at Univ of
Southern California, Los Angeles, US
968 Current HIV-1 Viral Load Is Less often Undetectable in
Young Adults Infected Perinatally than in Older Patients
Infected during Adulthood: France

Nelly Briand*
1
, J-P Viard
2
, C DollIus
3
, F BouIassa
1
, J Le Chenadec
1
,
C Goujard
1,4
, R Seng
1
, S Blanche
5
, L Meyer
1,4,6
, J Warszawski
1,4,6
, and
ANRS EPF, COVERTE, PRIMO, SEROCO, COPANA Study Groups
1
INSERM U1018, CESP, Le Kremlin-Bicetre, France,
2
AP-HP Hotel-
Dieu, Paris, France,
3
AP-HP, Hosp Trousseau, Paris, France,
4
AP-HP,
Hosp Bicetre, Paris, France,
5
AP-HP Hosp Necker-Enfants Malades,
Univ Paris Descartes, Paris, France, and
6
Univ Paris-Sud, Le Kremlin-
Bicetre, France
969 CD4 Count at Presentation to Care among Youth Infected with
HIV through Risk Behaviors (2002-2010)
Allison Agwu*
1
, A Neptune
2
, R Rutstein
3
, T Korthuis
4
, K Gebo
1
,
Ior HIV Res Network
1
Johns Hopkins Med Inst, Baltimore, MD, US,
2
Howard Univ Coll of
Med, Washington, DC, US,
3
Children`s Hosp of Philadelphia, PA, US,
and
4
Oregon Hlth and Sci Univ, Portland, US
970 Neurocognitive Functioning in ART-nave Youth with
Behaviorally Acquired HIV
Sharon Nichols*
1
, J Bethel
2
, P Garvie
3
, D Patton
4
, S Thornton
2
,
B Kapogiannis
5
, W Ren
2
, T Li
2
, H Major-Wilson
6
, S Woods
1
,
and Adolescent Trials Network Ior HIV/AIDS Interventions
1
2
Westat, Rockville, MD, US,
3
Independent Consultant, Memphis, TN, US,
4
Children`s Diagnostic and
Treatment Ctr, Inc, Fort Lauderdale, FL, US,
5
and
6
Univ of Miami, FL, US

"#$$%&' ()3*+&$,#- ./$,-01,$
Tenofovir in Children
972 48-Week Safety of Tenofovir when Administered According
to Weight-band Dosing in HIV
+
Children 15 kg as Part of a
Once-daily HAART Regimen
L Aurpibul
1
, T Narkbunnam
2
, Virat Sirisanthana*
1
, O Wittawatmongkol
2
,
W Phongsamart
2
, T Sudjaritruk
1
, T Cressey
1,3,4
, and K Chokephaibulkit
2
1
2
Mahidol Univ, Bangkok, Thailand,
3
Harvard Sch of Publ Hlth, Boston, MA, US, and
4
Inst de Recherche pour
le Devt, Marseille, France
973 Pharmacokinetics of Tenofovir in Thai Adolescents Using
Ritonavir-boosted Protease Inhibitor-based Regimens
Wasana Prasitsuebsai*
1
, S Kerr
1,2
, N Thammajaruk
1
, A Colbers
3
,
S Keadpudsa
1
, T Chuanjaroen
1
, M Gorowara
1
, D Burger
3
, A Sohn
4
,
and J Ananworanich
1,5
1
HIJ-NAT Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok,
2
Kirbv Inst, Univ of New South Wales, Svdnev, Australia,
3
Radboud Univ
Nifmegen Med Ctr, The Netherlands,
4
TREAT Asia/amfAR-Fndn for AIDS
Res, Bangkok, Thailand, and
5
Bangkok
!

"#$$%&' (24*+&$,#- ./$,-01,$
ARV Pharmacokinetics in Children
974 Raltegravir Pharmacokinetics and Safety in Neonates
(IMPAACT P1097)
Diana Clarke*
1
, E Acosta
2
, M Rizk
3
, Y Bryson
4
, S Spector
5
,
L MoIenson
6
, H Teppler
3
, C Welebob
3
, E Handelsman
7
, M Mirochnick
8
,
and IMPAACT P1097 Study Team
1
Boston Med Ctr, MA US,
2
3
Merck
Res Labs, Clin Res, North Wales, PA, US,
4
Angeles, US,
5
6
and Human Devt, NIH, Bethesda, MD, US,
7
NIAID, NIH, Bethesda, MD,
US, and
8
Boston Univ, MA, US
P
o
s
t
e
r

L
i
s
t
i
n
g
s
975a Is Nevirapine Dose Escalation Appropriate in Young African
HIV
+
Children?

Quirine Fillekes*
1
, V Mulenga
2
, D Kabamba
2
, C Kankasa
2
,
M Thomason
3
, A Cook
3
, C Chintu
2
, D Gibb
3
, S Walker
3
, and D Burger
1
1
2
Univ Teaching
Hosp, Lusaka, Zambia, and
3
MRC Clinical Trials Unit, London, UK
975b Pharmacokinetics and Acceptability of a New Generic
Lopinavir/Ritonavir Sprinkle Formulation in African, HIV
+

Children 1-4 Years: CHAPAS-2
Sabrina Bakeera-Kitaka*
1
, Q Fillekes
2
, R Keishanyu
3
, N Young
4
,
A Babirye
1
, C Tumusiime
3
, L Kendall
4
, M Lallemant
5
, D Burger
2
,
and D Gibb
4
1
Bavlor Coll of Med Childrens Fndn Uganda, Mulago Hosp, Kampala,
2
Radboud Univ Nifmegen Med Ctr, Nifmegen, The Netherlands,
3
Joint
Clinical Res Ctr, Kampala, Uganda,
4
MRC Clinical Trials Unit, London,
UK, and
5
Drugs for Neglected Diseases Initiative, Geneva, Swit:erland
976 Pharmacokinetics of Lopinavir/ritonavir Dosed According to
the WHO Pediatric Weight Band Dosing Guidelines: Interim
Results from IMPAACT P1083
Jorge Pinto*
1
, E Capparelli
2
, M Mirochnick
3
, M Warshaw
4
, B Zimmer
5
,
J Roa
6
, B Smith
7
, C Worrell
7
, T Cressey
8
, M Martinez-Tristani
9
,
and IMPAACT P1083 Team
1
Univ Federal de Minas Gerais, Belo Hori:onte, Bra:il,
2
Univ of
3
4
Harvard Sch of
5
Frontier Sci & Tech Res Fndn, Buffalo, NY,
US,
6
Social & Scientific Svstems, Silver Spring, MD, US,
7
NIH, Bethesda,
MD, US,
8
Prgm for HIJ Prevention and Treatment, Chiang Mai,
Thailand, and
9
Abbott Labs, Miami, FL, US
977 Randomized Comparison of Once- vs Twice-daily Abacavir
and Lamivudine among 669 HIV
+
Children in the Anti-
Retroviral Research for Watoto Trial

Victor Musiime*
1
, P Kasirye
2
, B Naidoo-James
3
, P Nahirya-Ntege
4
,
T Mhute
5
, L Mugarura
1
, M Munjoma
5
, M Spyer
3
, M Thomason
3
,
S Walker
3
, and ARROW Trial Team
1
2
Bavlor-Uganda, Paediatric
Infectious Diseases Clin, Mulago Hosp, Kampala,
3
MRC Clinical Trials
Unit, London, UK,
4
MRC/Uganda Res Unit on AIDS, Uganda Jirus Res
Inst, Entebbe, and
5
978 Pharmacokinetics of Darunavir 800 mg with Ritonavir 100 mg
Once Daily in HIV
+
Adolescents and Young Adults
JenniIer King*
1
, R Hazra
2
, A Wiznia
3
, P Jean-Philipe
4
, B Graham
5
,
P Britto
6
, V Carey
6
, E Acosta
1
, R Yogev
7
, and IMPAACT P1058A Team
1
2
Human Devt, NIH, Bethesda, MD, US,
3
Jacobi Med Ctr, Bronx, NY,
US,
4
Henrv M Jackson Fndn for the Advancement of Militarv Med, NIH,
Bethesda, MD, US,
5
Frontier Sci & Tech, Amherst, NY, US,
6
Harvard
7
Children`s Memorial Hosp,
Northwestern Univ Feinberg Sch of Med, Chicago, IL, US
979 Methylphenidate Concentrations and Dose Requirements in
HIV
+
and HIV
-
Children, Adolescents, and Young Adults
Brookie Best*
1
, M Farhad
2
, S Rossi
1
, J Hodge
3
, S Kapetanovic
4
,
E Capparelli
1
, P Brouwers
4
, G Siberry
5
, E Smith
6
, M Paul
7
,
and IMPAACT P1080
1
2
MA, US,
3
Frontier Sci & Tech Res Fndn, Amherst, NY, US,
4
Natl Inst
of Mental Hlth, NIH, Rockville, MD, US,
5
Human Devt, NIH, Bethesda, MD, US,
6
and
7
Bavlor Coll of Med, Houston, TX, US
!

"#$$%&' ()(*+&$,#- ./$,-01,$
Immune Response to Perinatal HIV
980 Microbial Translocation and Immune Activation Occur
Early in HIV
+
Infants but Are Not Associated with Mortality
Andrew Prendergast*
1,2,3
, B Chasekwa
1
, S Rukobo
1
, T MupIudze
1,2
,
M Govha
1
, K Mutasa
1
, and J Humphrey
1,2
1
Zvitambo Profect, Harare, Zimbabwe,
2
Johns Hopkins Univ Bloomberg Sch
of Publ Hlth, Baltimore, MD, US, and
3
Queen Marv Univ of London, UK
!

"#$$%&' ()2*+&$,#- ./$,-01,$
Response to Pediatric Vaccines in Children and
Youth
981 Human Papillomavirus Vaccination in ARV-treated HIV
+

Adolescents and Young Adults Induces Strong Human
Papillomavirus-specific Cell-mediated Immune Responses
Daria Trabattoni*
1
, V Rainone
1
, F Penagini
2
, F Dinello
2
, F Calascibetta
1
,
V Giacomet
2
, A Vigano
1,2
, M Clerici
1,3
, and GV Zuccotti
1,2
1
Univ of Milan,
2
Luigi Sacco Hosp, and
3
Don G Gnocchi Fndn
982 Baseline CD4 T Cell Immune Activation and Exhaustion
Influences Antibody Responses to H1N1/09 Vaccine in HIV
+

Pediatric and Adolescent Patients
George Varghese*, S Pallikkuth, S Andreansky, I Gonzalez, and S Pahwa
983 Microarray Analysis Reveals Novel Insights into Immunity
to H1N1/09 Influenza Vaccine in HIV
+
Children and
Adolescents in the International Maternal Pediatric
Adolescent AIDS Clinical Trials, Study P1088
Savita Pahwa*
1
, L Trautmann
2
, M Cameron
2
, C Steel
2
, R-P Sekaly
2
,
A Weinberg
3
, C Cunningham
4
, P Flynn
5
, and IMPAACT P1088 Team
1
Univ of Miami Miller Sch of Med, FL, US,
2
Jaccine and Gene Therapv
Inst Florida, Port St Lucie, US,
3
Univ of Colorado Denver, US,
4
Duke Univ,
Durham, NC, US, and
5
St Jude Childrens Res Hosp, Memphis, TN, US
984 Higher Regulatory B and T Cell Rates Are Associated with
Decreased Immune Responses to pH1N1 Influenza Vaccine in
HIV
+
Children and Youth
Adriana Weinberg*
1
, P Muresan
2
, T Fenton
2
, K Richardson
1
,
T Dominguez
1
, A Bloom
3
, C Cunningham
4
, S Spector
5
, S Nachman
6
,
P Flynn
7
, and IMPAACT P1088 Study Team
1
Univ of Colorado Denver, Aurora, US,
2
Boston, MA, US,
3
Frontier Sci & Tech Res Fndn, Amherst, NY, US,
4
Duke
Univ Med Ctr, Durham, NC, US,
5
Univ of California, San Diego, La
Jolla, US,
6
Stonv Brook Hlth Sci Ctr, NY, US, and
7
St Jude Childrens Res
Hosp, Memphis, TN, US
!

"#$$%&' ()3*+&$,#- ./$,-01,$
Preclinical Studies of Topical ARV for Prevention
985 Impact of Depo-Provera and Menstrual Cycle on Vaginal
Absorption of ARV Drugs from Gels in Pigtail Macaques
Charles Dobard*, S Sharma, R West, A Martin, N Makarova, A Taylor,
J Mitchell, C-P Pau, and W Heneine
986 A Novel Intravaginal Ring Design Releasing Tenofovir
Delivers Comparable Tenofovir Diphosphate Levels in
Vaginal Target Cells in Macaques to Gel Dosing
James Smith*
1
, R Rastogi
2
, R Teller
2
, P Srinivasan
1
, C-P Pau
1
,
J McNicholl
1
, M Hendry
1
, P Mesquita
3
, B Herold
3
, and P Kiser
2
1
2
Univ of Utah, Salt Lake Citv, US, and
3
Albert
Einstein Coll of Med, Bronx, NY, US
987 Differential Intracellular Retention of Drugs: A Tool for
Rational Design of Pre-exposure Prophylaxis Combinations
Pedro Mesquita*
1
, M Kay
2
, and B Herold
1
1
Albert Einstein Coll of Med, Bronx, NY, US and
2
Univ of Utah, Salt Lake
Citv, US
988 cARV Drugs for Topical Rectal Microbicide Development:
Implications for HIV Prevention
Julie Russo*
1
, L Wang
1
, L Rohan
1,2
, I McGowan
1,2
, and C Dezzutti
1,2
1
Magee-Womens Res Inst, Pittsburgh, PA, US and
2
Univ of Pittsbugh,
PA, US
989 Higher Quantities of Broadly Neutralizing Monoclonal
Antibodies Are Required to Protect Human Mucosal Tissue
from HIV-1 Infection

Yanille Scott*
1
, K Whaley
2
, and C Dezzutti
1
1
2
Mapp Biopharmaceutical Inc,
San Diego, CA, US
990 Y Chromosomal DNA in Vaginal Swabs as a Biomarker of
Semen Exposure in Women from HIV: Prevention Trials
Network 035, a Phase II/IIb Trial of Vaginal Microbicides
Kerri Penrose*
1
, B Richardson
2
, G Besson
1
, B Harold
3
, C Dezzutti
1
,
S Abdool Karim
4
, J Mellors
1
, U Parikh
1
, and MTN Biomed Sci Working
Group and HPTN 035 Protocol Team
1
2
3
Albert
Einstein Coll of Med, New York, NY, US, and
4
Ctr for the AIDS Prgm of
Res in South Africa, Durban
!

"#$$%&' ()4*+&$,#- ./$,-01,$
Non-human Primate Models of STI, PrEP, and
Vaccines
991 Co-infection with STI 567089:%0 ,-016&80,%$ and
;-%16&8&'0$ <0=%'07%$ Increases Susceptibility to SHIV in
Pigtail Macaques
Tara Henning*
1
, K Butler
1
, D Hanson
1
, D Garber
1
, E Secor
1
, J Papp
1
,
H Caldwell
2
, G Sturdevant
2
, J McNicholl
1
, and E Kersh
1
1
2
Natl Inst of Allergv and Infectious Diseases,
Hamilton, MT, US
992 The Injectable Contraceptive Depo-Provera Does Not Reduce
the Prophylactic Efficacy of Truvada in Pigtail Macaques

Jessica Radzio*
1
, K Hanley
2
, J Mitchell
1
, S Bachman
1
, F Deyounks
1
,
W Heneine
1
, and G Garcia-Lerma
1
1
2
993 Prophylactic Efficacy of Oral Truvada against a Tenofovir-
resistant SHIV Containing the K65R Mutation
M-E Cong, J Mitchell, E Sweeney, S Bachman, D Hanson, W Heneine,
and Gerardo Garcia-Lerma*
Program 65
P
o
s
t
e
r

L
i
s
t
i
n
g
s
994 A Polyvalent VLP HIV Vaccine Combined with Partially
Protective Truvada Pre-exposure Prophylaxis Prevents SHIV
Infection in Macaques
Ted Ross*
1
, A Luckay
2
, J McNicholl
2
, G Garcia-Lerma
2
, H Eugene
1
,
B Pierce
1
, L Pereira
3
, J Zhang
2
, M Hendry
2
, and J Smith
2
1
2
CDC, Atlanta, GA, US, and
3
ICF Intl,
Atlanta, GA, US
995 Does the Intravenous Administration of the Primatized
Anti-o47 Monoclonal Antibody Reach the Cervico-vaginal
Resident o47-Expressing Target Cells in Rhesus Macaques?
Brianne Kallam*
1
, F Villinger
1
, A Mayne
1
, D Little
1
, J McNicholl
2
,
E Kersh
2
, R Aubert
2
, J Arthos
3
, C Cicala
3
, and A Ansari
1
1
Emorv Univ Sch of Med, Atlanta, GA, US,
2
and
3
Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US
!

"#$$%&' ()*+,&$-#. /0$-.12-$
Oral PrEP and ARV Adherence
996 Does Sexual Behavior Influence Adherence to Pre-exposure
Prophylaxis? Data from a Pre-exposure Prophylaxis Trial
among Young MSM
Sybil Hosek*
1
, K Telander
1
, C Balthazar
1
, M Lally
2
, G Siberry
3
,
B Kapogiannis
3
, C Wilson
4
, and Adolescent Trials Network Ior HIV/AIDS
Interventions
1
John Stroger Hosp of Cook Countv, Chicago, IL, US,
2
Alpert Med Sch
of Brown Univ, Providence, RI, US,
3
Natl Inst of Child Hlth and Human
Devt, NIH, Bethesda, MD, US, and
4
Univ of Alabama at Birmingham, US
997 Pre-exposure Prophylaxis in Young MSM: Needs and Challenges
Linda-Gail Bekker*
1
, D Glidden
2
, S Hosek
3
, B Brown
1
, A Liu
2
, R Amico
4,5
,
J Guanira
6
, J Lama
6
, V McMahan
7
, R Grant
2,7
, Ior iPrEx Study Team
1
Desmond Tutu HIJ Ctr, Univ of Cape Town, South Africa, 2Univ of
3
Stroger Hosp of Cook Countv, Chicago,
IL, US,
4
Ctr for Hlth, Intervention, and Prevention, Univ of Connecticut,
Storrs, US,
5
Applied Hlth Res, Brighton, MI, US,
6
and
7
Gladstone Inst of Jirologv and Immunologv, San Francisco, CA, US
998 Changes in Renal Function during Use of Oral Emtricitabine/
Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis:
iPrEx
Marc Solomon*
1
, J Lama
2
, K Mulligan
1
, A Liu
3
, V McMahan
4
, J Guanira
2
,
M Schechter
5
, D Burns
6
, D Glidden
1
, R Grant
1,4
, and iPrEx Study Team
1
2
3
San
4
Gladstone Inst, San Francisco,
CA, US,
5
Praca On:e, Federal Univ of Rio de Janeiro, Bra:il, and
6
NIH,
Bethesda, MD, US
999 Daily Oral Tenofovir and Emtricitabine/Tenofovir Pre-
exposure Prophylaxis and Prevention of Herpes Simplex Virus
Type 2 Acquisition among Heterosexual Men and Women
Connie Celum*
1
, R Morrow
2
, D Donnell
1,2
, T Hong
1
, K FiIe
3
,
E Nakku-Joloba
4
, A Mujugira
1
, J Baeten
1
, and Partners PrEP Study Team
1
2
Fred Hutchinson Cancer Res Ctr,
Seattle, WA, US,
3
Indiana Univ, Indianapolis, US, and
4
Makerere Univ,
Kampala, Uganda
1000 Daily Oral Pre-exposure Prophylaxis Is Highly Effective among
Subsets of Highest-risk Participants: Partners PrEP Study
Pamela Murnane*
1
, C Celum
1
, E Kahle
1
, D Donnell
1,2
, E Bukusi
1,3
,
N Mugo
1,3
, A Mujugira
1
, K Thomas
1
, J Baeten
1
, and Partners PrEP Study
Team
1
2
Fred Hutchinson Cancer Res Ctr,
Seattle, WA, US, and
3
Univ of Nairobi, Kenva
1001 No Evidence of Sexual Risk Compensation in the iPrEx Trial
of HIV Pre-exposure Prophylaxis

Julia Marcus*
1,2
, K Mayer
3
, J Guanira
4
, M Casapia
5
, O Montoya
6
,
S Chariyalertsak
7
, L-G Bekker
8
, V McMahan
1
, D Glidden
9
, R Grant
1,9
,
and iPrEx Study Team
1
Gladstone Inst of Jirologv and Immunologv, San Francisco, CA, US,
2
3
Fenwav Inst, Fenwav Hlth, Boston,
MA, US,
4
Investigaciones Med en Salud, Lima, Peru,
5
Assn Civil Selva
Ama:onica, Iquitos, Peru,
6
Fndn Ecuatoriana Equidad, Guavaquil-
Guavas, Ecuador,
7
Res Inst for Hlth Sci, Chiang Mai Univ, Thailand,
8
Desmond Tutu HIJ Ctr, Univ of Cape Town, South Africa, and
9
Univ of
1002 When to Stop Pre-exposure Prophylaxis: A Prospective
Analysis of Discontinuation of Sexual Activity and Initiation
of ART among HIV Serodiscordant Couples
Jared Baeten*
1
, P Murnane
1
, N Mugo
1,2
, E Katabira
3
, R HeIIron
1
,
A Mujugira
1
, D Donnell
1,4
, C Celum
1
, and Partners PrEP Study Team
1
2
Kenvatta Natl Hosp, Nairobi, Kenva,
3
4
Fred Hutchinson Cancer Res
Ctr, Seattle, WA, US
1003 Preferred Pre-exposure Prophylaxis Dosing Regimens and
Sex Planning among Kenyan HIV-1 Serodiscordant Couples

Renee HeIIron*
1
,

K Ngure
2
, N Mugo
3
, C Celum
1
, K Curran
1
,
A Kurth
4
, and J Baeten
1
1
2
Jomo Kenvatta Univ of Agriculture
and Tech, Nairobi, Kenva,
3
Kenvatta Natl Hosp, Nairobi, Kenva, and
4
New York Univ, NY, US
1004 Daily Assessment of Sexual Activity and Pre-exposure
Prophylaxis Use among Kenyan HIV Serodiscordant Couples

Kathryn Curran*
1
, N Mugo
2
,

A Kurth
3
, K Ngure
2,4
, R HeIIron
1
,
C Celum
1
, and J Baeten
1
1
2
Kenvatta Natl Hosp, Nairobi, Kenva,
3
New York Univ, NY, US, and
4
Jomo Kenvatta Univ of Agriculture and
Tech, Nairobi, Kenva
1005 Fertility Intentions and Interest in Early ART among East
African HIV
+
Individuals in HIV Serodiscordant Partnerships
Andrew Mujugira*
1
, R HeIIron
1
, C Celum
1
, N Mugo
1,2
, E Nakku-Joloba
3
,
and J Baeten
1
1
2
and
3
1006 Tenofovir Diphosphate in Dried Blood Spots as an Objective
Measure of ARV Medication Adherence in HIV-1
+
Women
Amie Meditz*
1
, J Predhomme
1
, K Searls
1
, P Caraway
2
, E Gardner
2
,
J-H Zheng
1
, L Bushman
1
, and P Anderson
1
1
Univ of Colorado, Anschut: Med Campus, Aurora, US and
2
Denver Publ
Hlth, CO, US
!

"#$$%&' ()3+,&$-#. /0$-.12-$
Implementation and Cost-effectiveness of Male
Circumcision
1007 Shang Ring vs Forceps-guided Adult Male Circumcision,
a Randomized Controlled Effectiveness Study: Western
Uganda
Samuel Kanyago*
1,2
, D Riding
1,3
, E Mutakooha
1
, A Lopez
1
, and M Siedner
4
1
2
Good Shepherd Hosp, Siteki,
Swa:iland,
3
Northwest Deanerv, Manchester, UK, and
4
Massachusetts
Gen Hosp Ctr for Global Hlth, Boston, US
1008 Factors Associated with Voluntary Medical Male Circumcision
Adverse Events: Nyanza Province, Kenya
Kipruto Chesang*
1
, Z Mwandi
1
, S Mwalili
1
, P Cherutich
2
, A Ochieng
2
,
P Oyaro
3
, G Otieno
4
, K Serrem
5
, D Odera
6
, and A Kim
1
1
CDC, Ctr for Global Hlth, Nairobi, Kenva,
2
Natl AIDS and STD Control
Prgm, Kenva Ministrv of Publ Hlth and Sanitation, Nairobi,
3
Kenva Med
Res Inst, Nairobi,
4
Nvan:a Reproductive Hlth Societv, Kisumu, Kenva,
5
Catholic Med Mission Board, Nairobi, Kenva, and
6
Impact Res and Devt
Org, Kisumu, Kenva
1009 Male Circumcision Coverage by Risk Profiles: Rakai, Uganda
Xiangrong Kong*
1
, A Ndyanabo
2
, G Kigozi
2
, F Nalugoda
2
,
D Serwadda
3
, M Wawer
1
, R Gray
1
, and Rakai Hlth Sci Prgm
1
2
Rakai Hlth Sci Prgm, Kalisi:o,
Uganda, and
3
1010 Costs and Effectiveness of Male Circumcision Scale-up for
the Prevention of HIV and Other Sexually Transmitted
Infections: Sub-Saharan Africa

Seema Kacker*
1
, K Frick
2
, T Quinn
1,3
, R Gray
2
, and A Tobian
1
1
2
Johns Hopkins
Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US, and
3
NIAID, NIH,
Bethesda, MD, US
1011 Uptake of Neonatal Male Circumcision as Part of HIV
Prevention Efforts in Botswana: Maternal Motivators and
Barriers
Rebeca Plank*
1,2,3
, K Wirth
2,3
, N Ndubuka
3
, P Kebaabetswe
4
, C Lesetedi
5
,
J Makhema
3
, D Halperin
6
, R Shapiro
2,3,7
, M Mmalane
3
, and S Lockman
1,2,3
1
2
3
Botswana-
Harvard Partnership,
4
Univ of Botswana, Sch of Med,
5
Botswana
Ministrv of Hlth,
6
Univ of North Carolina at Chapel Hill, and
7
Beth Israel
Deaconess Med Ctr
!

"#$$%&' ()4+,&$-#. /0$-.12-$
Voluntary Medical Male Circumcision
1012 Male Circumcision Decreases High Risk of Human
Papillomavirus Viral Shedding in Female Partners: Analyses
from a Randomized Trial in Rakai, Uganda
Aaron Tobian*
1,2
, M-A Davis
1
, M Grabowski
1
, D Serwadda
2,3
, G Kigozi
2
,
P Gravitt
1
, F Nalugoda
2
, M Wawer
1,2
, T Quinn
4
, and R Gray
1,2
1
2
Rakai Hlth Sci Prgm, Entebbe,
Uganda,
3
4
NIH, Bethesda, MD, US
1013 Voluntary Medical Male Circumcision Scale-up Expands Access
to Sexually Transmitted Infection Screening and Management
and HIV Testing: Tanzania
Augustino Hellar*
1
, D Boyee
1
, K Curran
2,3
, H Mahler
1
, M Plotkin
1
,
TA Ashengo
2,3
, M Machaku
1
, F Hezwa
1
, S Koshuma
4
, and P Luvanda
5
1
Jhpiego, Dar es Salaam, Tan:ania,
2
3
Johns
4
Iringa
Regional Hosp, Tan:ania, and
5
Ministrv of Hlth and Social Welfare,
Iringa Region, Tan:ania
P
o
s
t
e
r

L
i
s
t
i
n
g
s
1014 Outreach Voluntary Medical Male Circumcision Sites Attract
a Significantly Younger Clientele than Fixed Sites in Tanzania
H Mahler
1
, M Plotkin
1
, F Hezwa
1
, Tigistu Adamu Ashengo*
2,3
,
K Curran
2,3
, J Lija
4
, S Greenberg
5
, and E Njeuhmeli
6
1
Jhpiego, Dar es Salaam, Tan:ania,
2
3
Johns
4
Ministrv
of Hlth and Social Welfare, Dar es Salaam, Tan:ania,
5
USAID, Dar es
Salaam, Tan:ania, and
6
USAID, Washington, DC, US
1015 HIV Prevention: Male Circumcision with a Nonsurgical
Device-Evaluation of Training Efficacy and Usage of
Lidocaine 5 Dermal Cream
Vincent Mutabazi*
1
, JP Bitega
2
, LM Ngeruka
2
, S Kaplan
3
,
T Hategekimana
4
, F Mugabo
2
, C Karema
1
, and A Binagwaho
1
1
Ministrv of Hlth, Kigali, Rwanda,
2
Kanombe Militarv Hosp, Kigali,
Rwanda,
3
Weill Cornell Med Coll, New York, NY, US, and
4
Kigali Univ
Teaching Hosp, Rwanda
!

"#$$%&' ())*+&$,#- ./$,-01,$
The Ongoing Epidemic in MSM
1016 Early HIV Infections among MSM - this is a global search: 5
US Cities, 2011
Gabriela Paz-Bailey*
1
, A Smith
1
, S Masciotra
1
, H Pham
2
, C Flynn
3
,
M Lalota
4
, A Al-Tayyib
5
, T Bingham
6
, M Mangus
7
, and M Owen
1
1
2
ICF Intl, Atlanta, GA, US,
3
Marvland Dept of
Hlth and Mental Hvgiene, Baltimore, US,
4
Florida Dept of Hlth, Fort
Lauderdale, US,
5
Denver Publ Hlth, Denver Hlth and Hosp Authoritv,
CO, US,
6
Dept of Publ Hlth, Los Angeles Countv, CA, US, and
7
George
Washington Univ, Washington, DC, US
1017 Risk Behaviors Among HIV
+
Bisexual Men Receiving
Medical Care: US, Medical Monitoring Project, 2009
Mark Freedman*
1
, C Mattson
1
, L Beer
1
, P Sullivan
2
, J Skarbinski
1
,
and the Med Monitoring Project
1
2
Emorv Univ, Rollins Sch of Publ Hlth,
Atlanta, GA, US
1018 Concurrency and HIV Risk among MSM: New York City
Hong Van Tieu*
1,2
, V Nandi
1
, V Frye
1
, K Stewart
1
, H Oquendo
1
, B Bush
1
,
M Cerda
3
, D Ompad
4
, D Hoover
5
, B Koblin
1
, and M2M Study Team
1
New York Blood Ctr, NY US,
2
Columbia Univ Med Ctr, New York, NY,
US,
3
Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US,
4
New
York Univ, NY, US, and
5
Rutgers Univ, NJ, US
1019 Sexually Transmitted Infections Identify MSM at High Risk
for Undiagnosed HIV and HIV Transmission and Acquisition
Matthew Golden*
1,2
, J Dombrowksi
1,2
, R Kerani
1,2
, J Kent
2
, and J Stekler
1,2
1
Ctr for AIDS and STD, Univ of Washington, US and
2
Publ Hlth-Seattle &
King Countv, WA, US
1020 HIV Incidence in the Open Cohort of 35,000 MSM Attendees
of Sexually Transmitted Infection Clinics: England, 2008-2011
Sarika Desai*
1
, A Nardone
1
, G Hughes
1
, V Delpech
1
, F Burns
2
,
G Hart
2
, and N Gill
1
1
Hlth Protection Agencv, London, UK and
2
!

"#$$%&' ()2*+&$,#- ./$,-01,$
MSM in the Developing World
1021 HIV Prevalence and Associated Risk Factors among MSM: A
Respondent-driven Sampling Survey, Abidjan, Cote dÌvoire
Avi Hakim*
1
, J Aho
2
, G Semde
3
, M Diarrassouba
4
, K Ehoussou
4
,
B Vuylsteke
2
, C Murrill
1
, M Thiam
5
, T Wingate
4
, and SHARM Study Group
1
2
Inst of Tropical Med, Antwerp, Belgium,
3
Familv
Hlth Intl 360, Abidfan, Cote dIvoire,
4
CDC, Abidfan, Cote dIvoire, and
5
Ministrv of Hlth and Publ Hvgiene, Abidfan, Cote dIvoire
1022 HIV Prevalence and Correlates of Infection among MSM: 4
Areas in Ghana, the Ghana Mens Health Study, 2010-2011
John Aberle-Grasse*
1
, W McFarland
2,3
, A El-Adas
4
, S Quaye
1
, K
Atuahene
4
, W AmpoIo
5
, R Adanu
6
, S Chaturvedi
2
, R Fisher
2
, and E Harrison
5
1
2
3
San
4
Ghana AIDS Commission, Accra,
5
Univ of Ghana, Noguchi Memorial Inst for Med Res, Legon, and
6
Univ of
Ghana, Sch of Publ Hlth, Legon
1023 Risk Factors for Unprotected Anal Sex and HIV Infection
among Male Sex Workers: Vietnam
Donn Colby*
1,2,3
, N Trang
4
, T Mai
2
, T Nguyen
2
, HT Lan
4
, DD Thien
4
,
NA Ngoc
5
, K Mayer
1,3,6
, and M Mimiaga
3,6,7,8
1
Beth Israel Deaconess Med Ctr, Boston, MA, US,
2
Harvard Med Sch
AIDS Initiative in Jietnam, Ho Chi Minh Citv,
3
Harvard Med Sch,
Boston, MA, US,
4
Life Ctr, Ho Chi Minh Citv, Jietnam,
5
Ctr for Applied
Res on Men and Hlth, Ho Chi Minh Citv, Jietnam,
6
The Fenwav Inst,
Fenwav Hlth, Boston, MA, US,
7
and
8
1024 Longitudinal Analysis of HIV-risk Behavior Patterns and
Their Predictors in MSM: Bangkok, Thailand, 2006-2008
P Girault
1
, W Wimonsate
2
, Timothy Holtz*
2,3
, A Varangrat
2
,
S Chaikummao
2
, W Thienkrua
2
, T Chemnasri
2
, W Sukwicha
2
,
R Thiebaut
4
, and F van Griensven
2,3,5
1
FHI 360 AsiaPacific Regional Office, Bangkok, Thailand,
2
Thailand
Ministrv of Publ HlthCDC Collaboration, Nonthaburi,
3
CDC, Atlanta, GA,
US,
4
INSERM U897 and Inst de Sante Publ, dEpidemiologie et de Devt,
Univ Bordeaux Segalen, France, and
5
AJRAM Corp, Miami, FL, US
1025 Herpes Simplex 2 Virus Type 2 Incidence and Risk Factors
among MSM: Bangkok, Thailand
Warunee Thienkrua*
1
, W Chonwattana
1
, P Mock
1
, S Chaikummao
1
,
W Wimonsate
1
, J Tongtoyai
1
, C Todd
1,2,3
, A Chitwarakorn
4
, M Curlin
1,5
,
and F van Griensven
1,3,5
1
2
FHI360 Asia Pacific Regional Office, Bangkok, Thailand,
3
AJRAM Corp,
Miami, FL, US,
4
Thailand Ministrv of Publ Hlth, Nonthaburi, and
5
CDC,
Atlanta, GA, US
!

"#$$%&' (23*+&$,#- ./$,-01,$
The Cascade of Care
1026 Application of Indicators to Monitor US Department of
Health and Human Services-funded HIV Services in the
North American AIDS Cohort Collaboration on Research
and Design
Keri AlthoII*
1
, P Rebeiro
1
, M Horberg
2
, K Buchacz
3
, K Gebo
1
,
T Sterling
4
, M Kitahata
5
, A Justice
6
, J Brooks
3
, R Moore
1
, Ior North
American AIDS Cohort Collaboration on Res and Design
1
2
Atlantic States, Rockville, MD, US,
3
4
Janderbilt
Univ, Nashville, TN, US,
5
6
Yale
Univ and the JA Connecticut Hlthcare Svstem, New Haven, US
1027 An Encouraging HIV Care Cascade: Anomaly, Progress, or
1ust More Accurate Data?
Julia Dombrowski*
1,2
, J Kent
2
, S Buskin
1,2
, J Stekler
1,2
, E Barash
2
,
A Bennett
2
, and M Golden
1,2
1
2
Publ Hlth-Seattle & King Countv,
WA, US
1028 Health Insurance Coverage and Type Predict Durable Viral
Suppression among HIV
+
Adults in Care: US, Medical
Monitoring Project, 2009
Kelly Quinn* and J Skarbinski
1029 The Evolution of the Cascade of HIV Care: British Columbia,
Canada, 1996-2010
Julio Montaner*
1
, B Nosyk
1
, G Colley
1
, H Samji
1
, R Hogg
1
,
R GustaIson
2
, and M Gilbert
3
1
2
Jancouver
Coastal Hlth, Canada, and
3
BC Ctr for Disease Control, Canada
1030 The Spectrum of Engagement in HIV Care in France:
Strengths and Gaps
V Supervie
1
and Dominique Costagliola*
1,2
1
INSERM U943, UMR S943, UPMC Univ Paris 06, Paris, France and
2
APHP, Hosp Pitie Salpetriere, Paris, France
!

"#$$%&' (2(*+&$,#- ./$,-01,$
Engagement and Retention in Care
1031a Continuum of HIV Care among Ryan White HIV/AIDS
Program Clients: US, 2010
Rupali Doshi*, T Matthews, D Isenberg, M Matosky, J Milberg,
F Malitz, and L Cheever
Hlth Resources and Svc Admin, Rockville, MD, US
1031b Surveillance-based Outreach to Promote HIV Care
Engagement and ARV Use: Results from the Pilot Phase of a
Health Department Intervention
Julia Dombrowski*
1,2
, M Fleming
2
, J Simoni
1
, J Hughes
1
, and M Golden
1,2
1
2
Publ Hlth-Seattle & King Countv,
WA, US
1032a Disparities in Initiation of HAART and in Virologic
Suppression among Patients in the HIV Outpatient Study,
2000-2010
Richard Novak*
1
, R Debes
2
, J Chmiel
3
, J Brooks
4
, K Buchacz
4
,
and HOPS Investigators
1
Univ of Illinois, Chicago, US,
2
3
Northwestern Univ Feinberg Sch of Med, Chicago, IL, US, and
4
CDC,
Atlanta, GA, US
Program 67
P
o
s
t
e
r

L
i
s
t
i
n
g
s
1032b Changes in HIV Viral Load Suppression among HIV
+
New
Yorkers, 2006-2007 to 2010-2011
Laura Stadelmann*
1
, A Terzian
1
,
2
, M Irvine
1
, S Braunstein
1
, and
C Shepard
1

1
New York Citv Dept of Hlth and Mental Hvgiene, NY, US and
2
Long Island Univ, Sch of Hlth Professions, Brooklvn, NY, US
1033 HIV Spectrum of Engagement Cascade in a Large Integrated
Care System by Gender, Age, and Methodologies
Michael Horberg*
1,2
, L Hurley
3,4
, W Towner
5
, R Gambatese
6
, D Klein
7
,
D Antoniskis
8
, P Kadlecik
9
, D Kovach
10
, C Remmers
6
, and M Silverberg
3,4
1
Mid-Atlantic Permanente Res Inst of Kaiser Permanente Mid-Atlantic
States, Rockville, MD, US,
2
HIJ Initiative of Kaiser Permanente,
Rockville, MD, US,
3
HIJ Initiative of Kaiser Permanente, Oakland, CA,
US,
4
Kaiser Permanente Northern California, Oakland, US,
5
Kaiser
Permanente Southern California, Los Angeles, US,
6
Kaiser Permanente,
Oakland, CA, US,
7
Kaiser Permanente Northern California, Havward,
US,
8
Kaiser Permanente Northwest, Portland, OR, US,
9
Kaiser
Permanente Mid-Atlantic States, Washington, DC, US, and
10
Kaiser
Permanente Hawaii, Honolulu, US
1034 Impact of Recent Incarceration on HIV
+
Adults Receiving
Outpatient Medical Care: US
Muazzam Nasrullah*, J Fagan, E Frazier, F Hardnett, and J Skarbinski
1035 No Meaningful Difference between Retention Indicators from
US Government Agencies within the Largest HIV Cohort
Collaboration in North America
Peter Rebeiro*
1
, M Horberg
2
, K Gebo
1
, J Brooks
3
, K Buchacz
3
,
M Silverberg
4
, J Gill
5
, R Moore
1
, K AlthoII
1
, and North American AIDS
Cohort Collaboration on Res and Design
1
2
Atlantic, Rockville, MD, US,
3
4
Kaiser Permanente
Northern California, Oakland, US, and
5
Univ of Calgarv, Canada
1036 HIV Laboratory Tests Used as a Proxy for Medical Visits for
Defining Engagement in Care
B Dean
1
, R Debes
1
, Sam Bozzette*
1,2
, K Buchacz
3
, J Brooks
3
,
and HIV Outpatient Study Investigators
1
2
and
3
1037 Nationally Representative Estimates of Quality of HIV Care:
US, Data from the Medical Monitoring Project, 2009
Jacek Skarbinski*, C Furlow-Parmley, and E Frazier
1038 ART-nave Individuals` Attitudes to Starting ART at High
CD4 Counts for Potential Health Benefit or to Prevent HIV
Transmission
Alison Rodger*
1
, A Phillips
1
, A Speakman
1
, R Gilson
1
, M Fisher
2
,
E Wilkins
3
, J Anderson
4
, S Collins
5
, L Sherr
1
, F Lampe
1
, and ASTRA
Study Group
1
2
Roval Sussex Countv Hosp, Brighton, UK,
3
North Manchester Gen Hosp, UK,
4
Homerton Univ Hosp, London, UK,
and
5
HIJ iBase, London, UK
1039 How Effective Could the Seek, Test, Treat, and Retain
Strategy Be in France?
Lise Cuzin*
1
, C Allavena
2
, P Pugliese
3
, D Rey
4
, B Hoen
5
, I Poizot-Martin
6
,
A Cabie
7
, Y Yazdanpanah
8
, and DatÀIDS Study Group
1
CHU Toulouse, France,
2
CHU Nantes, France,
3
CHU Nice, France,
4
CHU Strasbourg, France,
5
CHU Besancon, France,
6
Hosp Ste
Marguerite, Marseille, France,
7
CHU Fort de France, and
8
Hosp Bichat,
Paris, France
1040a A Decline in Community Viral Load in Cape Town and
1ohannesburg, South Africa between 2004 to 2011
Sergio Carmona*
1,2
, B Macleod
3,4
, N Cassim
1
, S Nene
2
, G Sherman
1,2
,
and W Stevens
1,2
1
Natl Hlth Lab Svc, Johannesburg, South Africa,
2
Univ of the
Witwatersrand, Johannesburg, South Africa,
3
Right to Care,
4
Boston Univ, MA, US
1040b CD4 Count Distribution and ART Use in a Nationally
Representative Sample of HIV
+
Adults: Swaziland HIV
Incidence Measurement Survey
Charles Azih*
1
, N Bock
2
, D Donnell
3
, G Bicego
2
, V Okello
1
,
P Ehrenkranz
2
, and R Nkambule
1
1
Ministrv of Hlth, Mbabane, Swa:iland,
2
CDC, Atlanta, GA, US, and
3
Statistical Ctr for HIJ/AIDS Res and Prevention and the Jaccine and
Infectious Disease Inst, Fred Hutchinson Cancer Res Ctr, Seattle, WA, US
!

"#$$%&' ()*+,&$-#. /0$-.12-$
Disease Progression, Morbidity, and Mortality
1041 The Incidence and Risk of AIDS-defining Illnesses at Current
CD4 Counts of 500/mm
3
or Higher
Amanda MocroIt and COHERE in EuroCOORD
1042 Risk of Non-AIDS-defining Events amongst HIV
+
Patients
Not Yet on ART
Ard van Sighem*
1
, A Kesselring
1
, L Gras
1
, J Prins
2
, E Hassink
3
,
R KauIImann
4
, C Richter
5
, P Reiss
2
, F de WolI
1,6
, and ATHENA Natl
Observational Cohort
1
Stichting HIJ Monitoring Fndn, Amsterdam, The Netherlands,
2
3
Soa Aids
Nederland, Amsterdam, The Netherlands,
4
HAGA Hosp, The Hague, The
Netherlands,
5
Rifnstate Hosp, Arnhem, The Netherlands, and
6
Imperial
Coll Sch of Med, London, UK
1043 Rate and Predictors of Non-AIDS Events in a Cohort of Elite
and Viremic Controllers
C Lucero, B Torres, A Leon, M Calvo, L Leal, I Perez, M Plana,
J Mallolas, J Gatell, and Felipe Garcia*
Hosp Clin, Univ of Barcelona, Spain
1044 A Lower CD4 Cell Count at Presentation Is Associated with
Increased Mortality for Most Causes of Death
G Sturm
1
, M Sarcletti
1
, S Gogl
1
, A Rieger
2
, M Geit
3
, A Steuer
4
, B Haas
5
,
N Taylor
6
, Robert Zangerle*
1
, and AHIVCOS Group
1
2
Jienna Med Univ, Austria,
3
Gen Hosp
Lin:, Austria,
4
Otto Wagner Hosp Jienna, Austria,
5
Gen Hosp Gra: West,
Austria, and
6
Paracelsus Univ Sal:burg, Austria
1045a Continued Declines in AIDS and Non-AIDS-related
Mortality with Persistently Higher Mortality among Blacks
and Publicly Insured: HIV Outpatient Study, 1996-2009
Frank Palella*
1
, K Buchacz
2
, R Debes
3
, R Baker
3
, C Armon
3
, J Brooks
2
,
and HOPS Investigators
1
2
and
3
Cerner Corp, Jienna, JA, US
1045b Is HIV Development Assistance Reducing Child Mortality in
Sub-Saharan Africa?
Eran Bendavid* and J Bhattacharya
1046 Predictors of Mortality in a South African Military Cohort
Initiated on Randomized cART

Judith Dlamini*
1,2
, L Kondlo
1
, G Louwagie
2
, L Dzikiti
2
, S Emery
3
,
and Phidisa II Study Group
1
Profect Phidisa, Pretoria, South Africa,
2
Univ of Pretoria, South Africa,
and
3
Univ of New South Wales, Svdnev, Australia
1047 Viremia Copy-years as a Predictive Marker in HIV-1
+

Patients Initiating a Protease Inhibitor-containing HAART
Catherine Chirouze*
1
, V Journot
2
, V Le Moing
3
, L Bernard
4
, A Taieb
5
,
C Katlama
6
, G Chene
5
, C Leport
7
, F RaIIi
8
, B Hoen
1
, and ANRS CO 08
Aproco Copilote Study Group
1
Univ Hosp, Besancon, France,
2
INSERM U897, Bordeaux, France,
3
Univ
Hosp, Montpellier, France,
4
Univ Hosp, Tours, France,
5
INSERM U897,
Univ Bordeaux Segalen, Bordeaux, France,
6
INSERM U943, Univ Pierre
et Marie Curie, Paris, France,
7
UMR 738 INSERM, Paris Diderot Univ,
France, and
8
Univ Hosp, Nantes, France
1048 Cardiovascular-related Deaths in HIV
+
Patients between
2000 and 2010: Agence Nationale de Recherche sur le Sida
EN20 Mortalit 2010 Survey
Sandrine Henard*
1
, C Roussillon
2,3
, F Bonnet
3,4
, A Taieb
2,3
, P Cacoub
5
,
D Salmon
6
, E Rosenthal
7
, P Morlat
3,4
, G Chene
2,3,4
, and T May
1
1
Ctr Hosp et Univ, Nancv, France,
2
INSERM U897, Bordeaux, France,
3
Univ Bordeaux, France,
4
CHU de Bordeaux, France,
5
Hosp La Pitie-
Salpetriere, Univ Paris 6, France,
6
Hosp Cochin, Univ Paris 5, France,
and
7
Hosp LArchet, Nice, France
1049 Evolution in Causes of Death by Hepatitis C Virus Co-infection
in a Large Italian Cohort over the Last 25 Years

Manuela Colafgli*
1
, E Foca
2
, F Maggiolo
3
, A Scalzini
4
, N Ladisa
5
,
S Lo Caputo
6
, F Castelli
2
, L SighinolIi
7
, P Nasta
2
,
1
1
Catholic Univ of Sacred Heart, Italv,
2
Univ of Brescia, Italv,
3
Ospedali
Riuniti, Bergamo, Italv,
4
Spedali Civili di Brescia, Italv,
5
Policlinico
di Bari, Italv,
6
S Maria Annun:iata Hosp, Florence, Italv, and
7
S Anna
Hosp, Ferrara, Italv
1050 Prevalence of and Risk Factors for Nonalcoholic Fatty Liver
Disease in HIV
+
and HIV
-
Men: Multi-center AIDS Cohort
Study
JenniIer Price*
1
, W Post
2
, E Seaberg
3
, M BudoII
4
, L Kingsley
5
,
F Palella
6
, M Witt
4
, and C Thio
2
1
2
Baltimore, MD, US,
3
Baltimore, MD, US,
4
Los Angeles Biomed Res Inst at Harbor-UCLA Med
Ctr, US,
5
Univ of Pittsburgh Sch of Publ Hlth, PA, US, and
6
Northwestern
Univ Feinberg Sch of Med, Chicago, IL, US
1051 Prevalence and Factors Associated with Liver Steatosis
Measured by Transient Elastography with Controlled
Attenuation Parameter in HIV Infection
Juan Macias*
1
, J Gonzalez
2
, C Tural
3
, E Ortega
4
, F Pulido
5
, R Rubio
5
,
C CiIuentes
1
, C de Alvaro
6
, A Burgos
6
, J Pineda
1
, and ESTAMPA Study
Group
1
2
Hosp Univ La Pa:, Madrid, Spain,
3
Hosp Univ Germans Trias i Pufol, Badalona, Spain,
4
Hosp Gen Univ de
Jalencia, Spain,
5
Hosp Univ 12 de Octubre, Madrid, Spain, and
6
Abbott
Labs, Madrid, Spain
P
o
s
t
e
r

L
i
s
t
i
n
g
s
1052 Polymorphisms in the Interleukin-7 Receptor-o Gene Are
Associated with Survival in Treatment-nive Individuals with
HIV Infection

Hans Hartling*
1
, LW Thorner
1
, C Erikstrup
2
, R Zinyama
3,4
,
P Kallestrup
5
, EG Gomo
4
, S Nielsen
1
, and H Ullum
1
1
!"#$%&$'"()*+(, .&'+/%)#+/, 0+/1)234
2
5)2%6$ 7/"8 9&$', :3+;<=
:=#+%6$, 0+/1)234
3
>"/"$(2= &? 9*(% )/@ .%"*@ A+*?)2+, 9)2)2+,
B"1<)<C+4
4
7/"8 &? B"1<)<C+, 9)2)2+4 )/@
5
5)2%6$ 7/"8, 0+/1)23
!

"#$$%&' ()*+,&$-#. /0$-.12-$
Estimating Incidence
1053 Use of a Multi-assay Algorithm for Cross-sectional HIV
Incidence Estimation in HIV Prevention Trials Network 061
(the Brothers Study)
Oliver Laeyendecker*
1,2
, L Wang
3
, J Hughes
4
, V Cummings
2
,
E Piwowar-Manning
2
, D Wheeler
5
, S GriIIith
6
, K Mayer
7
, B Koblin
8
,
S Eshleman
2
, and HPTN 061 Study Team
1
DE5E0, DE9, F+(%+$@), >0, 7:4
2
G&%/$ 9&'3"/$ 7/"8 :H% &? >+@,
F)*("1&2+, >0, 7:4
3
:()("$("H)* .(2 ?&2 9EIJ5E0: !+$ )/@ K2+8+/("&/,
:+)((*+, A5, 7:4
4
7/"8 &? A)$%"/#(&/, :+)((*+, 7:4
5
L&=&*) 7/"8
.%"H)#&, EL, 7:4
6
M9E NOP, !+$+)2H% Q2")/#*+ K)23, D., 7:4
7
9)28)2@
>+@ :H%, F&$(&/, >5, 7:4 )/@
8
D+C R&23 F*&&@ .(2, DR, 7:
1054 Comparison of 3 HIV-1 Incidence Assays Performance
with the German Seroconverter Cohort: BED-EIA, BioRad
Avidity, and Limiting Ag Avidity

Andrea Hauser*
1
, S Masciotra
2
, S Fiedler
1
, C Santos-Hoevener
1
,
K Meixenberger
1
, S Somogyi
1
, B Bartmeyer
1
, N Bannert
1
, M Owen
2
,
and C Kuecherer
1
1
!&<+2( S&H%TE/$(, F+2*"/, U+21)/= )/@
2
.0., 5(*)/(), U5, 7:
1055 Performance of Dried Blood Spots with a Modified Genetic
Systems HIV-1/2 plus O Antibody Avidity-based Assay for
Identifying Recent HIV Infections
Silvina Masciotra*, X Wei, W Luo, A Smith, I Miles, C Sionean,
G Paz-Bailey, J Johnson, and M Owen
.0., 5(*)/(), U5, 7:
1056 The Performance of Candidate Assays to Detect Recent
HIV Infection for Cross-sectional Incidence Estimation: An
Independent, Comparative Evaluation
Reshma Kassanjee*
1,2
, G Murphy
3
, M Busch
4
, C Pilcher
5
, E McKinney
3
,
S Keating
4
, S Facente
5
, J MacArthur
4
, and A Welte
2
1
7/"8 &? (%+ A"(C)(+2$2)/@, G&%)//+$<62#, :&6(% 5?2"H)4
2
:&6(% 5?2"H)/
.(2 ?&2 V'"@+1"&*&#"H)* >&@+**"/# )/@ 5/)*=$"$, :(+**+/<&$H%4
3
9*(%
K2&(+H("&/ 5#+/H=, L&/@&/, 7S4
4
F*&&@ :=$(+1$ !+$ E/$(, :)/ M2)/H"$H&,
.5, 7:4 )/@
5
7/"8 &? .)*"?&2/"), :)/ M2)/H"$H&, 7:
1057 Characterization of Immune Response in Ugandan Women
Infected with Subtype A and D HIV Using the BED Capture
Immunoassay and an Antibody Avidity Assay

Andrew Longosz*
1
, C Morrison
2
, P-L Chen
2
, E Arts
3
, I Nankya
3
,
R Salata
3
, V Franco
4
, T Quinn
1,4
, S Eshleman
4
, and O Laeyendecker
1,4
1
DE5E0, DE9, F)*("1&2+, >0, 7:4
2
.*"/"H)* :H", M9E NOP, 062%)1,
D., 7:4
3
.)$+ A+$(+2/ !+$+28+ 7/"8, .*+8+*)/@, W9, 7:4 )/@
4
G&%/$
9&'3"/$ 7/"8 :H% &? >+@, F)*("1&2+, >0, 7:
1058 Estimating HIV Incidence in Rural Western Kenya:
Comparison of 3 Laboratory-based Methods
Clement Zeh*
1
, A Kim
2
, S Inzaule
3
, A Morwabe
3
, P Amornkul
4
,
M Owen
4
, L Mills
1
, and B Parekh
4
1
.0., S"$616, S+/=)4
2
.0., D)"2&<", S+/=)4
3
S+/=) >+@ !+$ E/$(J.0.
!+$ )/@ K6<* 9*(% .&**)<&2)("&/, S"$6164 )/@
4
.0., 5(*)/(), U5, 7:
!

"#$$%&' ()3+,&$-#. /0$-.12-$
New Testing Strategies
1059 Trends of HIV Testing before and after the CDC
Recommendations, 2002-2010

Florence Momplaisir*, B Fetzer, M Harhay, and J Long
7/"8 &? K+//$=*8)/") K+2+*1)/ :H% &? >+@, K%"*)@+*'%"), 7:
1060 Pharmacy-based HIV Testing: Reaching Those at Risk for
HIV with Limited Healthcare Access
Silvia Amesty*
1,2
, V Nandi
3
, M Sutton
4
, L Willis
4
, P Weidle
4
, and C Fuller
2
1
.(2 ?&2 M)1"*= )/@ .&116/"(= >+@, .&** &? K%=$"H")/$ )/@ :62#+&/$,
.&*61<") 7/"8, D+C R&23, DR, 7:4
2
>)"*1)/ :H% &? K6<* 9*(%, .&*61<")
7/"8, D+C R&23, DR, 7:4
3
L"/@$*+= M S"1<)** !+$ E/$(, D+C R&23 F*&&@
.(2, DR, 7:4 )/@
4
.0., 5(*)/(), U5, 7:
1061 A Tale of 1 City, 2 Venues: Comparing Costs of Routine
Rapid HIV Testing in a High-volume 1ail and a High-volume
Emergency Department, Atlanta, Georgia
Anne Spaulding*
1
, L Reid
2
, C Bowden
1
, B Copeland
3
, R Macgowan
2
,
A Margolis
2
, R Shresta
2
, G MustaaIaa
1
, K Heilpern
1
, and B Shah
1
1
V1&2= 7/"8 !&**"/$ :H% &? K6<* 9*(%, 5(*)/(), U5, 7:4
2
.0., 5(*)/(),
U5, 7:4 )/@
3
V1&2= 7/"8 :H% &? >+@, 5(*)/(), U5, 7:
1062 Randomized Comparison of Universal or Targeted HIV
Screening in the Emergency Department
Michael Lyons*, C Lindsell, A RuIIner, B Wayne, K Hart, M Sperling,
A Trott, and C Fichtenbaum
7/"8 &? ."/H"//)(", W9, 7:
1063 Outcomes from a Routine Screening Program for HIV
in a Large Urban Healthcare System Support Continued
Aggressive Routine Testing
Thomas Giordano*
1,2
, S Pasalar
2
, M Arya
1
, C Flash
1
, J Davila
1
,
N Miertschin
2
, K Malone
2
, and S Hoxhaj
1
1
F)=*&2 .&** &? >+@, 9&6$(&/, QX, 7: )/@
2
9)22"$ .&6/(= 9&$' 0"$(2"H(,
9&6$(&/, QX, 7:
1064 Replacing Clinic Testing with Home-use Tests May Increase
HIV Transmission among Seattle MSM: Evidence from a
Mathematical Model
David Katz*
1
, S Cassels
1
, and J Stekler
1,2
1
7/"8 &? A)$%"/#(&/, :+)((*+, 7: )/@
2
K6<* 9*(%T:+)((*+ Y S"/# .&6/(=,
A5, 7:
1065 Characteristics and Testing Uptake of Heterosexual Couples
Identified through Home-based Testing and Facilitated
Referral: South Africa and Uganda
Heidi van Rooyen*
1
, R Barnabas
2,3
, E Tumwesigye
4
, H Humphries
1
,
H Tumwebaze
4
, P Joseph
1
, M Krows
2
, P Murnane
2
, J Baeten
2
, and C Celum
2,3
1
961)/ :H" !+$ .&6/H"*, :C++(C)(+2$, :&6(% 5?2"H)4
2
7/"8 &?
A)$%"/#(&/, :+)((*+, 7:4
3
M2+@ 96(H%"/$&/ .)/H+2 !+$ .(2, :+)((*+, A5,
7:4 )/@
4
E/(+#2)(+@ .&116/"(= F)$+@ E/"(")("8+$, S)<C&%+, 7#)/@)
1066 An Integrated Youth Center Model Improves HIV Testing in
Young Adolescents: Cape Town, South Africa
Samantha Black*, M Wallace, K Middelkoop, D Robbertze, T Bennie,
R Wood, and L-G Bekker
0+$1&/@ Q6(6 9EI .(2, 7/"8 &? .)'+ Q&C/, :&6(% 5?2"H)
1067 Doubling of HIV Prevalence among Female Sex Workers in
Zanzibar Assessed through Respondent-driven Sampling
Surveys, 2007 to 2011
F Khalid
1
, M Kibona
2
, A Khatib
1
, A Leidich
3
, A Othman
1
,
Irene Benech*
4
, M Dahoma
5
, C Mullen
3
, E Kim
4
, and G Arthur
6
1
B)/Z"<)2 5E0: .&/(2&* K2#1, >"/"$(2= &? 9*(%, Q)/Z)/")4
2
.0., 0)2 +$
:)*))1, Q)/Z)/")4
3
U*&<)* 9*(% :H", 7/"8 &? .)*"?&2/"), :)/ M2)/H"$H&,
7:4
4
.0., 5(*)/(), U5, 7:4
5
0"2+H(&2)(+ &? K2+8+/("8+ :8H$ )/@ 9*(% V@,
>"/"$(2= &? 9*(%, B)/Z"<)2, Q)/Z)/")4 )/@
6
.Q: U*&<)* 7:5 )$$"#/+@ (&
0"8 &? U*&<)* 9EIJ5E0:, .0., 0)2 +$ :)*))1, Q)/Z)/")
1068 Patterns of HIV Retesting among Clients of Voluntary HIV
Testing and Counseling Facilities: Lesotho, 1anuary 2006-
1une 2010
Cari Courtenay-Quirk*
1
, K Grabbe
1
, A Baughman
1
, G Djomand
1
,
and B Pederson
2
1
.0., 5(*)/(), U5, 7: )/@
2
K&'6*)("&/ :8H$ E/(*, >)$+26, L+$&(%&
!

"#$$%&' ()4+,&$-#. /0$-.12-$
Biological and Behavioral Transmission Risks
1069 HIV Transmission Risk Behavior in a Cohort of HIV
+

Treatment-nave Men and Women: US
Raphael Landovitz*
1
, T Tran
2
, S Cohn
3
, I OIotokun
4
, J Lennox
4
,
J Currier
1
, and H Ribaudo
2
1
7.L5 .(2 ?&2 .*"/"H)* 5E0: !+$ )/@ V@, 7:4
2
9)28)2@ :H% &? K6<* 9*(%,
F&$(&/, >5, 7:4
3
D&2(%C+$(+2/ 7/"8 M+"/<+2# :H% &? >+@, .%"H)#&, EL,
7:4 )/@
4
V1&2= 7/"8 :H% &? >+@, 5(*)/(), U5, 7:
1070 Risk for HIV following a Diagnosis of Syphilis, Gonorrhea, or
Chlamydia: 328,456 Women and 161,498 Men, Florida, 2000-
2011
Thomas Peterman*
1
, D Newman
1
, L Maddox
2
, K Schmitt
2,3
, and S Shiver
2
1
.0., 5(*)/(), U5, 7:4
2
M*&2"@) 0+'( &? 9*(%, 0"8 &? 0"$+)$+ .&/(2&*
)/@ 9*(% K2&(+H("&/, Q)**)%)$$++, 7:4 )/@
3
M*&2"@) :()(+ 7/"8 .&** &?
D62$"/#, Q)**)%)$$++, 7:
1071 Correlates of Asymptomatic Gonococcal and Chlamydial
Infections among US Military Men Infected with HIV
R Carpenter
1
, Oliver ReIugio*
2
, K O`Brien
2
, N Adams
1
, M Bavaro
1
,
M Johnson
1
, R Maves
1
, J Sklar
1
, H GroII
1
, and N Crum
1,2
1
D)8)* >+@ .(2, :)/ 0"+#&, .5, 7: )/@
2
:)/ 0"+#& :()(+ 7/"8, .5, 7:
1072 Incidence of Acute Sexually Transmitted Infections among
HIV Diagnosed Individuals Attending Sexual Health Clinics:
England, 2008-2011
Sarika Desai*, V Delpech, L Peters, and G Hughes
9*(% K2&(+H("&/ 5#+/H=, L&/@&/, 7S
1073 Association between Phosphodiesterase Type 5 Inhibitor and
Sexually Transmitted Infections among HIV
+
Men
Nimish Patel*
1
, M Nasiri
1
, S Kwon
2
, C Miller
2
, L-A McNutt
3
, and D Fish
2
1
5*<)/= .&** &? K%)21)H= )/@ 9*(% :H", DR, 7:4
2
5*<)/= >+@ .&**, DR,
7:4 )/@
3
7/"8 )( 5*<)/=, :()(+ 7/"8 &? D+C R&23, :H% &? K6<* 9*(%,
!+/$$+*)+2, 7:
Program 69
P
o
s
t
e
r

L
i
s
t
i
n
g
s
1074 Prevalence of HIV, Other Sexually Transmitted Infections,
and Viral Hepatitis by Urbanicity, Overall and among MSM,
Injecting Drug Users, and Heterosexuals: US
Alexandra Oster*, M Sternberg, S Nebenzahl, D Broz, F Xu, S Hariri,
I Miles, and G Paz-Bailey
1075 A Socioenvironmental Exploration of Community-level Social
Determinants of HIV among Blacks: Washington, DC, 2008
Leigh Willis*
1
, J Opoku
2
, R Wiegand
1
, A Murray
1
, Y Jia
2
, K Elmore
1
,
T West
2
, G Pappas
2
, and M Sutton
1
1
2
District of Columbia Dept of Hlth, HIJ/
AIDS, Hepatitis, STD, and TB Admin, US
1076 Geospatial and Individual Factors Are Associated with High-
risk Transmission Behavior among HIV
+
Subjects in Care:
Data from CNICS
Richard Haubrich*
1
, S Jain
1
, C Perez-Heydrich
2
, C Hurt
2
, S Morris
1
,
S Sun
1
, S Napravnik
2
, H Crane
3
, M Emch
2
, J Eron
2
, and CNICS 040 Study
Team
1
2
Univ of North Carolina at Chapel
Hill, US, and
3
1077 Investigation of HIV Incidence Rates in a High-risk, High-
prevalence Kenyan Population: Lessons for Intervention
Trials and Programmatic Strategies
Rennatus Mdodo*
1
, D Gust
1
, F Otieno
2
, E McLellan-Lemal
1
, R Chen
1
,
C LeBaron
1
, F Hardnett
1
, C Zeh
1,2
, T Samandari
1
, and L Mills
1,2
1
2
Kenva Med Res Inst/CDC Res and Publ Hlth
Collaboration, Kisumu
1078 Determinants of Couple Sexual Concurrency among
Fishermen and Their Spouses: Lake Victoria, Kenya

Zachary Kwena*
1
, I Mwanzo
2
, E Bukusi
1
, L Achiro
1
, and C Shisanya
2
1
Kenva Med Res Inst, Nairobi and
2
Kenvatta Univ, Nairobi, Kenva
1079 Shedding of HIV and Human Herpesviruses in the Semen of
Effectively Treated HIV
+
Men

Sara Gianella Weibel*
1
, D Smith
1,2
, M Vargas
1
, S Little
1
, D Richman
1,2
,
E Daar
3
, M Dube
4
, C Ginocchio
5
, R Haubrich
4
, and S Morris
1
1
2
JA San Diego Hlthcare Svstem, CA,
US,
3
Los Angeles Biomed Res Inst at Harbor-UCLA Med Ctr, Torrance,
CA, US,
4
Univ of Southern California Keck Sch of Med, Los Angeles, US,
and
5
Hofstra North Shore-LIJ Sch of Med, Hempstead, NY, US
1080 Genital Shedding of HIV-1 after Switching to 2
nd
-line
Lopinavir/ritonavir Monotherapy
T Bunupuradah
1
, C Bowonwattanuwong
2
, S Jirajariyavej
3
, W Munsakul
4
,
V Klinbuayaem
5
, J Sophonphan
1
, A Mahanontharit
1
, B Hirschel
6
,
K Ruxrungtham
1,7
, Jintanat Ananworanich*
1,7,8
, and HIV STAR Study
1
HIJ-NAT, Thai Red Cross AIDS Res Ctr, Bangkok,
2
Chonburi Hosp,
Thailand,
3
Taksin Hosp, Bangkok, Thailand,
4
Facultv of Med, Univ of
Bangkok Metropolitan Admin, Thailand,
5
Sanpatong Hosp, Chiang Mai,
Thailand,
6
Geneva Univ, Swit:erland,
7
Facultv of Med, Chulalongkorn
Univ, Bangkok, Thailand, and
8
Bangkok
1081 Semen Interferon-y and Interleukin-17 Are Positively
Associated with Semen HIV-1 Shedding

JenniIer HoIIman*, D ElashoII, D Anisman-Posner, K Tanner,
C Sugar, J Elliott, GC Baldwin, P Anton, O Yang, and R HoIIman
UCLA Med Ctr, US
!

"#$$%&' ()*+,&$-#. /0$-.12-$
Reducing Risk
1082 ~No one`s at home and they won`t pick up the phone: Using
the Internet and SMS to Enhance Partner Services: North
Carolina
Lisa Hightow-Weidman*
1
, S Beagle
1
, J Embry
1
, E Pike
1
, J Kuruc
1
,
P Leone
1,2
, E Foust
2
, and C Gay
1
1
Univ of North Carolina at Chapel Hill, US and
2
North Carolina DHHS,
Communicable Disease Branch, Raleigh, US
1083 Impact of Language Barriers on HIV Serodisclosure and
Risk Behaviors among MSM during International Travel
Hong-Ha Truong*
1,2
, T Kellogg
3
, Y-H Chen
3
, M Grasso
3
, T Robertson
3
,
A Curotto
1
, W McFarland
1,3
, R Grant
1,2
, O Reznick
1
, and W Steward
1
1
2
Gladstone Inst of Jirologv and
Immunologv, San Francisco, CA, US, and
3
San Francisco Dept of Publ
Hlth, CA, US
1084 The Effect of HIV Counseling and Testing on HIV Acquisition
among South African Youth: A Protective Association

Nora Rosenberg*
1,2
, D Westreich
3
, T Barnighausen
2,4
, W Miller
1
,
F Behets
1
, S Maman
1
, M-L Newell
2
, and A PettiIor
1
1
2
Population Studies, Mtubatuba, South Africa,
3
Duke Univ, Durham, NC,
US, and
4
Harvard Univ, Boston, MA, US
1085 Decline in HIV
+
Test Results among First-time Testers:
Botswana, Tebelopele Voluntary Counseling and Testing
Centers, 2005-2012
Spana Motsisi*
1
, P Loeto
2
, M Boima
1
, K Molosiwa
1
, L Manthe
1
,
MG Alwano
2
, and A Voetsch
2
1
Tebelopele Joluntarv Counseling and Testing Ctrs, Gaborone, Botswana
and
2
CDC, Gaborone, Botswana
1086 HIV Control in West Africa: The End of the Tunnel? Zero
HIV-1 Seroconversion among Young Female Sex Workers in
Ouagadougou, Burkina Faso
Isidore Traore*
1
, N Meda
1,2
, N Hema
1
, I Konate
2
, D Drabo
1
, F Some
1
,
R Some
1
, P Mayaud
3
, P Van De Perre
4
, and N Nagot
4
1
Univ of Ouagadougou, Burkina Faso,
2
Ctr Mura:, Bobo-Dioulasso,
Burkina Faso,
3
London Sch of Hvgiene and Tropical Med, UK, and
4
Univ
of Montpellier 1 and INSERM U1058, France
1087 Fertility Intentions and Interest in Peri-conception HIV-1
Risk Reduction Strategies among HIV-1 Serodiscordant
Couples: Kenya

Kenneth Ngure*
1,2
, R HeIIron
2
, N Mugo
2,3
, C Celum
2
, K Curran
2
,
A Kurth
4
, and J Baeten
2
1
Jomo Kenvatta Univ of Agriculture and Tech, Nairobi, Kenva,
2
Univ of
3
Kenvatta Natl Hosp, Nairobi, Kenva, and
4
New
York Univ, NY, US
1088 4-Year Trends in Risky Sexual Behavior after ARV Initiation:
Rural Southwestern Uganda

Annet Kembabazi*
1
, F Bajunirwe
1
, J Martin
2
, C Muzoora
1
, P Hunt
2
,
J Haberer
3
, D Bangsberg
3,4
, and M Siedner
3
1
2
Francsico, US,
3
Massachusetts Gen Hosp Ctr for Global Hlth, Boston,
US, and
4
!

"#$$%&' ()3+,&$-#. /0$-.12-$
Performance and Innovation in ART Programs in RLS
1089 Time Trends of CD4 Cell Count Levels at the Initiation of
ART among Asian HIV
+
Patients

Sasisopin Kiertiburanakul*
1
, D Boettiger
2
, M Po Lee
3
, S Omar
4
,
J Tanuma
5
, O Tek Ng
6
, N Durier
7
, S Sungkanuparph
1
, and TREAT Asia
HIV Observational Databases and TREAT Asia Studies to Evaluate
Resistance
1
Facultv of Med Ramathibodi Hosp, Mahidol Univ,
2
The Kirbv Inst, Univ
of New South Wales, Australia,
3
Queen Eli:abeth Hosp, Hong Kong,
China,
4
Univ of Malava, Malavsia,
5
Natl Ctr for Global Hlth and Med,
Japan,
6
Tan Tock Seng Hosp, Singapore, and
7
TREAT Asia, amfARFndn
for AIDS Res, Thailand
1090 Trends in and Determinants of CD4 Count at ART Initiation
after Changes in National ART Guidelines: Data from 3 HIV
Clinics, Kigali, Rwanda
Eugene Mutimura*
1
, D Addison
1
, K Anastos
2
, D Hoover
3
, JC Dusingize
4
,
Q Shi
5
, D Duggan
6
, B Karenzi
7
, I Izimukwiye
8
, D Nash
1
, and Central
AIrican Intl Epidemiologic Database to Evaluate AIDS Study Group
1
CUNY Sch of Publ Hlth Hunter Coll, US,
2
Albert Einstein Coll of Med
and Montefiore Med Ctr, New York, NY, US,
3
State Univ of New Jersev,
New Brunswick, US,
4
Women`s Equitv in Access to Care and Treatment,
Kigali, Rwanda,
5
Sch of Hlth Sci, New York Med Coll, NY, US,
6
Stevens
Inst of Tech, Hoboken, NY, US,
7
Rwanda Militarv Hosp Kigali, and
8
Masaka District Hosp Kigali, Rwanda
1091 Time to Eligibility for ART in Adults with CD4 Count >500
cells/L: Rural KwaZulu-Natal, South Africa
Nuala McGrath*
1,2
, R Lessells
1,2
, and M-L Newell
2,3
1
2
Population Studies, KwaZulu-Natal, South Africa, and
3
Inst of Child Hlth,
1092 The Effect of a Maturing ARV Program on Early Mortality
for Patients with Advanced Immune-compromise: Soweto,
South Africa

Kennedy Otwombe*, T Tutu-Gxashe, L Mohapi, G Gray, and F Laher
Perinatal HIJ Res Unit, Univ of the Witwatersrand, Johannesburg, South
Africa
1093 The Survival Benefits of ART: South Africa
M April
1,2
, R Wood
3
, B Berkowitz
4
, D Paltiel
5
, X Anglaret
6,7
, E Losina
8,9,10
,
K Freedberg
4,8,10,11
, and Rochelle Walensky*
4,9,10
1
San Antonio Uniformed Svcs Hlth Ed Consortium, TX, US,
2
Harvard Med
Sch, Boston, MA, US,
3
4
Massachusetts
5
Yale Sch of Publ Hlth, New Haven, CT, US,
6
Univ Bordeaux, INSERM U897, France,
7
Prgm PAC-CI/ANRS Res Site,
Abidfan, Cote dIvoire,
8
Boston Univ, MA, US,
9
Brigham and Women`s
Hosp, Boston, MA, US,
10
Ctr for AIDS Res, Harvard Univ, Boston, MA,
US, and
11
1094 Long-term Outcomes of 1
st
-line NNRTI-based ART: Ghana

Fred SarIo*
1
, A Kasim
2
, G Bedu-Ado
1
, R Phillips
1
, M Booth
2
,
and D Chadwick
3
1
Komfo Anokve Teaching Hosp, Kumasi, Ghana,
2
Durham Univ, Stockton
on Tees, UK, and
3
James Cook Univ Hosp, Middlesbrough, UK
P
o
s
t
e
r

L
i
s
t
i
n
g
s
1095 Sex Differences in 3.5-year CD4 Trajectories after ART
Initiation: Rwandan Adults
Kathryn Anastos*
1
, Q Shi
2
, JC Dusingize
3
, E Mutimura
3
, D Duggan
4
,
B Karenzi
5
, I Izimukwiye
6
, D Nash
7
, D Smith
4
, and D Hoover
8
1
Albert Einstein Coll of Med and Montefiore Med Ctr, Bronx, NY, US,
2
Sch of Hlth Sci, New York Med Coll, Jalhalla, US,
3
Women`s Equitv in
Access to Care and Treatment, Kigali, Rwanda,
4
Stevens Inst of Tech,
Hoboken, NY, US,
5
Rwanda Militarv Hosp, Kigali,
6
Masaka District
Hosp Kigali, Rwanda,
7
CUNY Sch of Publ Hlth Hunter Coll, NY, US,
and
8
Rutgers, the State Univ of New Jersev, New Brunswick, US
1096 Finding HIV in Hard-to-reach Populations: Mobile HIV
Testing and Geospatial Mapping: Umlazi Township, Durban,
South Africa
Ingrid Bassett*
1
, S Regan
1
, H Mbonambi
2
, J Blossom
3
, S Bogan
3
,
R Walensky
1,4
, B Mhlongo
2
, H Thulare
2
, K Freedberg
1
, and E Losina
1,4
1
2
Ithembalabantu People`s Hope
Clin/AIDS Hlthcare Fndn, Durban, South Africa,
3
Harvard Univ Ctr for
Geographic Analvsis, Cambridge, MA, US, and
4
Brigham and Women`s
Hosp, Boston, MA, US
1097 Mobile HIV Screening in Cape Town, South Africa: Clinical
Impact, Cost, and Cost-effectiveness
Ingrid Bassett*
1,2
, D Govindasamy
3
, A Erlwanger
1
, E Hyle
1
, N van Schaik
3
,
F Noubary
1
, R Wood
3
, E Losina
1,4,5
, L-G Bekker
3
, and K Freedberg
1,2,6
1
2
Harvard Univ Ctr for AIDS
Res, Boston, MA, US,
3
4
Brigham and
5
Boston Univ Sch of Publ Hlth, MA, US,
and
6
1098 The Effect of 30 vs 40 mg of Stavudine vs Tenofovir on
Treatment Outcomes amongst HIV
+
Patients: 1ohannesburg,
South Africa

Alana Brennan*
1,2
, M Maskew
2
, I Sanne
2,3,4
, and M Fox
1,2,5
1
2
Hlth Economics
and Epidemiologv Res Office, Dept of Internal Med, Sch of Clin Med,
Facultv of Hlth Sci, Univ of the Witwatersrand, Johannesburg, South
Africa,
3
4
Clin HIJ Res Unit,
Dept of Internal Med, Sch of Clin Med, Facultv of Hlth Sci, Univ of the
Witwatersrand, Johannesburg, South Africa, and
5
Boston Univ Sch of
Publ Hlth, MA, US
1099 Longitudinal Assessment of Associations between Food
Insecurity and HIV Treatment Outcomes: Rural Uganda
Sheri Weiser*
1,2
, K Palar
3
, E Frongillo
4
, A Tsai
5
, E Kumbakumba
6
,
N Grede
7
, P Hunt
1,2
, K Ragland
1,2
, J Martin
2
, and D Bangsberg
5,6,8
1
San Francisco Gen Hosp, CA, US,
2
US,
3
4
Arnold Sch of Publ Hlth,
Univ of South Carolina, Columbia, US,
5
Massachusetts Gen Hosp Ctr
for Global Hlth, Boston, US,
6
7
United Nations World Food Prgm, Rome, Italv, and
8
Ragon Inst of MGH,
MIT, and Harvard, Boston, MA, US
1100 Does ART Attenuate the Stigma of HIV? Evidence from a
Cohort Study in Rural Uganda
Alexander Tsai*
1
, D Bangsberg
1
, M Bwana
2
, J Haberer
1
, E Frongillo
3
,
C Muzoora
2
, E Kumbakumba
2
, P Hunt
4
, J Martin
4
, and S Weiser
4
1
2
Mbarara Univ of Sci and Tech,
Uganda,
3
Univ of South Carolina, Columbia, US, and
4
Univ of California,
San Francisco, US
!

"#$$%&' ()*+,&$-#. /0$-.12-$
Adherence and Retention in RLS
1101 Validating Measures of Distance to HIV Clinic in Rural
Uganda and Its Impact on Clinic Attendance

Mark Siedner*
1
, A Lankowski
1
, A Tsai
1,2
, C Muzoora
3
, P Hunt
4
,
J Martin
4
, J Haberer
1
, and D Bangsberg
1,5
1
Massachusetts Gen Hosp Ctr for Global Hlth, Boston, US,
2
3
Mbarara Univ of Sci and Tech,
Uganda,
4
Univ of California, San Francisco, US, and
5
Ragon Inst of
MGH, MIT, and Harvard Med Sch, Boston, US
1102 Site and Program Determinants of Patient Retention in HIV
Care: Nigeria

Chinenye Ugoji*
1
, R Ake-Uzoigwe
1
, MY Ladele
1
, C Akolo
1
, G Mendy
1
,
P Dakum
1
, M Charurat
2
, D Onotu
3
, O Nwanyanwu
3
, and W Blattner
2
1
2
Inst of Human Jirologv,
Univ of Marvland, Baltimore, US, and
3
Ctr for Disease Control, Nigeria
1103 Attrition through Multiple Stages of HIV Care in South
Africa: A Challenge for Test-and-Treat
Matthew Fox*
1,2,3
and K Shearer
3
1
2
Boston Univ Sch of
Publ Hlth, MA, US, and
3
Hlth Economics and Epidemiologv Res Office,
1104 Retention in Care up to ART Initiation within a Decentralized
HIV Program in South Africa: The Critical Role of the First
Clinic Visit

Melanie Plazy*
1,2
, R Dray-Spira
3
, J Orne-Gliemann
1,2
, F Dabis
1,2
,
and M-L Newell
4
1
Univ Bordeaux, ISPED, INSERM U897, France,
2
ISPED, INSERM
U897, Bordeaux, France,
3
Epidemiologv of Occupational and Social
Determinants of Hlth-Ctr for Res in Epidemiologv and Population
Hlth, INSERM U1018, Jillefuif, France, and
4
Population Studies, Univ of KwaZulu-Natal, South Africa
1105 Co-enrollment of HIV
+
Family Members in Care Is Associated
with Improved Outcomes for Women on ART: A Cohort Study
Landon Myer*
1
, J Duong
2
, Y Zhang
2
, E Abrams
3
, R Carter
3
,
and MTCT-Plus Initiative
1
2
Mailman Sch of Publ Hlth, Columbia
Univ, New York, US, and
3
Intl Ctr for AIDS Care and Treatment Prgms,
Mailman Sch of Publ Hlth, Columbia Univ, New York, NY, US
1106 A Sampling-based Approach to Assessing Patient-reported
Barriers to Retention among HIV
+
Patients on ART: East
Africa
Elvin Geng*
1
, T Odeny
2
, L Rita
3
, A Nakiwogga-Muwanga
4
, M Bwana
5
,
E Bukusi
6
, G Somi
3
, P Braitstein
7
, C Yiannoutsos
7
, J Martin
1
,
and East AIrica Intl Epidemiologic Databases to Evaluate AIDS
1
2
Familv AIDS Care and Ed Svcs,
Kisumu, Kenva,
3
Natl AIDS Control Prgm, Dar es Salaam, Tan:ania,
4
5
Mbarara Univ of Sci
and Tech, Uganda,
6
Kenva Med Res Inst, Nairobi, and
7
Indiana Univ,
Indianapolis, US
1107 Real-time HIV ART Adherence Monitoring Predicts Loss
of Viral Suppression and Subsequent Resuppression: Rural
Uganda
Jessica Haberer*
1,2
, C Muzoora
3
, P Hunt
4
, J Martin
4
, M Siedner
1,2
,
and D Bangsberg
1,2,3
1
2
US,
3
Mbarara Univ of Sci and Tech, Uganda, and
4
Univ of California,
San Francisco, US
!

"#$$%&' ())+,&$-#. /0$-.12-$
Virologic Failure, 2
nd
- and 3
rd
1108 Risk Factors for Virologic Failure for Patients on 1
st
-line
ART: Durban, South Africa
Vincent Marconi*
1,2,3
, B Johnson
2
, J Hampton
4
, B Wu
2
, M Gordon
5,6
,
S John
4
, C Ordonez
4
, R Murphy
7
, D Kuritzkes
8,9
, H Sunpath
4
, and
South AIrica Resistance Cohort Study
1
Emorv Univ Sch of Med, Atlanta, GA, US,
2
Emorv Univ Rollins Sch of
Publ Hlth, Atlanta, GA, US,
3
Atlanta JAMC, GA, US,
4
McCord Hosp,
5
Doris Duke Med Res Inst, Durban, South Africa,
6
7
Albert Einstein Med Sch,
Bronx, NY, US,
8
and
9
1109 Determinants of Treatment Failure in HIV
+
Adults on 2
nd
-line
ART: Ho Chi Minh City, Vietnam

Vu Thao*
1
, V Quang
2
, M Wolbers
1
, N Anh
1
, N Chinh
2
, C Shikuma
3
,
J Day
1
, J Farrar
1
, S Dunstan
1
, and T Le
1,3
1
Oxford Univ Clin Res Unit, Ho Chi Minh Citv, Jietnam,
2
Hosp for
Tropical Diseases, Ho Chi Minh Citv, Jietnam, and
3
Hawaii Ctr for
AIDS, Univ of Hawaii at Manoa, Honolulu, US
1110 Failure to Switch following Confirmed Virologic Failure Is
Associated with Elevated Mortality among HIV
+
Patients
Treated in Africa
Maya Petersen*
1
, L Tran
1
, E Geng
2
, S Deeks
2
, S Reynolds
3
, A Kambugu
4
,
R Wood
5
, D Bangsberg
6
, C Yiannoutsos
7
, and J Martin
2
1
2
US,
3
Rakai Hlth Sci Prgm, Entebbe, Uganda,
4
Infectious Diseases Inst,
Makerere, Uganda,
5
6
Harvard Med
Sch, Boston, MA, US, and
7
Indiana Univ Sch of Med, Indianapolis, US
1111 The Impact of Different CD4 Monitoring and Switching
Strategies on Mortality in HIV
+
African Adults on ART
D Ford
1
, J Robins
2
, M Petersen
3
, D Gibb
1
, C Gilks
4
, P Mugyenyi
5
,
H Grosskurth
6
, J Hakim
7
, A Babiker
1
, Sarah Walker*
1
, and DART Trial
Team
1
2
Harvard Sch of Publ Hlth, Harvard
Univ, Boston, MA, US,
3
4
Imperial
Coll London, UK,
5
Joint Clin Res Ctr, Kampala, Uganda,
6
MRC/UJRI
Uganda Res Unit on AIDS, Entebbe, and
7
1112 Lopinavir/ritonavir Mono-therapy after Virologic Failure of
1
st
-line NNRTI-containing ART in Resource-limited Settings:
Week 104 Analysis
of ACTG 5230
Nagalingeswaran Kumarasamy*
1
, E Aga
2
, H Ribaudo
2
, C Wallis
3
,
D Katzenstein
4
, W Stevens
5
, M Norton
6
, K Klingman
7
, and J Bartlett
8
1
YRG CARE Med Ctr, Chennai, India,
2
Statistical Data Analvsis Ctr,
3
Lancet Labs, Johanesburg, South Africa,
4
5
Univ of the Witwatersrand, Johannesburg, South
Africa,
6
Abbott, IL, US,
7
DAIDS, NIAID, NIH, Bethesda, MD, US, and
8
Duke Univ Med Ctr, NC, US
Program 71
P
o
s
t
e
r

L
i
s
t
i
n
g
s
1113 Tenofovir vs Zidovudine in 2
nd
-line ART after Stavudine
Failure in Southern Africa: A Causal Modeling Study
Gilles Wandeler*
1,2
, F Gerber
1
, J Rohr
3
, C Chimbetete
4
, C Orrell
5
,
H Prozesky
6
, A Boulle
7
, C HoIImann
8
, B Chi
9
, M Egger
1
,
and IeDEA-Southern AIrica
1
2
Univ Hosp Bern, Swit:erland,
3
Boston
Univ Ctr for Global Hlth and Devt, MA, US,
4
Newlands Clin, Harare,
Zimbabwe,
5
Desmond Tutu HIJ Ctr, Inst of Infectious Disease and
Molecular Med, Univ of Cape Town, South Africa,
6
Univ of Stellenbosch
and Tvgerberg Academic Hosp, Cape Town, South Africa,
7
Khavelitsha
ART Prgm, Medecins Sans Frontieres, Cape Town, South Africa,
8
Aurum
Inst for Hlth Res, Johannesburg, South Africa, and
9
Ctr for Infectious
Disease Res in Zambia, Lusaka
1114 High Rates of Re-suppression among Patients with Viral
Load Failure on 2
nd
-line ART: Nigeria
Holly Rawizza*
1
, B Chaplin
2
, S Meloni
2
, O Agbaji
3
, W Gashau
4
,
P Okonkwo
5
, P Kanki
2
, and APIN PEPFAR Team
1
2
Harvard Sch of Publ
3
Jos Univ Teaching Hosp, Nigeria,
4
Univ of
Maiduguri Teaching Hosp, Nigeria, and
5
AIDS Prevention Initiative
Nigeria, Abufa
1115 Clinical Impact and Cost-effectiveness of Making 3
rd
-line
ART Available in Sub-Saharan Africa:
A Model-based Analysis in Cote dÌvoire

Eric Ouattara*
1,2
, E Ross
3
, Y Yazdanpanah
4
, A Wong
3
, E Losina
3,5,6
,
R Walensky
3,6
, D Paltiel
7
, S Eholie
1,8
, K Freedberg
3,6
, and X Anglaret
1,2
1
Prgm PAC-CI/ANRS Res Site, Abidfan, Cote dIvoire,
2
Univ Bordeaux,
INSERM U897, France,
3
4
Ctr
Hosp Univ Bichat Claude-Bernard, Paris, France,
5
Brigham and
Womens Hosp, Boston, MA, US,
6
Harvard Univ Ctr for AIDS Res,
Harvard Med Sch, Harvard Sch of Publ Hlth, and Boston Univ Sch of
Publ Hlth, MA, US,
7
Yale Sch of Med, New Haven, CT, US, and
8
Ctr
Hosp Univ de Treichville, Abidfan, Cote dIvoire
1116 Benefits of Early ART Initiation Outweigh Risk of
Transmitted HIV Drug Resistance: A Modeling Study of 2
East African Settings

Brooke Nichols*
1
, K SigaloII
2,3
, C Kityo
4
, K Mandaliya
5
, R Hamers
2,3
,
S Bertagnolio
6
, M Jordan
7
, C Boucher
1
, T Rinke de Wit
2,3
,
and D van de Vijver
1
1
Erasmus Med Ctr, Rotterdam, The Netherlands,
2
PharmAccess Fndn,
Amsterdam, The Netherlands,
3
Amsterdam Inst for Global Hlth and Devt,
The Netherlands,
4
5
Coast
Province Gen Hosp, Intl Ctr for Reproductive Hlth, Mombasa, Kenva,
6
WHO, Geneva, Swit:erland, and
7
Tufts Univ Sch of Med, Boston, MA, US
Building B Georgia World Congress Center
285 International Blvd NW, Atlanta, GA 30313
CROI Message Center 404-222-5800
Level One
Breakout Rm Hall B1
Poster Hall Hall B2
CyberCafe Hall B2
First Aid
Level Two
Media Ctr B202
Speaker Svcs/Poster Drop-off B208
CROI Headquarters B211
Level Three
Breakout Rms B308
B313
Overflow Rms B310
B311
Level Five
Breakout Rms Ballroom 1-2
Ballroom 3-4
Level Four
Breakout Rms B402
B406
Overflow Rms B403
B404
Registration Lobby
Message Center Lobby
Coat Check Lobby
B308
B310
Overflow
for B308
B311
Overflow
for B313 B313
Elevators Elevators
Escalators Escalators
Speaker Svcs/
Poster Drop-off
B211
HQ B202
Media
Ctr
Escalators Escalators
Escalators
Elevators
Escalators
B208
+
Hall B2
Poster Hall
Hall B1
General Session
C
y
b
e
r
C
a
f
e
Elevators Elevators
E
s
c
a
l
a
t
o
r
s
E
s
c
a
l
a
t
o
r
s
Coffee
breaks
Coat
Check
Elevators
B404
Overflow
for B406
B403
Overflow
for B402 B406 B402
Terrace
Restaurant
R
e
g
i
s
t
r
a
t
i
o
n
M
e
s
s
a
g
e

C
t
r
Escalators Escalators Escalators
S
t
r
e
e
t

E
n
t
r
a
n
c
e

t
o

B
l
d
g

B
Escalators
Up to
Ballroom
Level Five
Ballroom
1-2
Ballroom
3-4
Elevators
Escalators
Down to
Level Four
41209wo_PA_BM-R7.indd 4 2/20/13 6:06 PM
POSTER SESSIONS
Poster Hall open from 7 am to 7 pm; all posters will be available for viewing for the duration of the conference
MDNDA 3/4/l3 2:30-4 PM TUE5DA 3/5/l3 2:30-4 PM WEDNE5DA 3/6/l3 2:30-4 PM
53. HIV Persistence, Reservoirs, and Viremic Control
55. Envelope/Entry/Tropism/Transmission
58. AssemblyPutting It All Together
59. Restriction Factors: Old and New
64. HIV Compartments
67. HIV Infection Models
71. Immune Restoration
73. Immune Activation/Function in HIV Infection
74. Immune Activation, T Cell Homeostasis, and Therapy
75. Mucosal Factors in HIV Transmission and Infection
77. HIV Compartmentalization and Evolution on Therapy
84. Progressive Multifocal Leukoencephalopathy and Other
Central Nervous System Infections
85. Central Nervous System Penetration, ART Intensification,
and Cerebrospinal Fluid Escape
86. ART, Neurocognitive Outcomes, and New Central
Nervous System-targeted Therapies
87. Central Nervous System Viral Evolution and
95. Mining Sequence Data to Understand Transmission and
Disease
96. Transmission Clusters
98. Within-patient Diversity Compartmentalization, Dual
Infection, and Recombination
100. ARV Pharmacogenetics: Metabolism, Drug Interactions,
and Response
101. ARV Drug Exposure, Safety, and Efficacy
105. New ARV Agents
106. Randomized Trials of ART: A Potpourri
118. Hepatic Injury and Fibrosis
119. Laboratory Assessment and Imaging of Hepatic Injury
120. Hepatitis E Virus
121. Hepatitis B Virus
128. HIV-associated Malignancies: Miscellaneous
130. Cardiovascular Disease: Predicting Risk and Monitoring
Outcomes
131. Endothelial Dysfunction in HIV Infection
132. Vascular Imaging and Subclinical Atherosclerosis
141. Diabetes, Metabolic Syndrome, and Vitamin D Deficiency
143. Bone Loss: Risk Factors and Pathogenesis
144. ART and Bone Disease
150. Cryptococcal Infections
151. Herpes Zoster
152. CytomegalovirusHost Pathogen Interactions
153. Syphilis: Not Gone, Not Forgotten
154. Opportunistic Infections and Other Novel Pathogens
155. Vaccines: TB, Pneumococcus, and Influenza
156. HIV Shedding and Impact of Infection on Immune Cells in
Women
161. HIV Testing and ARV Drug Resistance during Pregnancy
162. ART, Viral Suppression, and MTCT
170. Incidence and Prevention of PMTCT-associated Drug
Resistance
171. New HIV Infections among Children in the US
172. ART Initiation and Immune Reconstitution Inflammatory
Syndrome among Infants and Children
173. ART Strategies and Outcomes among Children
174. Cost and Cost-effectiveness of ART and Monitoring
178. Characteristics of Youth with HIV
180. ARV Pharmacokinetics in Children
183. Preclinical Studies of Topical ARV for Prevention
187. Voluntary Medical Male Circumcision
190. The Cascade of Care
191. Engagement and Retention in Care
197. Performance and Innovation in ART Programs in RLS
56. Transcription/Reverse and Forward, Splicing/Replication
60. Restriction Factors: APOBEC and Others
62. Shutting the Door on HIV Entry
63. Transmitted/Founder Viruses
66. Markers of HIV Disease Progression
69. CD8 T Cells in HIV Infection
70. Killer T Cells
78. Viral DNA Dynamics
79. Infected Cell Dynamics on Therapy
80. What Is Latency and What Can We Do about It?
82. Novel Vaccine Strategies
88. Neuropathogenesis Mechanisms
89. Central Nervous System Inflammation and Biomarkers
of HIV-associated Neurocognitive Disorders
90. Aging and Neurocognitive Function in HIV Infection
94. Simian Viral Reservoirs
97. HIV Subtypes: Epidemiology and Disease Progression
99. New Approaches to ARV Drug Delivery
102. ARV Pharmacokinetics: New Assays, Drugs, and Special
Populations
110. Tropism Testing/Maraviroc Resistance
111. HIV Drug Resistance: Trends and Emergence
112. Detecting and Interpreting HIV Drug Resistance
113. Innovation in Measuring Viral Nucleic Acids
114. Transmitted Drug Resistance
115. Drug Resistance Mutational Pathways and Subtype
Associations
116. Advances in Sequencing and Analysis
117. Detecting HIV Infection
122. Hepatitis C Virus Treatment Today and Tomorrow
123. Hepatitis C Virus Resistance and Virology
124. Innate Immunity and Hepatitis C Virus
126. Hepatic Failure and Transplantation
127. Emergence and Persistence of HPV-associated
133. Statin Use and HIV: How Sweet Is It?
134. Dyslipidemia: Risks, Pathogenesis, and Treatment
135. Risk Prediction, Risk Factors, Biomarkers, and Outcomes
137. Inflammatory Biomarkers, Microparticles, and Clinical
Outcomes in HIV
138. ART Effects: Monocyte and T Cell Activation
147. TB Screening Strategies: Diagnostics New and Old and
Latent TB Treatment
149. Mechanisms of Immune Reconstitution
157. Hepatitis C Virus Testing in Women
163. ARV Strategies, MTCT, and HIV-free Survival
164. PMTCT Implementation: Barriers and Program
Innovations
167. Breast Feeding and Prevention of Postnatal MTCT
168. ARV Pharmacokinetics during Pregnancy and Breast
Feeding
169. ARV Regimens and Safety during Pregnancy
175. HIV Drug Resistance in Children and Youth
176. Co-infections among HIV-infected and -exposed Children
184. Non-human Primate Models of STI, PrEP, and Vaccines
186. Implementation and Cost-effectiveness of Male
Circumcision
188. The Ongoing Epidemic in MSM
193. Estimating Incidence
194. New Testing Strategies
198. Adherence and Retention in RLS
54. ART, Complications, and TB
57. Accessory Proteins/Gag
61. MacrophageHIV Interactions: Cell Biology and
Treatment
65. HIV Genotypes and Phenotypes
68. HIV and Monocytes, Macrophages, and Dendritic Cells
72. Microbial Translocation
76. Neutralizing Antibodies and How to Stimulate Them
81. Mechanism of HIV Latency and Reactivation
83. Gene and Adoptive Immunotherapy
91. NeuroAIDS Clinical Studies
92. Neuroimaging Studies
93. Human Genomics
103. Compartment Penetration of ARV
104. ARV Drug Interactions
107. ART: Too Early or Too Late? Or Better Late than Never!
108. ART: Host and Viral Determinants of Outcome
109. ART: Care and Adherence
125. Hepatitis C Virus Epidemiology and Clinical Outcomes
129. HIV-associated Malignancies: Lymphoma
136. Microbial Translocation Measurement and Associations
139. ART Effects: Gene Expression and Cellular Function
140. Frailty: From Mice to Men and Women
142. Renal Disease: Diagnosis, Predictors, and Drugs
145. TB: Incidence, Risk Factors, and Outcomes
146. TB Diagnostics
148. The ART of TB Treatment
158. HIV Risk Factors, Prevalence, and Barriers to Care
159. Family Planning: Unintended Pregnancy and Unmet Need
160. HIV in Peri- and Post-menopause
165. Pregnancy Complications among HIV
+
Women
166. PMTCT: Maternal and Child Health Outcomes
177. HIV and ART-related Complications and Treatment in
Children and Youth
179. Tenofovir in Children
181. Immune Response to Perinatal HIV
182. Response to Pediatric Vaccines in Children and Youth
185. Oral PrEP and ARV Adherence
189. MSM in the Developing World
192. Disease Progression, Morbidity, and Mortality
195. Biological and Behavioral Transmission Risks
196. Reducing Risk
199. Virologic Failure, 2
nd
- and 3
rd
CR I 2O13
Program at-a-Glance
DAY HALL B2 TIME/ T YPE B402 B406 B308 B313 Ballroom 3- 4 Ballroom 1-2 Hall B1 TIME/ T YPE DAY
S
U
N
D
A
Y

3
/
3
/
1
3
Poster
Set-up
7 am-7 pm
9 am-1:30 pm
Workshop
1. New Investigators and
Trainees Workshop
9 am-1:30 pm
Workshop
S
U
N
D
A
Y

3
/
3
/
1
3
2:30-4:30 pm
Workshop
2. Frontiers in Lab Sci 3. Clinical Trials Design
2:30-4:30 pm
Workshop
5-7 pm
Opening
4. 18
th
Bernard Fields
Lecture and 7
th

NGaly-Mann Lecture
5-7 pm
Opening
7-10 pm 7-10 pm
Welcome Reception
M
O
N
D
A
Y

3
/
4
/
1
3
Posters
Open
7 am-7 pm
8:30-9 am
Plenary
5. HIV-1 Eradication
Strategies: Design,
Assessment, and
Clinical Consequences
8:30-9 am
Plenary
M
O
N
D
A
Y

3
/
4
/
1
3
9-9:30 am
Plenary
6. Reality Check: Is the
End of AIDS in Sight?
9-9:30 am
Plenary
10 am-12 n
Oral Abstracts
10-11:30 am
7. Neurocognitive
Disorders: New
Developments and
Therapies
10 am-12:15 pm
8. HIV Prevention:
ARV, Counselling,
Contraception, and
Condoms
10 am-12:15 pm
9. Advances in Hepatitis
Therapy
10 am-12:15 pm
10. Is There Hope for
HIV Eradication?
10 am-12 n
Oral Abstracts
1:30-2:30 pm
Themed
Discussion
11. Simian Viral
Reservoirs
12. Tenofovir in Children 13. New Approaches to
ARV Drug Delivery
14. Implementation and
Cost-effectiveness
of Male Circumcision
15. What Is Latency and
What Can We Do
about It?
16. Statin Use and HIV:
How Sweet Is It?
1:30-2:30 pm
Themed
Discussion
2:30-4 pm
Poster Abstracts
2:30-4 pm
Poster Abstracts
4-6 pm
Symposia + Oral
Abstracts
17. Is Something
Bugging You?
18. Preventing HIV/AIDS
in the US: Can We Do
Better?
Oral Abstracts Session
19. Cardiovascular
Disease and Other
Non-AIDS Events:
Epidemiology and
Pathogenesis
20. New Frontiers in
Hepatitis C Virus
Treatment
4-6 pm
Symposia + Oral
Abstracts
T
U
E
S
D
A
Y

3
/
5
/
1
3
Posters
Open
7 am-7 pm
8:30-9 am
Plenary
21. The Global MSM
HIV Epidemic:
Time to Act
8:30-9 am
Plenary
T
U
E
S
D
A
Y

3
/
5
/
1
3
9-9:30 am
Plenary
22. Evolution of the
HostVirus
Interaction: A Guide
to the Development
of Novel
Therapeutics?
9-9:30 am
Plenary
10 am-12 n
Oral Abstracts
23. HIV/SIVHost
Interaction
10 am-12:15 pm
24. MTCT and HIV
Treatment in Children
25. North and South:
Epidemiology and
Engagement in Care
10 am-12:15 pm
26. ART: New Agents
and New Insights
10 am-12 n
Oral Abstracts
1:30-2:30 pm
Themed
Discussion
27. Mining Sequence
Data to Understand
Transmission and
Disease
28. Restriction Factors:
Old and New
29. MSM in the
Developing World
30. Family Planning:
Unintended
Pregnancy and
Unmet Need
31. The Cascade
of Care
32. Cardiovascular
Disease: Predicting
Risk and Monitoring
Outcomes
1:30-2:30 pm
Themed
Discussion
2:30-4 pm
Poster Abstracts
2:30-4 pm
Poster Abstracts
4-6 pm
Symposia
33. HIVHost Cell
Interactions
34. Reproductive
Hormones and HIV
35. When Worlds
CollideAdolescents
and HIV
36. Opportunities
and Threats to
ART Success
4-6 pm
Symposia
W
E
D
N
E
S
D
A
Y

3
/
6
/
1
3
Posters
Open
7 am-6 pm
Poster
Removal
6-9 pm
8:30-9 am
Plenary
37. Incorporating New
Drugs into Regimens
that Will Change the
TB Treatment
Paradigm: The
Magic Mountain
Meets Table
Mountain
8:30-9 am
Plenary
W
E
D
N
E
S
D
A
Y

3
/
6
/
1
3
9-9:30 am
Plenary
38. Treatment with
Gene-modified
Hematopoietic Stem
Cells May
Definitively Abolish
HIV-1 Infection
9-9:30 am
Plenary
10 am-12 n
Oral Abstracts
10-11:45 am
39. New Discoveries in
Vaccines and Gene
Therapy
40. Virology: From the
Outside In
10-11 am
41. HIV-associated
Malignancies
11 am-12:15 pm
42. TB and Cryptococcal
Meningitis
10 am-12:15 pm
43. Advances in ARV
and Anti-Hepatitis C
Virus Therapy
10 am-12 n
Oral Abstracts
1:30-2:30 pm
Themed
Discussion
44. Aging and
Neurocognitive
Function in HIV
Infection
45. Transmitted/
Founder Viruses
46. Emergence and
Persistence of
HPV-associated
Malignancies in
the ART Era
47. Mechanisms
of Immune
Reconstitution
48. Adherence and
Retention in RLS
49. Inflammatory
Biomarkers,
Microparticles,
and Clinical
Outcomes in HIV
1:30-2:30 pm
Themed
Discussion
2:30-4 pm
Poster Abstracts
2:30-4 pm
Poster Abstracts
4-6 pm
Symposium
50. Progress in
Deciphering HIV
Protective Immunity
51. HIV Testing and
Monitoring the
Epidemic: New Tools
for Patients and
Populations
52. TB on the Verge
4-6 pm
Symposium

Croi 2013 Pocket Program

Uploaded by

Copyright:

Available Formats

Croi 2013 Pocket Program

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Croi 2013 Pocket Program

Uploaded by

Copyright:

Available Formats

What is the purpose of the CROI conference?

What are the objectives of the conference?

March 3-6, 2013

Georgia World Congress Center

persons with controlled viremia, appreciate the current state-

You might also like